Nivolumab Clinical Trials (2026): 1,624 Studies for Melanoma & Metastatic Melanoma

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

1,624 Nivolumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 718 indications (including Melanoma & Metastatic Melanoma) and 236,575 total planned enrollment. 137 Phase 3 Nivolumab trials and 732 Phase 2, 15 Phase 4 are listed. 291 Nivolumab clinical trials are actively recruiting at 4,858 U.S. sites across 51 states. Most recent activity: NCT05732389 (Feb 2052).

Where to Participate: All Nivolumab Trial Sites in the U.S. (4,858 sites across 51 states)

Every actively recruiting Nivolumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ALChildren's Hospital of AlabamaBirmingham35233NCT04546399Map
ALChildren's Hospital of AlabamaBirmingham35233NCT05675410Map
ALChildren's Hospital of AlabamaBirmingham35233NCT06064097Map
ALUniversity of Alabama at BirminghamBirmingham35294NCT06364917Map
ALUniversity of Alabama at BirminghamBirmingham35294NCT06618287Map
ALUniversity of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)Birmingham35294-3300NCT07246863Map
ALUniversity of Alabama at Birmingham Cancer CenterBirmingham35233NCT05112601Map
ALUniversity of Alabama at Birmingham Cancer CenterBirmingham35233NCT04511013Map
ALUniversity of Alabama at Birmingham Comprehensive Cancer CenterBirmingham35294NCT02693535Map
ALSouthern Cancer Center, PCDaphne36526NCT06646276Map
ALThomas HospitalFairhope36532NCT04511013Map
ALMobile Infirmary Medical CenterMobile36607NCT04511013Map
ALUSA Health Strada Patient Care CenterMobile36604NCT04546399Map
ALUSA Health Strada Patient Care CenterMobile36604NCT05675410Map
AKAlaska Breast Care and Surgery LLCAnchorage99508NCT04511013Map
AKAlaska Breast Care and Surgery LLCAnchorage99508NCT05647265Map
AKAlaska Breast Care and Surgery LLCAnchorage99508NCT05677490Map
AKAlaska Oncology and Hematology LLCAnchorage99508NCT04511013Map
AKAlaska Oncology and Hematology LLCAnchorage99508NCT05647265Map
AKAlaska Oncology and Hematology LLCAnchorage99508NCT05677490Map
AKAlaska Women's Cancer CareAnchorage99508NCT04511013Map
AKAlaska Women's Cancer CareAnchorage99508NCT05647265Map
AKAlaska Women's Cancer CareAnchorage99508NCT05677490Map
AKAnchorage Associates in Radiation MedicineAnchorage98508NCT04511013Map
AKAnchorage Associates in Radiation MedicineAnchorage98508NCT05647265Map
AKAnchorage Associates in Radiation MedicineAnchorage98508NCT05677490Map
AKAnchorage Oncology CentreAnchorage99508NCT04511013Map
AKAnchorage Radiation Therapy CenterAnchorage99504NCT04511013Map
AKKatmai Oncology GroupAnchorage99508NCT04511013Map
AKKatmai Oncology GroupAnchorage99508NCT05647265Map
AKKatmai Oncology GroupAnchorage99508NCT05677490Map
AKProvidence Alaska Medical CenterAnchorage99508NCT04511013Map
AKProvidence Alaska Medical CenterAnchorage99508NCT05647265Map
AKProvidence Alaska Medical CenterAnchorage99508NCT05675410Map
AKProvidence Alaska Medical CenterAnchorage99508NCT05677490Map
AKFairbanks Memorial HospitalFairbanks99701NCT04511013Map
AZPioneer Research Center, LLCBullhead City86442NCT06463665Map
AZIronwood Cancer & Research CentersChandler85224NCT06246916Map
AZBanner MD Anderson Cancer CenterGilbert85234NCT05266612Map
AZBanner MD Anderson Cancer CenterGilbert85234NCT06246916Map
AZBanner MD Anderson Cancer CenterGilbert85234NCT06264180Map
AZCTCA at Western Regional Medical CenterGoodyear85338NCT05675410Map
AZI-Mab Site 1016Goodyear85338NCT07432295Map
AZKingman Regional Medical CenterKingman86401NCT05647265Map
AZKingman Regional Medical CenterKingman86401NCT05677490Map
AZBanner Children's at DesertMesa85202NCT04546399Map
AZBanner Children's at DesertMesa85202NCT05675410Map
AZCancer Center at Saint Joseph'sPhoenix85004NCT05987241Map
AZCancer Center at Saint Joseph'sPhoenix85004NCT06632327Map
AZCancer Treatment Centers of America-PhoenixPhoenix85338NCT02693535Map
AZExelixis Clinical Site #67Phoenix85054NCT05176483Map
AZMayo ClinicPhoenix85054NCT05223816Map
AZMayo ClinicPhoenix85054NCT05919264Map
AZMayo ClinicPhoenix85054NCT06743126Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT05136196Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT03866382Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT05647265Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT05987241Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT06632327Map
AZPhoenix Childrens HospitalPhoenix85016NCT04546399Map
AZPhoenix Childrens HospitalPhoenix85016NCT05675410Map
AZPhoenix Childrens HospitalPhoenix85016NCT06064097Map
AZHonor HealthScottsdale85258NCT05919264Map
AZHonor Health Research InstituteScottsdale85258NCT06743126Map
AZHonorHealth Research InsisuteScottsdale85258NCT06581406Map
AZMayo Clinic in ArizonaScottsdale85259NCT03866382Map
AZMayo Clinic in ArizonaScottsdale85259NCT03017820Map
AZMayo Clinic in ArizonaScottsdale85259NCT05647265Map
AZMayo Clinic in ArizonaScottsdale85259NCT07226856Map
AZArizona Cancer Center at University of ArizonaTucson85719NCT05919264Map
AZBanner University Medical Center - TucsonTucson85719NCT04546399Map
AZBanner University Medical Center - TucsonTucson85719NCT05987241Map
AZExelixis Clinical Site #1Tucson85711NCT05176483Map
AZSouthern Arizona VA Health Care SystemTucson85723NCT06561386Map
AZUniversity of ArizonaTucson85720NCT06112314Map
AZUniversity of Arizona Cancer CenterTucson85719NCT05901285Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT05987241Map
ARHighlands Oncology Group - FayettevilleFayetteville72703NCT05987241Map
ARHighlands Oncology Group - FayettevilleFayetteville72703NCT07383441Map
ARMercy Hospital Fort SmithFort Smith72903NCT04511013Map
ARMercy Hospital Fort SmithFort Smith72903NCT05677490Map
ARMercy Hospital Fort SmithFort Smith72903NCT06632327Map
ARNEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro72401NCT06632327Map
ARNEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro72401NCT07383441Map
ARArkansas Children's HospitalLittle Rock72202-3591NCT04546399Map
ARArkansas Children's HospitalLittle Rock72202-3591NCT05675410Map
ARArkansas Children's HospitalLittle Rock72202-3591NCT06064097Map
ARBaptist Health Medical Center - Little RockLittle Rock72205NCT06203600Map
ARCARTI Cancer CenterLittle Rock72205NCT05677490Map
ARCARTI Cancer CenterLittle Rock72205NCT06632327Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT05136196Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT05327686Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT06203600Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT06246916Map
ARHighlands Oncology Group - RogersRogers72758NCT05987241Map
ARHighlands Oncology Group - RogersRogers72758NCT07383441Map
ARHighlands Oncology GroupSpringdale72762NCT05987241Map
ARHighlands Oncology GroupSpringdale72762NCT07383441Map
CAKaiser Permanente-AnaheimAnaheim92806NCT04546399Map
CAKaiser Permanente-AnaheimAnaheim92806NCT05987241Map
CAKaiser Permanente-AnaheimAnaheim92806NCT06203600Map
CAKaiser Permanente-Deer Valley Medical CenterAntioch94531NCT05677490Map
CAMission Hope Medical Oncology - Arroyo GrandeArroyo Grande93420NCT06632327Map
CAPCR OncologyArroyo Grande93420NCT05327686Map
CAPCR OncologyArroyo Grande93420NCT05647265Map
CAPCR OncologyArroyo Grande93420NCT05677490Map
CASutter AuburnAuburn95602NCT02693535Map
CASutter Auburn Faith HospitalAuburn95602NCT05677490Map
CASutter Cancer Centers Radiation Oncology Services-AuburnAuburn95603NCT05677490Map
CAKaiser Permanente - Baldwin ParkBaldwin Park91706NCT06534983Map
CAKaiser Permanente-Baldwin ParkBaldwin Park91706NCT05987241Map
CAKaiser Permanente-Baldwin ParkBaldwin Park91706NCT06203600Map
CAKaiser Permanente-BellflowerBellflower90706NCT05987241Map
CAKaiser Permanente-BellflowerBellflower90706NCT06203600Map
CAAlta Bates Summit Medical Center-Herrick CampusBerkeley94704NCT05677490Map
CAAlta Bates Summit Medical Center-Herrick CampusBerkeley94704NCT07166406Map
CASutter Alta BatesBerkeley94705NCT02693535Map
CAPrecision NextGen OncologyBeverly Hills90212NCT06047379Map
CATower Cancer Research FoundationBeverly Hills90211NCT05136196Map
CATower Cancer Research FoundationBeverly Hills90211NCT06203600Map
CAProvidence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank91505NCT04511013Map
CAProvidence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank91505NCT05647265Map
CAProvidence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank91505NCT05677490Map
CAMills-Peninsula Medical CenterBurlingame94010NCT05327686Map
CAMills-Peninsula Medical CenterBurlingame94010NCT05677490Map
CASutter Cancer Centers Radiation Oncology Services-Cameron ParkCameron Park95682NCT05677490Map
CASutter Cancer Centers Radiation Oncology Services-Cameron ParkCameron Park95682NCT07166406Map
CAMercy Cancer Center - CarmichaelCarmichael95608NCT05675410Map
CAMercy Cancer Center - CarmichaelCarmichael95608NCT06632327Map
CAMercy San Juan Medical CenterCarmichael95608NCT05675410Map
CAMercy San Juan Medical CenterCarmichael95608NCT06632327Map
CAEden Hospital Medical CenterCastro Valley94546NCT05677490Map
CAEnloe Medical CenterChico95926NCT06632327Map
CACity of Hope CoronaCorona92882NCT05675410Map
CAUC Irvine Health Cancer Center-NewportCosta Mesa92627NCT05675410Map
CAUC Irvine Health Cancer Center-NewportCosta Mesa92627NCT05677490Map
CASutter Davis HospitalDavis95616NCT05677490Map
CAKaiser Permanente Downey Medical CenterDowney90242NCT04546399Map
CAKaiser Permanente Downey Medical CenterDowney90242NCT05675410Map
CAKaiser Permanente Downey Medical CenterDowney90242NCT06064097Map
CACity of Hope Comprehensive Cancer CenterDuarte91010NCT05272384Map
CACity of Hope Comprehensive Cancer CenterDuarte91010NCT05675410Map
CACity of Hope Medical CenterDuarte91010NCT04561206Map
CACity of Hope Medical CenterDuarte91010NCT06399419Map
CACity of Hope Medical CenterDuarte91010NCT07128680Map
CACity of Hope National Medical CenterDuarte91010NCT05361720Map
CACity of Hope National Medical CenterDuarte91010NCT06743126Map
CAI-MAB Site 1005Duarte91010NCT07432295Map
CAEpic Care-DublinDublin94568NCT04511013Map
CAKaiser Permanente DublinDublin94568NCT05675410Map
CAKaiser Permanente DublinDublin94568NCT05677490Map
CAKaiser Permanente DublinDublin94568NCT05987241Map
CAKaiser Permanente DublinDublin94568NCT06029270Map
CAKaiser Permanente DublinDublin94568NCT06203600Map
CAMercy Cancer Center - Elk GroveElk Grove95758NCT05675410Map
CAMercy Cancer Center - Elk GroveElk Grove95758NCT06632327Map
CABay Area Breast Surgeons IncEmeryville94608NCT04511013Map
CAEpic Care Partners in Cancer CareEmeryville94608NCT04511013Map
CAUC San Diego Health System - EncinitasEncinitas92024NCT05327686Map
CAKaiser Permanente-FontanaFontana92335NCT04546399Map
CAKaiser Permanente-FontanaFontana92335NCT05987241Map
CAKaiser Permanente-FontanaFontana92335NCT06203600Map
CAKaiser Permanente-FremontFremont94538NCT05675410Map
CAKaiser Permanente-FremontFremont94538NCT05677490Map
CAKaiser Permanente-FremontFremont94538NCT05987241Map
CAKaiser Permanente-FremontFremont94538NCT06029270Map
CAKaiser Permanente-FremontFremont94538NCT06203600Map
CAPalo Alto Medical Foundation-FremontFremont94538NCT05677490Map
CAPalo Alto Medical Foundation-FremontFremont94538NCT07166406Map
CAClinRé 001-022 (Premier Cancer Care and Infusion Center)Fresno93710NCT07195695Map
CAFresno Cancer CenterFresno93720NCT05677490Map
CAKaiser Permanente Fresno Orchard PlazaFresno93720NCT05677490Map
CAKaiser Permanente Fresno Orchard PlazaFresno93720NCT05987241Map
CAKaiser Permanente Fresno Orchard PlazaFresno93720NCT06029270Map
CAKaiser Permanente Fresno Orchard PlazaFresno93720NCT06203600Map
CAKaiser Permanente-FresnoFresno93720NCT05675410Map
CAKaiser Permanente-FresnoFresno93720NCT05677490Map
CAKaiser Permanente-FresnoFresno93720NCT05987241Map
CAKaiser Permanente-FresnoFresno93720NCT06029270Map
CAKaiser Permanente-FresnoFresno93720NCT06203600Map
CAProvidence Medical FoundationFullerton92835NCT06246916Map
CAOPN Healthcare, IncGlendale91203NCT06047379Map
CAOPN Healthcare, Inc.Glendale91203NCT07195695Map
CAKaiser Permanente South BayHarbor City90710NCT05987241Map
CAKaiser Permanente South BayHarbor City90710NCT06203600Map
CACity of Hope SeacliffHuntington Beach92648NCT05675410Map
CACity of HopeIrvine92618NCT06053658Map
CACity of Hope at Irvine LennarIrvine92618NCT05675410Map
CAKaiser Permanente-IrvineIrvine92618NCT05987241Map
CAKaiser Permanente-IrvineIrvine92618NCT06203600Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT05136196Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT05327686Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT05675410Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT05677490Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT07166406Map
CAUniversity of California, IrvineIrvine92868NCT06624475Map
CAUniversity of California, Irvine (UCI) Health - UC Irvine Medical CenterIrvine92612NCT06697197Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT05327686Map
CAUC San Diego Moores Cancer CenterLa Jolla92037NCT06581406Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT05647265Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT05896839Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT05987241Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT06203600Map
CAUC San Diego Moores Cancer CenterLa Jolla92037NCT06264180Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT06632327Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT06743126Map
CAUniversity of California - San DiegoLa Jolla92093-0698NCT06112314Map
CAUniversity of California San DiegoLa Jolla92093NCT05502315Map
CAUniversity of California San DiegoLa Jolla92093NCT06863311Map
CAUniversity of California, San Diego Moores Cancer CenterLa Jolla92093NCT06624475Map
CACity of Hope Antelope ValleyLancaster93534NCT05675410Map
CALoma Linda University Medical CenterLoma Linda92354NCT04546399Map
CALoma Linda University Medical CenterLoma Linda92354NCT05675410Map
CALoma Linda University Medical CenterLoma Linda92354NCT06064097Map
CACity of Hope at Long Beach ElmLong Beach90813NCT05675410Map
CAMiller Children's and Women's Hospital Long BeachLong Beach90806NCT04546399Map
CAMiller Children's and Women's Hospital Long BeachLong Beach90806NCT05675410Map
CACancer and Blood Specialty ClinicLos Alamitos90720NCT06246916Map
CACedars-Sinai Medical CenterLos Angeles90048NCT04609046Map
CACedars-Sinai Medical CenterLos Angeles90048NCT05136196Map
CACedars-Sinai Medical CenterLos Angeles90048NCT04546399Map
CACedars-Sinai Medical CenterLos Angeles90048NCT05675410Map
CACedars-Sinai Medical CenterLos Angeles90048NCT06203600Map
CAChildren's Hospital Los AngelesLos Angeles90027NCT04546399Map
CAChildren's Hospital Los AngelesLos Angeles90027NCT05675410Map
CAChildren's Hospital Los AngelesLos Angeles90027NCT06064097Map
CAESC Norris Comprehensive Cancer CenterLos Angeles90033NCT06112314Map
CAKaiser Permanente Los Angeles Medical CenterLos Angeles90027NCT05987241Map
CAKaiser Permanente Los Angeles Medical CenterLos Angeles90027NCT06203600Map
CAKaiser Permanente West Los AngelesLos Angeles90034NCT05987241Map
CAKaiser Permanente West Los AngelesLos Angeles90034NCT06203600Map
CAKeck Medicine of USC KoreatownLos Angeles90020NCT03866382Map
CAKeck Medicine of USC KoreatownLos Angeles90020NCT05677490Map
CAKeck Medicine of USC KoreatownLos Angeles90020NCT05896839Map
CAKeck Medicine of USC KoreatownLos Angeles90020NCT06029270Map
CAKeck Medicine of USC KoreatownLos Angeles90020NCT06203600Map
CALos Angeles General Medical CenterLos Angeles90033NCT05327686Map
CALos Angeles General Medical CenterLos Angeles90033NCT05677490Map
CALos Angeles General Medical CenterLos Angeles90033NCT05896839Map
CALos Angeles General Medical CenterLos Angeles90033NCT06029270Map
CALos Angeles General Medical CenterLos Angeles90033NCT06203600Map
CAMattel Children's Hospital UCLALos Angeles90095NCT04546399Map
CASite 03Los Angeles90025NCT07276373Map
CAThe Angeles Clinic and Research InstituteLos Angeles90025NCT06581406Map
CAThe Angeles Clinic and Research InstituteLos Angeles90025NCT05533697Map
CAThe Angeles Clinic and Research InstituteLos Angeles90025NCT06264180Map
CAThe Angeles Clinic and Research Institute - West Los Angeles OfficeLos Angeles90025NCT05136196Map
CAThe Angeles Clinic and Research Institute - West Los Angeles OfficeLos Angeles90025NCT06697197Map
CAThe Angeles Clinic and Research Institute- West Los AngelesLos Angeles90025NCT06112314Map
CAThe Angeles Clinic and Research Institute, A Cedars-Sinai AffiliateLos Angeles90025NCT02693535Map
CAThe Angeles Clinic at Cedars SinaiLos Angeles90025NCT05428007Map
CAUCLA / Jonsson Comprehensive Cancer CenterLos Angeles90095NCT04511013Map
CAUCLA / Jonsson Comprehensive Cancer CenterLos Angeles90095NCT05987241Map
CAUCLA Department of Medicine - Hematology/OncologyLos Angeles90095NCT06264180Map
CAUCLA Hematology/OncologyLos Angeles90095NCT06112314Map
CAUCLA Hematology/OncologyLos Angeles90024NCT06743126Map
CAUniversity of California Los AngelesLos Angeles90095NCT06581406Map
CAUniversity of California Los AngelesLos Angeles90024NCT06246916Map
CAUniversity of California, Los Angeles (UCLA)Los Angeles90095NCT05919264Map
CAUniversity of Southern CaliforniaLos Angeles90033NCT06047379Map
CAUSC / Norris Comprehensive Cancer CenterLos Angeles90033NCT05327686Map
CAUSC / Norris Comprehensive Cancer CenterLos Angeles90033NCT05677490Map
CAUSC / Norris Comprehensive Cancer CenterLos Angeles90033NCT05896839Map
CAUSC / Norris Comprehensive Cancer CenterLos Angeles90033NCT06029270Map
CAUSC / Norris Comprehensive Cancer CenterLos Angeles90033NCT06203600Map
CAUSC Norris Comprehensive Cancer CenterLos Angeles90033NCT06264180Map
CAUSC Norris Comprehensive Cancer CenterLos Angeles90033NCT07246863Map
CAValley Children's HospitalMadera93636NCT04546399Map
CAValley Children's HospitalMadera93636NCT06064097Map
CAContra Costa Regional Medical CenterMartinez94553-3156NCT04511013Map
CAFremont - Rideout Cancer CenterMarysville95901NCT06632327Map
CAMercy Cancer CenterMerced95340NCT06632327Map
CAKaiser Permanente- Modesto MOB IIModesto95356NCT05677490Map
CAKaiser Permanente- Modesto MOB IIModesto95356NCT05987241Map
CAKaiser Permanente- Modesto MOB IIModesto95356NCT06029270Map
CAKaiser Permanente- Modesto MOB IIModesto95356NCT06203600Map
CAKaiser Permanente-ModestoModesto95356NCT05675410Map
CAKaiser Permanente-ModestoModesto95356NCT05677490Map
CAKaiser Permanente-ModestoModesto95356NCT05987241Map
CAKaiser Permanente-ModestoModesto95356NCT06029270Map
CAKaiser Permanente-ModestoModesto95356NCT06203600Map
CAMemorial Medical CenterModesto95355NCT05327686Map
CAMemorial Medical CenterModesto95355NCT05677490Map
CAPalo Alto Medical Foundation-Camino DivisionMountain View94040NCT05677490Map
CAPalo Alto Medical Foundation-Camino DivisionMountain View94040NCT07166406Map
CAPalo Alto Medical Foundation-Gynecologic OncologyMountain View94040NCT05677490Map
CAProvidence Queen of The ValleyNapa94558NCT04511013Map
CAProvidence Queen of The ValleyNapa94558NCT05647265Map
CAProvidence Queen of The ValleyNapa94558NCT05677490Map
CACity of Hope Newport BeachNewport Beach92660NCT05675410Map
CAUSC Newport BeachNewport Beach92663NCT06624644Map
CAUSC Norris Oncology/Hematology-Newport BeachNewport Beach92663NCT05677490Map
CAUSC Norris Oncology/Hematology-Newport BeachNewport Beach92663NCT06029270Map
CAUSC Norris Oncology/Hematology-Newport BeachNewport Beach92663NCT06203600Map
CASutter Cancer Research ConsortiumNovato94945NCT05677490Map
CABay Area Tumor InstituteOakland94609NCT04511013Map
CAKaiser Permanente - Oakland Medical CenterOakland94611NCT02693535Map
CAKaiser Permanente Oakland-BroadwayOakland94611NCT05677490Map
CAKaiser Permanente-OaklandOakland94611NCT04546399Map
CAKaiser Permanente-OaklandOakland94611NCT05675410Map
CAKaiser Permanente-OaklandOakland94611NCT05677490Map
CAKaiser Permanente-OaklandOakland94611NCT05987241Map
CAKaiser Permanente-OaklandOakland94611NCT06029270Map
CAKaiser Permanente-OaklandOakland94611NCT06064097Map
CAKaiser Permanente-OaklandOakland94611NCT06203600Map
CAUCSF Benioff Children's Hospital OaklandOakland94609NCT06064097Map
CAKaiser Permanente-OntarioOntario91761NCT05987241Map
CAKaiser Permanente-OntarioOntario91761NCT06203600Map
CAChao Family Comprehensive Cancer CenterOrange92868NCT05361720Map
CAChao Family Comprehensive Cancer Center, UniversityOrange92868NCT05733689Map
CAChao Family Comprehensive Cancer Center, University of California, IrvineOrange92868NCT04472767Map
CAChao Family Comprehensive Cancer Center, University of California, IrvineOrange92868NCT06682728Map
CAChildren's Hospital of Orange CountyOrange92868NCT04546399Map
CAChildren's Hospital of Orange CountyOrange92868NCT05675410Map
CASt. Joseph Hospital OrangeOrange92868NCT06246916Map
CAStern Center for Cancer Clinical Trials and ResearchOrange92868NCT04900818Map
CAUC Irvine Health, Chao Family Comprehensive Cancer CenterOrange92868NCT06264180Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT05136196Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT05327686Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT05675410Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT05677490Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT07166406Map
CAUniversity of California IrvineOrange92868NCT05655312Map
CAUniversity of California Irvine, UCI Medical CenterOrange92868NCT06246916Map
CAUniversity of California, IrvineOrange92868NCT03259867Map
CAUniversity of California, Irvine (UCI) Health - UC Irvine Medical CenterOrange92868NCT07221149Map
CAExelixis Clinical Site #123Palo Alto94304NCT05176483Map
CALucile Packard Children's Hospital Stanford UniversityPalo Alto94304NCT04546399Map
CAPalo Alto Medical Foundation Health CarePalo Alto94301NCT05677490Map
CAPalo Alto Medical Foundation Health CarePalo Alto94301NCT07166406Map
CAStanford Cancer InstitutePalo Alto94304NCT06581406Map
CAStanford Cancer InstitutePalo Alto94304NCT06264180Map
CAStanford Cancer Institute Palo AltoPalo Alto94304NCT05987241Map
CAStanford Cancer Institute Palo AltoPalo Alto94304NCT06029270Map
CAStanford Cancer Institute, Stanford UniversityPalo Alto94304NCT05919264Map
CAStanford UniversityPalo Alto94304NCT06712927Map
CASutter Palo Alto Medical Foundation: Palo AltoPalo Alto94301NCT02693535Map
CAKaiser Permanente - Panorama CityPanorama City91402NCT05987241Map
CAKaiser Permanente - Panorama CityPanorama City91402NCT06203600Map
CAKaiser Permanente-Rancho Cordova Cancer CenterRancho Cordova95670NCT05677490Map
CAEisenhower Medical CenterRancho Mirage92270NCT05677490Map
CAEmad Ibrahim, MD, Inc.Redlands92373NCT06246916Map
CAKaiser Permanente- Marshall Medical OfficesRedwood City94063NCT05677490Map
CAKaiser Permanente-RichmondRichmond94801NCT05677490Map
CAKaiser Permanente-RiversideRiverside92505NCT05987241Map
CAKaiser Permanente-RiversideRiverside92505NCT06203600Map
CAMercy Cancer Center - RocklinRocklin95765NCT05675410Map
CAMercy Cancer Center - RocklinRocklin95765NCT06632327Map
CARohnert Park Cancer CenterRohnert Park94928NCT05677490Map
CAKaiser Permanente - Roseville Medical CenterRoseville95661NCT02693535Map
CAKaiser Permanente-RosevilleRoseville95661NCT05677490Map
CAKaiser Permanente-RosevilleRoseville95661NCT05987241Map
CAKaiser Permanente-RosevilleRoseville95661NCT06029270Map
CAKaiser Permanente-RosevilleRoseville95661NCT06203600Map
CASutter Cancer Centers Radiation Oncology Services-RosevilleRoseville95661NCT05327686Map
CASutter Cancer Centers Radiation Oncology Services-RosevilleRoseville95661NCT05677490Map
CASutter Cancer Centers Radiation Oncology Services-RosevilleRoseville95661NCT07166406Map
CASutter RosevilleRoseville95661NCT02693535Map
CASutter Roseville Medical CenterRoseville95661NCT05327686Map
CASutter Roseville Medical CenterRoseville95661NCT05677490Map
CASutter Roseville Medical CenterRoseville95661NCT07166406Map
CAThe Permanente Medical Group-Roseville Radiation OncologyRoseville95678NCT05677490Map
CAKaiser Permanente - Sacramento Medical CenterSacramento95814NCT02693535Map
CAKaiser Permanente Downtown CommonsSacramento95814NCT05675410Map
CAKaiser Permanente Downtown CommonsSacramento95814NCT05677490Map
CAKaiser Permanente Downtown CommonsSacramento95814NCT05987241Map
CAKaiser Permanente Downtown CommonsSacramento95814NCT06029270Map
CAKaiser Permanente Downtown CommonsSacramento95814NCT06203600Map
CAKaiser Permanente-South SacramentoSacramento95823NCT05675410Map
CAKaiser Permanente-South SacramentoSacramento95823NCT05677490Map
CAKaiser Permanente-South SacramentoSacramento95823NCT05987241Map
CAKaiser Permanente-South SacramentoSacramento95823NCT06029270Map
CAKaiser Permanente-South SacramentoSacramento95823NCT06203600Map
CAMercy Cancer Center - SacramentoSacramento95816NCT05675410Map
CAMercy Cancer Center - SacramentoSacramento95816NCT06632327Map
CASouth Sacramento Cancer CenterSacramento95823NCT05677490Map
CASutter HealthSacramento95816NCT06246916Map
CASutter Medical Center SacramentoSacramento95816NCT04546399Map
CASutter Medical Center SacramentoSacramento95816NCT05327686Map
CASutter Medical Center SacramentoSacramento95816NCT05677490Map
CASutter Medical Center SacramentoSacramento95816NCT07166406Map
CASutter SacramentoSacramento95816NCT02693535Map
CAUniversity of California Davis (UC Davis) Comprehensive Cancer CenterSacramento95817NCT06561386Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT03816345Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT04546399Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT05272384Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT05987241Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT06029270Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT06632327Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT07166406Map
CAKaiser Permanente-San Diego ZionSan Diego92120NCT04546399Map
CAKaiser Permanente-San Diego ZionSan Diego92120NCT05987241Map
CAKaiser Permanente-San Diego ZionSan Diego92120NCT06203600Map
CANaval Medical Center -San DiegoSan Diego92134NCT05675410Map
CARady Children's Hospital - San DiegoSan Diego92123NCT04546399Map
CARady Children's Hospital - San DiegoSan Diego92123NCT05675410Map
CARady Children's Hospital - San DiegoSan Diego92123NCT06064097Map
CASharp Memorial HospitalSan Diego92123NCT04511013Map
CAUC San Diego Medical Center - HillcrestSan Diego92103NCT05327686Map
CACalifornia Pacific Medical Center Research InstituteSan Francisco94115NCT02693535Map
CACalifornia Pacific Medical Center-Pacific CampusSan Francisco94115NCT05677490Map
CACalifornia Pacific Medical Center-Pacific CampusSan Francisco94115NCT07166406Map
CAKaiser Permanente - San Francisco Medical CenterSan Francisco94115NCT02693535Map
CAKaiser Permanente - South San Francisco Medical CenterSan Francisco94080NCT02693535Map
CAKaiser Permanente-San FranciscoSan Francisco94115NCT05675410Map
CAKaiser Permanente-San FranciscoSan Francisco94115NCT05677490Map
CAKaiser Permanente-San FranciscoSan Francisco94115NCT05987241Map
CAKaiser Permanente-San FranciscoSan Francisco94115NCT06029270Map
CAKaiser Permanente-San FranciscoSan Francisco94115NCT06203600Map
CASan Francisco Oncology AssociatesSan Francisco94115NCT06561386Map
CASan Francisco Oncology AssociatesSan Francisco94115NCT06264180Map
CASutter Cancer Research ConsortiumSan Francisco94115NCT02693535Map
CAUCSFSan Francisco94143NCT06624644Map
CAUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco94158NCT04665206Map
CAUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco94143NCT05533697Map
CAUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco94143NCT06264180Map
CAUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco94143NCT06743126Map
CAUCSF Medical Center-Mission BaySan Francisco94158NCT04546399Map
CAUCSF Medical Center-Mission BaySan Francisco94158NCT05327686Map
CAUCSF Medical Center-Mission BaySan Francisco94158NCT06064097Map
CAUCSF Medical Center-ParnassusSan Francisco94143NCT04609046Map
CAUniversity of California San FranciscoSan Francisco94143NCT07195695Map
CAUniversity of California San Francisco (UCSF)San Francisco94143NCT06246916Map
CAUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer CenterSan Francisco94158NCT05919264Map
CAUniversity of California, San FranciscoSan Francisco94158NCT06624475Map
CAKaiser Permanente - San Jose Medical CenterSan Jose95119NCT02693535Map
CAKaiser Permanente-Santa Teresa-San JoseSan Jose95119NCT05675410Map
CAKaiser Permanente-Santa Teresa-San JoseSan Jose95119NCT05677490Map
CAKaiser Permanente-Santa Teresa-San JoseSan Jose95119NCT05987241Map
CAKaiser Permanente-Santa Teresa-San JoseSan Jose95119NCT06029270Map
CAKaiser Permanente-Santa Teresa-San JoseSan Jose95119NCT06203600Map
CAKaiser Permanente - San Leandro Medical CenterSan Leandro94577NCT02693535Map
CAKaiser Permanente San LeandroSan Leandro94577NCT05675410Map
CAKaiser Permanente San LeandroSan Leandro94577NCT05677490Map
CAKaiser Permanente San LeandroSan Leandro94577NCT05987241Map
CAKaiser Permanente San LeandroSan Leandro94577NCT06029270Map
CAKaiser Permanente San LeandroSan Leandro94577NCT06203600Map
CAPacific Central Coast Health Center-San Luis ObispoSan Luis Obispo93401NCT06632327Map
CAKaiser Permanente-San MarcosSan Marcos92078NCT05987241Map
CAKaiser Permanente-San MarcosSan Marcos92078NCT06203600Map
CAMills Health CenterSan Mateo94401NCT05327686Map
CAMills Health CenterSan Mateo94401NCT05677490Map
CAKaiser San Rafael-GallinasSan Rafael94903NCT05675410Map
CAKaiser San Rafael-GallinasSan Rafael94903NCT05677490Map
CAKaiser San Rafael-GallinasSan Rafael94903NCT05987241Map
CAKaiser San Rafael-GallinasSan Rafael94903NCT06029270Map
CAKaiser San Rafael-GallinasSan Rafael94903NCT06203600Map
CAExelixis Clinical Site #59Santa Barbara93463NCT05176483Map
CARidley-Tree Cancer CenterSanta Barbara93105NCT05327686Map
CARidley-Tree Cancer CenterSanta Barbara93105NCT05677490Map
CASansum ClinicSanta Barbara93105NCT06246916Map
CASanta Barbara Cottage HospitalSanta Barbara93102NCT05675410Map
CASutter Sansum ClinicSanta Barbara93105NCT02693535Map
CAKaiser Permanente - Santa Clara Medical CenterSanta Clara95051NCT02693535Map
CAKaiser Permanente Medical Center - Santa ClaraSanta Clara95051NCT05677490Map
CAKaiser Permanente Medical Center - Santa ClaraSanta Clara95051NCT05987241Map
CAKaiser Permanente Medical Center - Santa ClaraSanta Clara95051NCT06029270Map
CAKaiser Permanente Medical Center - Santa ClaraSanta Clara95051NCT06203600Map
CAPalo Alto Medical Foundation-Santa CruzSanta Cruz95065NCT05677490Map
CASanta Cruz Radiation Oncology Medical GroupSanta Cruz95065NCT05677490Map
CASutter Palo Alto Medical Foundation: FremontSanta Cruz994538NCT02693535Map
CASutter Palo Alto Medical Foundation: Santa CruzSanta Cruz95065NCT02693535Map
CAMission Hope Medical Oncology - Santa MariaSanta Maria93444NCT06632327Map
CASaint John's Health Center - John Wayne Cancer Institute (JWCI)Santa Monica90404NCT06112314Map
CASant P ChawlaSanta Monica90403NCT04535713Map
CASarcoma Oncology CenterSanta Monica90403NCT03886311Map
CASarcoma Oncology CenterSanta Monica90403NCT05919264Map
CASarcoma Oncology Research CenterSanta Monica90403NCT03138161Map
CASt John's Cancer InstituteSanta Monica90404NCT06246916Map
CAUCLA Hematology/Oncology - Santa MonicaSanta Monica90404NCT06561386Map
CAUniversity of California Los AngelesSanta Monica90404NCT07195695Map
CAKaiser Permanente-Santa RosaSanta Rosa95403NCT05675410Map
CAKaiser Permanente-Santa RosaSanta Rosa95403NCT05677490Map
CAKaiser Permanente-Santa RosaSanta Rosa95403NCT05987241Map
CAKaiser Permanente-Santa RosaSanta Rosa95403NCT06029270Map
CAKaiser Permanente-Santa RosaSanta Rosa95403NCT06203600Map
CAProvidence Medical Foundation - Santa RosaSanta Rosa95403NCT04511013Map
CAProvidence Medical Foundation - Santa RosaSanta Rosa95403NCT05647265Map
CAProvidence Medical Foundation - Santa RosaSanta Rosa95403NCT05677490Map
CAProvidence Santa Rosa Memorial HospitalSanta Rosa95405NCT04511013Map
CAProvidence Santa Rosa Memorial HospitalSanta Rosa95405NCT05647265Map
CAProvidence Santa Rosa Memorial HospitalSanta Rosa95405NCT05677490Map
CASutter Pacific Medical FoundationSanta Rosa95403NCT05327686Map
CASutter Pacific Medical FoundationSanta Rosa95403NCT05677490Map
CASutter Pacific Medical FoundationSanta Rosa95403NCT07166406Map
CACity of Hope South PasadenaSouth Pasadena91030NCT05675410Map
CAKaiser Permanente Cancer Treatment CenterSouth San Francisco94080NCT05677490Map
CAKaiser Permanente-South San FranciscoSouth San Francisco94080NCT05675410Map
CAKaiser Permanente-South San FranciscoSouth San Francisco94080NCT05677490Map
CAKaiser Permanente-South San FranciscoSouth San Francisco94080NCT05987241Map
CAKaiser Permanente-South San FranciscoSouth San Francisco94080NCT06029270Map
CAKaiser Permanente-South San FranciscoSouth San Francisco94080NCT06203600Map
CAStanfordStanford94305NCT06624644Map
CAStanford Cancer CenterStanford94305NCT06743126Map
CAStanford Cancer InstituteStanford94305NCT03686124Map
CAKaiser Permanente-StocktonStockton95210NCT05677490Map
CASaint Joseph's Medical CenterStockton95204NCT06632327Map
CAPalo Alto Medical Foundation-SunnyvaleSunnyvale94086NCT05677490Map
CAPalo Alto Medical Foundation-SunnyvaleSunnyvale94086NCT07166406Map
CASutter Palo Alto Medical Foundation: SunnyvaleSunnyvale94086NCT02693535Map
CACity of Hope South BayTorrance90503NCT05675410Map
CACity of Hope UplandUpland91786NCT05675410Map
CAKaiser Permanente Medical Center-VacavilleVacaville95688NCT05677490Map
CAKaiser Permanente - Vallejo Medical CenterVallejo94589NCT02693535Map
CAKaiser Permanente-VallejoVallejo94589NCT05675410Map
CAKaiser Permanente-VallejoVallejo94589NCT05677490Map
CAKaiser Permanente-VallejoVallejo94589NCT05987241Map
CAKaiser Permanente-VallejoVallejo94589NCT06029270Map
CAKaiser Permanente-VallejoVallejo94589NCT06203600Map
CASutter Solano Medical Center/Cancer CenterVallejo94589NCT05677490Map
CAEpic Care Cyberknife CenterWalnut Creek94597NCT04511013Map
CAKaiser Permanente - Walnut Creek Medical CenterWalnut Creek94596NCT02693535Map
CAKaiser Permanente-Walnut CreekWalnut Creek94596NCT05675410Map
CAKaiser Permanente-Walnut CreekWalnut Creek94596NCT05677490Map
CAKaiser Permanente-Walnut CreekWalnut Creek94596NCT05987241Map
CAKaiser Permanente-Walnut CreekWalnut Creek94596NCT06029270Map
CAKaiser Permanente-Walnut CreekWalnut Creek94596NCT06203600Map
CAWoodland Memorial HospitalWoodland95695NCT05675410Map
CAWoodland Memorial HospitalWoodland95695NCT06632327Map
CAKaiser Permanente-Woodland HillsWoodland Hills91367NCT05987241Map
CAKaiser Permanente-Woodland HillsWoodland Hills91367NCT06203600Map
COChildren's Hospital ColoradoAurora80045NCT04546399Map
COChildren's Hospital ColoradoAurora80045NCT05675410Map
COChildren's Hospital ColoradoAurora80045NCT06064097Map
CORocky Mountain Cancer Centers-AuroraAurora80012NCT04511013Map
CORocky Mountain Cancer Centers, LLPAurora80012NCT07392892Map
CORocky Mountain Regional VA Medical CenterAurora80045NCT06246916Map
COUCHealth Cancer Care - Anschutz Medical CampusAurora80045NCT04900818Map
COUCHealth University of Colorado HospitalAurora80045NCT05327686Map
COUCHealth University of Colorado HospitalAurora80045NCT05675410Map
COUCHealth University of Colorado HospitalAurora80045NCT05987241Map
COUniversity of ColoradoAurora80045NCT05919264Map
COUniversity of Colorado AnschutzAurora80045NCT06624644Map
COUniversity of Colorado Cancer CenterAurora80045NCT05533697Map
COUniversity of Colorado Cancer CenterAurora80045NCT06246916Map
COUniversity of Colorado Cancer CenterAurora84005NCT06362369Map
COUniversity of Colorado HospitalAurora80045NCT04511013Map
COUniversity of Colorado Hospital - Anschutz Cancer PavilionAurora80045NCT06264180Map
COUniversity of Colorado Hospital - Anschutz Cancer Pavilion(ACP)Aurora80045NCT06581406Map
COUniversity of Colorado, Anschutz Medical CampusAurora80045NCT03686124Map
COUniversity of Colorado, Anschutz Medical CampusAurora80045NCT06112314Map
COUniversity of Colorado, Anschutz Medical CampusAurora80045NCT06743126Map
COBoulder Community Foothills HospitalBoulder80303NCT04511013Map
CORocky Mountain Cancer Centers-BoulderBoulder80304NCT04511013Map
CORocky Mountain Cancer Centers, LLPBoulder80303NCT07392892Map
COIntermountain Health Platte Valley HospitalBrighton80601NCT05677490Map
CORocky Mountain Cancer Centers - CentennialCentennial80112NCT04511013Map
CORocky Mountain Cancer Centers, LLPCentennial80112NCT07392892Map
COMemorial Hospital NorthColorado Springs80920NCT05136196Map
COMemorial Hospital NorthColorado Springs80920NCT05675410Map
COMemorial Hospital NorthColorado Springs80920NCT06203600Map
COPenrose-Saint Francis HealthcareColorado Springs80907NCT06632327Map
CORocky Mountain Cancer Centers-PenroseColorado Springs80907NCT06632327Map
CORocky Mountain Cancer Centers, LLPColorado Springs80907NCT07392892Map
CORocky Mountain Cancer Centers, LLPColorado Springs80923NCT07392892Map
COSaint Francis Cancer CenterColorado Springs80923NCT06632327Map
COUCHealth Memorial Hospital CentralColorado Springs80909NCT05136196Map
COUCHealth Memorial Hospital CentralColorado Springs80909NCT05675410Map
COUCHealth Memorial Hospital CentralColorado Springs80909NCT06203600Map
COCancer Center of Colorado at Sloan's LakeDenver80204NCT05677490Map
COColorado Blood Cancer InstituteDenver80218NCT04511013Map
COKaiser Permanente-FranklinDenver80205NCT05987241Map
CONational Jewish Health-Main CampusDenver80206NCT05677490Map
COPresbyterian - Saint Lukes Medical Center - Health OneDenver80218NCT04511013Map
CORocky Mountain Cancer Centers-MidtownDenver80218NCT04511013Map
CORocky Mountain Cancer Centers-RoseDenver80220NCT04511013Map
CORocky Mountain Cancer Centers, LLPDenver80218NCT07392892Map
CORocky Mountain Cancer Centers, LLPDenver80220NCT07392892Map
CORocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical CenterDenver80218NCT04546399Map
CORocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical CenterDenver80218NCT05675410Map
COSaint Joseph Hospital - Cancer Centers of ColoradoDenver80218NCT05677490Map
COSarah Cannon Research Institute at HealthONEDenver80218NCT05901285Map
COThe Melanoma & Skin Cancer InstituteDenver80222NCT06112314Map
COThe Women's Imaging CenterDenver80209NCT04511013Map
COUCHealth - Cherry CreekDenver80206NCT05327686Map
COUniversity of ColoradoDenver80204NCT06624644Map
COCommonSpirit Cancer Center MercyDurango81301NCT06632327Map
COMercy Medical CenterDurango81301NCT06632327Map
COMountain Blue Cancer Care Center - SwedishEnglewood80113NCT04511013Map
CORocky Mountain Cancer Centers - SwedishEnglewood80113NCT04511013Map
CORocky Mountain Cancer Centers, LLPEnglewood80113NCT07392892Map
COSwedish Medical CenterEnglewood80113NCT04511013Map
COThe Melanoma & Skin Cancer InstituteEnglewood80113NCT06581406Map
COThe Melanoma and Skin Cancer InstituteEnglewood80113NCT04511013Map
COThe Melanoma and Skin Cancer InstituteEnglewood80113NCT06264180Map
COThe Melanoma And Skin Cancer InstituteEnglewood80113NCT06246916Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT05136196Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT05327686Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT05675410Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT05677490Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT05987241Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT06203600Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT07166406Map
COPoudre Valley HospitalFort Collins80524NCT05136196Map
COPoudre Valley HospitalFort Collins80524NCT05327686Map
COPoudre Valley HospitalFort Collins80524NCT05675410Map
COPoudre Valley HospitalFort Collins80524NCT05677490Map
COPoudre Valley HospitalFort Collins80524NCT05987241Map
COPoudre Valley HospitalFort Collins80524NCT06203600Map
COPoudre Valley HospitalFort Collins80524NCT07166406Map
COLutheran Hospital - Cancer Centers of ColoradoGolden80401NCT05677490Map
CONational Jewish Health-Western Hematology OncologyGolden80401NCT05677490Map
COSaint Mary's Hospital and Regional Medical CenterGrand Junction81501NCT05677490Map
COSaint Mary's Hospital and Regional Medical CenterGrand Junction81501NCT07166406Map
COUCHealth Greeley HospitalGreeley80631NCT05136196Map
COUCHealth Greeley HospitalGreeley80631NCT05327686Map
COUCHealth Greeley HospitalGreeley80631NCT05675410Map
COUCHealth Greeley HospitalGreeley80631NCT05677490Map
COUCHealth Greeley HospitalGreeley80631NCT05987241Map
COUCHealth Greeley HospitalGreeley80631NCT06203600Map
COUCHealth Greeley HospitalGreeley80631NCT07166406Map
COUCHealth Highlands Ranch HospitalHighlands Ranch80129NCT05327686Map
COUCHealth Highlands Ranch HospitalHighlands Ranch80129NCT05987241Map
COGood Samaritan Hospital - Cancer Centers of ColoradoLafayette80026NCT05677490Map
COKaiser Permanente-Rock CreekLafayette80026NCT05987241Map
COCommonSpirit Saint Anthony Hospital Cancer CenterLakewood80228NCT06632327Map
CORocky Mountain Cancer Centers-LakewoodLakewood80228NCT04511013Map
CORocky Mountain Cancer Centers, LLPLakewood80228NCT07392892Map
COExelixis Clinical Site #87Littleton80124NCT05176483Map
CORocky Mountain Cancer Centers-LittletonLittleton80120NCT04511013Map
CORocky Mountain Cancer Centers, LLPLittleton80120NCT07392892Map
COKaiser Permanente-Lone TreeLone Tree80124NCT05987241Map
CORocky Mountain Cancer Centers-Sky RidgeLone Tree80124NCT04511013Map
CORocky Mountain Cancer Centers, LLPLone Tree80124NCT07392892Map
COUCHealth Lone Tree Health CenterLone Tree80124NCT05327686Map
COUCHealth Lone Tree Health CenterLone Tree80124NCT05987241Map
COLongmont United HospitalLongmont80501NCT06632327Map
CORocky Mountain Cancer Centers, LLPLongmont80504NCT07392892Map
COMedical Center of the RockiesLoveland80538NCT05136196Map
COMedical Center of the RockiesLoveland80538NCT05327686Map
COMedical Center of the RockiesLoveland80538NCT05675410Map
COMedical Center of the RockiesLoveland80538NCT05677490Map
COMedical Center of the RockiesLoveland80538NCT05987241Map
COMedical Center of the RockiesLoveland80538NCT06203600Map
COMedical Center of the RockiesLoveland80538NCT07166406Map
CORocky Mountain Cancer Centers, LLPPueblo81003NCT07392892Map
COSaint Mary Corwin Medical CenterPueblo81004NCT06632327Map
CONational Jewish Health-Northern Hematology OncologyThornton80260NCT05677490Map
CORocky Mountain Cancer Centers-ThorntonThornton80260NCT04511013Map
CORocky Mountain Cancer Centers, LLPThornton80260NCT07392892Map
COSaint Anthony North HospitalWestminster80023NCT06632327Map
COIntermountain Health Lutheran HospitalWheat Ridge80401NCT05677490Map
CTHartford HealthCare - AvonAvon06001NCT05677490Map
CTHartford HealthCare - AvonAvon06001NCT05987241Map
CTHartford HealthCare - Saint Vincent's Medical CenterBridgeport06606NCT05987241Map
CTSaint Vincent's Medical Center (SVMC)Bridgeport06606NCT02693535Map
CTSmilow Cancer Hospital-Derby Care CenterDerby06418NCT05675410Map
CTSmilow Cancer Hospital-Derby Care CenterDerby06418NCT05987241Map
CTSmilow Cancer Hospital-Derby Care CenterDerby06418NCT06203600Map
CTSmilow Cancer Hospital-Derby Care CenterDerby06418NCT07166406Map
CTHartford Healthcare - FairfieldFairfield06824NCT05987241Map
CTSmilow Cancer Hospital Care Center-FairfieldFairfield06824NCT05675410Map
CTSmilow Cancer Hospital Care Center-FairfieldFairfield06824NCT05987241Map
CTSmilow Cancer Hospital Care Center-FairfieldFairfield06824NCT06203600Map
CTSmilow Cancer Hospital Care Center-FairfieldFairfield06824NCT07166406Map
CTSmilow Cancer Hospital Care Center at GlastonburyGlastonbury06033NCT05675410Map
CTSmilow Cancer Hospital Care Center at GlastonburyGlastonbury06033NCT05987241Map
CTSmilow Cancer Hospital Care Center at GlastonburyGlastonbury06033NCT06203600Map
CTSmilow Cancer Hospital Care Center at GlastonburyGlastonbury06033NCT07166406Map
CTSmilow Cancer Hospital Care Center at GreenwichGreenwich06830NCT05675410Map
CTSmilow Cancer Hospital Care Center at GreenwichGreenwich06830NCT05987241Map
CTSmilow Cancer Hospital Care Center at GreenwichGreenwich06830NCT06203600Map
CTSmilow Cancer Hospital Care Center at GreenwichGreenwich06830NCT07166406Map
CTSmilow Cancer Hospital Care Center - GuilfordGuilford06437NCT05675410Map
CTSmilow Cancer Hospital Care Center - GuilfordGuilford06437NCT05987241Map
CTSmilow Cancer Hospital Care Center - GuilfordGuilford06437NCT06203600Map
CTSmilow Cancer Hospital Care Center - GuilfordGuilford06437NCT07166406Map
CTSmilow Cancer Hospital-Hamden Care CenterHamden06518NCT07166406Map
CTConnecticut Children's Medical CenterHartford06106NCT04546399Map
CTConnecticut Children's Medical CenterHartford06106NCT05675410Map
CTConnecticut Children's Medical CenterHartford06106NCT06064097Map
CTHartford HospitalHartford06102NCT02693535Map
CTHartford HospitalHartford06102NCT05677490Map
CTHartford HospitalHartford06102NCT05987241Map
CTSmilow Cancer Hospital Care Center at Saint FrancisHartford06105NCT05675410Map
CTSmilow Cancer Hospital Care Center at Saint FrancisHartford06105NCT05987241Map
CTSmilow Cancer Hospital Care Center at Saint FrancisHartford06105NCT06203600Map
CTSmilow Cancer Hospital Care Center at Saint FrancisHartford06105NCT07166406Map
CTHartford HealthCare - ManchesterManchester06042NCT05677490Map
CTHartford HealthCare - ManchesterManchester06042NCT05987241Map
CTMidstate Medical CenterMeriden06451NCT05677490Map
CTMidstate Medical CenterMeriden06451NCT05987241Map
CTMidstate Medical Center (MSMC)Meriden06451NCT02693535Map
CTThe Hospital of Central ConnecticutNew Britain06050NCT05677490Map
CTThe Hospital of Central ConnecticutNew Britain06050NCT05987241Map
CTThe Hospital of Central Connecticut (HOCC) Cancer CenterNew Britain06053NCT02693535Map
CTExelixis Clinical Site #62New Haven06510NCT05176483Map
CTSmilow Cancer Center/Yale-New Haven HospitalNew Haven06510NCT03816345Map
CTSmilow Cancer Center/Yale-New Haven HospitalNew Haven06510NCT07166406Map
CTYale Cancer CenterNew Haven06510NCT06246916Map
CTYale Cancer CenterNew Haven06510NCT06743126Map
CTYale UniversityNew Haven06520NCT03816345Map
CTYale UniversityNew Haven06520NCT05272384Map
CTYale UniversityNew Haven06511NCT05317000Map
CTYale UniversityNew Haven06520NCT05675410Map
CTYale UniversityNew Haven06520NCT05987241Map
CTYale UniversityNew Haven06520NCT06203600Map
CTYale UniversityNew Haven06510NCT06963905Map
CTYale UniversityNew Haven06520NCT07166406Map
CTYale University School of MedicineNew Haven06520NCT05919264Map
CTYale-New Haven Hospital - Yale Cancer CenterNorth Haven06473 2195NCT07527858Map
CTYale-New Haven Hospital North Haven Medical CenterNorth Haven06473NCT05675410Map
CTYale-New Haven Hospital North Haven Medical CenterNorth Haven06473NCT05987241Map
CTYale-New Haven Hospital North Haven Medical CenterNorth Haven06473NCT06203600Map
CTYale-New Haven Hospital North Haven Medical CenterNorth Haven06473NCT07166406Map
CTWilliam W. Backus HospitalNorwich06360NCT02693535Map
CTSmilow Cancer Hospital Care Center at Long RidgeStamford06902NCT05675410Map
CTSmilow Cancer Hospital Care Center at Long RidgeStamford06902NCT05987241Map
CTSmilow Cancer Hospital Care Center at Long RidgeStamford06902NCT06203600Map
CTSmilow Cancer Hospital Care Center at Long RidgeStamford06902NCT07166406Map
CTCharlotte HungerfordTorrington06790NCT02693535Map
CTSmilow Cancer Hospital-Torrington Care CenterTorrington06790NCT05675410Map
CTSmilow Cancer Hospital-Torrington Care CenterTorrington06790NCT05987241Map
CTSmilow Cancer Hospital-Torrington Care CenterTorrington06790NCT06203600Map
CTSmilow Cancer Hospital-Torrington Care CenterTorrington06790NCT07166406Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT05675410Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT05987241Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT06203600Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT07166406Map
CTSmilow Cancer Hospital-Waterbury Care CenterWaterbury06708NCT05675410Map
CTSmilow Cancer Hospital-Waterbury Care CenterWaterbury06708NCT05987241Map
CTSmilow Cancer Hospital-Waterbury Care CenterWaterbury06708NCT06203600Map
CTSmilow Cancer Hospital-Waterbury Care CenterWaterbury06708NCT07166406Map
CTSmilow Cancer Hospital Care Center - WaterfordWaterford06385NCT05675410Map
CTSmilow Cancer Hospital Care Center - WaterfordWaterford06385NCT05987241Map
CTSmilow Cancer Hospital Care Center - WaterfordWaterford06385NCT06203600Map
CTSmilow Cancer Hospital Care Center - WaterfordWaterford06385NCT07166406Map
CTVA Connecticut Healthcare System West Haven Campus, West Haven, CTWest Haven06516-2770NCT06275360Map
CTWindham Hospital (WH)Willimantic06226NCT02693535Map
DEBeebe Medical CenterLewes19958NCT05327686Map
DEBeebe Medical CenterLewes19958NCT05677490Map
DEBeebe Medical CenterLewes19958NCT06632327Map
DEBeebe South Coastal Health CampusMillville19967NCT05327686Map
DEBeebe South Coastal Health CampusMillville19967NCT05677490Map
DEBeebe South Coastal Health CampusMillville19967NCT06203600Map
DEBeebe South Coastal Health CampusMillville19967NCT06632327Map
DEChristiana Care Health System- Site Number : 8400011Newark19713-2072NCT05584670Map
DEChristiana Care Health System-Christiana HospitalNewark19718NCT05327686Map
DEChristiana Care Health System-Christiana HospitalNewark19718NCT05677490Map
DEChristiana Care Health System-Christiana HospitalNewark19718NCT06632327Map
DEHelen F Graham Cancer CenterNewark19713NCT05136196Map
DEHelen F Graham Cancer CenterNewark19713NCT05327686Map
DEHelen F Graham Cancer CenterNewark19713NCT05677490Map
DEHelen F Graham Cancer CenterNewark19713NCT05987241Map
DEHelen F Graham Cancer CenterNewark19713NCT06203600Map
DEHelen F Graham Cancer CenterNewark19713NCT06632327Map
DEMedical Oncology Hematology Consultants PANewark19713NCT05136196Map
DEMedical Oncology Hematology Consultants PANewark19713NCT05327686Map
DEMedical Oncology Hematology Consultants PANewark19713NCT05677490Map
DEMedical Oncology Hematology Consultants PANewark19713NCT05987241Map
DEMedical Oncology Hematology Consultants PANewark19713NCT06203600Map
DEMedical Oncology Hematology Consultants PANewark19713NCT06632327Map
DEBeebe Health CampusRehoboth Beach19971NCT05327686Map
DEBeebe Health CampusRehoboth Beach19971NCT05677490Map
DEBeebe Health CampusRehoboth Beach19971NCT06203600Map
DEBeebe Health CampusRehoboth Beach19971NCT06632327Map
DEAlfred I duPont Hospital for ChildrenWilmington19803NCT04546399Map
DEAlfred I duPont Hospital for ChildrenWilmington19803NCT05675410Map
DEAlfred I duPont Hospital for ChildrenWilmington19803NCT06064097Map
DEChristiana Care Health System-Wilmington HospitalWilmington19801NCT05327686Map
DEChristiana Care Health System-Wilmington HospitalWilmington19801NCT05677490Map
DEChristiana Care Health System-Wilmington HospitalWilmington19801NCT06632327Map
DCChildren's National HospitalWashington D.C.20010NCT07017816Map
DCChildren's National Medical CenterWashington D.C.20010NCT04546399Map
DCChildren's National Medical CenterWashington D.C.20010NCT05675410Map
DCChildren's National Medical CenterWashington D.C.20010NCT06064097Map
DCGeorge Washington UniversityWashington D.C.20037NCT05533697Map
DCGeorge Washington UniversityWashington D.C.20052NCT05901285Map
DCGeorge Washington University Medical CenterWashington D.C.20037NCT05677490Map
DCGeorge Washington University Medical CenterWashington D.C.20037NCT05987241Map
DCGeorgetown Lombardi Comprehensive Cancer CenterWashington D.C.20007NCT06015724Map
DCGeorgetown UniversityWashington D.C.20007NCT06112314Map
DCGeorgetown University Medical CenterWashington D.C.20007NCT06581406Map
DCJohns Hopkins University, Sibley Memorial HospitalWashington D.C.20016NCT05919264Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT03816345Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT03866382Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT05675410Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT05677490Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT05987241Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT06203600Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT06632327Map
DCMedStar Washington Hospital CenterWashington D.C.20010NCT05677490Map
DCMedStar Washington Hospital CenterWashington D.C.20010NCT05987241Map
DCMedStar Washington Hospital CenterWashington D.C.20010NCT06264180Map
DCMedStar Washington Hospital CenterWashington D.C.20010NCT06632327Map
DCSibley Memorial HospitalWashington D.C.20016NCT05677490Map
DCSibley Memorial HospitalWashington D.C.20016NCT05896839Map
DCSibley Memorial HospitalWashington D.C.20016NCT05987241Map
DCSibley Memorial HospitalWashington D.C.20016NCT07293351Map
DCVA Central Office, Washington, DCWashington D.C.20420-0001NCT06275360Map
FLMount Sinai Comprehensive Cancer Center at AventuraAventura33180NCT05327686Map
FLMount Sinai Comprehensive Cancer Center at AventuraAventura33180NCT05677490Map
FLMount Sinai Comprehensive Cancer Center at AventuraAventura33180NCT05987241Map
FLUM Sylvester Comprehensive Cancer Center at AventuraAventura33180NCT05896839Map
FLUniversity of Miami/Sylvester Cancer Institute - AventuraAventura33180NCT02693535Map
FLSchulze Family Foundation Cancer Clinic - Bonita Health CenterBonita Springs34135NCT05677490Map
FLExelixis Clinical Site #48Celebration34747NCT05176483Map
FLClermont Oncology CenterClermont34711NCT06246916Map
FLClermont Oncology CenterClermont34711NCT06463665Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT04609046Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT05896839Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT05987241Map
FLUniversity of Miami/Sylvester Cancer Institute - LennarCoral Gables33146NCT02693535Map
FLOncology & Hematology Associates of West BrowardCoral Springs33065NCT06463665Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT04609046Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT05896839Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT05987241Map
FLUniversity of Miami/Sylvester Cancer Institute - Deerfield BeachDeerfield Beach33442NCT02693535Map
FLBroward Health Medical CenterFort Lauderdale33316NCT05675410Map
FLHelios Clinical ResearchFort Lauderdale33316NCT06463665Map
FLHoly Cross HospitalFort Lauderdale33308NCT03866382Map
FLHoly Cross HospitalFort Lauderdale33308NCT02693535Map
FLHoly Cross HospitalFort Lauderdale33308NCT05677490Map
FLFlorida Cancer Specialists - SouthFort Myers33901NCT06646276Map
FLFlorida Cancer Specialists - SouthFort Myers33901NCT07221149Map
FLGolisano Children's Hospital of Southwest FloridaFort Myers33908NCT04546399Map
FLGolisano Children's Hospital of Southwest FloridaFort Myers33908NCT05675410Map
FLRegional Cancer Center-Lee Memorial Health SystemFort Myers33905NCT05677490Map
FLExelixis Clinical Site #11Gainesville32610NCT05176483Map
FLMalcom Randall Veterans Administration Medical CenterGainesville32610NCT05987241Map
FLUF Health Cancer Institute - GainesvilleGainesville32610NCT04546399Map
FLUF Health Cancer Institute - GainesvilleGainesville32610NCT05675410Map
FLUF Health Cancer Institute - GainesvilleGainesville32610NCT05987241Map
FLUF Health Cancer Institute - GainesvilleGainesville32610NCT06064097Map
FLUniversity of Florida HealthGainesville32610NCT02693535Map
FLBioresearch PartnerHialeah33013NCT06463665Map
FLMemorial Cancer Institute at Memorial Regional HospitalHollywood33021NCT06264180Map
FLMemorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood33021NCT04546399Map
FLMemorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood33021NCT05327686Map
FLMemorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood33021NCT05675410Map
FLMemorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood33021NCT05677490Map
FLMemorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood33021NCT05987241Map
FLBaptist MD Anderson Cancer CenterJacksonville32207NCT06264180Map
FLCancer Specialist of North FloridaJacksonville32256NCT06246916Map
FLExelixis Clinical Site #78Jacksonville32224NCT05176483Map
FLMayo ClinicJacksonville32224NCT05655312Map
FLMayo ClinicJacksonville32224NCT05919264Map
FLMayo Clinic - Jacksonville FLJacksonville32224NCT06581406Map
FLMayo Clinic FloridaJacksonville32224NCT05223816Map
FLMayo Clinic FloridaJacksonville32224NCT06112314Map
FLMayo Clinic FloridaJacksonville32224NCT06246916Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT05136196Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT05327686Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT05675410Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT06265285Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT07226856Map
FLNemours Children's Clinic-JacksonvilleJacksonville32207NCT04546399Map
FLNemours Children's Clinic-JacksonvilleJacksonville32207NCT05675410Map
FLNemours Children's Clinic-JacksonvilleJacksonville32207NCT06064097Map
FLJupiter Medical CenterJupiter33458NCT05677490Map
FLOrlando Health Cancer Institute - Lake MaryLake Mary32746NCT06632327Map
FLThe Watson ClinicLakeland33805NCT05677490Map
FLBioresearch PartnerMiami33155NCT06463665Map
FLExelixis Clinical Site #47Miami33136NCT05176483Map
FLMiami Cancer InstituteMiami33176NCT05327686Map
FLMiami Cancer InstituteMiami33176NCT05987241Map
FLMiami Cancer Institute at Baptist HealthMiami33176NCT05317858Map
FLNicklaus Children's HospitalMiami33155NCT05675410Map
FLNicklaus Children's HospitalMiami33155NCT06064097Map
FLSylvester Comprehensive Cancer CenterMiami33136NCT06581406Map
FLSylvester Comprehensive Cancer Center - MiamiMiami33136-1002NCT05267626Map
FLUM Sylvester Comprehensive Cancer Center at KendallMiami33176NCT04609046Map
FLUM Sylvester Comprehensive Cancer Center at KendallMiami33176NCT05896839Map
FLUM Sylvester Comprehensive Cancer Center at KendallMiami33176NCT05987241Map
FLUniversity of MiamiMiami33136NCT05655312Map
FLUniversity of MiamiMiami33136NCT06889493Map
FLUniversity of Miami - Sylvester Comprehensive Cancer CenteMiami33136NCT06743126Map
FLUniversity of Miami - Sylvester Comprehensive Cancer CenterMiami33136NCT06463665Map
FLUniversity of Miami Health System-Sylvester Comprehensive Cancer Center-MiamiMiami33136NCT06112314Map
FLUniversity of Miami Hospital and ClinicsMiami33136NCT03686124Map
FLUniversity of Miami Hospital and Clinics, Sylvester Cancer CenterMiami33136NCT06561386Map
FLUniversity of Miami Hospital and Clinics, Sylvester Cancer CenterMiami33136NCT06618287Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT04609046Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT05675410Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT05896839Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT05987241Map
FLUniversity of Miami Sylvester Comprehensive Cancer CenterMiami33136NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - Alex's PlaceMiami33136NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - Griffin Cancer Research BuildingMiami33136NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - KendallMiami33176NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - Sole MiaMiami33181NCT02693535Map
FLMount Sinai Medical CenterMiami Beach33140NCT05327686Map
FLMount Sinai Medical CenterMiami Beach33140NCT05675410Map
FLMount Sinai Medical CenterMiami Beach33140NCT05677490Map
FLUniversity of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami33181NCT04609046Map
FLUniversity of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami33181NCT05896839Map
FLUniversity of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami33181NCT05987241Map
FLHealth CentralOcoee34761NCT06632327Map
FLMid Florida Hematology and Oncology CenterOrange City32763NCT06463665Map
FLMid Florida Hematology and Oncology CenterOrange City32763NCT06646276Map
FLMid Florida Hematology and Oncology CenterOrange City32763NCT07195695Map
FLAdventHealth OrlandoOrlando32803NCT04546399Map
FLAdventHealth OrlandoOrlando32803NCT05675410Map
FLAdventHealth OrlandoOrlando32803NCT05987241Map
FLAdventHealth OrlandoOrlando32803NCT06203600Map
FLArnold Palmer Hospital for ChildrenOrlando32806NCT04546399Map
FLArnold Palmer Hospital for ChildrenOrlando32806NCT05675410Map
FLArnold Palmer Hospital for ChildrenOrlando32806NCT06064097Map
FLNemours Children's HospitalOrlando32827NCT04546399Map
FLNemours Children's HospitalOrlando32827NCT05675410Map
FLNemours Children's HospitalOrlando32827NCT06064097Map
FLOrlando Health Cancer InstituteOrlando32806NCT03866382Map
FLOrlando Health Cancer InstituteOrlando32806NCT04511013Map
FLOrlando Health Cancer InstituteOrlando32806NCT06632327Map
FLOrlando Health UF Health Cancer CenterOrlando32806NCT05533697Map
FLMemorial Hospital WestPembroke Pines33028NCT05327686Map
FLMemorial Hospital WestPembroke Pines33028NCT06561386Map
FLMemorial Hospital WestPembroke Pines33028NCT05677490Map
FLMemorial Hospital WestPembroke Pines33028NCT05987241Map
FLNemours Children's Clinic - PensacolaPensacola32504NCT04546399Map
FLNemours Children's Clinic - PensacolaPensacola32504NCT05675410Map
FLNemours Children's Clinic - PensacolaPensacola32504NCT06064097Map
FLBRCR Medical Center, Inc.Plantation33322NCT06463665Map
FLExelixis Clinical Site #61Plantation33322NCT05176483Map
FLUM Sylvester Comprehensive Cancer Center at PlantationPlantation33324NCT04609046Map
FLUM Sylvester Comprehensive Cancer Center at PlantationPlantation33324NCT05896839Map
FLUM Sylvester Comprehensive Cancer Center at PlantationPlantation33324NCT05987241Map
FLUniversity of Miami/Sylvester Cancer Institute - PlantationPlantation33324NCT02693535Map
FLSarasota Memorial HospitalSarasota34239NCT05655312Map
FLFlorida Cancer Specialists - NorthSt. Petersburg33705NCT06561386Map
FLFlorida Cancer Specialists - NorthSt. Petersburg33705NCT06646276Map
FLFlorida Cancer Specialists - NorthSt. Petersburg33701NCT07221149Map
FLJohns Hopkins All Children's HospitalSt. Petersburg33701NCT04546399Map
FLJohns Hopkins All Children's HospitalSt. Petersburg33701NCT05675410Map
FLBoca Raton Clinical Research (BRCR) GlobalTamarac33321NCT06246916Map
FLExelixis Clinical Site #8Tampa33612NCT05176483Map
FLH. Lee Moffitt Cancer CenterTampa33612NCT06246916Map
FLMoffitt Cancer CenterTampa33612NCT04741997Map
FLMoffitt Cancer CenterTampa33612NCT05076760Map
FLMoffitt Cancer CenterTampa33612NCT04511013Map
FLMoffitt Cancer CenterTampa33612NCT04562129Map
FLMoffitt Cancer CenterTampa33612NCT05317858Map
FLMoffitt Cancer CenterTampa33612NCT05681780Map
FLMoffitt Cancer CenterTampa33612NCT06264180Map
FLMoffitt Cancer CenterTampa33612NCT06295159Map
FLMoffitt Cancer CenterTampa87535NCT06624644Map
FLMoffitt Cancer CenterTampa33612NCT06743126Map
FLMoffitt Cancer Center - McKinley CampusTampa33612NCT04511013Map
FLMoffitt Cancer Center-International PlazaTampa33607NCT04511013Map
FLSaint Joseph's Hospital/Children's Hospital-TampaTampa33607NCT04546399Map
FLSaint Joseph's Hospital/Children's Hospital-TampaTampa33607NCT05675410Map
FLSaint Joseph's Hospital/Children's Hospital-TampaTampa33607NCT06064097Map
FLTampa General HospitalTampa33606NCT04546399Map
FLTampa General HospitalTampa33606NCT05675410Map
FLFlorida Cancer Specialists - EastWest Palm Beach33401NCT06561386Map
FLSaint Mary's Medical CenterWest Palm Beach33407NCT04546399Map
FLSaint Mary's Medical CenterWest Palm Beach33407NCT05675410Map
GAUniversity Cancer & Blood CenterAthens30607NCT06246916Map
GACancer Treatment Centers of America - AtlantaAtlanta30265NCT02693535Map
GAChildren's Healthcare of Atlanta - Arthur M Blank HospitalAtlanta30329NCT04546399Map
GAChildren's Healthcare of Atlanta - Arthur M Blank HospitalAtlanta30329NCT05675410Map
GAEmory Proton Therapy CenterAtlanta30308NCT05675410Map
GAEmory Proton Therapy CenterAtlanta30308NCT07166406Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT05039073Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT05675410Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT05987241Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT06203600Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT06495125Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT07166406Map
GAEmory University Hospital MidtownAtlanta30308NCT03690986Map
GAEmory University Hospital MidtownAtlanta30308NCT03866382Map
GAEmory University Hospital MidtownAtlanta30308NCT05675410Map
GAEmory University Hospital MidtownAtlanta30308NCT05987241Map
GAEmory University Hospital MidtownAtlanta30308NCT06029270Map
GAEmory University Hospital MidtownAtlanta30308NCT06203600Map
GAEmory University Hospital MidtownAtlanta30308NCT06731270Map
GAEmory University Hospital MidtownAtlanta30308NCT07166406Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT03866382Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT05039073Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT05675410Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT05987241Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT06203600Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT06495125Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT06731270Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT07155317Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT07166406Map
GAEmory University Winship Cancer InstituteAtlanta30322NCT02693535Map
GAEmory Winship Cancer InstituteAtlanta30322NCT06581406Map
GAGrady Health SystemAtlanta30303NCT05675410Map
GAGrady Health SystemAtlanta30303NCT05987241Map
GAGrady Health SystemAtlanta30303NCT07166406Map
GANorthside HospitalAtlanta30342NCT05987241Map
GAPiedmont Cancer InstituteAtlanta30318NCT07195695Map
GAWinship Cancer Institute, Emory UniversityAtlanta30322NCT06264180Map
GAAugusta University Medical CenterAugusta30912NCT05675410Map
GAEmory Decatur HospitalDecatur30033NCT06203600Map
GANorthside Hospital - DuluthDuluth30096NCT05987241Map
GAEmory Johns Creek HospitalJohns Creek30097NCT05987241Map
GAEmory Johns Creek HospitalJohns Creek30097NCT06203600Map
GANorthside Hospital - GwinnettLawrenceville30046NCT05987241Map
GAAtrium Health NavicentMacon31201NCT05675410Map
GANorthwest Georgia Oncology CentersMarietta30060NCT07195695Map
GANorthwest Georgia Oncology Centers, a Service of Wellstar Cobb HospitalMarietta30060NCT06646276Map
GACTCA at Southeastern Regional Medical CenterNewnan30265NCT06632327Map
GAGynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research PavilionSavannah31405NCT02693535Map
GALewis Cancer & Research PavilionSavannah31405NCT02693535Map
GALewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma InstituteSavannah31405NCT02693535Map
GAMemorial Health University Medical CenterSavannah31404NCT04546399Map
GAMemorial Health University Medical CenterSavannah31404NCT05675410Map
GASummit Cancer CareSavannah31405NCT02693535Map
GATift Regional Medical CenterTifton31794NCT05677490Map
HIHawaii Cancer Care - Westridge‘Aiea96701NCT05677490Map
HIHawaii Cancer Care - Westridge‘Aiea96701NCT06203600Map
HIPali Momi Medical Center‘Aiea96701NCT05677490Map
HIPali Momi Medical Center‘Aiea96701NCT06203600Map
HIQueen's Cancer Center - Pearlridge‘Aiea96701NCT05677490Map
HIThe Queen's Medical Center - West Oahu‘Ewa Beach96706NCT02693535Map
HIThe Queen's Medical Center - West Oahu‘Ewa Beach96706NCT05677490Map
HIThe Queen's Medical Center - West Oahu‘Ewa Beach96706NCT06203600Map
HIHawaii Cancer Care Inc - Waterfront PlazaHonolulu96813NCT05677490Map
HIHawaii Cancer Care Inc - Waterfront PlazaHonolulu96813NCT06203600Map
HIKaiser Permanente Moanalua Medical CenterHonolulu96819NCT05677490Map
HIKaiser Permanente Moanalua Medical CenterHonolulu96819NCT05987241Map
HIKaiser Permanente Moanalua Medical CenterHonolulu96819NCT06029270Map
HIKaiser Permanente Moanalua Medical CenterHonolulu96819NCT06203600Map
HIKapiolani Medical Center for Women and ChildrenHonolulu96826NCT04546399Map
HIKapiolani Medical Center for Women and ChildrenHonolulu96826NCT05675410Map
HIKapiolani Medical Center for Women and ChildrenHonolulu96826NCT06203600Map
HIQueen's Cancer Cenrer - POB IHonolulu96813NCT05677490Map
HIQueen's Cancer Cenrer - POB IHonolulu96813NCT06203600Map
HIQueen's Cancer Center - KuakiniHonolulu96817NCT05677490Map
HIQueen's Cancer Center - KuakiniHonolulu96817NCT06203600Map
HIQueen's Medical CenterHonolulu96813NCT05677490Map
HIQueen's Medical CenterHonolulu96813NCT06203600Map
HIStraub Clinic and HospitalHonolulu96813NCT05677490Map
HIStraub Clinic and HospitalHonolulu96813NCT06203600Map
HIThe Queen's Medical CenterHonolulu96813NCT07075120Map
HIThe Queen's Medical Center - KuakiniHonolulu96817NCT02693535Map
HIThe Queen's Medical Center - POB IHonolulu96813NCT02693535Map
HIThe Queen's Medical Center - PunchbowlHonolulu96813NCT02693535Map
HIStraub Medical Center - Kahului ClinicKahului96732NCT05677490Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT05136196Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT03866382Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT04511013Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT05327686Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT05677490Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT05987241Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT06203600Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05112601Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05136196Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT04511013Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT04546399Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05647265Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05675410Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05677490Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT05136196Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT03866382Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT04511013Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT05327686Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT05677490Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT05987241Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT06203600Map
IDBeacon ClinicCoeur d'Alene83815NCT06246916Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT05112601Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT05136196Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT03866382Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT04511013Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT05677490Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT05987241Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT06029270Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT06203600Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT06632327Map
IDWalter Knox Memorial HospitalEmmett83617NCT04511013Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05112601Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05136196Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT04511013Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05647265Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05675410Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05677490Map
IDIdaho Urologic Institute-MeridianMeridian83642NCT04511013Map
IDIdaho Urologic Institute-MeridianMeridian83642NCT05677490Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05112601Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05136196Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT04511013Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05647265Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05675410Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05677490Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05136196Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT03866382Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT04511013Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05327686Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05675410Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05677490Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05987241Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT06203600Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05112601Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05136196Map
IDSaint Luke's Cancer Institute - NampaNampa83686NCT04511013Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05647265Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05675410Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05677490Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT05112601Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT05136196Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT03866382Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT04511013Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT05677490Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT05987241Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT06029270Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT06203600Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT06632327Map
IDKootenai Cancer ClinicSandpoint83864NCT04511013Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT05112601Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT05136196Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT03866382Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT05677490Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT05987241Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT06029270Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT06203600Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT06632327Map
IDSaint Luke's Cancer Institute - Twin FallsTwin Falls83301NCT05136196Map
IDSaint Luke's Cancer Institute - Twin FallsTwin Falls83301NCT04511013Map
IDSaint Luke's Cancer Institute - Twin FallsTwin Falls83301NCT05647265Map
IDSaint Luke's Cancer Institute - Twin FallsTwin Falls83301NCT05675410Map
IDSaint Luke's Cancer Institute - Twin FallsTwin Falls83301NCT05677490Map
ILOSF Saint Anthony's Health CenterAlton62002NCT05677490Map
ILOSF Saint Anthony's Health CenterAlton62002NCT06632327Map
ILSaint Anthony's HealthAlton62002NCT04511013Map
ILIllinois Cancer SpecialistsArlington Heights60005NCT07392892Map
ILAdvocate Outpatient Center - AuroraAurora60506NCT05677490Map
ILAdvocate Outpatient Center - AuroraAurora60506NCT06203600Map
ILRush - Copley Medical CenterAurora60504NCT04511013Map
ILRush-Copley Medical CenterAurora60504NCT05136196Map
ILRush-Copley Medical CenterAurora60504NCT05647265Map
ILRush-Copley Medical CenterAurora60504NCT05675410Map
ILRush-Copley Medical CenterAurora60504NCT05677490Map
ILRush-Copley Medical CenterAurora60504NCT06203600Map
ILRush-Copley Medical CenterAurora60504NCT06632327Map
ILAdvocate Good Shepherd HospitalBarrington60010NCT05675410Map
ILAdvocate Good Shepherd HospitalBarrington60010NCT05677490Map
ILAdvocate Good Shepherd HospitalBarrington60010NCT05987241Map
ILAdvocate Good Shepherd HospitalBarrington60010NCT06203600Map
ILIllinois CancerCare - BloomingtonBloomington61704NCT07392892Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT05136196Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT04511013Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT05677490Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT05987241Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT06632327Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT07383441Map
ILIllinois CancerCare-CantonCanton61520NCT05136196Map
ILIllinois CancerCare-CantonCanton61520NCT04511013Map
ILIllinois CancerCare-CantonCanton61520NCT05677490Map
ILIllinois CancerCare-CantonCanton61520NCT05987241Map
ILIllinois CancerCare-CantonCanton61520NCT06632327Map
ILIllinois CancerCare-CantonCanton61520NCT07383441Map
ILMemorial Hospital of CarbondaleCarbondale62902NCT04511013Map
ILMemorial Hospital of CarbondaleCarbondale62902NCT05677490Map
ILMemorial Hospital of CarbondaleCarbondale62902NCT06632327Map
ILSIH Cancer InstituteCarterville62918NCT04511013Map
ILSIH Cancer InstituteCarterville62918NCT05677490Map
ILSIH Cancer InstituteCarterville62918NCT06632327Map
ILIllinois CancerCare-CarthageCarthage62321NCT05136196Map
ILIllinois CancerCare-CarthageCarthage62321NCT04511013Map
ILIllinois CancerCare-CarthageCarthage62321NCT05677490Map
ILIllinois CancerCare-CarthageCarthage62321NCT05987241Map
ILIllinois CancerCare-CarthageCarthage62321NCT06632327Map
ILIllinois CancerCare-CarthageCarthage62321NCT07383441Map
ILCentralia Oncology ClinicCentralia62801NCT05136196Map
ILCentralia Oncology ClinicCentralia62801NCT04511013Map
ILCentralia Oncology ClinicCentralia62801NCT05327686Map
ILCentralia Oncology ClinicCentralia62801NCT05677490Map
ILCentralia Oncology ClinicCentralia62801NCT06632327Map
ILSaint Mary's HospitalCentralia62801NCT04511013Map
ILAdvocate Illinois Masonic Medical CenterChicago60657NCT05675410Map
ILAdvocate Illinois Masonic Medical CenterChicago60657NCT05677490Map
ILAdvocate Illinois Masonic Medical CenterChicago60657NCT05987241Map
ILAdvocate Illinois Masonic Medical CenterChicago60657NCT06203600Map
ILAnn & Robert H. Lurie Children's Hospital of ChicagoChicago60611NCT06712875Map
ILCancer Treatment Centers of America-ChicagoChicago60099NCT02693535Map
ILExelixis Clinical Site #26Chicago60612NCT05176483Map
ILIllinois Cancer SpecialistsChicago60631NCT07392892Map
ILJohn H Stroger Jr Hospital of Cook CountyChicago60612NCT05677490Map
ILJohn H Stroger Jr Hospital of Cook CountyChicago60612NCT06632327Map
ILLurie Children's Hospital-ChicagoChicago60611NCT04546399Map
ILLurie Children's Hospital-ChicagoChicago60611NCT05675410Map
ILLurie Children's Hospital-ChicagoChicago60611NCT06064097Map
ILMount Sinai Hospital Medical CenterChicago60608NCT05675410Map
ILMount Sinai Hospital Medical CenterChicago60608NCT05677490Map
ILNorthwestern Memorial HospitalChicago60611NCT06581406Map
ILNorthwestern Memorial HospitalChicago60611NCT06264180Map
ILNorthwestern UniversityChicago60611NCT05136196Map
ILNorthwestern UniversityChicago60611NCT05327686Map
ILNorthwestern UniversityChicago60611NCT05647265Map
ILNorthwestern UniversityChicago60611NCT05675410Map
ILNorthwestern UniversityChicago60611NCT05896839Map
ILNorthwestern UniversityChicago60611NCT05987241Map
ILNorthwestern UniversityChicago60611NCT06029270Map
ILNorthwestern UniversityChicago60611NCT06203600Map
ILNorthwestern UniversityChicago60611NCT06632327Map
ILNorthwestern University - Robert H. Lurie Comprehensive Cancer Center - NMDTIChicago60611NCT06112314Map
ILRush MD Anderson Cancer CenterChicago60612NCT03866382Map
ILSwedish Covenant HospitalChicago60625NCT05675410Map
ILSwedish Covenant HospitalChicago60625NCT05987241Map
ILSwedish Covenant HospitalChicago60625NCT06203600Map
ILThe University of Chicago MedicineChicago60637NCT05533697Map
ILUniversity of Chicago Cancer Research CenterChicago60637NCT04561206Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT03866382Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT04546399Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05272384Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05327686Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05647265Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05675410Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05677490Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05987241Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT06064097Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT07166406Map
ILUniversity of Chicago Medical CenterChicago60637NCT03686124Map
ILUniversity of Chicago Medical CenterChicago60637NCT04665206Map
ILUniversity of Chicago Medical CenterChicago60637NCT04572451Map
ILUniversity of Chicago Medical CenterChicago60637NCT06581406Map
ILUniversity of Chicago Medical CenterChicago60637NCT05502315Map
ILUniversity of Chicago Medical CenterChicago60637NCT06743126Map
ILUniversity Of Chicago Medicine Comprehensive Cancer CenterChicago60637NCT04295863Map
ILUniversity of IllinoisChicago60612NCT05136196Map
ILUniversity of IllinoisChicago60612NCT04546399Map
ILUniversity of IllinoisChicago60612NCT05675410Map
ILUniversity of IllinoisChicago60612NCT05677490Map
ILUniversity of IllinoisChicago60612NCT05987241Map
ILUniversity of IllinoisChicago60612NCT06029270Map
ILUniversity of IllinoisChicago60612NCT06203600Map
ILUniversity of IllinoisChicago60612NCT06632327Map
ILUniversity of Illinois Hospital and Health Sciences SystemChicago60612NCT07195695Map
ILAffiliated Oncologists, LLCChicago Ridge60415NCT06561386Map
ILAMG Crystal Lake - OncologyCrystal Lake60014NCT05675410Map
ILAMG Crystal Lake - OncologyCrystal Lake60014NCT05677490Map
ILAMG Crystal Lake - OncologyCrystal Lake60014NCT05987241Map
ILAMG Crystal Lake - OncologyCrystal Lake60014NCT06203600Map
ILCarle at The RiverfrontDanville61832NCT05112601Map
ILCarle at The RiverfrontDanville61832NCT04511013Map
ILCarle at The RiverfrontDanville61832NCT05327686Map
ILCarle at The RiverfrontDanville61832NCT05647265Map
ILCarle at The RiverfrontDanville61832NCT05675410Map
ILCarle at The RiverfrontDanville61832NCT05677490Map
ILCarle at The RiverfrontDanville61832NCT05987241Map
ILCarle at The RiverfrontDanville61832NCT06029270Map
ILCarle at The RiverfrontDanville61832NCT06203600Map
ILCarle at The RiverfrontDanville61832NCT06632327Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT05136196Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT03866382Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT04511013Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT05327686Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT05677490Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT05987241Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT06203600Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT06632327Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT07383441Map
ILDecatur Memorial HospitalDecatur62526NCT05136196Map
ILDecatur Memorial HospitalDecatur62526NCT04511013Map
ILDecatur Memorial HospitalDecatur62526NCT05327686Map
ILDecatur Memorial HospitalDecatur62526NCT05675410Map
ILDecatur Memorial HospitalDecatur62526NCT05677490Map
ILDecatur Memorial HospitalDecatur62526NCT05987241Map
ILDecatur Memorial HospitalDecatur62526NCT06203600Map
ILDecatur Memorial HospitalDecatur62526NCT06632327Map
ILDecatur Memorial HospitalDecatur62526NCT07383441Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT05136196Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT05327686Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT05647265Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT05675410Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT05987241Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT06029270Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT06203600Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT06632327Map
ILIllinois CancerCare-DixonDixon61021NCT05136196Map
ILIllinois CancerCare-DixonDixon61021NCT04511013Map
ILIllinois CancerCare-DixonDixon61021NCT05677490Map
ILIllinois CancerCare-DixonDixon61021NCT05987241Map
ILIllinois CancerCare-DixonDixon61021NCT06632327Map
ILAdvocate Good Samaritan HospitalDowners Grove60515NCT05675410Map
ILAdvocate Good Samaritan HospitalDowners Grove60515NCT05677490Map
ILAdvocate Good Samaritan HospitalDowners Grove60515NCT05987241Map
ILAdvocate Good Samaritan HospitalDowners Grove60515NCT06203600Map
ILCarle Physician Group-EffinghamEffingham62401NCT05112601Map
ILCarle Physician Group-EffinghamEffingham62401NCT04511013Map
ILCarle Physician Group-EffinghamEffingham62401NCT05327686Map
ILCarle Physician Group-EffinghamEffingham62401NCT05647265Map
ILCarle Physician Group-EffinghamEffingham62401NCT05675410Map
ILCarle Physician Group-EffinghamEffingham62401NCT05677490Map
ILCarle Physician Group-EffinghamEffingham62401NCT05987241Map
ILCarle Physician Group-EffinghamEffingham62401NCT06029270Map
ILCarle Physician Group-EffinghamEffingham62401NCT06203600Map
ILCarle Physician Group-EffinghamEffingham62401NCT06632327Map
ILCrossroads Cancer CenterEffingham62401NCT05136196Map
ILCrossroads Cancer CenterEffingham62401NCT03866382Map
ILCrossroads Cancer CenterEffingham62401NCT04511013Map
ILCrossroads Cancer CenterEffingham62401NCT05327686Map
ILCrossroads Cancer CenterEffingham62401NCT05675410Map
ILCrossroads Cancer CenterEffingham62401NCT05677490Map
ILCrossroads Cancer CenterEffingham62401NCT05987241Map
ILCrossroads Cancer CenterEffingham62401NCT06203600Map
ILCrossroads Cancer CenterEffingham62401NCT06632327Map
ILAdvocate Sherman HospitalElgin60123NCT05675410Map
ILAdvocate Sherman HospitalElgin60123NCT05677490Map
ILAdvocate Sherman HospitalElgin60123NCT05987241Map
ILAdvocate Sherman HospitalElgin60123NCT06203600Map
ILElmhurst Memorial HospitalElmhurst60126NCT05675410Map
ILIllinois CancerCare-EurekaEureka61530NCT05136196Map
ILIllinois CancerCare-EurekaEureka61530NCT04511013Map
ILIllinois CancerCare-EurekaEureka61530NCT05677490Map
ILIllinois CancerCare-EurekaEureka61530NCT05987241Map
ILIllinois CancerCare-EurekaEureka61530NCT06632327Map
ILIllinois CancerCare-EurekaEureka61530NCT07383441Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT05675410Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT05987241Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT06203600Map
ILIllinois CancerCare - GalesburgGalesburg61401NCT07392892Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT05136196Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT04511013Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT05677490Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT05987241Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT06632327Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT07383441Map
ILWestern Illinois Cancer Treatment CenterGalesburg61401NCT04511013Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT05136196Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT05327686Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT05647265Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT05675410Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT05987241Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT06029270Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT06203600Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT06632327Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT05675410Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT05987241Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT06203600Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT05327686Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT05647265Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT05987241Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT06029270Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT06203600Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT06632327Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT05327686Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT05647265Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT05987241Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT06029270Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT06203600Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT06632327Map
ILIngalls Memorial HospitalHarvey60426NCT05327686Map
ILIngalls Memorial HospitalHarvey60426NCT05677490Map
ILIngalls Memorial HospitalHarvey60426NCT05987241Map
ILAdvocate South Suburban HospitalHazel Crest60429NCT05675410Map
ILAdvocate South Suburban HospitalHazel Crest60429NCT05677490Map
ILAdvocate South Suburban HospitalHazel Crest60429NCT05987241Map
ILAdvocate South Suburban HospitalHazel Crest60429NCT06203600Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT05675410Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT05987241Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT06203600Map
ILEdward Hines Jr VA HospitalHines60141NCT06632327Map
ILHope and Healing Cancer ServicesHinsdale60521NCT06246916Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT05136196Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT04511013Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT05677490Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT05987241Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT06632327Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT07383441Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT05136196Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT05327686Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT05647265Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT05987241Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT06029270Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT06203600Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT06632327Map
ILAMG Libertyville - OncologyLibertyville60048NCT05675410Map
ILAMG Libertyville - OncologyLibertyville60048NCT05677490Map
ILAMG Libertyville - OncologyLibertyville60048NCT05987241Map
ILAMG Libertyville - OncologyLibertyville60048NCT06203600Map
ILCondell Memorial HospitalLibertyville60048NCT05675410Map
ILCondell Memorial HospitalLibertyville60048NCT05677490Map
ILCondell Memorial HospitalLibertyville60048NCT05987241Map
ILCondell Memorial HospitalLibertyville60048NCT06203600Map
ILIllinois CancerCare-MacombMacomb61455NCT05136196Map
ILIllinois CancerCare-MacombMacomb61455NCT04511013Map
ILIllinois CancerCare-MacombMacomb61455NCT05677490Map
ILIllinois CancerCare-MacombMacomb61455NCT05987241Map
ILIllinois CancerCare-MacombMacomb61455NCT06632327Map
ILIllinois CancerCare-MacombMacomb61455NCT07383441Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05112601Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05327686Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05647265Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05675410Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05677490Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05987241Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT06029270Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT06203600Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT06632327Map
ILLoyola University Medical CenterMaywood60153NCT05136196Map
ILLoyola University Medical CenterMaywood60153NCT03866382Map
ILLoyola University Medical CenterMaywood60153NCT04546399Map
ILLoyola University Medical CenterMaywood60153NCT05675410Map
ILTrinity Medical CenterMoline61265NCT05677490Map
ILGood Samaritan Regional Health CenterMount Vernon62864NCT04511013Map
ILSSM Health Good SamaritanMount Vernon62864NCT05677490Map
ILSSM Health Good SamaritanMount Vernon62864NCT06632327Map
ILEdward Hospital/Cancer CenterNaperville60540NCT05675410Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT05272384Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT05327686Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT05677490Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT05987241Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT07166406Map
ILIllinois Cancer SpecialistsNiles60714NCT07392892Map
ILCarle BroMenn Medical CenterNormal61761NCT05112601Map
ILCarle Cancer Institute NormalNormal61761NCT05112601Map
ILCarle Cancer Institute NormalNormal61761NCT05677490Map
ILCancer Care Center of O'FallonO'Fallon62269NCT05136196Map
ILCancer Care Center of O'FallonO'Fallon62269NCT04511013Map
ILCancer Care Center of O'FallonO'Fallon62269NCT05327686Map
ILCancer Care Center of O'FallonO'Fallon62269NCT05677490Map
ILCancer Care Center of O'FallonO'Fallon62269NCT05987241Map
ILCancer Care Center of O'FallonO'Fallon62269NCT06203600Map
ILCancer Care Center of O'FallonO'Fallon62269NCT06632327Map
ILHSHS Saint Elizabeth's HospitalO'Fallon62269NCT05327686Map
ILHSHS Saint Elizabeth's HospitalO'Fallon62269NCT05675410Map
ILHSHS Saint Elizabeth's HospitalO'Fallon62269NCT05677490Map
ILHSHS Saint Elizabeth's HospitalO'Fallon62269NCT06632327Map
ILNorthwestern Medicine Oak BrookOak Brook60523NCT05327686Map
ILNorthwestern Medicine Oak BrookOak Brook60523NCT05987241Map
ILNorthwestern Medicine Oak BrookOak Brook60523NCT06203600Map
ILNorthwestern Medicine Oak BrookOak Brook60523NCT06632327Map
ILAdvocate Children's Hospital-Oak LawnOak Lawn60453NCT05675410Map
ILAdvocate Christ Medical CenterOak Lawn60453-2699NCT05675410Map
ILAdvocate Christ Medical CenterOak Lawn60453-2699NCT05677490Map
ILAdvocate Christ Medical CenterOak Lawn60453-2699NCT05987241Map
ILAdvocate Christ Medical CenterOak Lawn60453-2699NCT06203600Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05136196Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05327686Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05647265Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05675410Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05987241Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT06029270Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT06203600Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT06632327Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT05272384Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT05327686Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT05677490Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT05987241Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT07166406Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT05136196Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT04511013Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT05677490Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT05987241Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT06632327Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT07383441Map
ILIllinois CancerCare-Ottawa-Fox River Cancer CenterOttawa61350NCT07392892Map
ILAdvocate Children's Hospital-Park RidgePark Ridge60068NCT05675410Map
ILAdvocate Lutheran General HospitalPark Ridge60068NCT05675410Map
ILAdvocate Lutheran General HospitalPark Ridge60068NCT05677490Map
ILAdvocate Lutheran General HospitalPark Ridge60068NCT05987241Map
ILAdvocate Lutheran General HospitalPark Ridge60068NCT06203600Map
ILAdvocate Lutheran General HospitalPark Ridge60068NCT06246916Map
ILIllinois CancerCare-PekinPekin61554NCT05136196Map
ILIllinois CancerCare-PekinPekin61554NCT04511013Map
ILIllinois CancerCare-PekinPekin61554NCT05677490Map
ILIllinois CancerCare-PekinPekin61554NCT05987241Map
ILIllinois CancerCare-PekinPekin61554NCT06632327Map
ILIllinois CancerCare-PekinPekin61554NCT07383441Map
ILIllinois CancerCare-PekinPekin61554NCT07392892Map
ILIllinois Cancer CarePeoria61615NCT06646276Map
ILIllinois CancerCarePeoria61615NCT06246916Map
ILIllinois CancerCare-PeoriaPeoria61615NCT05136196Map
ILIllinois CancerCare-PeoriaPeoria61615NCT04511013Map
ILIllinois CancerCare-PeoriaPeoria61615NCT05677490Map
ILIllinois CancerCare-PeoriaPeoria61615NCT05987241Map
ILIllinois CancerCare-PeoriaPeoria61615NCT06632327Map
ILIllinois CancerCare-PeoriaPeoria61615NCT07383441Map
ILIllinois CancerCare, P.C.Peoria61615NCT07392892Map
ILMethodist Medical Center of IllinoisPeoria61636NCT04511013Map
ILMethodist Medical Center of IllinoisPeoria61636NCT05677490Map
ILMethodist Medical Center of IllinoisPeoria61636NCT06632327Map
ILOSF Children's Hospital of IllinoisPeoria61637NCT04546399Map
ILOSF Children's Hospital of IllinoisPeoria61637NCT05675410Map
ILIllinois CancerCare-PeruPeru61354NCT05136196Map
ILIllinois CancerCare-PeruPeru61354NCT04511013Map
ILIllinois CancerCare-PeruPeru61354NCT05677490Map
ILIllinois CancerCare-PeruPeru61354NCT05987241Map
ILIllinois CancerCare-PeruPeru61354NCT06632327Map
ILIllinois CancerCare-PeruPeru61354NCT07383441Map
ILIllinois CancerCare-Peru - Valley Regional Cancer CenterPeru61354NCT07392892Map
ILValley Radiation OncologyPeru61354NCT04511013Map
ILValley Radiation OncologyPeru61354NCT05677490Map
ILValley Radiation OncologyPeru61354NCT06632327Map
ILEdward Hospital/Cancer Center?PlainfieldPlainfield60585NCT05675410Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT05136196Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT04511013Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT05677490Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT05987241Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT06632327Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT07383441Map
ILMercyhealth Cancer Institute - RockfordRockford61114NCT06203600Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT05327686Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT05675410Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT05677490Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT05987241Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT06203600Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT06632327Map
ILMemorial Hospital EastShiloh62269NCT05136196Map
ILMemorial Hospital EastShiloh62269NCT03866382Map
ILMemorial Hospital EastShiloh62269NCT05675410Map
ILMemorial Hospital EastShiloh62269NCT05896839Map
ILMemorial Hospital EastShiloh62269NCT05987241Map
ILMemorial Hospital EastShiloh62269NCT06203600Map
ILMemorial Hospital EastShiloh62269NCT06632327Map
ILMemorial Hospital EastShiloh62269NCT07166406Map
ILMemorial Medical CenterSpringfield62781NCT04511013Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05136196Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT03866382Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT04511013Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05327686Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05675410Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05677490Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05987241Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT06203600Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT06632327Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT07383441Map
ILSpringfield ClinicSpringfield62702NCT05136196Map
ILSpringfield ClinicSpringfield62702NCT03866382Map
ILSpringfield ClinicSpringfield62702NCT04511013Map
ILSpringfield ClinicSpringfield62702NCT05327686Map
ILSpringfield ClinicSpringfield62702NCT05677490Map
ILSpringfield ClinicSpringfield62702NCT05987241Map
ILSpringfield ClinicSpringfield62702NCT06203600Map
ILSpringfield ClinicSpringfield62702NCT06632327Map
ILSpringfield Memorial HospitalSpringfield62781NCT05136196Map
ILSpringfield Memorial HospitalSpringfield62781NCT03866382Map
ILSpringfield Memorial HospitalSpringfield62781NCT05327686Map
ILSpringfield Memorial HospitalSpringfield62781NCT05677490Map
ILSpringfield Memorial HospitalSpringfield62781NCT05987241Map
ILSpringfield Memorial HospitalSpringfield62781NCT06203600Map
ILSpringfield Memorial HospitalSpringfield62781NCT06632327Map
ILCarle Cancer CenterUrbana61801NCT05112601Map
ILCarle Cancer CenterUrbana61801NCT04511013Map
ILCarle Cancer CenterUrbana61801NCT05327686Map
ILCarle Cancer CenterUrbana61801NCT05647265Map
ILCarle Cancer CenterUrbana61801NCT05675410Map
ILCarle Cancer CenterUrbana61801NCT05677490Map
ILCarle Cancer CenterUrbana61801NCT05987241Map
ILCarle Cancer CenterUrbana61801NCT06029270Map
ILCarle Cancer CenterUrbana61801NCT06203600Map
ILCarle Cancer CenterUrbana61801NCT06632327Map
ILThe Carle Foundation HospitalUrbana61801NCT04511013Map
ILThe Carle Foundation HospitalUrbana61801NCT05327686Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT05136196Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT05327686Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT05647265Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT05675410Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT05987241Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT06029270Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT06203600Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT06632327Map
ILIllinois CancerCare - WashingtonWashington61571NCT05136196Map
ILIllinois CancerCare - WashingtonWashington61571NCT04511013Map
ILIllinois CancerCare - WashingtonWashington61571NCT05677490Map
ILIllinois CancerCare - WashingtonWashington61571NCT05987241Map
ILIllinois CancerCare - WashingtonWashington61571NCT06632327Map
ILIllinois CancerCare - WashingtonWashington61571NCT07383441Map
ILIllinois CancerCare-WashingtonWashington61571NCT07392892Map
ILRush-Copley Healthcare CenterYorkville60560NCT05136196Map
ILRush-Copley Healthcare CenterYorkville60560NCT04511013Map
ILRush-Copley Healthcare CenterYorkville60560NCT05647265Map
ILRush-Copley Healthcare CenterYorkville60560NCT05675410Map
ILRush-Copley Healthcare CenterYorkville60560NCT05677490Map
ILRush-Copley Healthcare CenterYorkville60560NCT06632327Map
ILMidwestern Regional Medical CenterZion60099NCT06632327Map
INIU Health North HospitalCarmel46032NCT05112601Map
INNorthwest Cancer Center - Crown PointCrown Point46307NCT05112601Map
INNorthwest Cancer Center - Crown PointCrown Point46307NCT05677490Map
INNorthwest Cancer Center - Crown PointCrown Point46307NCT06203600Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT05327686Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT05677490Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT05987241Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT07166406Map
INNorthwest Oncology LLCDyer46311NCT05112601Map
INNorthwest Oncology LLCDyer46311NCT05677490Map
INNorthwest Oncology LLCDyer46311NCT06203600Map
INFort Wayne Medical Oncology and HematologyFort Wayne46825NCT06246916Map
INGoshen Center for Cancer CareGoshen46526NCT06632327Map
INNorthwest Cancer Center - HobartHobart46342NCT05112601Map
INNorthwest Cancer Center - HobartHobart46342NCT05677490Map
INNorthwest Cancer Center - HobartHobart46342NCT06203600Map
INSaint Mary Medical CenterHobart46342NCT05112601Map
INSaint Mary Medical CenterHobart46342NCT05677490Map
INSaint Mary Medical CenterHobart46342NCT06203600Map
INAscension Saint Vincent Indianapolis HospitalIndianapolis46260NCT05675410Map
INCommunity Health Network (The University of Texas MD Anderson Cancer Center)Indianapolis46250NCT02693535Map
INExelixis Clinical Site #4Indianapolis46250NCT05176483Map
INFranciscan Health IndianapolisIndianapolis46237NCT05327686Map
INIndiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis46202NCT06863311Map
INIndiana University/Melvin and Bren Simon Cancer CenterIndianapolis46202NCT05112601Map
INIndiana University/Melvin and Bren Simon Cancer CenterIndianapolis46202NCT05987241Map
INRichard L. Roudebush VA Medical Center, Indianapolis, INIndianapolis46202-2884NCT06275360Map
INRiley Hospital for ChildrenIndianapolis46202NCT04546399Map
INRiley Hospital for ChildrenIndianapolis46202NCT05675410Map
INRiley Hospital for ChildrenIndianapolis46202NCT06064097Map
INSaint Catherine HospitalIndianapolis46312NCT05112601Map
INSaint Catherine HospitalIndianapolis46312NCT05677490Map
INSaint Catherine HospitalIndianapolis46312NCT06203600Map
INFranciscan Health MooresvilleMooresville46158NCT05327686Map
INThe Community HospitalMunster46321NCT05112601Map
INThe Community HospitalMunster46321NCT05677490Map
INThe Community HospitalMunster46321NCT06203600Map
INWomen's Diagnostic Center - MunsterMunster46321NCT05112601Map
INWomen's Diagnostic Center - MunsterMunster46321NCT05677490Map
INWomen's Diagnostic Center - MunsterMunster46321NCT06203600Map
INReid HealthRichmond47374NCT04511013Map
INNorthwest Cancer Center - ValparaisoValparaiso46383NCT05112601Map
INNorthwest Cancer Center - ValparaisoValparaiso46383NCT05677490Map
INNorthwest Cancer Center - ValparaisoValparaiso46383NCT06203600Map
IAMary Greeley Medical CenterAmes50010NCT05136196Map
IAMary Greeley Medical CenterAmes50010NCT03866382Map
IAMary Greeley Medical CenterAmes50010NCT04511013Map
IAMary Greeley Medical CenterAmes50010NCT05327686Map
IAMary Greeley Medical CenterAmes50010NCT05677490Map
IAMary Greeley Medical CenterAmes50010NCT05987241Map
IAMcFarland Clinic - AmesAmes50010NCT05136196Map
IAMcFarland Clinic - AmesAmes50010NCT03866382Map
IAMcFarland Clinic - AmesAmes50010NCT04511013Map
IAMcFarland Clinic - AmesAmes50010NCT05327686Map
IAMcFarland Clinic - AmesAmes50010NCT05677490Map
IAMcFarland Clinic - AmesAmes50010NCT05987241Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT04609046Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT05136196Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT03866382Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT05327686Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT05675410Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT05677490Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT05987241Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT06029270Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT06203600Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT07166406Map
IAUniversity of Iowa Healthcare Cancer Services Quad CitiesBettendorf52722NCT03866382Map
IAUniversity of Iowa Healthcare Cancer Services Quad CitiesBettendorf52722NCT05677490Map
IAMcFarland Clinic - BooneBoone50036NCT04511013Map
IASaint Anthony Regional HospitalCarroll51401NCT04609046Map
IASaint Anthony Regional HospitalCarroll51401NCT04511013Map
IASaint Anthony Regional HospitalCarroll51401NCT06029270Map
IASaint Anthony Regional HospitalCarroll51401NCT06203600Map
IAMercy HospitalCedar Rapids52403NCT05136196Map
IAMercy HospitalCedar Rapids52403NCT05677490Map
IAMercy HospitalCedar Rapids52403NCT06203600Map
IAMercy HospitalCedar Rapids52403NCT06632327Map
IAMercy HospitalCedar Rapids52403NCT07383441Map
IAOncology Associates at Mercy Medical CenterCedar Rapids52403NCT05136196Map
IAOncology Associates at Mercy Medical CenterCedar Rapids52403NCT05677490Map
IAOncology Associates at Mercy Medical CenterCedar Rapids52403NCT06203600Map
IAOncology Associates at Mercy Medical CenterCedar Rapids52403NCT06632327Map
IAOncology Associates at Mercy Medical CenterCedar Rapids52403NCT07383441Map
IAMercy Cancer Center-West LakesClive50325NCT05136196Map
IAMercy Cancer Center-West LakesClive50325NCT07166406Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT04609046Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT05136196Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT03866382Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT05327686Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT05675410Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT05677490Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT05987241Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT06029270Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT06203600Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT07166406Map
IAHeartland Oncology and Hematology LLPCouncil Bluffs51503NCT05677490Map
IAMethodist Jennie Edmundson HospitalCouncil Bluffs51503NCT05677490Map
IAMethodist Jennie Edmundson HospitalCouncil Bluffs51503NCT06029270Map
IANebraska Cancer Specialists/Oncology Hematology West PC - MEJCouncil Bluffs51503NCT06029270Map
IAGreater Regional Medical CenterCreston50801NCT07166406Map
IABlank Children's HospitalDes Moines50309NCT04546399Map
IABlank Children's HospitalDes Moines50309NCT05675410Map
IABroadlawns Medical CenterDes Moines50314NCT04609046Map
IABroadlawns Medical CenterDes Moines50314NCT04511013Map
IABroadlawns Medical CenterDes Moines50314NCT06029270Map
IABroadlawns Medical CenterDes Moines50314NCT06203600Map
IAIowa Lutheran HospitalDes Moines50316NCT04511013Map
IAIowa Methodist Medical CenterDes Moines50309NCT04609046Map
IAIowa Methodist Medical CenterDes Moines50309NCT03866382Map
IAIowa Methodist Medical CenterDes Moines50309NCT04511013Map
IAIowa Methodist Medical CenterDes Moines50309NCT05327686Map
IAIowa Methodist Medical CenterDes Moines50309NCT05675410Map
IAIowa Methodist Medical CenterDes Moines50309NCT05677490Map
IAIowa Methodist Medical CenterDes Moines50309NCT05987241Map
IAIowa Methodist Medical CenterDes Moines50309NCT06029270Map
IAIowa Methodist Medical CenterDes Moines50309NCT06203600Map
IAIowa Methodist Medical CenterDes Moines50309NCT07166406Map
IAMedical Oncology and Hematology Associates-Des MoinesDes Moines50309NCT04511013Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT04609046Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT05136196Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT03866382Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT05987241Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT06029270Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT07166406Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT04609046Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT05136196Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT03866382Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT05327686Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT05675410Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT05677490Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT05987241Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT06029270Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT06203600Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT07166406Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT04609046Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT05136196Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT03866382Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT05327686Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT05675410Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT05677490Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT05987241Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT06029270Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT06203600Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT07166406Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT05136196Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT03866382Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT04511013Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT05677490Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT05987241Map
IATrinity Regional Medical CenterFort Dodge50501NCT04511013Map
IAUI Healthcare Mission Cancer and Blood - Fort DodgeFort Dodge50501NCT06029270Map
IAUI Healthcare Mission Cancer and Blood - Fort DodgeFort Dodge50501NCT06203600Map
IAUniversity of IowaIowa City52242NCT06581406Map
IAUniversity of IowaIowa City52242NCT05655312Map
IAUniversity of IowaIowa City52242NCT06264180Map
IAUniversity of Iowa Health CareIowa City52242NCT07404332Map
IAUniversity of Iowa- Site Number : 8400014Iowa City52242-1009NCT05584670Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT05112601Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT03866382Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT04546399Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT05675410Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT05677490Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT05987241Map
IAMcFarland Clinic - JeffersonJefferson50129NCT04511013Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT05136196Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT03866382Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT04511013Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT05677490Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT05987241Map
IAUI Healthcare Mission Cancer and Blood - PellaPella50219NCT05677490Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT04609046Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT05136196Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT03866382Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT05327686Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT05675410Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT05677490Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT05987241Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT06029270Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT06203600Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT07166406Map
IAMercy Medical Center-West LakesWest Des Moines50266NCT07166406Map
IAMethodist West HospitalWest Des Moines50266-7700NCT04511013Map
IAThe Iowa Clinic PCWest Des Moines50266NCT07166406Map
KSUniversity of Kansas Cancer Center Clinical Research Center (Fairway) Site Number : 8400008Fairway66205-2528NCT05584670Map
KSUniversity of Kansas Clinical Research CenterFairway66205NCT03816345Map
KSCentral Care Cancer Center - Garden CityGarden City67846NCT04511013Map
KSCentral Care Cancer Center - Garden CityGarden City67846NCT05677490Map
KSCentral Care Cancer Center - Garden CityGarden City67846NCT06632327Map
KSCentral Care Cancer Center - Great BendGreat Bend67530NCT04511013Map
KSCentral Care Cancer Center - Great BendGreat Bend67530NCT05677490Map
KSCentral Care Cancer Center - Great BendGreat Bend67530NCT06632327Map
KSHaysMedHays67601NCT03816345Map
KSHaysMedHays67601NCT03866382Map
KSHaysMedHays67601NCT05677490Map
KSHaysMedHays67601NCT05987241Map
KSHaysMedHays67601NCT06203600Map
KSHaysMedHays67601NCT06632327Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT03816345Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT05987241Map
KSLawrence Memorial HospitalLawrence66044NCT03816345Map
KSLawrence Memorial HospitalLawrence66044NCT03866382Map
KSLawrence Memorial HospitalLawrence66044NCT05677490Map
KSLawrence Memorial HospitalLawrence66044NCT05987241Map
KSLawrence Memorial HospitalLawrence66044NCT06632327Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT03816345Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT03866382Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT05677490Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT05987241Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT06203600Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT06632327Map
KSUniversity of Kansas Cancer Center-Overland ParkOverland Park66210NCT03816345Map
KSUniversity of Kansas Cancer Center-Overland ParkOverland Park66210NCT05987241Map
KSUniversity of Kansas Hospital-Indian Creek CampusOverland Park66211NCT03816345Map
KSFreeman Physician Group of PittsburgPittsburg66762NCT03866382Map
KSFreeman Physician Group of PittsburgPittsburg66762NCT05677490Map
KSMercy Hospital PittsburgPittsburg66762NCT05677490Map
KSMercy Hospital PittsburgPittsburg66762NCT06632327Map
KSSalina Regional Health CenterSalina67401NCT03816345Map
KSSalina Regional Health CenterSalina67401NCT03866382Map
KSSalina Regional Health CenterSalina67401NCT05677490Map
KSSalina Regional Health CenterSalina67401NCT05987241Map
KSSalina Regional Health CenterSalina67401NCT06203600Map
KSSalina Regional Health CenterSalina67401NCT06632327Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT03816345Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT03866382Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT05677490Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT05987241Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT06203600Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT06632327Map
KSThe University of Kansas Cancer CenterWestwood66205NCT06246916Map
KSThe University of Kansas Cancer CenterWestwood66205NCT07174453Map
KSThe University of Kansas Cancer Center (KUCC) - WestwoodWestwood66205NCT06112314Map
KSUniversity of Kansas Cancer CenterWestwood66205NCT06264180Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT03816345Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT03866382Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT05987241Map
KSCancer Center of KansasWichita67214NCT06561386Map
KSWesley Medical CenterWichita67214NCT05675410Map
KYKing's Daughter's Medical CenterAshland41101NCT06632327Map
KYFlaget Memorial HospitalBardstown40004NCT06632327Map
KYCommonwealth Cancer Center-CorbinCorbin40701NCT06632327Map
KYSaint Elizabeth Medical Center EdgewoodEdgewood41017NCT06561386Map
KYSt. Elizabeth Healthcare - EdgewoodEdgewood41017NCT06112314Map
KYBaptist Health LexingtonLexington40503NCT06561386Map
KYMarkey Cancer Center Clinical Research OrganizationLexington40536NCT06246916Map
KYSaint Joseph HospitalLexington40504NCT06632327Map
KYSaint Joseph Hospital EastLexington40509NCT06203600Map
KYSaint Joseph Hospital EastLexington40509NCT06632327Map
KYSaint Joseph Radiation Oncology Resource CenterLexington40504NCT06632327Map
KYUniversity of KentuckyLexington40536NCT05655312Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT03816345Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT04546399Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT05675410Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT05896839Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT05987241Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT07166406Map
KYSaint Joseph LondonLondon40741NCT06632327Map
KYExelixis Clinical Site #122Louisville40202NCT05176483Map
KYNorton Children's HospitalLouisville40202NCT04546399Map
KYNorton Children's HospitalLouisville40202NCT05675410Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT05112601Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT05675410Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT05677490Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT05987241Map
KYUniversity of LouisvilleLouisville40202NCT03080974Map
KYUniversity of Louisville Brown Cancer CenterLouisville40202NCT06264180Map
KYUniversity of Louisville-James Graham Brown Cancer CenterLouisville40202NCT03899155Map
KYUofL Health Medical Center NortheastLouisville40245NCT05112601Map
KYUofL Health Medical Center NortheastLouisville40245NCT05675410Map
KYUofL Health Medical Center NortheastLouisville40245NCT05677490Map
KYUofL Health Medical Center NortheastLouisville40245NCT05987241Map
KYSaint Joseph Mount SterlingMount Sterling40353NCT06632327Map
KYOwensboro Health Mitchell Memorial Cancer CenterOwensboro42303NCT06632327Map
KYMercy Health - Paducah Medical Oncology and HematologyPaducah42003NCT04511013Map
LALouisiana Hematology Oncology Associates LLCBaton Rouge70809NCT05327686Map
LALouisiana Hematology Oncology Associates LLCBaton Rouge70809NCT05987241Map
LAMary Bird Perkins Cancer CenterBaton Rouge70809NCT05327686Map
LAMary Bird Perkins Cancer CenterBaton Rouge70809NCT06246916Map
LAOchsner Hematology Oncology North Shore - Covington (West Region)Covington70433NCT06203600Map
LAMary Bird Perkins Cancer Center - MetairieMetairie70002NCT05327686Map
LAMary Bird Perkins Cancer Center - MetairieMetairie70002NCT05987241Map
LAChildren's Hospital New OrleansNew Orleans70118NCT04546399Map
LAChildren's Hospital New OrleansNew Orleans70118NCT05675410Map
LAChildren's Hospital New OrleansNew Orleans70118NCT06064097Map
LAOchsner Medical Center JeffersonNew Orleans70121NCT05675410Map
LAOchsner Medical Center JeffersonNew Orleans70121NCT05987241Map
LAOchsner Medical Center JeffersonNew Orleans70121NCT06203600Map
LATulane University School of MedicineNew Orleans70112NCT06632327Map
LAUniversity Medical Center New OrleansNew Orleans70112NCT05677490Map
LAUniversity Medical Center New OrleansNew Orleans70112NCT06632327Map
MEHarold Alfond Center for Cancer CareAugusta04330NCT02693535Map
MEJackson Laboratory - Maine Cancer Genomics InitiativeAugusta04330NCT02693535Map
MEEastern Maine Medical CenterBangor04401NCT04546399Map
MEEastern Maine Medical CenterBangor04401NCT05675410Map
MEEastern Maine Medical CenterBangor04401NCT06632327Map
MEMaineHealth Coastal Cancer Treatment CenterBath04530NCT05675410Map
MEWaldo County General HospitalBelfast04915NCT02693535Map
MESMHC Cancer Care and Blood Disorders -BiddefordBiddeford04005NCT02693535Map
MELafayette Family Cancer Center-EMMCBrewer04412NCT05987241Map
MELafayette Family Cancer Center-EMMCBrewer04412NCT06632327Map
MENorthern Light Cancer CareBrewer04412NCT02693535Map
MERaish Peavey Haskell Children's Cancer and Treatment CenterBrewer04412NCT02693535Map
MEMaineHealth Cancer Care -BrunswickBrunswick04011NCT02693535Map
MENew England Cancer SpecialistKennebunk04043NCT02693535Map
MEYork Hopsital Oncology & Infusion Care in KitteryKittery03904NCT02693535Map
MEStephens Memorial HospitalNorway04268NCT02693535Map
MEMaineHealth Maine Medical Center - PortlandPortland04102NCT04609046Map
MEMaineHealth Maine Medical Center - PortlandPortland04102NCT05675410Map
MEPenobscot Bay Medical CenterRockport04856NCT02693535Map
MEMaineHealth Cancer Care Center of York CountySanford04073NCT05675410Map
MESMHC Cancer Care and Blood Disorders -SandfordSanford04073NCT02693535Map
MEMaine Children's Cancer ProgramScarborough04074NCT04546399Map
MEMaine Children's Cancer ProgramScarborough04074NCT02693535Map
MEMaine Children's Cancer ProgramScarborough04074NCT05675410Map
MEMaine Children's Cancer ProgramScarborough04074NCT06064097Map
MEMaine Medical Partner's Women's HealthScarborough04074NCT02693535Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT04609046Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT05112601Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT05675410Map
MENew England Cancer SpecialistScarborough04074NCT02693535Map
MEMaineHealth Cancer Care -South PortlandSouth Portland04106NCT02693535Map
MEMaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland04106NCT04609046Map
MEMaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland04106NCT05675410Map
MENew England Cancer SpecialistTopsham04086NCT02693535Map
MEYork Hospital Oncology & Infusion Care in WellsWells04090NCT02693535Map
MEYork Hospital Oncology & Infusion Care in YorkYork Village03909NCT02693535Map
MDMaryland Oncology Hematology, P.A.Annapolis21401NCT07392892Map
MDExelixis Clinical Site #14Baltimore21201NCT05176483Map
MDJohns Hopkins HospitalBaltimore21231NCT03521830Map
MDJohns Hopkins HospitalBaltimore21287NCT03465592Map
MDJohns Hopkins HospitalBaltimore21287NCT07293351Map
MDJohns Hopkins University, The Sidney Kimmel Comprehensive Cancer CenterBaltimore21287NCT05919264Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT03816345Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT04546399Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT05675410Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT05677490Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT05896839Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT05987241Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT06064097Map
MDMaryland Proton Treatment CenterBaltimore21201NCT06800339Map
MDMedStar Franklin Square Medical Center/Weinberg Cancer InstituteBaltimore21237NCT06632327Map
MDMedStar Good Samaritan HospitalBaltimore21239NCT06632327Map
MDSidney Kimmel Comprehensive Cancer CenterBaltimore21231NCT04248569Map
MDSidney Kimmel Comprehensive Cancer CenterBaltimore21231NCT06941857Map
MDSinai Hospital of BaltimoreBaltimore21215NCT04546399Map
MDSinai Hospital of BaltimoreBaltimore21215NCT05675410Map
MDUniversity of MarylandBaltimore21201NCT05317858Map
MDUniversity of Maryland Greenebaum Cancer CenterBaltimore21201NCT06800339Map
MDUniversity of Maryland/Greenebaum Cancer CenterBaltimore21201NCT05675410Map
MDUniversity of Maryland/Greenebaum Cancer CenterBaltimore21201NCT05987241Map
MDUniversity of MD Greenebaum Comprehensive Cancer CenterBaltimore21201NCT06743126Map
MDUpper Chesapeake- Kaufman Cancer CenterBel Air21014NCT06800339Map
MDMaryland Oncology Hematology, P.A.Bethesda20817NCT07392892Map
MDNational Cancer Institute Developmental Therapeutics ClinicBethesda20892NCT03816345Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT03258567Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT03866382Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT04902443Map
MDWalter Reed National Military Medical CenterBethesda20889-5600NCT05675410Map
MDMaryland Oncology Hematology, P.A.Brandywine20613NCT07392892Map
MDMaryland Oncology Hematology, P.A.Columbia21044NCT06246916Map
MDMaryland Oncology Hematology, P.A.Columbia21044NCT07392892Map
MDUPMC Western MarylandCumberland21502NCT05987241Map
MDUPMC Western MarylandCumberland21502NCT06203600Map
MDChristiana Care - Union HospitalElkton21921NCT05677490Map
MDChristiana Care - Union HospitalElkton21921NCT06632327Map
MDFMH James M Stockman Cancer InstituteFrederick21702NCT03866382Map
MDFMH James M Stockman Cancer InstituteFrederick21702NCT05987241Map
MDMaryland Oncology Hematology, P.A.Germantown20876NCT07392892Map
MDBaltimore Washington Medical Center- Tate Cancer CenterGlen Burnie21061NCT06800339Map
MDMaryland Oncology Hematology, P.A.Largo20774NCT07392892Map
MDMaryland Oncology Hematology, P.A.Rockville20850NCT07392892Map
MDMaryland Oncology Hematology, P.A.Silver Spring20904NCT07392892Map
MABeverly HospitalBeverly01915NCT05327686Map
MABeverly HospitalBeverly01915NCT05987241Map
MABeverly HospitalBeverly01915NCT06632327Map
MABeth Israel Deaconess Medical CenterBoston02215NCT05987241Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06053658Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06708949Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06743126Map
MABeth Israel Deaconess Medical CenterBoston02215NCT07527858Map
MABeth Israel Deaconess Medical Center ( Site 0107)Boston02215NCT07405164Map
MABoston Medical CenterBoston02118NCT05677490Map
MABrigham and Women's HospitalBoston02115NCT05327686Map
MADana FarberBoston02215NCT06624644Map
MADana Farber Cancer InstituteBoston02215NCT05428007Map
MADana Farber Cancer InstituteBoston02215NCT05533697Map
MADana Farber Cancer InstituteBoston02215NCT05901285Map
MADana Farber Cancer InstituteBoston02215NCT05919264Map
MADana Farber Cancer InstituteBoston02215NCT06112314Map
MADana_Farber Cancer Institute (DFCI)Boston02215NCT03899155Map
MADana-Farber Cancer InstituteBoston02215NCT04665206Map
MADana-Farber Cancer InstituteBoston02215NCT03816345Map
MADana-Farber Cancer InstituteBoston02215NCT04561206Map
MADana-Farber Cancer InstituteBoston02215NCT05327686Map
MADana-Farber Cancer InstituteBoston02215NCT05675410Map
MADana-Farber Cancer InstituteBoston02215NCT05677490Map
MADana-Farber Cancer InstituteBoston02215NCT05987241Map
MADana-Farber Cancer InstituteBoston02215NCT06053658Map
MADana-Farber Cancer InstituteBoston02215NCT06064097Map
MADana-Farber Cancer InstituteBoston02215NCT07195695Map
MADana-Farber Cancer Institute ( Site 0105)Boston02215NCT07405164Map
MAExelixis Clinical Site #7Boston02215NCT05176483Map
MAI-Mab Site 1002Boston02114NCT07432295Map
MAMass General HospitalBoston02114NCT04900818Map
MAMassachusetts General HospitalBoston02114NCT03686124Map
MAMassachusetts General HospitalBoston02114NCT04665206Map
MAMassachusetts General HospitalBoston02115NCT03803553Map
MAMassachusetts General HospitalBoston02114NCT06581406Map
MAMassachusetts General HospitalBoston02114NCT05428007Map
MAMassachusetts General HospitalBoston02114NCT05533697Map
MAMassachusetts General HospitalBoston02114NCT05919264Map
MAMassachusetts General HospitalBoston02114NCT06112314Map
MAMassachusetts General HospitalBoston02114NCT06743126Map
MAMassachusetts General Hospital Cancer CenterBoston02114NCT03816345Map
MAMassachusetts General Hospital Cancer CenterBoston02114NCT05327686Map
MAMassachusetts General Hospital Cancer CenterBoston02114NCT05779423Map
MATufts Medical CenterBoston02111NCT06632327Map
MADana-Farber Cancer Institute at Boston Medical Center - BrightonBrighton02135NCT05677490Map
MADana-Farber Cancer Institute at Boston Medical Center - BrightonBrighton02135NCT05987241Map
MALahey Hospital and Medical CenterBurlington01805NCT03866382Map
MALahey Hospital and Medical CenterBurlington01805NCT05327686Map
MALahey Hospital and Medical CenterBurlington01805NCT05987241Map
MALahey Hospital and Medical CenterBurlington01805NCT06632327Map
MALahey Hospital and Medical CenterBurlington01805NCT07383441Map
MADana-Farber Cancer Institute at FoxboroughFoxborough02035NCT05677490Map
MADana-Farber Cancer Institute at FoxboroughFoxborough02035NCT05987241Map
MAAddison Gilbert HospitalGloucester01930NCT05327686Map
MAAddison Gilbert HospitalGloucester01930NCT05987241Map
MAAddison Gilbert HospitalGloucester01930NCT06632327Map
MADana Farber-Merrimack ValleyMethuen01844NCT05677490Map
MADana-Farber/Brigham and Women's Cancer Center at Milford RegionalMilford01757NCT05677490Map
MADana-Farber/Brigham and Women's Cancer Center at Milford RegionalMilford01757NCT05987241Map
MALahey Clinic PeabodyPeabody01960NCT03866382Map
MALahey Clinic PeabodyPeabody01960NCT05987241Map
MALahey Medical Center-PeabodyPeabody01960NCT05327686Map
MALahey Medical Center-PeabodyPeabody01960NCT06632327Map
MALahey Medical Center-PeabodyPeabody01960NCT07383441Map
MADana-Farber/Brigham and Women's Cancer Center at South ShoreSouth Weymouth02190NCT05677490Map
MADana-Farber/Brigham and Women's Cancer Center at South ShoreSouth Weymouth02190NCT05987241Map
MABaystate Medical CenterSpringfield01199NCT05136196Map
MATufts Medical Center Cancer Center StonehamStoneham02180NCT06632327Map
MAUMass Memorial Medical Center - University CampusWorcester01655NCT05675410Map
MIMyMichigan Medical Center GratiotAlma48801NCT05677490Map
MIMyMichigan Medical Center AlpenaAlpena49707NCT05677490Map
MIC S Mott Children's HospitalAnn Arbor48109NCT04546399Map
MIC S Mott Children's HospitalAnn Arbor48109NCT05675410Map
MITrinity Health Ann Arbor HospitalAnn Arbor48106NCT02693535Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT05136196Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT03866382Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT05327686Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT05675410Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT05677490Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT05987241Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT06203600Map
MIUniversity of MichiganAnn Arbor48109NCT06053658Map
MIUniversity of MichiganAnn Arbor48109NCT06246916Map
MIUniversity of MichiganAnn Arbor48109NCT06743126Map
MIUniversity of Michigan Comprehensive Cancer CenterAnn Arbor48109NCT04511013Map
MIUniversity of Michigan Comprehensive Cancer CenterAnn Arbor48109NCT06866262Map
MIUniversity of Michigan Rogel Cancer CenterAnn Arbor48109NCT05136196Map
MIUniversity of Michigan Rogel Cancer CenterAnn Arbor48109NCT05327686Map
MIUniversity of Michigan Rogel Cancer CenterAnn Arbor48109NCT05987241Map
MIVA Ann Arbor Healthcare System, Ann Arbor, MIAnn Arbor48105-2303NCT06275360Map
MIBronson Battle CreekBattle Creek49017NCT05112601Map
MIBronson Battle CreekBattle Creek49017NCT05136196Map
MIBronson Battle CreekBattle Creek49017NCT04511013Map
MIBronson Battle CreekBattle Creek49017NCT05675410Map
MIBronson Battle CreekBattle Creek49017NCT05987241Map
MIMcLaren Cancer Institute-Bay CityBay City48706NCT05677490Map
MIMcLaren Cancer Institute-Bay CityBay City48706NCT05987241Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05136196Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT03866382Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05327686Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05675410Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05677490Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05987241Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT06203600Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT07383441Map
MITrinity Health Medical Center - BrightonBrighton48114NCT05136196Map
MITrinity Health Medical Center - BrightonBrighton48114NCT03866382Map
MITrinity Health Medical Center - BrightonBrighton48114NCT05327686Map
MITrinity Health Medical Center - BrightonBrighton48114NCT05677490Map
MITrinity Health Medical Center - BrightonBrighton48114NCT06203600Map
MIUniversity of Michigan - Brighton Center for Specialty CareBrighton48116NCT04511013Map
MIUniversity of Michigan - Brighton Center for Specialty CareBrighton48116NCT05987241Map
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT03866382
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT05675410
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT05987241
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT06203600
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT07166406
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05136196Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT03866382Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05327686Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05675410Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05677490Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05987241Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT06203600Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT07383441Map
MITrinity Health Medical Center - CantonCanton48188NCT05136196Map
MITrinity Health Medical Center - CantonCanton48188NCT03866382Map
MITrinity Health Medical Center - CantonCanton48188NCT05327686Map
MITrinity Health Medical Center - CantonCanton48188NCT05677490Map
MITrinity Health Medical Center - CantonCanton48188NCT06203600Map
MIChelsea HospitalChelsea48118NCT05136196Map
MIChelsea HospitalChelsea48118NCT03866382Map
MIChelsea HospitalChelsea48118NCT05327686Map
MIChelsea HospitalChelsea48118NCT05677490Map
MIChelsea HospitalChelsea48118NCT06203600Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05136196Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT03866382Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05327686Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05675410Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05677490Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05987241Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT06203600Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT07383441Map
MIHematology Oncology Consultants-ClarkstonClarkston48346NCT03866382Map
MIHematology Oncology Consultants-ClarkstonClarkston48346NCT05677490Map
MIMcLaren Cancer Institute-ClarkstonClarkston48346NCT05677490Map
MINewland Medical Associates-ClarkstonClarkston48346NCT05677490Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT03866382Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT05675410Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT05987241Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT06203600Map
MICorewell Health Dearborn HospitalDearborn48124NCT05327686Map
MICorewell Health Dearborn HospitalDearborn48124NCT05675410Map
MICorewell Health Dearborn HospitalDearborn48124NCT05677490Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT03866382Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT05675410Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT05987241Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT06203600Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT07166406Map
MIMichigan Hematology and Oncology ConsultantsDearborn48126NCT06463665Map
MIBarbara Ann Karmanos Cancer Institute - Detroit- Site Number : 8400006Detroit48201NCT05584670Map
MIChildren's Hospital of MichiganDetroit48201NCT04546399Map
MIChildren's Hospital of MichiganDetroit48201NCT05675410Map
MIExelixis Clinical Site #13Detroit48202NCT05176483Map
MIExelixis Clinical Site #65Detroit48201NCT05176483Map
MIHenry Ford Cancer Center - MichiganDetroit04820NCT06112314Map
MIHenry Ford Cancer Institute/Henry Ford Health SystemDetroit48202NCT06246916Map
MIHenry Ford Health Saint John HospitalDetroit48236NCT03866382Map
MIHenry Ford Health Saint John HospitalDetroit48236NCT02693535Map
MIHenry Ford Health Saint John HospitalDetroit48236NCT05677490Map
MIHenry Ford HospitalDetroit48202NCT03866382Map
MIHenry Ford HospitalDetroit48202NCT05533697Map
MIHenry Ford HospitalDetroit48202NCT05675410Map
MIHenry Ford HospitalDetroit48202NCT05987241Map
MIHenry Ford HospitalDetroit48202NCT06203600Map
MIHenry Ford HospitalDetroit48202NCT07166406Map
MIKarmanos Cancer Center ( Site 0108)Detroit48201NCT07405164Map
MIWayne State University/Karmanos Cancer InstituteDetroit48201NCT05675410Map
MIWayne State University/Karmanos Cancer InstituteDetroit48201NCT05677490Map
MIWayne State University/Karmanos Cancer InstituteDetroit48201NCT05987241Map
MIHenry Ford River District HospitalEast China Township48054NCT03866382
MIHenry Ford River District HospitalEast China Township48054NCT05677490
MIOSF Saint Francis Hospital and Medical GroupEscanaba49829NCT05136196Map
MIOSF Saint Francis Hospital and Medical GroupEscanaba49829NCT05677490Map
MIOSF Saint Francis Hospital and Medical GroupEscanaba49829NCT05987241Map
MIOSF Saint Francis Hospital and Medical GroupEscanaba49829NCT06203600Map
MIOSF Saint Francis Hospital and Medical GroupEscanaba49829NCT06632327Map
MICorewell Health Farmington Hills HospitalFarmington Hills48336NCT05327686Map
MICorewell Health Farmington Hills HospitalFarmington Hills48336NCT05675410Map
MICorewell Health Farmington Hills HospitalFarmington Hills48336NCT05677490Map
MIOakland Medical GroupFarmington Hills48336NCT06463665Map
MIWeisberg Cancer Treatment CenterFarmington Hills48334NCT05675410Map
MIWeisberg Cancer Treatment CenterFarmington Hills48334NCT05677490Map
MIWeisberg Cancer Treatment CenterFarmington Hills48334NCT05987241Map
MICancer Hematology Centers - FlintFlint48503NCT05136196Map
MICancer Hematology Centers - FlintFlint48503NCT03866382Map
MICancer Hematology Centers - FlintFlint48503NCT05677490Map
MICancer Hematology Centers - FlintFlint48503NCT05987241Map
MICancer Hematology Centers - FlintFlint48503NCT06203600Map
MIGenesee Hematology Oncology PCFlint48503NCT05677490Map
MIGenesys Hurley Cancer InstituteFlint48503NCT05136196Map
MIGenesys Hurley Cancer InstituteFlint48503NCT03866382Map
MIGenesys Hurley Cancer InstituteFlint48503NCT02693535Map
MIGenesys Hurley Cancer InstituteFlint48503NCT05677490Map
MIGenesys Hurley Cancer InstituteFlint48503NCT05987241Map
MIGenesys Hurley Cancer InstituteFlint48503NCT06203600Map
MIHurley Medical CenterFlint48503NCT05136196Map
MIHurley Medical CenterFlint48503NCT03866382Map
MIHurley Medical CenterFlint48503NCT05677490Map
MIHurley Medical CenterFlint48503NCT05987241Map
MIHurley Medical CenterFlint48503NCT06203600Map
MIMcLaren Cancer Institute-FlintFlint48532NCT05677490Map
MIMyMichigan Medical Center GladwinGladwin48624NCT05677490Map
MICancer Research Consortium of West MichiganGrand Rapids49503NCT02693535Map
MICorewell HealthGrand Rapids49503NCT06264180Map
MICorewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids49503NCT05112601Map
MICorewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids49503NCT05136196Map
MICorewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids49503NCT05675410Map
MICorewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids49503NCT05987241Map
MICorewell Health Grand Rapids Hospitals - Helen DeVos Children's HospitalGrand Rapids49503NCT04546399Map
MICorewell Health Grand Rapids Hospitals - Helen DeVos Children's HospitalGrand Rapids49503NCT05675410Map
MICorewell Health Grand Rapids Hospitals - Helen DeVos Children's HospitalGrand Rapids49503NCT06064097Map
MIHelen DeVos Children's Hospital at Spectrum HealthGrand Rapids49503NCT04511013Map
MIResearch SiteGrand Rapids49503NCT07431281Map
MISite 04Grand Rapids49546NCT07276373Map
MISpectrum Health at Butterworth CampusGrand Rapids49503NCT04511013Map
MISTART MidwestGrand Rapids49503-2563NCT05267626Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT05112601Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT05136196Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT04511013Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT05675410Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT05987241Map
MIHenry Ford Saint John Hospital - AcademicGrosse Pointe Woods48236NCT03866382Map
MIHenry Ford Saint John Hospital - AcademicGrosse Pointe Woods48236NCT05677490Map
MIHenry Ford Saint John Hospital - BreastGrosse Pointe Woods48236NCT05677490Map
MIHenry Ford Saint John Hospital - Van ElslanderGrosse Pointe Woods48236NCT03866382Map
MIHenry Ford Saint John Hospital - Van ElslanderGrosse Pointe Woods48236NCT05677490Map
MIAllegiance HealthJackson49201NCT03866382Map
MIAllegiance HealthJackson49201NCT05675410Map
MIAllegiance HealthJackson49201NCT05987241Map
MIAllegiance HealthJackson49201NCT06203600Map
MIAllegiance HealthJackson49201NCT07166406Map
MIAscension Borgess Cancer CenterKalamazoo49009NCT04511013Map
MIBeacon Kalamazoo Cancer CenterKalamazoo49009NCT05112601Map
MIBeacon Kalamazoo Cancer CenterKalamazoo49009NCT05136196Map
MIBeacon Kalamazoo Cancer CenterKalamazoo49009NCT05675410Map
MIBorgess Medical CenterKalamazoo49048NCT04511013Map
MIBronson Methodist HospitalKalamazoo49007NCT05112601Map
MIBronson Methodist HospitalKalamazoo49007NCT05136196Map
MIBronson Methodist HospitalKalamazoo49007NCT04511013Map
MIBronson Methodist HospitalKalamazoo49007NCT04546399Map
MIBronson Methodist HospitalKalamazoo49007NCT05675410Map
MIBronson Methodist HospitalKalamazoo49007NCT05987241Map
MIWest Michigan Cancer CenterKalamazoo49007NCT05112601Map
MIWest Michigan Cancer CenterKalamazoo49007NCT05136196Map
MIWest Michigan Cancer CenterKalamazoo49007NCT04511013Map
MIWest Michigan Cancer CenterKalamazoo49007NCT05675410Map
MIWest Michigan Cancer CenterKalamazoo49007NCT05987241Map
MIKarmanos Cancer Institute at McLaren Greater LansingLansing48910NCT05677490Map
MIKarmanos Cancer Institute at McLaren Greater LansingLansing48910NCT05987241Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT05136196Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT03866382Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT02693535Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT05327686Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT05677490Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT05987241Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT06203600Map
MIMcLaren Cancer Institute-Lapeer RegionLapeer48446NCT05677490Map
MITrinity Health Livonia HospitalLivonia48154NCT02693535Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05136196Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT03866382Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05327686Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05675410Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05677490Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05987241Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT06203600Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT07383441Map
MIHenry Ford Saint John Hospital - Macomb MedicalMacomb48044NCT03866382Map
MIHenry Ford Saint John Hospital - Macomb MedicalMacomb48044NCT05677490Map
MIHenry Ford Warren Hospital - Breast MacombMacomb48044NCT05677490Map
MIMyMichigan Medical Center MidlandMidland48670NCT05677490Map
MIMcLaren Cancer Institute-MacombMount Clemens48043NCT05677490Map
MIMyMichigan Medical Center Mount PleasantMount Pleasant48858NCT05677490Map
MITrinity Health Muskegon HospitalMuskegon49444NCT05112601Map
MITrinity Health Muskegon HospitalMuskegon49444NCT05136196Map
MITrinity Health Muskegon HospitalMuskegon49444NCT04511013Map
MITrinity Health Muskegon HospitalMuskegon49444NCT05675410Map
MITrinity Health Muskegon HospitalMuskegon49444NCT05987241Map
MICorewell Health Lakeland Hospitals - Niles HospitalNiles49120NCT05112601Map
MICorewell Health Lakeland Hospitals - Niles HospitalNiles49120NCT05136196Map
MICorewell Health Lakeland Hospitals - Niles HospitalNiles49120NCT05987241Map
MILakeland Hospital NilesNiles49120NCT04511013Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT05112601Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT05136196Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT04511013Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT05675410Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT05987241Map
MIHenry Ford Health Providence Novi HospitalNovi48374NCT05675410Map
MIHenry Ford Health Providence Novi HospitalNovi48374NCT06203600Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT03866382Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT05675410Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT05987241Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT06203600Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT07166406Map
MIMcLaren Cancer Institute-Northern MichiganPetoskey49770NCT05677490Map
MIMcLaren Cancer Institute-Northern MichiganPetoskey49770NCT05987241Map
MIHope Cancer CenterPontiac48341NCT05677490Map
MIMichigan Healthcare Professionals PontiacPontiac48341NCT03866382Map
MIMichigan Healthcare Professionals PontiacPontiac48341NCT05677490Map
MINewland Medical Associates-PontiacPontiac48341NCT03866382Map
MINewland Medical Associates-PontiacPontiac48341NCT05677490Map
MITrinity Health Oakland HospitalPontiac48341NCT02693535Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT05136196Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT03866382Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT05675410Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT05677490Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT05987241Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT06203600Map
MIMcLaren-Port HuronPort Huron48060NCT05677490Map
MICorewell Health Reed City HospitalReed City49677NCT05112601Map
MICorewell Health Reed City HospitalReed City49677NCT05136196Map
MICorewell Health Reed City HospitalReed City49677NCT05675410Map
MICorewell Health Reed City HospitalReed City49677NCT05987241Map
MISpectrum Health Reed City HospitalReed City49677NCT04511013Map
MICancer Care Associates PCRoyal Oak48073NCT05677490Map
MIComprehensive Medical Center PLLCRoyal Oak48073NCT05677490Map
MICorewell Health Children'sRoyal Oak48073NCT04546399Map
MICorewell Health Children'sRoyal Oak48073NCT05675410Map
MICorewell Health William Beaumont University HospitalRoyal Oak48073NCT05327686Map
MICorewell Health William Beaumont University HospitalRoyal Oak48073NCT05675410Map
MICorewell Health William Beaumont University HospitalRoyal Oak48073NCT05677490Map
MIHematology Oncology Consultants PC-Royal OakRoyal Oak48073NCT05677490Map
MIOakland Colon Rectal AssociatesRoyal Oak48067NCT05677490Map
MIOakland Medical GroupRoyal Oak48073NCT05677490Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT03866382Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT02693535Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT05677490Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT05987241Map
MICorewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph49085NCT05112601Map
MICorewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph49085NCT05136196Map
MICorewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph49085NCT05675410Map
MICorewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph49085NCT05987241Map
MICorewell Health Lakeland Hospitals - Saint Joseph HospitalSaint Joseph49085NCT05112601Map
MICorewell Health Lakeland Hospitals - Saint Joseph HospitalSaint Joseph49085NCT05987241Map
MILakeland Medical Center Saint JosephSaint Joseph49085NCT04511013Map
MIMarie Yeager Cancer CenterSaint Joseph49085NCT04511013Map
MIHenry Ford Health Providence Southfield HospitalSouthfield48075NCT05675410Map
MIHenry Ford Health Providence Southfield HospitalSouthfield48075NCT06203600Map
MIPremier Hematology Oncology CareSterling Heights48312NCT05677490Map
MIMyMichigan Medical Center TawasTawas City48764NCT03866382Map
MIMyMichigan Medical Center TawasTawas City48764NCT05677490Map
MIMyMichigan Medical Center TawasTawas City48764NCT05987241Map
MIMichigan Cancer Research ConsortiumTraverse City48341NCT02693535Map
MIMunson Medical CenterTraverse City49684NCT05112601Map
MIMunson Medical CenterTraverse City49684NCT05136196Map
MIMunson Medical CenterTraverse City49684NCT04511013Map
MIMunson Medical CenterTraverse City49684NCT05675410Map
MIMunson Medical CenterTraverse City49684NCT05987241Map
MICorewell Health Beaumont Troy HospitalTroy48085NCT05327686Map
MICorewell Health Beaumont Troy HospitalTroy48085NCT05675410Map
MICorewell Health Beaumont Troy HospitalTroy48085NCT05677490Map
MIHematology Oncology Consultants PC-TroyTroy48098NCT05677490Map
MIMichigan Institute of Urology-Town CenterTroy48084NCT05677490Map
MIHenry Ford Health Warren HospitalWarren48093NCT03866382Map
MIHenry Ford Health Warren HospitalWarren48093NCT02693535Map
MIHenry Ford Health Warren HospitalWarren48093NCT05677490Map
MIHenry Ford Madison Heights Hospital - BreastWarren48093NCT05677490Map
MIHenry Ford Warren Hospital - GLCMSWarren48093NCT03866382Map
MIHenry Ford Warren Hospital - GLCMSWarren48093NCT05677490Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT03866382Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT05675410Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT05987241Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT06203600Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT07166406Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT03866382Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT05675410Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT05987241Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT06203600Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT07166406Map
MIUniversity of Michigan Health - WestWyoming49519NCT05112601Map
MIUniversity of Michigan Health - WestWyoming49519NCT05136196Map
MIUniversity of Michigan Health - WestWyoming49519NCT04511013Map
MIUniversity of Michigan Health - WestWyoming49519NCT05675410Map
MIUniversity of Michigan Health - WestWyoming49519NCT05987241Map
MIHuron Gastroenterology PCYpsilanti48106NCT05136196Map
MIHuron Gastroenterology PCYpsilanti48106NCT03866382Map
MIHuron Gastroenterology PCYpsilanti48106NCT05677490Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05136196Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT03866382Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05327686Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05675410Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05677490Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05987241Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT06203600Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT07383441Map
MNRiverwood Healthcare CenterAitkin56431NCT05677490Map
MNEssentia Health - Baxter ClinicBaxter56425NCT05677490Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT05136196Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT05327686Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT05677490Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT05987241Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT06203600Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT06632327Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT05136196Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT05327686Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT05677490Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT06203600Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT07166406Map
MNMinnesota Oncology - BurnsvilleBurnsville55337NCT04511013Map
MNMinnesota Oncology - BurnsvilleBurnsville55337NCT05677490Map
MNMinnesota Oncology - BurnsvilleBurnsville55337NCT06632327Map
MNCambridge Medical CenterCambridge55008NCT04511013Map
MNCambridge Medical CenterCambridge55008NCT05677490Map
MNCambridge Medical CenterCambridge55008NCT06632327Map
MNMinnesota Oncology Hematology PA-ChaskaChaska55318NCT05677490Map
MNMinnesota Oncology Hematology PA-ChaskaChaska55318NCT06632327Map
MNMercy HospitalCoon Rapids55433NCT05112601Map
MNMercy HospitalCoon Rapids55433NCT05136196Map
MNMercy HospitalCoon Rapids55433NCT04511013Map
MNMercy HospitalCoon Rapids55433NCT05675410Map
MNMercy HospitalCoon Rapids55433NCT05677490Map
MNMercy HospitalCoon Rapids55433NCT05987241Map
MNMercy HospitalCoon Rapids55433NCT06203600Map
MNMercy HospitalCoon Rapids55433NCT06632327Map
MNMinnesota Oncology - Coon RapidsCoon Rapids55433NCT05677490Map
MNMinnesota Oncology - Coon RapidsCoon Rapids55433NCT06632327Map
MNEssentia Health - Saint Joseph's Crosslake ClinicCrosslake56442NCT05677490Map
MNEssentia Health - Deer River ClinicDeer River56636NCT05112601Map
MNEssentia Health - Deer River ClinicDeer River56636NCT05136196Map
MNEssentia Health - Deer River ClinicDeer River56636NCT03866382Map
MNEssentia Health - Deer River ClinicDeer River56636NCT05327686Map
MNEssentia Health - Deer River ClinicDeer River56636NCT05677490Map
MNEssentia Health - Deer River ClinicDeer River56636NCT06203600Map
MNEssentia Health - Deer River ClinicDeer River56636NCT07166406Map
MNEssentia Health Saint Mary's - Detroit Lakes ClinicDetroit Lakes56501NCT05136196Map
MNEssentia Health Saint Mary's - Detroit Lakes ClinicDetroit Lakes56501NCT05677490Map
MNEssentia Health Cancer CenterDuluth55805NCT05112601Map
MNEssentia Health Cancer CenterDuluth55805NCT05136196Map
MNEssentia Health Cancer CenterDuluth55805NCT03866382Map
MNEssentia Health Cancer CenterDuluth55805NCT05327686Map
MNEssentia Health Cancer CenterDuluth55805NCT05677490Map
MNEssentia Health Cancer CenterDuluth55805NCT06203600Map
MNEssentia Health Cancer CenterDuluth55805NCT07166406Map
MNEssentia Health Saint Mary's Medical CenterDuluth55805NCT05327686Map
MNEssentia Health Saint Mary's Medical CenterDuluth55805NCT05677490Map
MNEssentia Health Saint Mary's Medical CenterDuluth55805NCT07166406Map
MNMiller-Dwan HospitalDuluth55805NCT05112601Map
MNMiller-Dwan HospitalDuluth55805NCT05327686Map
MNMiller-Dwan HospitalDuluth55805NCT05677490Map
MNMiller-Dwan HospitalDuluth55805NCT07166406Map
MNFairview Southdale HospitalEdina55435NCT05112601Map
MNFairview Southdale HospitalEdina55435NCT05136196Map
MNFairview Southdale HospitalEdina55435NCT03866382Map
MNFairview Southdale HospitalEdina55435NCT04511013Map
MNFairview Southdale HospitalEdina55435NCT05327686Map
MNFairview Southdale HospitalEdina55435NCT05675410Map
MNFairview Southdale HospitalEdina55435NCT05677490Map
MNFairview Southdale HospitalEdina55435NCT05987241Map
MNFairview Southdale HospitalEdina55435NCT06203600Map
MNFairview Southdale HospitalEdina55435NCT06632327Map
MNMinnesota Oncology - EdinaEdina55435NCT05677490Map
MNMinnesota Oncology - EdinaEdina55435NCT06632327Map
MNEssentia Health - Ely ClinicEly55731NCT05677490Map
MNEssentia Health - FosstonFosston56542NCT05136196Map
MNEssentia Health - FosstonFosston56542NCT05677490Map
MNMinnesota Oncology Hematology, P.AFridley55432NCT06246916Map
MNUnity HospitalFridley55432NCT04511013Map
MNEssentia Health Hibbing ClinicHibbing55746NCT05112601Map
MNEssentia Health Hibbing ClinicHibbing55746NCT05136196Map
MNEssentia Health Hibbing ClinicHibbing55746NCT03866382Map
MNEssentia Health Hibbing ClinicHibbing55746NCT05327686Map
MNEssentia Health Hibbing ClinicHibbing55746NCT05677490Map
MNEssentia Health Hibbing ClinicHibbing55746NCT06203600Map
MNEssentia Health Hibbing ClinicHibbing55746NCT07166406Map
MNEssentia Health - International Falls ClinicInternational Falls56649NCT05677490Map
MNFairview Clinics and Surgery Center Maple GroveMaple Grove55369NCT04511013Map
MNFairview Clinics and Surgery Center Maple GroveMaple Grove55369NCT05327686Map
MNFairview Clinics and Surgery Center Maple GroveMaple Grove55369NCT05677490Map
MNFairview Clinics and Surgery Center Maple GroveMaple Grove55369NCT06632327Map
MNMinnesota Oncology - Maple GroveMaple Grove55369NCT05677490Map
MNMinnesota Oncology - Maple GroveMaple Grove55369NCT06632327Map
MNMinnesota Oncology Hematology PA-MaplewoodMaplewood55109NCT04511013Map
MNMinnesota Oncology Hematology PA-MaplewoodMaplewood55109NCT05677490Map
MNMinnesota Oncology Hematology PA-MaplewoodMaplewood55109NCT06632327Map
MNSaint John's Hospital - HealtheastMaplewood55109NCT05136196Map
MNSaint John's Hospital - HealtheastMaplewood55109NCT04511013Map
MNSaint John's Hospital - HealtheastMaplewood55109NCT05677490Map
MNSaint John's Hospital - HealtheastMaplewood55109NCT06203600Map
MNSaint John's Hospital - HealtheastMaplewood55109NCT06632327Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05112601Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05136196Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT04511013Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05327686Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05675410Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05677490Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05987241Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT06203600Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT06632327Map
MNAllina Health Cancer InstituteMinneapolis55407NCT06246916Map
MNAllina Health Cancer Institute - MinneapolisMinneapolis55407NCT06112314Map
MNChildren's Hospitals and Clinics of Minnesota - MinneapolisMinneapolis55404NCT04546399Map
MNChildren's Hospitals and Clinics of Minnesota - MinneapolisMinneapolis55404NCT05675410Map
MNHealth Partners IncMinneapolis55454NCT04511013Map
MNHealth Partners IncMinneapolis55454NCT05677490Map
MNHealth Partners IncMinneapolis55454NCT06632327Map
MNHennepin County Medical CenterMinneapolis55415NCT03866382Map
MNHennepin County Medical CenterMinneapolis55415NCT04511013Map
MNHennepin County Medical CenterMinneapolis55415NCT05327686Map
MNHennepin County Medical CenterMinneapolis55415NCT05677490Map
MNHennepin County Medical CenterMinneapolis55415NCT05987241Map
MNHennepin County Medical CenterMinneapolis55415NCT06632327Map
MNM Health Fairview University of Minnesota Medical CenterMinneapolis55455NCT04665206Map
MNM Health Fairview University of Minnesota Medical CenterMinneapolis55455NCT05919264Map
MNMinnesota Oncology and Hematology PAMinneapolis55404-4526NCT05267626Map
MNUniversity of MinnesotaMinneapolis55455NCT03681561Map
MNUniversity of MinnesotaMinneapolis55455NCT06264180Map
MNUniversity of Minnesota/Masonic Cancer CenterMinneapolis55455NCT04546399Map
MNUniversity of Minnesota/Masonic Cancer CenterMinneapolis55455NCT05327686Map
MNUniversity of Minnesota/Masonic Cancer CenterMinneapolis55455NCT05647265Map
MNUniversity of Minnesota/Masonic Cancer CenterMinneapolis55455NCT05675410Map
MNMonticello Cancer CenterMonticello55362NCT04511013Map
MNMonticello Cancer CenterMonticello55362NCT05677490Map
MNMonticello Cancer CenterMonticello55362NCT06632327Map
MNEssentia Health - Moose Lake ClinicMoose Lake55767NCT05677490Map
MNNew Ulm Medical CenterNew Ulm56073NCT04511013Map
MNNew Ulm Medical CenterNew Ulm56073NCT05677490Map
MNNew Ulm Medical CenterNew Ulm56073NCT06632327Map
MNEssentia Health - Park RapidsPark Rapids56470NCT05136196Map
MNEssentia Health - Park RapidsPark Rapids56470NCT05677490Map
MNEssentia Health - Saint Joseph's Pequot Lakes ClinicPequot Lakes56472NCT05677490Map
MNEssentia Health - Saint Joseph's Pine River ClinicPine River56474NCT05677490Map
MNFairview Northland Medical CenterPrinceton55371NCT04511013Map
MNFairview Northland Medical CenterPrinceton55371NCT05677490Map
MNFairview Northland Medical CenterPrinceton55371NCT06632327Map
MNNorth Memorial Medical Health CenterRobbinsdale55422NCT04511013Map
MNNorth Memorial Medical Health CenterRobbinsdale55422NCT05677490Map
MNNorth Memorial Medical Health CenterRobbinsdale55422NCT06632327Map
MNExelixis Clinical Site #68Rochester55905NCT05176483Map
MNMayo ClinicRochester55905NCT05223816Map
MNMayo ClinicRochester55905NCT05919264Map
MNMayo Clinic in RochesterRochester55905NCT05136196Map
MNMayo Clinic in RochesterRochester55905NCT03866382Map
MNMayo Clinic in RochesterRochester55905NCT03017820Map
MNMayo Clinic in RochesterRochester55905NCT05327686Map
MNMayo Clinic in RochesterRochester55905NCT05647265Map
MNMayo Clinic in RochesterRochester55905NCT05675410Map
MNMayo Clinic in RochesterRochester55905NCT05802056Map
MNMayo Clinic in RochesterRochester55905NCT06064097Map
MNMayo Clinic in RochesterRochester55905NCT06632327Map
MNMayo Clinic in RochesterRochester55905NCT07226856Map
MNMayo Clinic in RochesterRochester55905NCT07510334Map
MNMayo Clinic RochesterRochester55905NCT06581406Map
MNMayo Clinic RochesterRochester55905NCT05655312Map
MNCoborn Cancer Center at Saint Cloud HospitalSaint Cloud56303NCT05677490Map
MNCoborn Cancer Center at Saint Cloud HospitalSaint Cloud56303NCT05987241Map
MNCoborn Cancer Center at Saint Cloud HospitalSaint Cloud56303NCT06632327Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05112601Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05136196Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT04511013Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05675410Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05677490Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05987241Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT06203600Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT06632327Map
MNRegions HospitalSaint Paul55101NCT05112601Map
MNRegions HospitalSaint Paul55101NCT05136196Map
MNRegions HospitalSaint Paul55101NCT03866382Map
MNRegions HospitalSaint Paul55101NCT04511013Map
MNRegions HospitalSaint Paul55101NCT05327686Map
MNRegions HospitalSaint Paul55101NCT05675410Map
MNRegions HospitalSaint Paul55101NCT05677490Map
MNRegions HospitalSaint Paul55101NCT05987241Map
MNRegions HospitalSaint Paul55101NCT06203600Map
MNRegions HospitalSaint Paul55101NCT06632327Map
MNUnited HospitalSaint Paul55102NCT05112601Map
MNUnited HospitalSaint Paul55102NCT05136196Map
MNUnited HospitalSaint Paul55102NCT04511013Map
MNUnited HospitalSaint Paul55102NCT05675410Map
MNUnited HospitalSaint Paul55102NCT05677490Map
MNUnited HospitalSaint Paul55102NCT05987241Map
MNUnited HospitalSaint Paul55102NCT06203600Map
MNUnited HospitalSaint Paul55102NCT06632327Map
MNEssentia Health SandstoneSandstone55072NCT05112601Map
MNEssentia Health SandstoneSandstone55072NCT05136196Map
MNEssentia Health SandstoneSandstone55072NCT03866382Map
MNEssentia Health SandstoneSandstone55072NCT05327686Map
MNEssentia Health SandstoneSandstone55072NCT05677490Map
MNEssentia Health SandstoneSandstone55072NCT06203600Map
MNEssentia Health SandstoneSandstone55072NCT07166406Map
MNSaint Francis Regional Medical CenterShakopee55379NCT05112601Map
MNSaint Francis Regional Medical CenterShakopee55379NCT04511013Map
MNSaint Francis Regional Medical CenterShakopee55379NCT05327686Map
MNSaint Francis Regional Medical CenterShakopee55379NCT05677490Map
MNSaint Francis Regional Medical CenterShakopee55379NCT06632327Map
MNEssentia Health - Saint Joseph's Staples ClinicStaples56479NCT05677490Map
MNLakeview HospitalStillwater55082NCT03866382Map
MNLakeview HospitalStillwater55082NCT04511013Map
MNLakeview HospitalStillwater55082NCT05327686Map
MNLakeview HospitalStillwater55082NCT05677490Map
MNLakeview HospitalStillwater55082NCT06632327Map
MNSanford Thief River Falls Medical CenterThief River Falls56701NCT05677490Map
MNSanford Thief River Falls Medical CenterThief River Falls56701NCT06632327Map
MNEssentia Health Virginia ClinicVirginia55792NCT05112601Map
MNEssentia Health Virginia ClinicVirginia55792NCT05136196Map
MNEssentia Health Virginia ClinicVirginia55792NCT03866382Map
MNEssentia Health Virginia ClinicVirginia55792NCT05327686Map
MNEssentia Health Virginia ClinicVirginia55792NCT05677490Map
MNEssentia Health Virginia ClinicVirginia55792NCT06203600Map
MNEssentia Health Virginia ClinicVirginia55792NCT07166406Map
MNRidgeview Medical CenterWaconia55387NCT05136196Map
MNRidgeview Medical CenterWaconia55387NCT03866382Map
MNRidgeview Medical CenterWaconia55387NCT04511013Map
MNRidgeview Medical CenterWaconia55387NCT05327686Map
MNRidgeview Medical CenterWaconia55387NCT05677490Map
MNRidgeview Medical CenterWaconia55387NCT06632327Map
MNRice Memorial HospitalWillmar56201NCT04511013Map
MNRice Memorial HospitalWillmar56201NCT05677490Map
MNRice Memorial HospitalWillmar56201NCT06632327Map
MNMinnesota Oncology Hematology PA-WoodburyWoodbury55125NCT05136196Map
MNMinnesota Oncology Hematology PA-WoodburyWoodbury55125NCT04511013Map
MNMinnesota Oncology Hematology PA-WoodburyWoodbury55125NCT05675410Map
MNMinnesota Oncology Hematology PA-WoodburyWoodbury55125NCT05677490Map
MNMinnesota Oncology Hematology PA-WoodburyWoodbury55125NCT06203600Map
MNMinnesota Oncology Hematology PA-WoodburyWoodbury55125NCT06632327Map
MNSanford Cancer Center WorthingtonWorthington56187NCT05677490Map
MNSanford Cancer Center WorthingtonWorthington56187NCT06632327Map
MNFairview Lakes Medical CenterWyoming55092NCT04511013Map
MNFairview Lakes Medical CenterWyoming55092NCT05677490Map
MNFairview Lakes Medical CenterWyoming55092NCT06632327Map
MSBaptist Memorial Hospital and Cancer Center-Golden TriangleColumbus39705NCT06632327Map
MSBaptist Memorial Hospital and Cancer Center-Golden TriangleColumbus39705NCT07383441Map
MSBaptist Cancer Center-GrenadaGrenada38901NCT06632327Map
MSBaptist Cancer Center-GrenadaGrenada38901NCT07383441Map
MSHattiesburg Clinic Hematology/OncologyHattiesburg39401-7233NCT06561386Map
MSUniversity of Mississippi Medical CenterJackson39216NCT03866382Map
MSUniversity of Mississippi Medical CenterJackson39216NCT04546399Map
MSUniversity of Mississippi Medical CenterJackson39216NCT05675410Map
MSUniversity of Mississippi Medical CenterJackson39216NCT05987241Map
MSUniversity of Mississippi Medical CenterJackson39216NCT06064097Map
MSBaptist Memorial Hospital and Cancer Center-Union CountyNew Albany38652NCT06632327Map
MSBaptist Memorial Hospital and Cancer Center-Union CountyNew Albany38652NCT07383441Map
MSBaptist Memorial Hospital and Cancer Center-OxfordOxford38655NCT06632327Map
MSBaptist Memorial Hospital and Cancer Center-OxfordOxford38655NCT07383441Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT06632327Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT07383441Map
MOMercy Oncology and Hematology - Clayton-ClarksonBallwin63011NCT05677490Map
MOMercy Oncology and Hematology - Clayton-ClarksonBallwin63011NCT06632327Map
MOSaint Louis Cancer and Breast Institute-BallwinBallwin63011NCT04511013Map
MOCentral Care Cancer Center - BolivarBolivar65613NCT04511013Map
MOCentral Care Cancer Center - BolivarBolivar65613NCT05677490Map
MOCentral Care Cancer Center - BolivarBolivar65613NCT06632327Map
MOCox Cancer Center BransonBranson65616NCT04511013Map
MOCox Cancer Center BransonBranson65616NCT05677490Map
MOCox Cancer Center BransonBranson65616NCT06632327Map
MOMercy Cancer Center - Cape GirardeauCape Girardeau63703NCT05677490Map
MOMercy Cancer Center - Cape GirardeauCape Girardeau63703NCT06632327Map
MOSaint Francis Medical CenterCape Girardeau63703NCT05136196Map
MOSaint Francis Medical CenterCape Girardeau63703NCT03866382Map
MOSaint Francis Medical CenterCape Girardeau63703NCT04511013Map
MOSaint Francis Medical CenterCape Girardeau63703NCT05327686Map
MOSaint Francis Medical CenterCape Girardeau63703NCT05675410Map
MOSaint Francis Medical CenterCape Girardeau63703NCT05677490Map
MOSaint Francis Medical CenterCape Girardeau63703NCT05987241Map
MOSaint Francis Medical CenterCape Girardeau63703NCT06203600Map
MOSaint Francis Medical CenterCape Girardeau63703NCT06632327Map
MOSaint Francis Medical CenterCape Girardeau63703NCT07383441Map
MOSoutheast Cancer CenterCape Girardeau63703NCT04511013Map
MOSaint Luke's HospitalChesterfield63017NCT05675410Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT04609046Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT05136196Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT03816345Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT03866382Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT05675410Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT05896839Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT05987241Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT06203600Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT06632327Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT07166406Map
MOMissouri Cancer AssociatesColumbia65201NCT07221149Map
MOMU Health - University Hospital/Ellis Fischel Cancer CenterColumbia65212NCT05112601Map
MOMU Health - University Hospital/Ellis Fischel Cancer CenterColumbia65212NCT05327686Map
MOMU Health - University Hospital/Ellis Fischel Cancer CenterColumbia65212NCT05987241Map
MOUniversity of Missouri Children's HospitalColumbia65212NCT05675410Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT04609046Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT05136196Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT03816345Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT03866382Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT05675410Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT05896839Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT05987241Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT06203600Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT06632327Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT07166406Map
MOParkland Health Center - FarmingtonFarmington63640NCT03866382Map
MOParkland Health Center - FarmingtonFarmington63640NCT04511013Map
MOParkland Health Center - FarmingtonFarmington63640NCT05677490Map
MOParkland Health Center - FarmingtonFarmington63640NCT05987241Map
MOParkland Health Center - FarmingtonFarmington63640NCT06632327Map
MOParkland Health Center - FarmingtonFarmington63640NCT07383441Map
MOCapital Region Southwest CampusJefferson City65109NCT04511013Map
MOFreeman Health SystemJoplin64804NCT04511013Map
MOFreeman Health SystemJoplin64804NCT05677490Map
MOFreeman Health SystemJoplin64804NCT06632327Map
MOMercy Hospital JoplinJoplin64804NCT04511013Map
MOMercy Hospital JoplinJoplin64804NCT05677490Map
MOMercy Hospital JoplinJoplin64804NCT06632327Map
MOChildren's Mercy Hospitals and ClinicsKansas City64108NCT04546399Map
MOChildren's Mercy Hospitals and ClinicsKansas City64108NCT05675410Map
MOChildren's Mercy Hospitals and ClinicsKansas City64108NCT06064097Map
MOUniversity Health Truman Medical CenterKansas City64108NCT03816345Map
MOUniversity Health Truman Medical CenterKansas City64108NCT03866382Map
MOUniversity Health Truman Medical CenterKansas City64108NCT05677490Map
MOUniversity Health Truman Medical CenterKansas City64108NCT05987241Map
MOUniversity Health Truman Medical CenterKansas City64108NCT06203600Map
MOUniversity Health Truman Medical CenterKansas City64108NCT06632327Map
MOUniversity of Kansas Cancer Center - BriarcliffKansas City64116NCT05987241Map
MOUniversity of Kansas Cancer Center - NorthKansas City64154NCT03816345Map
MOUniversity of Kansas Cancer Center - NorthKansas City64154NCT05987241Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT03816345Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT03866382Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT05987241Map
MOUniversity of Kansas Cancer Center at North Kansas City HospitalNorth Kansas City64116NCT03816345Map
MOLake Regional HospitalOsage Beach65065NCT05677490Map
MOLake Regional HospitalOsage Beach65065NCT06632327Map
MODelbert Day Cancer Institute at PCRMCRolla65401NCT04511013Map
MOMercy Clinic-Rolla-Cancer and HematologyRolla65401NCT04511013Map
MOMercy Clinic-Rolla-Cancer and HematologyRolla65401NCT05677490Map
MOMercy Clinic-Rolla-Cancer and HematologyRolla65401NCT06632327Map
MOPhelps Health Delbert Day Cancer InstituteRolla65401NCT05677490Map
MOPhelps Health Delbert Day Cancer InstituteRolla65401NCT06632327Map
MOHeartland Regional Medical CenterSaint Joseph64506NCT04511013Map
MOHeartland Regional Medical CenterSaint Joseph64506NCT05677490Map
MOHeartland Regional Medical CenterSaint Joseph64506NCT06632327Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT03866382Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT04511013Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT05677490Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT05987241Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT06632327Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT07383441Map
MOCoxHealth South HospitalSpringfield65807NCT04511013Map
MOCoxHealth South HospitalSpringfield65807NCT05677490Map
MOCoxHealth South HospitalSpringfield65807NCT06632327Map
MOMercy Hospital SpringfieldSpringfield65804NCT04511013Map
MOMercy Hospital SpringfieldSpringfield65804NCT05327686Map
MOMercy Hospital SpringfieldSpringfield65804NCT05677490Map
MOMercy Hospital SpringfieldSpringfield65804NCT05987241Map
MOMercy Hospital SpringfieldSpringfield65804NCT06632327Map
MOCardinal Glennon Children's Medical CenterSt Louis63104NCT04546399Map
MOCardinal Glennon Children's Medical CenterSt Louis63104NCT05675410Map
MOMercy Hospital Saint LouisSt Louis63141NCT03866382Map
MOMercy Hospital Saint LouisSt Louis63141NCT04511013Map
MOMercy Hospital Saint LouisSt Louis63141NCT04546399Map
MOMercy Hospital Saint LouisSt Louis63141NCT05327686Map
MOMercy Hospital Saint LouisSt Louis63141NCT05675410Map
MOMercy Hospital Saint LouisSt Louis63141NCT05677490Map
MOMercy Hospital Saint LouisSt Louis63141NCT05987241Map
MOMercy Hospital Saint LouisSt Louis63141NCT06029270Map
MOMercy Hospital Saint LouisSt Louis63141NCT06632327Map
MOMercy Hospital SouthSt Louis63128NCT05136196Map
MOMercy Hospital SouthSt Louis63128NCT03866382Map
MOMercy Hospital SouthSt Louis63128NCT04511013Map
MOMercy Hospital SouthSt Louis63128NCT05327686Map
MOMercy Hospital SouthSt Louis63128NCT05677490Map
MOMercy Hospital SouthSt Louis63128NCT05987241Map
MOMercy Hospital SouthSt Louis63128NCT06029270Map
MOMercy Hospital SouthSt Louis63128NCT06632327Map
MOMercy Infusion Center - ChippewaSt Louis63109NCT05677490Map
MOMercy Infusion Center - ChippewaSt Louis63109NCT06632327Map
MOMercy SouthSt Louis63128NCT06246916Map
MOMissouri Baptist Medical CenterSt Louis63131NCT03866382Map
MOMissouri Baptist Medical CenterSt Louis63131NCT04511013Map
MOMissouri Baptist Medical CenterSt Louis63131NCT05677490Map
MOMissouri Baptist Medical CenterSt Louis63131NCT05987241Map
MOMissouri Baptist Medical CenterSt Louis63131NCT06632327Map
MOMissouri Baptist Medical CenterSt Louis63131NCT07383441Map
MOResearch SiteSt Louis63110NCT07431281Map
MOSaint Louis Cancer and Breast Institute-South CitySt Louis63109NCT04511013Map
MOSaint Louis University HospitalSt Louis63110NCT05655312Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT04609046Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT05136196Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT03816345Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT03866382Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT05675410Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT05896839Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT05987241Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT06203600Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT06632327Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT07166406Map
MOSiteman Cancer Center-South CountySt Louis63129NCT04609046Map
MOSiteman Cancer Center-South CountySt Louis63129NCT05136196Map
MOSiteman Cancer Center-South CountySt Louis63129NCT03816345Map
MOSiteman Cancer Center-South CountySt Louis63129NCT03866382Map
MOSiteman Cancer Center-South CountySt Louis63129NCT05675410Map
MOSiteman Cancer Center-South CountySt Louis63129NCT05896839Map
MOSiteman Cancer Center-South CountySt Louis63129NCT05987241Map
MOSiteman Cancer Center-South CountySt Louis63129NCT06203600Map
MOSiteman Cancer Center-South CountySt Louis63129NCT06632327Map
MOSiteman Cancer Center-South CountySt Louis63129NCT07166406Map
MOVA St. Louis Healthcare SystemSt Louis63106NCT06246916Map
MOVeteran's Affairs Medical Center - Saint LouisSt Louis63125NCT05987241Map
MOVeteran's Affairs Medical Center - Saint LouisSt Louis63125NCT06632327Map
MOWashington UniversitySt Louis63110-1010NCT05267626Map
MOWashington UniversitySt Louis63110NCT05533697Map
MOWashington UniversitySt Louis63110NCT06246916Map
MOWashington University in St. LouisSt Louis63110NCT06745076Map
MOWashington University of St. LouisSt Louis63110NCT05655312Map
MOWashington University School of MedicineSt Louis63110NCT04609046Map
MOWashington University School of MedicineSt Louis63110NCT05112601Map
MOWashington University School of MedicineSt Louis63110NCT05136196Map
MOWashington University School of MedicineSt Louis63110NCT05187182Map
MOWashington University School of MedicineSt Louis63110NCT03816345Map
MOWashington University School of MedicineSt Louis63110NCT03866382Map
MOWashington University School of MedicineSt Louis63110NCT04546399Map
MOWashington University School of MedicineSt Louis63110NCT05629546Map
MOWashington University School of MedicineSt Louis63110NCT05675410Map
MOWashington University School of MedicineSt Louis63110NCT05896839Map
MOWashington University School of MedicineSt Louis63110NCT05919264Map
MOWashington University School of MedicineSt Louis63110NCT05987241Map
MOWashington University School of MedicineSt Louis63110NCT06064097Map
MOWashington University School of MedicineSt Louis63110NCT06203600Map
MOWashington University School of MedicineSt Louis63110NCT06632327Map
MOWashington University School of MedicineSt Louis63110NCT06639607Map
MOWashington University School of MedicineSt Louis63110NCT06794229Map
MOWashington University School of MedicineSt Louis63110NCT06863311Map
MOWashington University School of MedicineSt Louis63110NCT06968988Map
MOWashington University School of MedicineSt Louis63110NCT07166406Map
MOWashington University School of MedicineSt Louis63110NCT07293351Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT03866382Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT04511013Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT05677490Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT05987241Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT06632327Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT07383441Map
MOBJC Outpatient Center at Sunset HillsSunset Hills63127NCT03866382Map
MOBJC Outpatient Center at Sunset HillsSunset Hills63127NCT05677490Map
MOBJC Outpatient Center at Sunset HillsSunset Hills63127NCT05987241Map
MOBJC Outpatient Center at Sunset HillsSunset Hills63127NCT06632327Map
MOMissouri Baptist Outpatient Center-Sunset HillsSunset Hills63127NCT04511013Map
MOMercy Hospital WashingtonWashington63090NCT04511013Map
MOMercy Hospital WashingtonWashington63090NCT05677490Map
MOMercy Hospital WashingtonWashington63090NCT06632327Map
MTCommunity Hospital of AnacondaAnaconda59711NCT05112601Map
MTCommunity Hospital of AnacondaAnaconda59711NCT05136196Map
MTCommunity Hospital of AnacondaAnaconda59711NCT03866382Map
MTCommunity Hospital of AnacondaAnaconda59711NCT04511013Map
MTCommunity Hospital of AnacondaAnaconda59711NCT05677490Map
MTCommunity Hospital of AnacondaAnaconda59711NCT05987241Map
MTCommunity Hospital of AnacondaAnaconda59711NCT06029270Map
MTCommunity Hospital of AnacondaAnaconda59711NCT06203600Map
MTCommunity Hospital of AnacondaAnaconda59711NCT06632327Map
MTBillings Clinic Cancer CenterBillings59101NCT05112601Map
MTBillings Clinic Cancer CenterBillings59101NCT05136196Map
MTBillings Clinic Cancer CenterBillings59101NCT03866382Map
MTBillings Clinic Cancer CenterBillings59101NCT04511013Map
MTBillings Clinic Cancer CenterBillings59101NCT05677490Map
MTBillings Clinic Cancer CenterBillings59101NCT05987241Map
MTBillings Clinic Cancer CenterBillings59101NCT06029270Map
MTBillings Clinic Cancer CenterBillings59101NCT06203600Map
MTBillings Clinic Cancer CenterBillings59101NCT06632327Map
MTIntermountain Health West End ClinicBillings59106NCT05112601Map
MTSaint Vincent Frontier Cancer CenterBillings59102NCT05112601Map
MTSaint Vincent Frontier Cancer CenterBillings59102NCT05677490Map
MTSaint Vincent Frontier Cancer CenterBillings59102NCT06203600Map
MTSt. Vincent HealthcareBillings59102NCT06246916Map
MTBozeman Deaconess HospitalBozeman59715NCT04511013Map
MTBozeman Health Deaconess HospitalBozeman59715NCT05112601Map
MTBozeman Health Deaconess HospitalBozeman59715NCT05136196Map
MTBozeman Health Deaconess HospitalBozeman59715NCT03866382Map
MTBozeman Health Deaconess HospitalBozeman59715NCT05677490Map
MTBozeman Health Deaconess HospitalBozeman59715NCT05987241Map
MTBozeman Health Deaconess HospitalBozeman59715NCT06029270Map
MTBozeman Health Deaconess HospitalBozeman59715NCT06203600Map
MTBozeman Health Deaconess HospitalBozeman59715NCT06632327Map
MTSaint James Community Hospital and Cancer Treatment CenterButte59701NCT05677490Map
MTBenefis Healthcare- Sletten Cancer InstituteGreat Falls59405NCT04511013Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT05112601Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT05136196Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT03866382Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT05677490Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT05987241Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT06029270Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT06203600Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT06632327Map
MTGreat Falls ClinicGreat Falls59405NCT04511013Map
MTGreat Falls ClinicGreat Falls59405NCT05677490Map
MTGreat Falls ClinicGreat Falls59405NCT06632327Map
MTHi-Line Sletten Cancer CenterHavre59501NCT05677490Map
MTHi-Line Sletten Cancer CenterHavre59501NCT06632327Map
MTBenefis Helena Specialty CenterHelena59601NCT05677490Map
MTBenefis Helena Specialty CenterHelena59601NCT06632327Map
MTKalispell Regional Medical CenterKalispell59901NCT04511013Map
MTLogan Health Medical CenterKalispell59901NCT05112601Map
MTLogan Health Medical CenterKalispell59901NCT05136196Map
MTLogan Health Medical CenterKalispell59901NCT03866382Map
MTLogan Health Medical CenterKalispell59901NCT05677490Map
MTLogan Health Medical CenterKalispell59901NCT05987241Map
MTLogan Health Medical CenterKalispell59901NCT06029270Map
MTLogan Health Medical CenterKalispell59901NCT06203600Map
MTLogan Health Medical CenterKalispell59901NCT06632327Map
MTCommunity Medical CenterMissoula59804NCT05112601Map
MTCommunity Medical CenterMissoula59804NCT05136196Map
MTCommunity Medical CenterMissoula59804NCT03866382Map
MTCommunity Medical CenterMissoula59804NCT05677490Map
MTCommunity Medical CenterMissoula59804NCT05987241Map
MTCommunity Medical CenterMissoula59804NCT06029270Map
MTCommunity Medical CenterMissoula59804NCT06203600Map
MTCommunity Medical CenterMissoula59804NCT06632327Map
MTCommunity Medical HospitalMissoula59804NCT04511013Map
MTSaint Patrick Hospital - Community HospitalMissoula59802NCT04511013Map
MTSaint Patrick Hospital - Community HospitalMissoula59802NCT05647265Map
MTSaint Patrick Hospital - Community HospitalMissoula59802NCT05677490Map
NENebraska Medicine-BellevueBellevue68123NCT05136196Map
NENebraska Medicine-BellevueBellevue68123NCT03866382Map
NENebraska Medicine-BellevueBellevue68123NCT05327686Map
NENebraska Medicine-BellevueBellevue68123NCT05675410Map
NENebraska Medicine-BellevueBellevue68123NCT05677490Map
NENebraska Medicine-BellevueBellevue68123NCT05987241Map
NENebraska Medicine-BellevueBellevue68123NCT06203600Map
NECHI Health Saint FrancisGrand Island68803NCT06632327Map
NECHI Health Good SamaritanKearney68847NCT06632327Map
NECancer Partners of Nebraska - Pine LakeLincoln68516NCT04511013Map
NESoutheast Nebraska Cancer Center - 68th Street PlaceLincoln68516NCT04511013Map
NEAlegent Health Bergan Mercy Medical CenterOmaha68124NCT06632327Map
NEAlegent Health Immanuel Medical CenterOmaha68122NCT06632327Map
NEAlegent Health Lakeside HospitalOmaha68130NCT06632327Map
NEChildren's Hospital and Medical Center of OmahaOmaha68114NCT04546399Map
NEChildren's Hospital and Medical Center of OmahaOmaha68114NCT05675410Map
NEChildren's Hospital and Medical Center of OmahaOmaha68114NCT06064097Map
NECreighton University Medical CenterOmaha68131NCT06632327Map
NEExelixis Clinical Site #2Omaha68130NCT05176483Map
NENebraska Cancer SpecialistsOmaha68130NCT05655312Map
NENebraska Cancer Specialists/Oncology Hematology West PC - MECCOmaha68114NCT05677490Map
NENebraska Cancer Specialists/Oncology Hematology West PC - MECCOmaha68114NCT06029270Map
NENebraska Medicine-Village PointeOmaha68118NCT05136196Map
NENebraska Medicine-Village PointeOmaha68118NCT03866382Map
NENebraska Medicine-Village PointeOmaha68118NCT05327686Map
NENebraska Medicine-Village PointeOmaha68118NCT05675410Map
NENebraska Medicine-Village PointeOmaha68118NCT05677490Map
NENebraska Medicine-Village PointeOmaha68118NCT05987241Map
NENebraska Medicine-Village PointeOmaha68118NCT06203600Map
NENebraska Methodist HospitalOmaha68114NCT05112601Map
NENebraska Methodist HospitalOmaha68114NCT05677490Map
NENebraska Methodist HospitalOmaha68114NCT06029270Map
NEOmaha VA Nebraska-Western Iowa Health Care System, Omaha, NEOmaha68105-1850NCT06275360Map
NEOncology Hematology West P.C. dba Nebraska Cancer SpecialistsOmaha68130NCT06246916Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT05136196Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT03866382Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT04546399Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT02693535Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT05327686Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT05675410Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT05677490Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT05987241Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT06064097Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT06203600Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT06743126Map
NVCarson Tahoe Regional Medical CenterCarson City89703NCT05647265Map
NVCarson Tahoe Regional Medical CenterCarson City89703NCT05677490Map
NVCancer and Blood Specialists-HendersonHenderson89052NCT05647265Map
NVCancer and Blood Specialists-HendersonHenderson89052NCT05677490Map
NVComprehensive Cancer Centers of Nevada - HendersonHenderson89052NCT05647265Map
NVComprehensive Cancer Centers of Nevada - HendersonHenderson89052NCT05677490Map
NVComprehensive Cancer Centers of Nevada-Horizon RidgeHenderson89052NCT05647265Map
NVComprehensive Cancer Centers of Nevada-Horizon RidgeHenderson89052NCT05677490Map
NVComprehensive Cancer Centers of Nevada-Southeast HendersonHenderson89074NCT05647265Map
NVComprehensive Cancer Centers of Nevada-Southeast HendersonHenderson89074NCT05677490Map
NVLas Vegas Urology - Green ValleyHenderson89074NCT05647265Map
NVLas Vegas Urology - Green ValleyHenderson89074NCT05677490Map
NVLas Vegas Urology - PebbleHenderson89074NCT05647265Map
NVLas Vegas Urology - PebbleHenderson89074NCT05677490Map
NVOncology Las Vegas - HendersonHenderson89074NCT05647265Map
NVOncology Las Vegas - HendersonHenderson89074NCT05677490Map
NVUrology Specialists of Nevada - Green ValleyHenderson89074NCT05647265Map
NVUrology Specialists of Nevada - Green ValleyHenderson89074NCT05677490Map
NVAlliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas89135NCT04546399Map
NVAlliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas89135NCT05647265Map
NVAlliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas89135NCT05675410Map
NVAlliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas89135NCT05677490Map
NVComprehensive Cancer Centers of NevadaLas Vegas89148NCT05647265Map
NVComprehensive Cancer Centers of NevadaLas Vegas89148NCT05677490Map
NVComprehensive Cancer Centers of NevadaLas Vegas89148NCT06246916Map
NVComprehensive Cancer Centers of Nevada - Central ValleyLas Vegas89169NCT05647265Map
NVComprehensive Cancer Centers of Nevada - Central ValleyLas Vegas89169NCT05677490Map
NVComprehensive Cancer Centers of Nevada - NorthwestLas Vegas89128NCT05647265Map
NVComprehensive Cancer Centers of Nevada - NorthwestLas Vegas89128NCT05677490Map
NVComprehensive Cancer Centers of Nevada - Town CenterLas Vegas89144NCT05647265Map
NVComprehensive Cancer Centers of Nevada - Town CenterLas Vegas89144NCT05677490Map
NVComprehensive Cancer Centers of Nevada-SummerlinLas Vegas89144NCT05647265Map
NVComprehensive Cancer Centers of Nevada-SummerlinLas Vegas89144NCT05677490Map
NVExelixis Clinical Site #55Las Vegas89052NCT05176483Map
NVHope Cancer Care of NevadaLas Vegas89103NCT05647265Map
NVHope Cancer Care of NevadaLas Vegas89103NCT05677490Map
NVLas Vegas Prostate Cancer CenterLas Vegas89113NCT05647265Map
NVLas Vegas Prostate Cancer CenterLas Vegas89113NCT05677490Map
NVLas Vegas Urology - Cathedral RockLas Vegas89128NCT05647265Map
NVLas Vegas Urology - Cathedral RockLas Vegas89128NCT05677490Map
NVLas Vegas Urology - PecosLas Vegas89074NCT05647265Map
NVLas Vegas Urology - PecosLas Vegas89074NCT05677490Map
NVLas Vegas Urology - Smoke RanchLas Vegas89128NCT05647265Map
NVLas Vegas Urology - Smoke RanchLas Vegas89128NCT05677490Map
NVLas Vegas Urology - SunsetLas Vegas89113NCT05647265Map
NVLas Vegas Urology - SunsetLas Vegas89113NCT05677490Map
NVOncology Las Vegas - TenayaLas Vegas89128NCT05647265Map
NVOncology Las Vegas - TenayaLas Vegas89128NCT05677490Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT03866382Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT05647265Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT05677490Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT05987241Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT06203600Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT03866382Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT05647265Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT05677490Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT05987241Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT06203600Map
NVOptumCare Cancer Care at MountainViewLas Vegas89128NCT05647265Map
NVOptumCare Cancer Care at MountainViewLas Vegas89128NCT05677490Map
NVRadiation Oncology Centers of Nevada CentralLas Vegas89106NCT05647265Map
NVRadiation Oncology Centers of Nevada CentralLas Vegas89106NCT05677490Map
NVRadiation Oncology Centers of Nevada SoutheastLas Vegas89119NCT05647265Map
NVRadiation Oncology Centers of Nevada SoutheastLas Vegas89119NCT05677490Map
NVSummerlin Hospital Medical CenterLas Vegas89144NCT04546399Map
NVSummerlin Hospital Medical CenterLas Vegas89144NCT05647265Map
NVSummerlin Hospital Medical CenterLas Vegas89144NCT05677490Map
NVSunrise Hospital and Medical CenterLas Vegas89109NCT05647265Map
NVSunrise Hospital and Medical CenterLas Vegas89109NCT05677490Map
NVUniversity Cancer CenterLas Vegas89169NCT05647265Map
NVUniversity Cancer CenterLas Vegas89169NCT05677490Map
NVUniversity Medical Center of Southern NevadaLas Vegas89102NCT05647265Map
NVUniversity Medical Center of Southern NevadaLas Vegas89102NCT05677490Map
NVUrology Specialists of Nevada - CentralLas Vegas89106NCT05647265Map
NVUrology Specialists of Nevada - CentralLas Vegas89106NCT05677490Map
NVUrology Specialists of Nevada - NorthwestLas Vegas89128NCT05647265Map
NVUrology Specialists of Nevada - NorthwestLas Vegas89128NCT05677490Map
NVUrology Specialists of Nevada - SouthwestLas Vegas89113NCT05647265Map
NVUrology Specialists of Nevada - SouthwestLas Vegas89113NCT05677490Map
NVWomen's Cancer Center of NevadaLas Vegas89106NCT05112601Map
NVHope Cancer Care of Nevada-PahrumpPahrump89048NCT05647265Map
NVHope Cancer Care of Nevada-PahrumpPahrump89048NCT05677490Map
NVCancer Care SpecialistsReno89511NCT07195695Map
NVRadiation Oncology AssociatesReno89509NCT05647265Map
NVRadiation Oncology AssociatesReno89509NCT05677490Map
NVRenown Health Medical OncologyReno89502NCT07392892Map
NVRenown Office of Clinical ResearchReno89502NCT07392892Map
NVRenown Regional Medical CenterReno89502NCT04546399Map
NVRenown Regional Medical CenterReno89502NCT06561386Map
NVRenown Regional Medical CenterReno89502NCT05647265Map
NVRenown Regional Medical CenterReno89502NCT05675410Map
NVRenown Regional Medical CenterReno89502NCT05677490Map
NVRenown Regional Medical CenterReno89502NCT06203600Map
NVRenown Regional Medical CenterReno89502NCT07392892Map
NVSaint Mary's Regional Medical CenterReno89503NCT05647265Map
NVSaint Mary's Regional Medical CenterReno89503NCT05677490Map
NHNH Oncology - Hematology, PAConcord03103NCT02693535Map
NHDartmouth Cancer CenterLebanon03756NCT05901285Map
NHDartmouth HitchcockLebanon03756NCT06362369Map
NHDartmouth Hitchcock Cancer CenterLebanon03756NCT06264180Map
NHDartmouth Hitchcock Medical CenterLebanon03756NCT06246916Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT05136196Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT04546399Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT05675410Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT06632327Map
NHThe Dana-Farber Cancer Institute at LondonderryLondonderry03053NCT05677490Map
NHDartmouth Cancer Center - Manchester/ DCC ManchesterManchester03104NCT06632327Map
NHSolinsky Center for Cancer CareManchester03103NCT02693535Map
NHDartmouth Cancer Center - NashuaNashua03063NCT06632327Map
NHNew England Cancer SpecialistPortsmouth03801NCT02693535Map
NJMemorial Sloan Kettering at Basking Ridge Limited Protocol ActivitiesBasking Ridge07920NCT04991025Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT03866382Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT05327686Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT05987241Map
NJMemorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge07920NCT07532902Map
NJMemorial Sloan Kettering Cancer Center Basking RidgeBasking Ridge07920NCT06534983Map
NJCooper Hospital University Medical CenterCamden08103NCT05327686Map
NJCooper Hospital University Medical CenterCamden08103NCT05675410Map
NJCooper Hospital University Medical CenterCamden08103NCT06632327Map
NJJefferson Cherry Hill HospitalCherry Hill08002NCT05677490Map
NJJefferson Cherry Hill HospitalCherry Hill08002NCT05987241Map
NJJefferson Cherry Hill HospitalCherry Hill08002NCT06203600Map
NJExelixis Clinical Site #88East Brunswick08816NCT05176483Map
NJResearch SiteEast Brunswick08816NCT07431281Map
NJTrinitas Hospital and Comprehensive Cancer Center - Williamson Street CampusElizabeth07207NCT05675410Map
NJHunterdon Medical CenterFlemington08822NCT05675410Map
NJExelixis Clinical Site #105Hackensack07601NCT05176483Map
NJHackensack University Medical CenterHackensack07601NCT04546399Map
NJHackensack University Medical CenterHackensack07601NCT05675410Map
NJHackensack University Medical CenterHackensack07601NCT05987241Map
NJHackensack University Medical CenterHackensack07601NCT06064097Map
NJHackensack University Medical CenterHackensack07601NCT06264180Map
NJHackensack University Medical Center/John Theurer Cancer CenterHackensack07601NCT04561206Map
NJJohn Theurer Cancer CenterHackensack07601NCT05533697Map
NJJohn Theurer Cancer CenterHackensack07601NCT06246916Map
NJJohn Theurer Cancer Center at Hackensack University Medical CenterHackensack07601NCT06015724Map
NJJohn Theurer Cancer Center at Hackensack University Medical CenterHackensack07601NCT06112314Map
NJJohn Theurer Cancer Center at Hackensack University Medical CenterHackensack07601NCT06618287Map
NJJohn Theurer Cancer Center at Hackensack University Medical CenterHackensack07601NCT06697197Map
NJJohn Theurer Cancer Center at Hackensack University Medical CenterHackensack07601NCT06764771Map
NJJohn Theurer Cancer Center Site Number : 8400001Hackensack07601NCT05584670Map
NJJohn Theurer Cancer Center, Hackensack Meridian HealthHackensack07410NCT05715229Map
NJJersey City Medical CenterJersey City07302NCT05675410Map
NJJersey City Medical CenterJersey City07302NCT05987241Map
NJMonmouth Medical Center Southern CampusLakewood08701NCT05987241Map
NJSaint Barnabas Medical CenterLivingston07039NCT05675410Map
NJSaint Barnabas Medical CenterLivingston07039NCT05987241Map
NJMonmouth Medical CenterLong Branch07740NCT05675410Map
NJMonmouth Medical CenterLong Branch07740NCT05987241Map
NJSouthern Ocean County Medical CenterManahawkin08050NCT05987241Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT03866382Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT05327686Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT05987241Map
NJMemorial Sloan Kettering Monmouth (All Protocol Activities)Middletown07748NCT07532902Map
NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown07748NCT04991025Map
NJMSK MonmouthMiddletown07748NCT06534983Map
NJMemorial Sloan Kettering BergenMontvale07645NCT03866382Map
NJMemorial Sloan Kettering BergenMontvale07645NCT05327686Map
NJMemorial Sloan Kettering BergenMontvale07645NCT05987241Map
NJMemorial Sloan Kettering Bergen (All Protocol Activities)Montvale07645NCT07532902Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT04991025Map
NJMSK BergenMontvale07645NCT06534983Map
NJAtlantic Health SystemMorristown07960NCT05901285Map
NJAtlantic Health System/Morristown Medical CenterMorristown07960NCT06743126Map
NJAtlantic Healthcare SystemMorristown07960NCT05267626Map
NJMorristown Medical CenterMorristown07960NCT04546399Map
NJMorristown Medical CenterMorristown07960NCT05675410Map
NJMorristown Medical Center - Atlantic Health SystemMorristown07960NCT06264180Map
NJCooper CyberKnife CenterMount Laurel08054NCT05327686Map
NJCooper CyberKnife CenterMount Laurel08054NCT06632327Map
NJInspira Medical Center Mullica HillMullica Hill08062NCT06463665Map
NJJersey Shore Medical CenterNeptune City07753NCT05675410Map
NJJersey Shore Medical CenterNeptune City07753NCT06064097Map
NJJersey Shore Medical CenterNeptune City07753NCT06632327Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT03816345Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT04546399Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT05675410Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT05987241Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08901NCT06246916Map
NJRutgers Cancer Institute of New Jersey-Robert Wood Johnson University HospitalNew Brunswick08903NCT04546399Map
NJRutgers Cancer Institute of New Jersey-Robert Wood Johnson University HospitalNew Brunswick08903NCT05675410Map
NJRutgers Cancer Institute of New Jersey-Robert Wood Johnson University HospitalNew Brunswick08903NCT06064097Map
NJSaint Peter's University HospitalNew Brunswick08901NCT05675410Map
NJNewark Beth Israel Medical CenterNewark07112NCT04546399Map
NJNewark Beth Israel Medical CenterNewark07112NCT05675410Map
NJNewark Beth Israel Medical CenterNewark07112NCT06064097Map
NJThe Valley Hospital - Luckow PavilionParamus07652NCT06632327Map
NJThe Valley Hospital Inc.Paramus07652NCT06246916Map
NJSaint Joseph's Regional Medical CenterPaterson07503NCT04546399Map
NJSaint Joseph's Regional Medical CenterPaterson07503NCT05675410Map
NJValley Health System Ridgewood CampusRidgewood07450NCT06632327Map
NJSidney Kimmel Cancer Center Washington TownshipSewell08080NCT05677490Map
NJSidney Kimmel Cancer Center Washington TownshipSewell08080NCT05987241Map
NJSidney Kimmel Cancer Center Washington TownshipSewell08080NCT06203600Map
NJRobert Wood Johnson University Hospital SomersetSomerville08876NCT05987241Map
NJCommunity Medical CenterToms River08755NCT05675410Map
NJCommunity Medical CenterToms River08755NCT05987241Map
NJMD Anderson Cancer Center at Cooper-VoorheesVoorhees Township08043NCT06632327Map
NMLovelace Medical Center - Saint Joseph SquareAlbuquerque87102NCT02693535Map
NMLovelace Medical Center-Saint Joseph SquareAlbuquerque87102NCT05327686Map
NMLovelace Medical Center-Saint Joseph SquareAlbuquerque87102NCT06203600Map
NMLovelace Radiation OncologyAlbuquerque87109NCT05327686Map
NMPresbyterian HospitalAlbuquerque87106NCT05675410Map
NMPresbyterian Kaseman HospitalAlbuquerque87110NCT02693535Map
NMPresbyterian Kaseman HospitalAlbuquerque87110NCT05987241Map
NMThe University of New Mexico Comprehensive Cancer CenterAlbuquerque87131NCT02693535Map
NMUniversity of New MexicoAlbuquerque87106NCT06624644Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT05112601Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT05136196Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT06203600Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT06632327Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT07166406Map
NMUniversity of New Mexico Comprehensive Cancer CenterAlbuquerque87106NCT06646276Map
NMMemorial Medical CenterLas Cruces88011NCT02693535Map
NMMemorial Medical Center-Las CrucesLas Cruces88011NCT06632327Map
NMPresbyterian Rust Medical CenterRio Rancho87124NCT02693535Map
NMPresbyterian Rust Medical Center/Jorgensen Cancer CenterRio Rancho87124NCT05987241Map
NYAlbany Medical CenterAlbany12208NCT04546399Map
NYAlbany Medical CenterAlbany12208NCT05675410Map
NYAlbany Medical CenterAlbany12208NCT06064097Map
NYNew York Oncology HematologyAlbany12206NCT06246916Map
NYNorthwell Health Imbert Cancer CenterBay Shore11706NCT05327686Map
NYNorthwell Health Imbert Cancer CenterBay Shore11706NCT06203600Map
NYMaimonides Medical CenterBrooklyn11219NCT04546399Map
NYMaimonides Medical CenterBrooklyn11219NCT05987241Map
NYNew York-Presbyterian/Brooklyn Methodist HospitalBrooklyn11215NCT05677490Map
NYRoswell Park Cancer InstituteBuffalo14263NCT03899155Map
NYRoswell Park Cancer InstituteBuffalo14263NCT05675410Map
NYRoswell Park Cancer InstituteBuffalo14263NCT06203600Map
NYRoswell Park Cancer InstituteBuffalo14263NCT06264180Map
NYHematology Oncology Associates of CNY at CamillusCamillus13031NCT05675410Map
NYMemorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity)Commack11725NCT04991025Map
NYMemorial Sloan Kettering CommackCommack11725NCT03866382Map
NYMemorial Sloan Kettering CommackCommack11725NCT05327686Map
NYMemorial Sloan Kettering CommackCommack11725NCT05987241Map
NYMemorial Sloan Kettering Suffolk - Commack (All Protocol Activities)Commack11725NCT07532902Map
NYMSK CommackCommack11725NCT06534983Map
NYHematology Oncology Associates of Central New York-East SyracuseEast Syracuse13057NCT05675410Map
NYMemorial Sloan Kettering WestchesterEast White Plains10604NCT05327686Map
NYThe New York Hospital Medical Center of QueensFlushing11355NCT05677490Map
NYThe New York Hospital Medical Center of QueensFlushing11355NCT05987241Map
NYGlens Falls HospitalGlens Falls12801NCT05327686Map
NYGlens Falls HospitalGlens Falls12801NCT05675410Map
NYGlens Falls HospitalGlens Falls12801NCT05677490Map
NYGlens Falls HospitalGlens Falls12801NCT05987241Map
NYGlens Falls HospitalGlens Falls12801NCT06203600Map
NYGlens Falls HospitalGlens Falls12801NCT06632327Map
NYNorthwell Health Cancer Institute at HuntingtonGreenlawn11740NCT05327686Map
NYNorthwell Health Cancer Institute at HuntingtonGreenlawn11740NCT05677490Map
NYNorthwell Health Cancer Institute at HuntingtonGreenlawn11740NCT06203600Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT03866382Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT05384496Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT05987241Map
NYMemorial Sloan Kettering Westchester (All Protocol Activities)Harrison10604NCT04991025Map
NYMemorial Sloan Kettering Westchester (All Protocol Activities)Harrison10604NCT07532902Map
NYMSK WestchesterHarrison10604NCT06534983Map
NYNorthwell Health Cancer InstituteLake Success11042NCT06112314Map
NYNorthwell Health Monter Cancer CenterLake Success11042NCT02693535Map
NYNorthwell Health, R.J. Zuckerberg Cancer CenterLake Success11042NCT06264180Map
NYNorthwell Health/ RJ Zuckerberg Cancer CenterLake Success11042NCT06697197Map
NYNorthwell Health/ RJ Zuckerberg Cancer CenterLake Success11042NCT07221149Map
NYNorthwell Health/Center for Advanced MedicineLake Success11042NCT04609046Map
NYNorthwell Health/Center for Advanced MedicineLake Success11042NCT05327686Map
NYNorthwell Health/Center for Advanced MedicineLake Success11042NCT05677490Map
NYNorthwell Health/Center for Advanced MedicineLake Success11042NCT06203600Map
NYNorth Shore University HospitalManhasset11030NCT04609046Map
NYNYU Langone Hematology Oncology Associates-MineolaMineola11501NCT03899155Map
NYNYU Langone Hospital - Long IslandMineola11501NCT05136196Map
NYNYU Langone Hospital - Long IslandMineola11501NCT03816345Map
NYNYU Langone Hospital - Long IslandMineola11501NCT03866382Map
NYNYU Langone Hospital - Long IslandMineola11501NCT04546399Map
NYNYU Langone Hospital - Long IslandMineola11501NCT05272384Map
NYNYU Langone Hospital - Long IslandMineola11501NCT05675410Map
NYNYU Langone Hospital - Long IslandMineola11501NCT05896839Map
NYNYU Langone Hospital - Long IslandMineola11501NCT06203600Map
NYNorthern Westchester HospitalMount Kisco10549NCT02693535Map
NYNorthern Westchester HospitalMount Kisco10549NCT05327686Map
NYNorthern Westchester HospitalMount Kisco10549NCT05677490Map
NYNorthern Westchester HospitalMount Kisco10549NCT06203600Map
NYCohen Children's Medical CenterNew Hyde Park11040NCT02693535Map
NYThe Steven and Alexandra Cohen Children's Medical Center of New YorkNew Hyde Park11040NCT05675410Map
NYColumbia University Irving Medical CenterNew York10032NCT06863311Map
NYExelixis Clinical Site #6New York10065NCT05176483Map
NYExelixis Clinical Site #60New York10032NCT05176483Map
NYIcahn School of Medicine at Mount SinaiNew York10029NCT05188118Map
NYLaura & Isaac Perlmutter Cancer Center at NYU Langone HealthNew York10016NCT07195695Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT05136196Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT03816345Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT04546399Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT05272384Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT05327686Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT05675410Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT05896839Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT06203600Map
NYLaura and Isaac Perlmutter Cancer Center at NYU Langone HealthNew York10016NCT06743126Map
NYLenox Hill HospitalNew York10075NCT05327686Map
NYLenox Hill HospitalNew York10075NCT05677490Map
NYManhattan Eye Ear and Throat HospitalNew York10065NCT05327686Map
NYManhattan Eye Ear and Throat HospitalNew York10065NCT05677490Map
NYManhattan Eye, Ear, and Throat HospitalNew York10065NCT02693535Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT03686124Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT04665206Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT03803553Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT03866382Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT04900818Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT04546399Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05327686Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05384496Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06581406Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05675410Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05919264Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05987241Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06534983Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06743126Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06745076Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT07221149Map
NYMemorial Sloan Kettering Cancer Center - Melanoma & ImmunotherapeuticsNew York10065NCT05533697Map
NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)New York10065NCT04991025Map
NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)New York10065NCT07532902Map
NYMemorial Sloan-Kettering Cancer CenterNew York10065NCT07195695Map
NYMount Sinai ChelseaNew York10011NCT05987241Map
NYMount Sinai HospitalNew York10029NCT05675410Map
NYMount Sinai HospitalNew York10029NCT05987241Map
NYMount Sinai HospitalNew York10029NCT07166406Map
NYNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York10032NCT04609046Map
NYNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York10032NCT03816345Map
NYNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York10032NCT03866382Map
NYNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York10032NCT04546399Map
NYNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York10032NCT05675410Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT04609046Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT03816345Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT03866382Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT04546399Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT05675410Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT05677490Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT05987241Map
NYNYU LangoneNew York10016NCT04900818Map
NYNYU Langone HealthNew York10016NCT05428007Map
NYNYU Langone HealthNew York10016NCT07504796Map
NYNYU Langone Health-Perlmutter Cancer CenterNew York10016NCT05533697Map
NYNYU Langone Medical Center-New York- 550 1st Ave - BRANY - PPDS- Site Number : 8400013New York10016-6402NCT05584670Map
NYNYU Longone HealthNew York10016NCT07246863Map
NYStaten Island University HospitalNew York10305NCT02693535Map
NYVeterans Affairs New York Harbor Healthcare SystemNew York10016NCT06561386Map
NYWeill Cornell Medical CollegeNew York10065NCT03803553Map
NYQueens Cancer CenterRego Park11374NCT02693535Map
NYQueens Cancer CenterRego Park11374NCT05677490Map
NYRochester General HospitalRochester14621NCT05987241Map
NYUnity Park Ridge CampusRochester14626NCT05987241Map
NYUniversity of RochesterRochester14642NCT05112601Map
NYUniversity of RochesterRochester14642NCT04477343Map
NYUniversity of RochesterRochester14642NCT05675410Map
NYUniversity of RochesterRochester14642NCT05677490Map
NYUniversity of RochesterRochester14642NCT05987241Map
NYUniversity of RochesterRochester14642NCT06203600Map
NYUniversity of RochesterRochester14642NCT06632327Map
NYUniversity of RochesterRochester14642NCT06743126Map
NYUniversity of Rochester Medical CenterRochester14642NCT06561386Map
NYPhelps HospitalSleepy Hollow10591NCT02693535Map
NYPhelps Memorial Hospital CenterSleepy Hollow10591NCT05327686Map
NYPhelps Memorial Hospital CenterSleepy Hollow10591NCT05677490Map
NYPhelps Memorial Hospital CenterSleepy Hollow10591NCT06203600Map
NYStony Brook University Medical CenterStony Brook11794NCT04546399Map
NYStony Brook University Medical CenterStony Brook11794NCT05675410Map
NYStony Brook University Medical CenterStony Brook11794NCT05677490Map
NYStony Brook University Medical CenterStony Brook11794NCT05987241Map
NYExelixis Clinical Site #76Syracuse13210NCT05176483Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT05112601Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT04546399Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT05675410Map
NYSUNY Upstate Medical UniversitySyracuse13210NCT06561386Map
NYAlbert Einstein College of Medicine, Children's Hospital at MontefioreThe Bronx10467NCT03465592Map
NYJames J Peters VA Medical CenterThe Bronx10468NCT06632327Map
NYMontefiore Medical CenterThe Bronx10461NCT06264180Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT04546399Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT05675410Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT06064097Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT07166406Map
NYMontefiore Medical Center-Einstein CampusThe Bronx10461NCT05677490Map
NYMontefiore Medical Center-Einstein CampusThe Bronx10461NCT05987241Map
NYMontefiore Medical Center-Einstein CampusThe Bronx10461NCT07166406Map
NYMontefiore Medical Center-Weiler HospitalThe Bronx10461NCT05677490Map
NYMemorial Sloan Kettering NassauUniondale11553NCT03866382Map
NYMemorial Sloan Kettering NassauUniondale11553NCT05327686Map
NYMemorial Sloan Kettering NassauUniondale11553NCT05987241Map
NYMemorial Sloan Kettering Nassau (All Protocol Activities)Uniondale11553NCT07532902Map
NYMemorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale11553NCT04991025Map
NYMSK NassauUniondale11553NCT06534983Map
NYNew York Medical Center/ Maria Fareri Children's HospitalValhalla10595NCT03465592Map
NYNew York Medical CollegeValhalla10595NCT07013565Map
NYWilmot Cancer Institute at WebsterWebster14580NCT05112601Map
NYWilmot Cancer Institute at WebsterWebster14580NCT05675410Map
NYWilmot Cancer Institute at WebsterWebster14580NCT05677490Map
NYWilmot Cancer Institute at WebsterWebster14580NCT05987241Map
NYWilmot Cancer Institute at WebsterWebster14580NCT06632327Map
NCAtrium Health Stanly/LCI-AlbemarleAlbemarle28002NCT05987241Map
NCCone Health MedCenter AsheboroAsheboro27205NCT06203600Map
NCMessino Cancer CenterAsheville28806NCT06246916Map
NCMission HospitalAsheville28801NCT04546399Map
NCMission HospitalAsheville28801NCT05675410Map
NCCone Health Cancer Center at Alamance RegionalBurlington27215NCT06203600Map
NCDuke Cancer Center CaryCary27518NCT05327686Map
NCDuke Cancer Center CaryCary27518NCT05987241Map
NCLineberger Comprehensive Cancer CenterChapel Hill27599NCT02693535Map
NCUNC Hospitals, The University of North Carolina at Chapel HillChapel Hill27599NCT06743126Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT04609046Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT03866382Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT04546399Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT05327686Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT05675410Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT05677490Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT05987241Map
NCUniversity of North Carolina at Chapel HillChapel Hill27514NCT06264180Map
NCAtrium Health Pineville/LCI-PinevilleCharlotte28210NCT05327686Map
NCAtrium Health Pineville/LCI-PinevilleCharlotte28210NCT05987241Map
NCAtrium Health University City/LCI-UniversityCharlotte28262NCT05327686Map
NCAtrium Health University City/LCI-UniversityCharlotte28262NCT05987241Map
NCAtrium Health's Levine Cancer InstituteCharlotte28277NCT02693535Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT04546399Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT05327686Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT05675410Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT05987241Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT06064097Map
NCLevine Cancer InstituteCharlotte28204NCT06246916Map
NCLevine Cancer InstituteCharlotte28204NCT06697197Map
NCLevine Cancer Institute-BallantyneCharlotte28277NCT05327686Map
NCLevine Cancer Institute-BallantyneCharlotte28277NCT05987241Map
NCLevine Cancer Institute-SouthParkCharlotte28211NCT05987241Map
NCNovant Health Cancer InstituteCharlotte28204NCT06246916Map
NCNovant Health Weisiger Cancer Institute - CharlotteCharlotte28204NCT06246916Map
NCWake Forest University at ClemmonsClemmons27012NCT04511013Map
NCWake Forest University at ClemmonsClemmons27012NCT05327686Map
NCWake Forest University at ClemmonsClemmons27012NCT05987241Map
NCSoutheastern Medical Oncology Center-ClintonClinton28328NCT05136196Map
NCSoutheastern Medical Oncology Center-ClintonClinton28328NCT04511013Map
NCSoutheastern Medical Oncology Center-ClintonClinton28328NCT05677490Map
NCSoutheastern Medical Oncology Center-ClintonClinton28328NCT06203600Map
NCAtrium Health Cabarrus/LCI-ConcordConcord28025NCT05327686Map
NCAtrium Health Cabarrus/LCI-ConcordConcord28025NCT05987241Map
NCDuke Cancer CenterDurham27710NCT06264180Map
NCDuke Cancer Center SouthpointDurham27713NCT05647265Map
NCDuke Cancer Center SouthpointDurham27713NCT05987241Map
NCDuke Cancer InstituteDurham27710NCT06646276Map
NCDuke Cancer InstituteDurham27710NCT07325136Map
NCDuke Health SystemDurham27710NCT06246916Map
NCDuke UniversityDurham27705NCT05919264Map
NCDuke UniversityDurham27750NCT06816927Map
NCDuke University Medical CenterDurham27710NCT05112601Map
NCDuke University Medical CenterDurham27710NCT04546399Map
NCDuke University Medical CenterDurham27710NCT05327686Map
NCDuke University Medical CenterDurham27710NCT06581406Map
NCDuke University Medical CenterDurham27710NCT05647265Map
NCDuke University Medical CenterDurham27710NCT05675410Map
NCDuke University Medical CenterDurham27710NCT05987241Map
NCDuke University Medical CenterDurham27710NCT06064097Map
NCDuke University Medical CenterDurham27710NCT06708949Map
NCDuke University Medical CenterDurham27710NCT07246863Map
NCExelixis Clinical Site #12Durham27710NCT05176483Map
NCLevine Cancer Institute - RutherfordForest City28043NCT05987241Map
NCLevine Cancer Institute-GastonGastonia28054NCT05327686Map
NCLevine Cancer Institute-GastonGastonia28054NCT05987241Map
NCSoutheastern Medical Oncology Center-GoldsboroGoldsboro27534NCT05136196Map
NCSoutheastern Medical Oncology Center-GoldsboroGoldsboro27534NCT04511013Map
NCSoutheastern Medical Oncology Center-GoldsboroGoldsboro27534NCT05677490Map
NCSoutheastern Medical Oncology Center-GoldsboroGoldsboro27534NCT06203600Map
NCCone Health Cancer CenterGreensboro27403NCT06203600Map
NCCone Health Cancer Center at Drawbridge ParkwayGreensboro27410NCT06203600Map
NCEast Carolina UniversityGreenville27834NCT04546399Map
NCEast Carolina UniversityGreenville27858NCT06561386Map
NCEast Carolina UniversityGreenville27834NCT05675410Map
NCEast Carolina UniversityGreenville27834NCT05677490Map
NCEast Carolina UniversityGreenville27834NCT06064097Map
NCMargaret R Pardee Memorial HospitalHendersonville28791NCT03866382Map
NCMargaret R Pardee Memorial HospitalHendersonville28791NCT05677490Map
NCHayworth Cancer CenterHigh Point27262NCT05327686Map
NCUniversity of North Carolina-Hillsborough CampusHillsborough27278NCT05677490Map
NCCarolina Biooncology InstituteHuntersville28078NCT05267626Map
NCLevine Cancer Institute - HuntersvilleHuntersville28078NCT05987241Map
NCSoutheastern Medical Oncology Center-JacksonvilleJacksonville28546NCT05136196Map
NCSoutheastern Medical Oncology Center-JacksonvilleJacksonville28546NCT04511013Map
NCSoutheastern Medical Oncology Center-JacksonvilleJacksonville28546NCT05677490Map
NCSoutheastern Medical Oncology Center-JacksonvilleJacksonville28546NCT06203600Map
NCAtrium Health Lincoln/LCI-LincolntonLincolnton28092NCT05987241Map
NCLevine Cancer Institute - Union WestMatthews28104NCT05987241Map
NCAtrium Health Union/LCI-UnionMonroe28112NCT05327686Map
NCAtrium Health Union/LCI-UnionMonroe28112NCT05987241Map
NCFirstHealth of the Carolinas-Moore Regional HospitalPinehurst28374NCT05677490Map
NCFirstHealth of the Carolinas-Moore Regional HospitalPinehurst28374NCT05987241Map
NCFirstHealth of the Carolinas-Moore Regional HospitalPinehurst28374NCT06203600Map
NCDuke Cancer Center RaleighRaleigh27609NCT05327686Map
NCDuke Cancer Center RaleighRaleigh27609NCT05647265Map
NCDuke Cancer Center RaleighRaleigh27609NCT05987241Map
NCDuke Women's Cancer Care RaleighRaleigh27607NCT05112601Map
NCAnnie Penn Memorial HospitalReidsville27320NCT06203600Map
NCAtrium Health Cleveland/LCI-ClevelandShelby28150NCT05987241Map
NCWake Forest Baptist Health - Hematology Oncology - StatesvilleStatesville28677NCT04511013Map
NCWake Forest Baptist Health - Wilkes Medical CenterWilkesboro28659NCT04511013Map
NCWake Forest Baptist Health - Wilkes Medical CenterWilkesboro28659NCT05327686Map
NCNovant Health Zimmer Cancer Institute - WilmingtonWilmington28401NCT06246916Map
NCAtrium Health Wake Forest BaptistWinston-Salem27103NCT05317858Map
NCWake Forest University Health SciencesWinston-Salem27157NCT04511013Map
NCWake Forest University Health SciencesWinston-Salem27157NCT04546399Map
NCWake Forest University Health SciencesWinston-Salem27157NCT05327686Map
NCWake Forest University Health SciencesWinston-Salem27157NCT05675410Map
NCWake Forest University Health SciencesWinston-Salem27157NCT05987241Map
NCWake Forest University Health SciencesWinston-Salem27157NCT06064097Map
NDSanford Bismarck Medical CenterBismarck58501NCT05136196Map
NDSanford Bismarck Medical CenterBismarck58501NCT05327686Map
NDSanford Bismarck Medical CenterBismarck58501NCT05677490Map
NDSanford Bismarck Medical CenterBismarck58501NCT05987241Map
NDSanford Bismarck Medical CenterBismarck58501NCT06203600Map
NDSanford Bismarck Medical CenterBismarck58501NCT06632327Map
NDSanford Health- BismarckBismarck58501NCT02693535Map
NDSanford Medical CenterBismarck58501NCT06646276Map
NDEssentia Health Cancer Center-South University ClinicFargo58103NCT05112601Map
NDEssentia Health Cancer Center-South University ClinicFargo58103NCT05136196Map
NDEssentia Health Cancer Center-South University ClinicFargo58103NCT05677490Map
NDEssentia Health Cancer Center-South University ClinicFargo58103NCT06203600Map
NDSanford Broadway Medical CenterFargo58122NCT05136196Map
NDSanford Broadway Medical CenterFargo58122NCT04546399Map
NDSanford Broadway Medical CenterFargo58122NCT05327686Map
NDSanford Broadway Medical CenterFargo58122NCT05675410Map
NDSanford Broadway Medical CenterFargo58122NCT05677490Map
NDSanford Broadway Medical CenterFargo58122NCT05987241Map
NDSanford Broadway Medical CenterFargo58122NCT06064097Map
NDSanford Broadway Medical CenterFargo58122NCT06203600Map
NDSanford Broadway Medical CenterFargo58122NCT06632327Map
NDSanford Fargo Medical CenterFargo58102NCT06646276Map
NDSanford Health- FargoFargo58122NCT02693535Map
NDSanford Medical Center FargoFargo58104NCT05677490Map
NDSanford Medical Center FargoFargo58104NCT06632327Map
NDSanford Roger Maris Cancer CenterFargo58122NCT05136196Map
NDSanford Roger Maris Cancer CenterFargo58122NCT05327686Map
NDSanford Roger Maris Cancer CenterFargo58122NCT05677490Map
NDSanford Roger Maris Cancer CenterFargo58122NCT05987241Map
NDSanford Roger Maris Cancer CenterFargo58122NCT06203600Map
NDSanford Roger Maris Cancer CenterFargo58122NCT06632327Map
NDSanford South University Medical CenterFargo58103NCT05677490Map
NDSanford South University Medical CenterFargo58103NCT06632327Map
NDSouthpointe-Sanford Medical Center FargoFargo58103NCT05677490Map
NDSouthpointe-Sanford Medical Center FargoFargo58103NCT06632327Map
NDEssentia Health - Jamestown ClinicJamestown58401NCT05136196Map
NDEssentia Health - Jamestown ClinicJamestown58401NCT05677490Map
OHChildren's Hospital Medical Center of AkronAkron44308NCT04546399Map
OHChildren's Hospital Medical Center of AkronAkron44308NCT05675410Map
OHUH Seidman Cancer Center at UH Avon Health CenterAvon44011NCT05327686Map
OHUHHS-Chagrin Highlands Medical CenterBeachwood44122NCT05112601Map
OHUHHS-Chagrin Highlands Medical CenterBeachwood44122NCT04511013Map
OHUHHS-Chagrin Highlands Medical CenterBeachwood44122NCT05327686Map
OHIndu and Raj Soin Medical CenterBeavercreek45431NCT04511013Map
OHStrecker Cancer Center-BelpreBelpre45714NCT03866382Map
OHStrecker Cancer Center-BelpreBelpre45714NCT04511013Map
OHStrecker Cancer Center-BelpreBelpre45714NCT05677490Map
OHSaint Elizabeth Boardman HospitalBoardman44512NCT04511013Map
OHGabrail Cancer and Research CenterCanton44718NCT06463665Map
OHDayton Physicians LLC-Miami Valley SouthCenterville45459NCT04511013Map
OHMiami Valley Hospital SouthCenterville45459NCT05112601Map
OHMiami Valley Hospital SouthCenterville45459NCT05136196Map
OHMiami Valley Hospital SouthCenterville45459NCT05327686Map
OHMiami Valley Hospital SouthCenterville45459NCT05677490Map
OHMiami Valley Hospital SouthCenterville45459NCT06203600Map
OHGeauga HospitalChardon44024NCT05112601Map
OHGeauga HospitalChardon44024NCT04511013Map
OHAdena Regional Medical CenterChillicothe45601NCT03866382Map
OHAdena Regional Medical CenterChillicothe45601NCT04511013Map
OHAdena Regional Medical CenterChillicothe45601NCT05677490Map
OHBethesda North HospitalCincinnati45242NCT06632327Map
OHCincinnati Children's Hospital Medical CenterCincinnati45229NCT04546399Map
OHCincinnati Children's Hospital Medical CenterCincinnati45229NCT05675410Map
OHCincinnati Children's Hospital Medical CenterCincinnati45229NCT06064097Map
OHGood Samaritan Hospital - CincinnatiCincinnati45220NCT05112601Map
OHGood Samaritan Hospital - CincinnatiCincinnati45220NCT06203600Map
OHGood Samaritan Hospital - CincinnatiCincinnati45220NCT06632327Map
OHOncology Hematology CareCincinnati45242NCT03899155Map
OHOncology Hematology CareCincinnati45242NCT06646276Map
OHOncology Hematology Care Clinical TrialsCincinnati45242NCT06246916Map
OHOncology Hematology Care Clinical Trials, LLCCincinnati45211NCT07392892Map
OHOncology Hematology Care Clinical Trials, LLCCincinnati45242NCT07392892Map
OHOncology Hematology Care Clinical Trials, LLCCincinnati45245NCT07392892Map
OHOncology Hematology Care Inc-KenwoodCincinnati45236NCT04511013Map
OHTriHealth Cancer Institute-AndersonCincinnati45255NCT06632327Map
OHTriHealth Cancer Institute-WestsideCincinnati45247NCT06632327Map
OHUniversity of Cincinnati Cancer Center-UC Medical CenterCincinnati45219NCT05327686Map
OHUniversity of Cincinnati Cancer Center-UC Medical CenterCincinnati45219NCT05987241Map
OHUniversity of Cincinnati Medical CenterCincinnati45219NCT02693535Map
OHUniversity of Cincinnati Medical CenterCincinnati45219NCT06561386Map
OHCase Western Reserve UniversityCleveland44106NCT05112601Map
OHCase Western Reserve UniversityCleveland44106NCT04511013Map
OHCase Western Reserve UniversityCleveland44106NCT05327686Map
OHCleveland ClinicCleveland44195NCT05361720Map
OHCleveland ClinicCleveland44195NCT05901285Map
OHCleveland ClinicCleveland44195NCT05919264Map
OHCleveland ClinicCleveland44195NCT06618287Map
OHCleveland Clinic Cancer Center/Fairview HospitalCleveland44111NCT05112601Map
OHCleveland Clinic FoundationCleveland44195NCT05112601Map
OHCleveland Clinic FoundationCleveland44195NCT05675410Map
OHCleveland Clinic, Taussig Cancer InstituteCleveland44195NCT06743126Map
OHExelixis Clinical Site #10Cleveland44106NCT05176483Map
OHRainbow Babies and Childrens HospitalCleveland44106NCT04546399Map
OHRainbow Babies and Childrens HospitalCleveland44106NCT05675410Map
OHRainbow Babies and Childrens HospitalCleveland44106NCT06064097Map
OHSeidman Cancer CenterCleveland44106NCT06246916Map
OHUniversity Hospitals Cleveland Medical CenterCleveland44106NCT07325136Map
OHUniversity Hospitals Cleveland Medical Center, Seidman Cancer CenterCleveland44106NCT05919264Map
OHUniversity Hospitals Seidman Cancer CenterCleveland44106NCT05361720Map
OHColumbus Oncology and Hematology Associates IncColumbus43214NCT03866382Map
OHColumbus Oncology and Hematology Associates IncColumbus43214NCT04511013Map
OHDoctors HospitalColumbus43228NCT03866382Map
OHDoctors HospitalColumbus43228NCT04511013Map
OHGrant Medical CenterColumbus43215NCT03866382Map
OHGrant Medical CenterColumbus43215NCT04511013Map
OHMount Carmel East HospitalColumbus43213NCT03866382Map
OHMount Carmel East HospitalColumbus43213NCT04511013Map
OHMount Carmel East HospitalColumbus43213NCT05677490Map
OHMount Carmel Health Center WestColumbus43222NCT03866382Map
OHMount Carmel Health Center WestColumbus43222NCT04511013Map
OHMount Carmel Health Center WestColumbus43222NCT05677490Map
OHNationwide Children's HospitalColumbus43205NCT04546399Map
OHNationwide Children's HospitalColumbus43205NCT05675410Map
OHNationwide Children's HospitalColumbus43205NCT06064097Map
OHOhio State UniversityColumbus43210NCT06743126Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT03681561Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT04609046Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT04697576Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05112601Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05234307Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT03816345Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT03866382Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT04511013Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05327686Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05677490Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05987241Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT07166406Map
OHOhio State University Wexner Medical Center Gynecologic Oncology at Mill RunColumbus43026NCT03686124Map
OHRiverside Methodist HospitalColumbus43214NCT03866382Map
OHRiverside Methodist HospitalColumbus43214NCT04511013Map
OHThe Mark H Zangmeister CenterColumbus43219NCT03866382Map
OHThe Mark H Zangmeister CenterColumbus43219NCT04511013Map
OHThe Mark H Zangmeister CenterColumbus43219NCT05677490Map
OHThe Ohio State UniversityColumbus43210NCT06581406Map
OHThe Ohio State UniversityColumbus43210NCT06112314Map
OHThe Ohio State University Wexner Medical CenterColumbus43210NCT06246916Map
OHThe Ohio State University- Martha Morehouse TowerColumbus43210NCT06264180Map
OHThe Ohio UniversityColumbus43210NCT03899155Map
OHDayton Children's HospitalDayton45404NCT04546399Map
OHDayton Children's HospitalDayton45404NCT05675410Map
OHDayton Children's HospitalDayton45404NCT06064097Map
OHDayton Physician LLC-Miami Valley Hospital NorthDayton45415NCT04511013Map
OHMiami Valley HospitalDayton45409NCT05327686Map
OHMiami Valley HospitalDayton45409NCT05677490Map
OHMiami Valley HospitalDayton45409NCT06203600Map
OHMiami Valley Hospital NorthDayton45415NCT05136196Map
OHMiami Valley Hospital NorthDayton45415NCT05327686Map
OHMiami Valley Hospital NorthDayton45415NCT05677490Map
OHMiami Valley Hospital NorthDayton45415NCT06203600Map
OHPremier Blood and Cancer CenterDayton45409NCT05136196Map
OHPremier Blood and Cancer CenterDayton45409NCT05327686Map
OHPremier Blood and Cancer CenterDayton45409NCT05677490Map
OHPremier Blood and Cancer CenterDayton45409NCT06203600Map
OHDelaware Health Center-Grady Cancer CenterDelaware43015NCT03866382Map
OHDelaware Health Center-Grady Cancer CenterDelaware43015NCT04511013Map
OHGrady Memorial HospitalDelaware43015NCT03866382Map
OHGrady Memorial HospitalDelaware43015NCT04511013Map
OHColumbus Oncology and Hematology AssociatesDublin43016NCT04511013Map
OHDublin Methodist HospitalDublin43016NCT04511013Map
OHOncology Hematology Care Clinical Trials, LLCFairfield45014NCT07392892Map
OHArmes Family Cancer CenterFindlay45840NCT04511013Map
OHBlanchard Valley HospitalFindlay45840NCT04511013Map
OHOrion Cancer CareFindlay45840NCT04511013Map
OHAtrium Medical Center-Middletown Regional HospitalFranklin45005-1066NCT05136196Map
OHAtrium Medical Center-Middletown Regional HospitalFranklin45005-1066NCT05327686Map
OHAtrium Medical Center-Middletown Regional HospitalFranklin45005-1066NCT05677490Map
OHAtrium Medical Center-Middletown Regional HospitalFranklin45005-1066NCT06203600Map
OHDayton Physicians LLC-AtriumFranklin45005NCT04511013Map
OHCentral Ohio Breast and Endocrine SurgeryGahanna43230NCT04511013Map
OHCentral Ohio Breast and Endocrine SurgeryGahanna43230NCT05677490Map
OHDayton Physicians LLC-WayneGreenville45331NCT04511013Map
OHMiami Valley Cancer Care and InfusionGreenville45331NCT05136196Map
OHMiami Valley Cancer Care and InfusionGreenville45331NCT05327686Map
OHMiami Valley Cancer Care and InfusionGreenville45331NCT05677490Map
OHMiami Valley Cancer Care and InfusionGreenville45331NCT06203600Map
OHWayne HospitalGreenville45331NCT04511013Map
OHMount Carmel Grove City HospitalGrove City43123NCT04511013Map
OHMount Carmel Grove City HospitalGrove City43123NCT05677490Map
OHZangmeister Center Grove CityGrove City43123NCT04511013Map
OHZangmeister Center Grove CityGrove City43123NCT05677490Map
OHGreater Dayton Cancer CenterKettering45409NCT04511013Map
OHKettering HealthKettering45429NCT02693535Map
OHKettering Medical CenterKettering45429NCT03866382Map
OHKettering Medical CenterKettering45429NCT04511013Map
OHFairfield Medical CenterLancaster43130NCT03866382Map
OHFairfield Medical CenterLancaster43130NCT04511013Map
OHFairfield Medical CenterLancaster43130NCT05677490Map
OHSaint Rita's Medical CenterLima45801NCT04511013Map
OHSaint Rita's Medical CenterLima45801NCT05677490Map
OHOhioHealth Mansfield HospitalMansfield44903NCT03866382Map
OHOhioHealth Mansfield HospitalMansfield44903NCT04511013Map
OHMarietta Memorial HospitalMarietta45750NCT03866382Map
OHMarietta Memorial HospitalMarietta45750NCT04511013Map
OHMarietta Memorial HospitalMarietta45750NCT05677490Map
OHOhioHealth Marion General HospitalMarion43302NCT03866382Map
OHOhioHealth Marion General HospitalMarion43302NCT04511013Map
OHMemorial HospitalMarysville43040NCT03866382Map
OHMemorial HospitalMarysville43040NCT05677490Map
OHHillcrest Hospital Cancer CenterMayfield Heights44124NCT05112601Map
OHUH Seidman Cancer Center at Lake Health Mentor CampusMentor44060NCT05112601Map
OHUH Seidman Cancer Center at Lake Health Mentor CampusMentor44060NCT05327686Map
OHUH Seidman Cancer Center at Southwest General HospitalMiddleburg Heights44130NCT04511013Map
OHKnox Community HospitalMount Vernon43050NCT03866382Map
OHKnox Community HospitalMount Vernon43050NCT04511013Map
OHKnox Community HospitalMount Vernon43050NCT05677490Map
OHMount Carmel New Albany Surgical HospitalNew Albany43054NCT04511013Map
OHMount Carmel New Albany Surgical HospitalNew Albany43054NCT05677490Map
OHLicking Memorial HospitalNewark43055NCT03866382Map
OHLicking Memorial HospitalNewark43055NCT04511013Map
OHLicking Memorial HospitalNewark43055NCT05677490Map
OHNewark Radiation OncologyNewark43055NCT04511013Map
OHNewark Radiation OncologyNewark43055NCT05677490Map
OHUniversity Hospitals Parma Medical CenterParma44129NCT05112601Map
OHUniversity Hospitals Parma Medical CenterParma44129NCT04511013Map
OHUniversity Hospitals Parma Medical CenterParma44129NCT05327686Map
OHMercy Health - Perrysburg HospitalPerrysburg43551NCT05677490Map
OHMercy Health Perrysburg Cancer CenterPerrysburg43551NCT04511013Map
OHSouthern Ohio Medical CenterPortsmouth45662NCT03866382Map
OHSouthern Ohio Medical CenterPortsmouth45662NCT04511013Map
OHSouthern Ohio Medical CenterPortsmouth45662NCT05677490Map
OHUniversity Hospitals Portage Medical CenterRavenna44266NCT04511013Map
OHUniversity Hospitals Portage Medical CenterRavenna44266NCT05327686Map
OHUH Seidman Cancer Center at Firelands Regional Medical CenterSandusky44870NCT04511013Map
OHSpringfield Regional Cancer CenterSpringfield45504NCT03866382Map
OHSpringfield Regional Cancer CenterSpringfield45504NCT04511013Map
OHSpringfield Regional Cancer CenterSpringfield45504NCT05677490Map
OHSpringfield Regional Medical CenterSpringfield45505NCT04511013Map
OHSpringfield Regional Medical CenterSpringfield45504NCT05677490Map
OHProMedica Flower HospitalSylvania43560NCT05987241Map
OHMercy Health - Saint Anne HospitalToledo43623NCT04511013Map
OHMercy Health - Saint Anne HospitalToledo43623NCT05677490Map
OHMercy Health - Saint Vincent HospitalToledo43608NCT05677490Map
OHMercy Health Sylvania Radiation Oncology CenterToledo43623NCT05677490Map
OHProMedica Toledo Hospital/Russell J Ebeid Children's HospitalToledo43606NCT04546399Map
OHProMedica Toledo Hospital/Russell J Ebeid Children's HospitalToledo43606NCT05675410Map
OHSaint Vincent Mercy Medical CenterToledo43608NCT04511013Map
OHDayton Physicians LLC - TroyTroy45373NCT04511013Map
OHUpper Valley Medical CenterTroy45373NCT05136196Map
OHUpper Valley Medical CenterTroy45373NCT05327686Map
OHUpper Valley Medical CenterTroy45373NCT05677490Map
OHUpper Valley Medical CenterTroy45373NCT06203600Map
OHUniversity Hospitals Sharon Health CenterWadsworth44281NCT04511013Map
OHSaint Joseph Warren HospitalWarren44484NCT04511013Map
OHUniversity of Cincinnati Cancer Center-West ChesterWest Chester45069NCT05327686Map
OHUniversity of Cincinnati Cancer Center-West ChesterWest Chester45069NCT05987241Map
OHWest Chester HospitalWest Chester45069NCT02693535Map
OHSaint Ann's HospitalWesterville43081NCT03866382Map
OHSaint Ann's HospitalWesterville43081NCT04511013Map
OHSaint Ann's HospitalWesterville43081NCT05677490Map
OHUH Seidman Cancer Center at Saint John Medical CenterWestlake44145NCT05112601Map
OHUH Seidman Cancer Center at Saint John Medical CenterWestlake44145NCT04511013Map
OHClinton Memorial Hospital/Foster J Boyd Regional Cancer CenterWilmington45177NCT05677490Map
OHSaint Elizabeth Youngstown HospitalYoungstown44501NCT04511013Map
OHGenesis Healthcare System Cancer Care CenterZanesville43701NCT03866382Map
OHGenesis Healthcare System Cancer Care CenterZanesville43701NCT04511013Map
OHGenesis Healthcare System Cancer Care CenterZanesville43701NCT05677490Map
OKCancer Centers of Southwest Oklahoma ResearchLawton73505NCT03866382Map
OKCancer Centers of Southwest Oklahoma ResearchLawton73505NCT05987241Map
OKCancer Centers of Southwest Oklahoma ResearchLawton73505NCT06203600Map
OKCancer Centers of Southwest Oklahoma ResearchLawton73505NCT06632327Map
OKIntegris Cancer Institute of OklahomaOklahoma City73142NCT06203600Map
OKIntegris Southwest Medical CenterOklahoma City73109NCT06203600Map
OKMercy Hospital Oklahoma CityOklahoma City73120NCT04511013Map
OKMercy Hospital Oklahoma CityOklahoma City73120NCT05677490Map
OKMercy Hospital Oklahoma CityOklahoma City73120NCT06632327Map
OKUniversity of Oklahoma Health Science CenterOklahoma City73104NCT03259867Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT04609046Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05112601Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05136196Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT03866382Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT04511013Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT04546399Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05327686Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05675410Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05677490Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05987241Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT06029270Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT06064097Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT06203600Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT06632327Map
OKNatalie Warren Bryant Cancer Center at Saint FrancisTulsa74136NCT04546399Map
OKNatalie Warren Bryant Cancer Center at Saint FrancisTulsa74136NCT05675410Map
OKOklahoma Cancer Specialists and Research Institute-TulsaTulsa74146NCT05112601Map
OKOklahoma Cancer Specialists and Research Institute-TulsaTulsa74146NCT05327686Map
OKOklahoma Cancer Specialists and Research Institute-TulsaTulsa74146NCT06203600Map
OKOklahoma Cancer Specialists and Research Institute, LLCTulsa74146NCT06246916Map
ORSaint Alphonsus Cancer Care Center-Baker CityBaker City97814NCT05677490Map
ORSaint Alphonsus Medical Center-Baker CityBaker City97814NCT04511013Map
ORSaint Charles Health SystemBend97701NCT05136196Map
ORSaint Charles Health SystemBend97701NCT04511013Map
ORSaint Charles Health SystemBend97701NCT05647265Map
ORSaint Charles Health SystemBend97701NCT05677490Map
ORClackamas Radiation Oncology CenterClackamas97015NCT05136196Map
ORClackamas Radiation Oncology CenterClackamas97015NCT04511013Map
ORClackamas Radiation Oncology CenterClackamas97015NCT05647265Map
ORClackamas Radiation Oncology CenterClackamas97015NCT05677490Map
ORClackamas Radiation Oncology CenterClackamas97015NCT07166406Map
ORProvidence Cancer Institute Clackamas ClinicClackamas97015NCT04511013Map
ORBay Area HospitalCoos Bay97420NCT04511013Map
ORBay Area HospitalCoos Bay97420NCT05647265Map
ORBay Area HospitalCoos Bay97420NCT05677490Map
OROncology Associates of Oregon PCEugene97401NCT06246916Map
OROncology Associates Of Oregon, PcEugene97401NCT07221149Map
ORLegacy Mount Hood Medical CenterGresham97030NCT06632327Map
ORProvidence Hood River Memorial HospitalHood River97031NCT05647265Map
ORProvidence Hood River Memorial HospitalHood River97031NCT05677490Map
ORProvidence Newberg Medical CenterNewberg97132NCT05136196Map
ORProvidence Newberg Medical CenterNewberg97132NCT03866382Map
ORProvidence Newberg Medical CenterNewberg97132NCT04511013Map
ORProvidence Newberg Medical CenterNewberg97132NCT05647265Map
ORProvidence Newberg Medical CenterNewberg97132NCT05675410Map
ORProvidence Newberg Medical CenterNewberg97132NCT05677490Map
ORProvidence Newberg Medical CenterNewberg97132NCT06203600Map
ORProvidence Newberg Medical CenterNewberg97132NCT07166406Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT05136196Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT03866382Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT05677490Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT05987241Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT06203600Map
ORSaint Alphonsus Medical Center-OntarioOntario97914NCT04511013Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT05136196Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT03866382Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT04511013Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT05647265Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT05675410Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT05677490Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT05987241Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT06203600Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT07166406Map
ORExelixis Clinical Site #51Portland97239NCT05176483Map
ORKaiser Foundation HospitalsPortland97227NCT06246916Map
ORLegacy Emanuel Children's HospitalPortland97227NCT04546399Map
ORLegacy Emanuel Children's HospitalPortland97227NCT05675410Map
ORLegacy Good Samaritan Hospital and Medical CenterPortland97210NCT06632327Map
ORNorthwest Cancer Specialists, P.C.Portland97213-2982NCT07221149Map
OROregon Health & Science UniversityPortland97239NCT05317858Map
OROregon Health and Science UniversityPortland97239NCT03866382Map
OROregon Health and Science UniversityPortland97239NCT04546399Map
OROregon Health and Science UniversityPortland97239NCT05675410Map
OROregon Health and Science UniversityPortland97239NCT05919264Map
OROregon Health and Science UniversityPortland97239NCT05987241Map
OROregon Health and Science UniversityPortland97239NCT06203600Map
OROregon Health and Science UniversityPortland97239NCT06246916Map
ORProvidence Cancer InstitutePortland97213NCT07195695Map
ORProvidence Cancer Institute Franz ClinicPortland97213NCT06743126Map
ORProvidence Health & ServicesPortland97213NCT02693535Map
ORProvidence Portland Medical CenterPortland97213NCT05112601Map
ORProvidence Portland Medical CenterPortland97213NCT05136196Map
ORProvidence Portland Medical CenterPortland97213NCT03866382Map
ORProvidence Portland Medical CenterPortland97213NCT04511013Map
ORProvidence Portland Medical CenterPortland97213NCT05647265Map
ORProvidence Portland Medical CenterPortland97213NCT05675410Map
ORProvidence Portland Medical CenterPortland97213NCT05677490Map
ORProvidence Portland Medical CenterPortland97213NCT05987241Map
ORProvidence Portland Medical CenterPortland97213NCT06029270Map
ORProvidence Portland Medical CenterPortland97213NCT06203600Map
ORProvidence Portland Medical CenterPortland97213NCT07166406Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05112601Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05136196Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT03866382Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT04511013Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05647265Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05675410Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05677490Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05987241Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT06029270Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT06203600Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT07166406Map
ORSaint Charles Health System-RedmondRedmond97756NCT04511013Map
ORSaint Charles Health System-RedmondRedmond97756NCT05647265Map
ORSaint Charles Health System-RedmondRedmond97756NCT05677490Map
ORSalem HospitalSalem97301NCT06632327Map
ORLegacy Meridian Park HospitalTualatin97062NCT06632327Map
PALehigh Valley Hospital - Cedar CrestAllentown18103NCT02693535Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT03866382Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT04546399Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT05327686Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT05675410Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT05677490Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT05987241Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT06064097Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT06203600Map
PAUPMC AltoonaAltoona16601NCT05987241Map
PAUPMC-Heritage Valley Health System BeaverBeaver15009NCT05112601Map
PAUPMC-Heritage Valley Health System BeaverBeaver15009NCT05327686Map
PAUPMC-Heritage Valley Health System BeaverBeaver15009NCT05987241Map
PAUPMC-Heritage Valley Health System BeaverBeaver15009NCT06203600Map
PAAlliance Cancer Specialists, PCBensalem19020NCT07392892Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT03866382Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT05327686Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT05677490Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT05987241Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT06203600Map
PALehigh Valley Hospital- MuhlenbergBethlehem18017NCT02693535Map
PAUPMC Hillman Cancer Center at Butler Health SystemButler16001NCT05112601Map
PACarlisle Regional Cancer CenterCarlisle17015NCT05327686Map
PAChristiana Care Health System-Concord Health CenterChadds Ford19317NCT05327686Map
PAChristiana Care Health System-Concord Health CenterChadds Ford19317NCT05677490Map
PAChristiana Care Health System-Concord Health CenterChadds Ford19317NCT06632327Map
PAUPMC Hillman Cancer Center - Passavant - CranberryCranberry Township16066NCT05112601Map
PAGeisinger Medical CenterDanville17822NCT04546399Map
PAGeisinger Medical CenterDanville17822NCT05327686Map
PAGeisinger Medical CenterDanville17822NCT05675410Map
PAGeisinger Medical CenterDanville17822NCT05677490Map
PAGeisinger Medical CenterDanville17822NCT06203600Map
PAGeisinger Medical CenterDanville17822NCT06632327Map
PAGeisinger Medical CenterDanville17822NCT07166406Map
PAGeisinger Cancer Center Dickson CityDickson City18519NCT05677490Map
PAGeisinger Cancer Center Dickson CityDickson City18519NCT06203600Map
PAGeisinger Cancer Center Dickson CityDickson City18519NCT06632327Map
PAAlliance Cancer Specialists, PCDoylestown18901NCT07392892Map
PAPocono Medical CenterEast Stroudsburg18301NCT03866382Map
PAPocono Medical CenterEast Stroudsburg18301NCT02693535Map
PAPocono Medical CenterEast Stroudsburg18301NCT05677490Map
PAPocono Medical CenterEast Stroudsburg18301NCT05987241Map
PAPocono Medical CenterEast Stroudsburg18301NCT06203600Map
PASt. Luke's University Health NetworkEaston18045NCT06246916Map
PASaint Vincent HospitalErie16544NCT05327686Map
PAUPMC Hillman Cancer Center ErieErie16505NCT05112601Map
PAUPMC Hillman Cancer Center ErieErie16505NCT03866382Map
PAUPMC Hillman Cancer Center ErieErie16505NCT05327686Map
PAUPMC Hillman Cancer Center ErieErie16505NCT05987241Map
PAUPMC Hillman Cancer Center ErieErie16505NCT06203600Map
PAUPMC Cancer Center at UPMC HorizonFarrell16121NCT05112601Map
PAUPMC Cancer Center at UPMC HorizonFarrell16121NCT05327686Map
PAUPMC Cancer Centers - Arnold Palmer PavilionGreensburg15601NCT05112601Map
PAUPMC Cancer Centers - Arnold Palmer PavilionGreensburg15601NCT03866382Map
PAUPMC Cancer Centers - Arnold Palmer PavilionGreensburg15601NCT05327686Map
PAUPMC Cancer Centers - Arnold Palmer PavilionGreensburg15601NCT05987241Map
PAUPMC Cancer Centers - Arnold Palmer PavilionGreensburg15601NCT06203600Map
PAUPMC Pinnacle Cancer Center/Community Osteopathic CampusHarrisburg17109NCT05327686Map
PAUPMC Pinnacle Cancer Center/Community Osteopathic CampusHarrisburg17109NCT05987241Map
PAUPMC Pinnacle Cancer Center/Community Osteopathic CampusHarrisburg17109NCT06203600Map
PAGeisinger Medical Center-Cancer Center HazletonHazleton18201NCT05327686Map
PAGeisinger Medical Center-Cancer Center HazletonHazleton18201NCT05677490Map
PAGeisinger Medical Center-Cancer Center HazletonHazleton18201NCT06632327Map
PALehigh Valley Hospital-HazletonHazleton18201NCT03866382Map
PALehigh Valley Hospital-HazletonHazleton18201NCT02693535Map
PALehigh Valley Hospital-HazletonHazleton18201NCT05677490Map
PALehigh Valley Hospital-HazletonHazleton18201NCT06203600Map
PAExelixis Clinical Site #104Hershey17033NCT05176483Map
PAPenn State Children's HospitalHershey17033NCT04546399Map
PAPenn State Children's HospitalHershey17033NCT05675410Map
PAPenn State Children's HospitalHershey17033NCT06064097Map
PAPenn State Milton S Hershey Medical CenterHershey17033-0850NCT05327686Map
PAIRMC Cancer CenterIndiana15701NCT05112601Map
PAIRMC Cancer CenterIndiana15701NCT05327686Map
PAJefferson HospitalJefferson Hills15025NCT05327686Map
PAUPMC-Johnstown/John P. Murtha Regional Cancer CenterJohnstown15901NCT05112601Map
PAUPMC-Johnstown/John P. Murtha Regional Cancer CenterJohnstown15901NCT06203600Map
PALancaster General Ann B Barshinger Cancer InstituteLancaster17601NCT06203600Map
PALancaster General HealthLancaster17601NCT03899155Map
PALancaster General HospitalLancaster17601NCT03646617Map
PALancaster General Hospital - Ann B Barshinger Cancer InstituteLancaster17601NCT06561386Map
PAAlliance Cancer Specialists, PCLanghorne19047NCT07392892Map
PAGeisinger Medical Oncology-LewisburgLewisburg17837NCT05327686Map
PAGeisinger Medical Oncology-LewisburgLewisburg17837NCT05677490Map
PAGeisinger Medical Oncology-LewisburgLewisburg17837NCT06203600Map
PAGeisinger Medical Oncology-LewisburgLewisburg17837NCT06632327Map
PAGeisinger Medical Oncology-LewisburgLewisburg17837NCT07166406Map
PALewistown HospitalLewistown17044NCT05677490Map
PAUPMC Cancer Center at UPMC McKeesportMcKeesport15132NCT05112601Map
PAUPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer PavilionMechanicsburg17050NCT05112601Map
PAUPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer PavilionMechanicsburg17050NCT05327686Map
PAUPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer PavilionMechanicsburg17050NCT05987241Map
PAUPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer PavilionMechanicsburg17050NCT06203600Map
PAAlliance Cancer Specialists, PCMedia19063NCT07392892Map
PAForbes HospitalMonroeville15146NCT05327686Map
PAUPMC Hillman Cancer Center - MonroevilleMonroeville15146NCT05112601Map
PAUPMC Hillman Cancer Center - MonroevilleMonroeville15146NCT03866382Map
PAUPMC Hillman Cancer Center - MonroevilleMonroeville15146NCT05987241Map
PAUPMC Hillman Cancer Center - MonroevilleMonroeville15146NCT06203600Map
PAUPMC Hillman Cancer Center in CoraopolisMoon Township15108NCT05112601Map
PAUPMC Hillman Cancer Center - Part of Frick HospitalMount Pleasant15666NCT05112601Map
PAArnold Palmer Cancer Center Medical Oncology NorwinN. Huntingdon15642NCT05112601
PAArnold Palmer Cancer Center Medical Oncology NorwinN. Huntingdon15642NCT03866382
PAArnold Palmer Cancer Center Medical Oncology NorwinN. Huntingdon15642NCT06203600
PAUPMC Cancer Center-Natrona HeightsNatrona Heights15065NCT05112601Map
PAUPMC Hillman Cancer Center - New CastleNew Castle16105NCT05112601Map
PAUPMC Hillman Cancer Center - New CastleNew Castle16105NCT05327686Map
PAUPMC Hillman Cancer Center - New CastleNew Castle16105NCT06203600Map
PAAbramson Cancer CenterPhiladelphia19104NCT03646617Map
PAChildren's Hospital of PhiladelphiaPhiladelphia19104NCT04546399Map
PAChildren's Hospital of PhiladelphiaPhiladelphia19104NCT05675410Map
PAChildren's Hospital of PhiladelphiaPhiladelphia19104NCT06064097Map
PAEinstein Medical Center PhiladelphiaPhiladelphia19141NCT05677490Map
PAExelixis Clinical Site #98Philadelphia19104NCT05176483Map
PAFox Chase Cancer CenterPhiladelphia19111NCT03686124Map
PAFox Chase Cancer CenterPhiladelphia19111NCT05263050Map
PAFox Chase Cancer CenterPhiladelphia19111NCT02693535Map
PAFox Chase Cancer CenterPhiladelphia19111NCT05498792Map
PAFox Chase Cancer CenterPhiladelphia19111NCT05655312Map
PAFox Chase Cancer CenterPhiladelphia19111NCT06246916Map
PAFox Chase Cancer CenterPhiladelphia19111NCT06264180Map
PAFox Chase Cancer CenterPhiladelphia19111NCT06743126Map
PAHospital of the University of PennsylvaniaPhiladelphia19104NCT07319195Map
PAJefferson Torresdale HospitalPhiladelphia19114NCT05987241Map
PAJefferson Torresdale HospitalPhiladelphia19114NCT06203600Map
PAPenn Medicine Abramson Cancer CenterPhiladelphia19104NCT06708949Map
PASaint Christopher's Hospital for ChildrenPhiladelphia19134NCT04546399Map
PASaint Christopher's Hospital for ChildrenPhiladelphia19134NCT05675410Map
PAThomas Jeffersion University, Sidney Kimmel Cancer CenterPhiladelphia19107NCT06743126Map
PAThomas Jefferson UniversityPhiladelphia19107NCT06581406Map
PAThomas Jefferson UniversityPhiladelphia19107NCT06112314Map
PAThomas Jefferson UniversityPhiladelphia19107NCT06264180Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT05136196Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT05675410Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT05987241Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT06203600Map
PAThomas Jefferson University, Honickman CenterPhiladelphia19107NCT03686124Map
PAUniversity of Pennsylvania, Abramson Cancer CenterPhiladelphia19104NCT06743126Map
PAUniversity of Pennsylvania, Perelamn Center for Advanced MedicinePhiladelphia19104NCT03686124Map
PAUniversity of Pennsylvania, Perelman School of MedicinePhiladelphia19104NCT05919264Map
PAUPennPhiladelphia19107NCT06624644Map
PAAllegheny General HospitalPittsburgh15212NCT05327686Map
PAChildren's Hospital of Pittsburgh of UPMCPittsburgh15224NCT04546399Map
PAChildren's Hospital of Pittsburgh of UPMCPittsburgh15224NCT05675410Map
PAChildren's Hospital of Pittsburgh of UPMCPittsburgh15224NCT06064097Map
PAExelixis Clinical Site #24Pittsburgh15232NCT05176483Map
PAExelixis Clinical Site #32Pittsburgh15212NCT05176483Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05112601Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT03816345Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT03866382Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT04511013Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05327686Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05896839Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05987241Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT06203600Map
PAUniversity of Pittsburgh Medical CenterPittsburgh15232NCT03686124Map
PAUniversity of Pittsburgh Medical Center (UPMC) Hillman Cancer CenterPittsburgh15232NCT06246916Map
PAUniversity of Pittsburgh Medical Center, Hillman Cancer CenterPittsburgh15232NCT05919264Map
PAUPMCPittsburgh15232NCT06264180Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT04114136Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT04572451Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT06581406Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT05655312Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT06112314Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT06743126Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT07223411Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT07223424Map
PAUPMC-Magee Womens HospitalPittsburgh15213NCT05112601Map
PAUPMC-Magee Womens HospitalPittsburgh15213NCT05327686Map
PAUPMC-Mercy HospitalPittsburgh15219NCT05112601Map
PAUPMC-Passavant HospitalPittsburgh15237NCT05112601Map
PAUPMC-Passavant HospitalPittsburgh15237NCT03866382Map
PAUPMC-Passavant HospitalPittsburgh15237NCT05327686Map
PAUPMC-Passavant HospitalPittsburgh15237NCT05987241Map
PAUPMC-Passavant HospitalPittsburgh15237NCT06203600Map
PAUPMC-Saint Clair Hospital Cancer CenterPittsburgh15243NCT05112601Map
PAUPMC-Saint Clair Hospital Cancer CenterPittsburgh15243NCT03866382Map
PAUPMC-Saint Clair Hospital Cancer CenterPittsburgh15243NCT05327686Map
PAUPMC-Saint Clair Hospital Cancer CenterPittsburgh15243NCT05987241Map
PAUPMC-Saint Clair Hospital Cancer CenterPittsburgh15243NCT06203600Map
PAUPMC-Saint MargaretPittsburgh15215NCT05112601Map
PAUPMC-Saint MargaretPittsburgh15215NCT05327686Map
PAUPMC-Saint MargaretPittsburgh15215NCT05987241Map
PAUPMC-Saint MargaretPittsburgh15215NCT06203600Map
PAUPMC-Shadyside HospitalPittsburgh15232NCT05327686Map
PAWest Penn HospitalPittsburgh15224NCT05327686Map
PAGeisinger Cancer Services-PottsvillePottsville17901NCT05327686Map
PAGeisinger Cancer Services-PottsvillePottsville17901NCT05677490Map
PACommunity Medical CenterScranton18510NCT05327686Map
PACommunity Medical CenterScranton18510NCT05677490Map
PACommunity Medical CenterScranton18510NCT06203600Map
PAAlliance Cancer Specialists, PCSellersville18960NCT07392892Map
PAUPMC Cancer Center at UPMC NorthwestSeneca16346NCT05112601Map
PAUPMC Cancer Center at UPMC NorthwestSeneca16346NCT05327686Map
PAUPMC Cancer Center at UPMC NorthwestSeneca16346NCT06203600Map
PAUPMC Cancer Center-UniontownUniontown15401NCT06203600Map
PAUPMC Cancer Center-WashingtonWashington15301NCT05112601Map
PAUPMC West Mifflin-Cancer Center JeffersonWest Mifflin15122NCT05112601Map
PAReading HospitalWest Reading19611NCT05327686Map
PAReading HospitalWest Reading19611NCT05677490Map
PAReading HospitalWest Reading19611NCT05987241Map
PAWexford Health and Wellness PavilionWexford15090NCT05327686Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT05327686Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT05677490Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT06203600Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT06632327Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT07166406Map
PADivine Providence HospitalWilliamsport17754NCT05327686Map
PAAsplundh Cancer PavilionWillow Grove19090NCT05677490Map
PAAsplundh Cancer PavilionWillow Grove19090NCT05987241Map
PAAsplundh Cancer PavilionWillow Grove19090NCT06203600Map
PAAlliance Cancer Specialists, PCWynnewood19096NCT07392892Map
PAUPMC MemorialYork17408NCT05327686Map
RIBrown University Health Cancer InstituteProvidence02906NCT06362369Map
RILifespan Cancer InstituteProvidence02903NCT06246916Map
RIRhode Island HospitalProvidence02903NCT04609046Map
RIRhode Island HospitalProvidence02903NCT04933903Map
RIRhode Island HospitalProvidence02903NCT04546399Map
RIRhode Island HospitalProvidence02903NCT05317858Map
RIRhode Island HospitalProvidence02903NCT05675410Map
RIRhode Island HospitalProvidence02903NCT06264180Map
RIRhode Island Hospital Site Number : 8400004Providence02903NCT05584670Map
RIWomen and Infants HospitalProvidence02905NCT05112601Map
RISmilow Cancer Hospital Care Center - WesterlyWesterly02891NCT05675410Map
RISmilow Cancer Hospital Care Center - WesterlyWesterly02891NCT05987241Map
RISmilow Cancer Hospital Care Center - WesterlyWesterly02891NCT06203600Map
SCAnMed Health Cancer CenterAnderson29621NCT05987241Map
SCSC Cancer Specialists at St. Joseph's/Candler BlufftonBluffton29910NCT02693535Map
SCSt. Joseph's/Candler SmithBluffton29910NCT02693535Map
SCSummit Cancer Care at St. Josph's/Candler BlufftonBluffton29910NCT02693535Map
SCPrisma Health Cancer Institute - SpartanburgBoiling Springs29316NCT05675410Map
SCPrisma Health Cancer Institute - SpartanburgBoiling Springs29316NCT05987241Map
SCMedical University of South CarolinaCharleston29425NCT04609046Map
SCMedical University of South CarolinaCharleston29425NCT03866382Map
SCMedical University of South CarolinaCharleston29425NCT05327686Map
SCMedical University of South CarolinaCharleston29425NCT05675410Map
SCMedical University of South CarolinaCharleston29425NCT05677490Map
SCMedical University of South CarolinaCharleston29425NCT05987241Map
SCMedical University of South CarolinaCharleston29425NCT06029270Map
SCMedical University of South CarolinaCharleston29425NCT06203600Map
SCMedical University of South CarolinaCharleston29425NCT06632327Map
SCMUSC Hollings Cancer CenterCharleston29425NCT07293351Map
SCRalph H Johnson VA Medical CenterCharleston29401NCT06203600Map
SCPrisma Health Richland HospitalColumbia29203NCT04546399Map
SCPrisma Health Richland HospitalColumbia29203NCT05675410Map
SCPrisma Health Richland HospitalColumbia29203NCT06064097Map
SCPrisma Health Cancer Institute - EasleyEasley29640NCT05987241Map
SCMcLeod Regional Medical CenterFlorence29506NCT06632327Map
SCGibbs Cancer Center-GaffneyGaffney29341NCT05987241Map
SCGibbs Cancer Center-GaffneyGaffney29341NCT06632327Map
SCBI-LO Charities Children's Cancer CenterGreenville29605NCT04546399Map
SCBI-LO Charities Children's Cancer CenterGreenville29605NCT05675410Map
SCBI-LO Charities Children's Cancer CenterGreenville29605NCT06064097Map
SCPrisma Health Cancer InstituteGreenville29605NCT06112314Map
SCPrisma Health Cancer Institute - ButternutGreenville29605NCT05987241Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT04546399Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT05675410Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT05987241Map
SCPrisma Health Cancer Institute - FarisGreenville29605NCT05987241Map
SCPrisma Health Greenville Memorial HospitalGreenville29605NCT05987241Map
SCSaint Francis Cancer CenterGreenville29607NCT05675410Map
SCSaint Francis Cancer CenterGreenville29607NCT06632327Map
SCSaint Francis HospitalGreenville29601NCT05675410Map
SCSaint Francis HospitalGreenville29601NCT06632327Map
SCSelf Regional HealthcareGreenwood29646NCT05327686Map
SCSelf Regional HealthcareGreenwood29646NCT06632327Map
SCGibbs Cancer Center-PelhamGreer29651NCT05987241Map
SCGibbs Cancer Center-PelhamGreer29651NCT06632327Map
SCPrisma Health Cancer Institute - GreerGreer29650NCT05987241Map
SCSouth Carolina Cancer SpecialistsHilton Head Island29926NCT02693535Map
SCCarolina Urologic Research Center, LLCMyrtle Beach29572NCT07293351Map
SCExelixis Clinical Site #9Myrtle Beach29572NCT05176483Map
SCLevine Cancer Institute-Rock HillRock Hill29732NCT05987241Map
SCPrisma Health Cancer Institute - SenecaSeneca29672NCT05987241Map
SCNorth Grove Medical ParkSpartanburg29303NCT06632327Map
SCSpartanburg Medical CenterSpartanburg29303NCT05987241Map
SCSpartanburg Medical CenterSpartanburg29303NCT06632327Map
SCSpartanburg Medical Center - Mary Black CampusSpartanburg29307NCT06632327Map
SCSpartanburg Regional Healthcare System - Spartanburg Medical Center (SMC)Spartanburg29303NCT06112314Map
SCSMC Center for Hematology Oncology UnionUnion29379NCT05987241Map
SCSMC Center for Hematology Oncology UnionUnion29379NCT06632327Map
SDAvera Cancer Institute-AberdeenAberdeen57401NCT05677490Map
SDAvera Cancer Institute - MitchellMitchell57301NCT05677490Map
SDAvera Cancer Institute at PierrePierre57501NCT05677490Map
SDRapid City Regional HospitalRapid City57701NCT05136196Map
SDRapid City Regional HospitalRapid City57701NCT05677490Map
SDRapid City Regional HospitalRapid City57701NCT06203600Map
SDAvera Cancer InstituteSioux Falls57105NCT05677490Map
SDAvera Cancer InstituteSioux Falls57105NCT06743126Map
SDSanford Cancer CenterSioux Falls57104NCT06646276Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT05136196Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT05327686Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT05677490Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT05987241Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT06203600Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT06632327Map
SDSanford Cancer Center Oncology Clinic and PharmacySioux Falls57104NCT02693535Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT05136196Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT04546399Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT05327686Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT05675410Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT05677490Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT05987241Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT06064097Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT06203600Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT06632327Map
SDAvera Cancer Institute at YanktonYankton57078NCT05677490Map
TNT C Thompson Children's HospitalChattanooga37403NCT05675410Map
TNTennessee Oncology - ChattanoogaChattanooga37404NCT06246916Map
TNBaptist Memorial Hospital and Cancer Center-ColliervilleCollierville38017NCT06632327Map
TNBaptist Memorial Hospital and Cancer Center-ColliervilleCollierville38017NCT07383441Map
TNThe West Clinic, PLLC dba West Cancer CenterGermantown38138NCT06581406Map
TNThe West Clinic, PLLC dba West Cancer CenterGermantown38138NCT06764771Map
TNWest Cancer Center and Research InstituteGermantown38138NCT06264180Map
TNEast Tennessee Childrens HospitalKnoxville37916NCT04546399Map
TNEast Tennessee Childrens HospitalKnoxville37916NCT05675410Map
TNThe University of Tennessee - Knoxville (UTK)Knoxville37920NCT06112314Map
TNUniversity of TennesseeKnoxville37920NCT06264180Map
TNUniversity of Tennessee Medical CenterKnoxville37920NCT06581406Map
TNUniversity of Tennessee Medical CenterKnoxville37920NCT06246916Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT06632327Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT07383441Map
TNSaint Jude Children's Research HospitalMemphis38105NCT06064097Map
TNExelixis Clinical Site #3Nashville37203NCT05176483Map
TNResearch SiteNashville37203NCT07431281Map
TNSara Cannon Research Institute TennesseeNashville37203NCT05533697Map
TNSarah Cannon Research InstituteNashville37203NCT04561206Map
TNSarah Cannon Research InstituteNashville37203-1619NCT05267626Map
TNSarah Cannon Research InstituteNashville37203NCT06581406Map
TNSarah Cannon Research InstituteNashville37203NCT05919264Map
TNSarah Cannon Research Institute (SCRI) Oncology PartnersNashville37203NCT06246916Map
TNSarah Cannon Research Institute: USA/TNNashville37203NCT06112314Map
TNSCRI Oncology PartnersNashville37203NCT06646276Map
TNSCRI Oncology PartnersNashville37203NCT06743126Map
TNSCRI Oncology PartnersNashville37203NCT07221149Map
TNSCRI Oncology PartnersNashville37203NCT07325136Map
TNTennesse OncologyNashville37203NCT03899155Map
TNTennessee OncologyNashville37203NCT06246916Map
TNTennessee Oncology - Nashville / Sarah Cannon Research InstituteNashville37203NCT02693535Map
TNTennessee Oncology, PLLCNashville37203NCT06112314Map
TNThe Children's Hospital at TriStar CentennialNashville37203NCT04546399Map
TNThe Children's Hospital at TriStar CentennialNashville37203NCT05675410Map
TNThe Children's Hospital at TriStar CentennialNashville37203NCT06064097Map
TNVanderbilt Ingram Cancer CenterNashville37232NCT05919264Map
TNVanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic)Nashville37232NCT06581406Map
TNVanderbilt University Medical CenterNashville37232NCT06047379Map
TNVanderbilt University Medical CenterNashville37232NCT06708949Map
TNVanderbilt University Medical CenterNashville37232NCT07210632Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT03866382Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT04546399Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT05361720Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT05501665Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT05675410Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT05987241Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT06064097Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT06203600Map
TNVanderbilt-Ingram Cancer CenterNashville37232NCT07188896Map
TXHendrick HealthAbilene79601NCT07195695Map
TXTexas Oncology - West TexasAbilene79606NCT06561386Map
TXTexas Oncology - Amarillo Cancer CenterAmarillo79124NCT07221149Map
TXDell Children's Medical Center of Central TexasAustin78723NCT04546399Map
TXDell Children's Medical Center of Central TexasAustin78723NCT05675410Map
TXDell Children's Medical Center of Central TexasAustin78723NCT06064097Map
TXExelixis Clinical Site #46Austin78705NCT05176483Map
TXTexas Oncology - Austin CentralAustin78745NCT06463665Map
TXTexas Oncology - Austin Central, Central Austin Cancer CenterAustin78731NCT06246916Map
TXTexas Oncology - Austin Midtown, Midtown Medical Center IAustin78705NCT06246916Map
TXTexas Oncology - Central/South TexasAustin78705NCT06646276Map
TXTexas Oncology (Balcones) - SCRIAustin78731-4214NCT05267626Map
TXTexas Oncology-Austin CentralAustin78731NCT07221149Map
TXWorld Research LinkBaytown77521NCT06463665Map
TXTexas OncologyBeaumont77702NCT07221149Map
TXTexas Oncology - BedfordBedford76022NCT06246916Map
TXDriscoll Children's HospitalCorpus Christi78411NCT04546399Map
TXDriscoll Children's HospitalCorpus Christi78411NCT05675410Map
TXBaylor UniversityDallas75246NCT06743126Map
TXBaylor, Scott and White Research InstituteDallas75246NCT06047379Map
TXExelixis Clinical Site #111Dallas75246NCT05176483Map
TXExelixis Clinical Site #89Dallas75246NCT05176483Map
TXMedical City Dallas HospitalDallas75230NCT04546399Map
TXMedical City Dallas HospitalDallas75230NCT05675410Map
TXParkland Memorial HospitalDallas75235NCT05112601Map
TXParkland Memorial HospitalDallas75235NCT05327686Map
TXParkland Memorial HospitalDallas75235NCT05677490Map
TXTexas OncologyDallas75246NCT06246916Map
TXTexas OncologyDallas75246NCT06264180Map
TXTexas Oncology - Medical CityDallas75230NCT06246916Map
TXUniversity of Texas SouthwesternDallas75235-9179NCT06112314Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT05502315Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT06264180Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT06708949Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT06743126Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT06794229Map
TXUniversity of Texas, Southwestern Medical CenterDallas75390NCT05361720Map
TXUT Southwestern Medical CenterDallas75390NCT06581406Map
TXUT Southwestern Medical CenterDallas75390NCT06053658Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT03816345Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT03866382Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT05327686Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT05647265Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT05677490Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT05987241Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT04609046Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT05112601Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT03816345Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT03866382Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT04546399Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT05327686Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT05647265Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT05675410Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT05987241Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT06064097Map
TXTexas Oncology - Northeast TexasDenison75020NCT07221149Map
TXEl Paso Children's HospitalEl Paso79905NCT04546399Map
TXEl Paso Children's HospitalEl Paso79905NCT05675410Map
TXCenter For Disease And Blood DisorderFort Worth76104NCT06246916Map
TXCook Children's Medical CenterFort Worth76104NCT04546399Map
TXCook Children's Medical CenterFort Worth76104NCT05675410Map
TXCook Children's Medical CenterFort Worth76104NCT06064097Map
TXTarrant County Hospital District/JPS Health NetworkFort Worth76104NCT05677490Map
TXTexas Oncology - Fort WorthFort Worth76104NCT06246916Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT05112601Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT03816345Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT03866382Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT05327686Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT05647265Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT05677490Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT05987241Map
TXTexas Oncology - DFWGrapevine76051NCT07221149Map
TXTexas Oncology - GrapevineGrapevine76051NCT06246916Map
TXTexas Oncology - Harlingen, Medical Arts PavillionHarlingen78550NCT06246916Map
TXBaylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston77030NCT05675410Map
TXBaylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston77030NCT05987241Map
TXBaylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston77030NCT06064097Map
TXBaylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston77030NCT06203600Map
TXBen Taub General HospitalHouston77030NCT05987241Map
TXBen Taub General HospitalHouston77030NCT06203600Map
TXLyndon Baines Johnson General HospitalHouston77026-1967NCT05987241Map
TXM D Anderson Cancer CenterHouston77030NCT04745949Map
TXM D Anderson Cancer CenterHouston77030NCT05048212Map
TXM D Anderson Cancer CenterHouston77030NCT04380545Map
TXM D Anderson Cancer CenterHouston77030NCT04546399Map
TXM D Anderson Cancer CenterHouston77030NCT03025256Map
TXM D Anderson Cancer CenterHouston77030NCT05704647Map
TXM D Anderson Cancer CenterHouston77030NCT06053658Map
TXMD AndersonHouston77030NCT05266612Map
TXMD Anderson Cancer CenterHouston77030NCT04665206Map
TXMD Anderson Cancer CenterHouston77030-4000NCT05267626Map
TXMD Anderson Cancer CenterHouston77030NCT05663710Map
TXMD Anderson Cancer CenterHouston77030NCT06362369Map
TXMD Anderson Cancer CenterHouston77030NCT06534983Map
TXMD Anderson Cancer CenterHouston77090NCT06561087Map
TXMD Anderson Cancer CenterHouston77030NCT07401875Map
TXMichael E DeBakey VA Medical CenterHouston77030NCT05987241Map
TXMichael E. DeBakey VA Medical Center, Houston, TXHouston77030-4211NCT06275360Map
TXTexas Children's HospitalHouston77030NCT04995003Map
TXThe University of Texas M. D. Anderson Cancer CenterHouston77030NCT06708949Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT02693535Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT05919264Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT06246916Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT06264180Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT06743126Map
TXThe University Of Texas Md Anderson Cancer CenterHouston77030NCT06581406Map
TXUniversity of Texas MD Anderson Cancer CenterHouston77030NCT03686124Map
TXUniversity of Texas MD Anderson Cancer CenterHouston77030NCT06561386Map
TXUniversity of Texas MD Anderson Cancer Center Site Number : 8400005Houston77030-4000NCT05584670Map
TXUT MD Anderson Cancer CenterHouston77030NCT03816345Map
TXUT MD Anderson Cancer CenterHouston77030NCT05675410Map
TXUT MD Anderson Cancer CenterHouston77030NCT06064097Map
TXExelixis Clinical Site #73Irving75063NCT05176483Map
TXNEXT OncologyIrving75039NCT07563738Map
TXNEXT Oncology - IrvingIrving75039NCT06618287Map
TXUS Oncology Investigational Products Center (IPC)Irving75063NCT07392892Map
TXTexas Oncology - LongviewLongview75601NCT06246916Map
TXCovenant Children's HospitalLubbock79410NCT04546399Map
TXCovenant Children's HospitalLubbock79410NCT05675410Map
TXJoe Arrington Cancer Research & Treatment CenterLubbock79410NCT06246916Map
TXUMC Cancer Center / UMC Health SystemLubbock79415NCT04546399Map
TXUMC Cancer Center / UMC Health SystemLubbock79415NCT05675410Map
TXTexas Oncology - McAllenMcAllen78503NCT06246916Map
TXTexas Oncology-Palestine Cancer CenterPalestine75801NCT06246916Map
TXExelixis Clinical Site #50Plano75075NCT05176483Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT05112601Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT03816345Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT03866382Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT05327686Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT05647265Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT05677490Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT05987241Map
TXChildren's Hospital of San AntonioSan Antonio78207NCT04546399Map
TXChildren's Hospital of San AntonioSan Antonio78207NCT05675410Map
TXChildren's Hospital of San AntonioSan Antonio78207NCT06064097Map
TXMethodist Children's Hospital of South TexasSan Antonio78229NCT04546399Map
TXMethodist Children's Hospital of South TexasSan Antonio78229NCT05675410Map
TXNEXT OncologySan Antonio78229NCT04665206Map
TXSite 01San Antonio78229NCT07276373Map
TXSouth Texas Accelerated Research Therapeutics, LLCSan Antonio78229NCT05919264Map
TXSTART San Antonio ( Site 0104)San Antonio78229NCT07405164Map
TXSTART South Texas Accelerated Research TherapeuticsSan Antonio78229NCT05267626Map
TXTexas Oncology - San AntonioSan Antonio78240NCT07221149Map
TXUniversity of Texas Health Science Center at San AntonioSan Antonio78229NCT04546399Map
TXUniversity of Texas Health Science Center at San AntonioSan Antonio78229NCT05675410Map
TXScott and White Memorial HospitalTemple76508NCT05327686Map
TXScott and White Memorial HospitalTemple76508NCT05675410Map
TXExelixis Clinical Site #70Tyler75601NCT05176483Map
TXTexas Oncology - Northeast TexasTyler75702NCT06646276Map
TXTexas Oncology-Tyler, Northeast Texas Cancer InstituteTyler75702NCT06246916Map
TXThe University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer CenterTyler75701NCT06561386Map
TXTexas Oncology - Weslaco, Knapp Medical PlazaWeslaco78596NCT06246916Map
UTCedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer CenterCedar City84720NCT02693535Map
UTFarmington Health CenterFarmington84025NCT05677490Map
UTFarmington Health CenterFarmington84025NCT06203600Map
UTIntermountain HealthMurray84107NCT06264180Map
UTCommunity Cancer Trials of UtahOgden84405NCT07195695Map
UTHuntsman Cancer InstituteSalt Lake City84112NCT06264180Map
UTHuntsman Cancer InstituteSalt Lake City84112NCT06365619Map
UTHuntsman Cancer Institute at the University of UtahSalt Lake City84112NCT03646617Map
UTHuntsman Cancer Institute, University of UtahSalt Lake City84112NCT06743126Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05136196Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT04511013Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05675410Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05677490Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05896839Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05987241Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT06203600Map
UTIntermountain HealthcareSalt Lake City84107NCT02693535Map
UTPrimary Children's HospitalSalt Lake City84113NCT04546399Map
UTPrimary Children's HospitalSalt Lake City84113NCT05675410Map
UTUniversity of Utah - Huntsman Cancer InstituteSalt Lake City84112NCT05267626Map
UTUniversity of Utah Huntsman Cancer InstituteSalt Lake City84112NCT06112314Map
UTUniversity of Utah Huntsman Cancer InstituteSalt Lake City84112NCT06246916Map
UTUniversity of Utah Sugarhouse Health CenterSalt Lake City84106NCT05677490Map
UTUniversity of Utah Sugarhouse Health CenterSalt Lake City84106NCT06203600Map
UTDixie Regional Medical Center-River Road CampusSt. George84770NCT02693535Map
UTSite 02West Valley City84119NCT07276373Map
VTCentral Vermont Medical Center/National Life Cancer TreatmentBerlin Corners05602NCT05327686Map
VTCentral Vermont Medical Center/National Life Cancer TreatmentBerlin Corners05602NCT05677490Map
VTCentral Vermont Medical Center/National Life Cancer TreatmentBerlin Corners05602NCT05987241Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT04546399Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT05327686Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT05675410Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT05677490Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT05987241Map
VTUniversity of Vermont Medical CenterBurlington05401NCT05327686Map
VTUniversity of Vermont Medical CenterBurlington05401NCT05677490Map
VTUniversity of Vermont Medical CenterBurlington05401NCT05987241Map
VTUniversity of Vermont Medical CenterBurlington05401NCT06264180Map
VTDartmouth Cancer Center - NorthSaint Johnsbury05819NCT05136196Map
VTDartmouth Cancer Center - NorthSaint Johnsbury05819NCT06632327Map
VAInova Alexandria HospitalAlexandria22304NCT05136196Map
VAInova Alexandria HospitalAlexandria22304NCT05327686Map
VAInova Alexandria HospitalAlexandria22304NCT07166406Map
VAVirginia Cancer Specialists, PCArlington22201NCT04665206Map
VAVirginia Cancer Specialists, PCArlington22201NCT07392892Map
VAExelixis Clinical Site #66Charlottesville22903NCT05176483Map
VAUniversity of VirginiaCharlottesville22908NCT05919264Map
VAUniversity of VirginiaCharlottesville22908NCT06246916Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT05112601Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT05675410Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT05677490Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT05987241Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT06064097Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT06632327Map
VAUVA Health-UVA Emily Couric Clinical Cancer CenterCharlottesville22903NCT06112314Map
VAVirginia Oncology AssociatesChesapeake23320NCT07392892Map
VAInova Fair Oaks HospitalFairfax22033NCT05136196Map
VAInova Fair Oaks HospitalFairfax22033NCT05327686Map
VAInova Fair Oaks HospitalFairfax22033NCT05677490Map
VAInova Fair Oaks HospitalFairfax22033NCT07166406Map
VAInova Schar Cancer InstituteFairfax22031NCT05136196Map
VAInova Schar Cancer InstituteFairfax22042NCT02693535Map
VAInova Schar Cancer InstituteFairfax22031NCT05327686Map
VAInova Schar Cancer InstituteFairfax22031NCT05677490Map
VAInova Schar Cancer InstituteFairfax22031NCT06246916Map
VAInova Schar Cancer InstituteFairfax22031NCT07166406Map
VANEXT Oncology VirginiaFairfax22031NCT07563738Map
VAVirginia Cancer Specialists, PCFairfax22031NCT06246916Map
VAVirginia Cancer Specialists, PCFairfax22031NCT07392892Map
VAInova Fairfax HospitalFalls Church22042NCT05136196Map
VAInova Fairfax HospitalFalls Church22042NCT04546399Map
VAInova Fairfax HospitalFalls Church22042NCT05675410Map
VAInova Fairfax HospitalFalls Church22042NCT05677490Map
VAInova Fairfax HospitalFalls Church22042NCT07166406Map
VAVirginia Oncology AssociatesHampton23666NCT07392892Map
VAInova Loudoun HospitalLeesburg20176NCT07166406Map
VACentra Alan B Pearson Regional Cancer CenterLynchburg24501NCT05136196Map
VACentra Alan B Pearson Regional Cancer CenterLynchburg24501NCT05677490Map
VAVirginia Cancer Specialists, PCManassas20110NCT07392892Map
VABon Secours Memorial Regional Medical CenterMechanicsville23116NCT05987241Map
VABon Secours Saint Francis Medical CenterMidlothian23114NCT05327686Map
VABon Secours Saint Francis Medical CenterMidlothian23114NCT05987241Map
VAVirginia Oncology AssociatesNewport News23606NCT07392892Map
VAChildren's Hospital of The King's DaughtersNorfolk23507NCT04546399Map
VAChildren's Hospital of The King's DaughtersNorfolk23507NCT05675410Map
VAChildren's Hospital of The King's DaughtersNorfolk23507NCT06064097Map
VAVirginia Oncology AssociatesNorfolk23502NCT06246916Map
VAVirginia Oncology AssociatesNorfolk23502NCT07392892Map
VANaval Medical Center - PortsmouthPortsmouth23708-2197NCT05675410Map
VAVirginia Cancer Specialists, PCReston20190NCT07392892Map
VABon Secours Cancer Institute at Reynolds CrossingRichmond23230NCT05327686Map
VABon Secours Richmond Community HospitalRichmond23223NCT05987241Map
VABon Secours Saint Mary's HospitalRichmond23226NCT05987241Map
VAHenrico Doctor's HospitalRichmond23229NCT05112601Map
VAJohnston Willis HospitalRichmond23235NCT05317858Map
VARichmond VA Medical Center, Richmond, VARichmond23249-0001NCT06275360Map
VAVCU Massey Cancer Center at Stony PointRichmond23235NCT05136196Map
VAVCU Massey Cancer Center at Stony PointRichmond23235NCT05677490Map
VAVCU Massey Cancer Center at Stony PointRichmond23235NCT05987241Map
VAVCU Massey Cancer Center at Stony PointRichmond23235NCT06203600Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT05136196Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT03816345Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT04546399Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT05675410Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT05677490Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT05987241Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT06064097Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT06203600Map
VAVirginia Cancer InstituteRichmond23229NCT05136196Map
VAVirginia Cancer InstituteRichmond23229NCT05677490Map
VAVirginia Commonwealth UniversityRichmond23219NCT06743126Map
VAVirginia Commonwealth UniversityRichmond23298NCT06794229Map
VAVirginia Commonwealth University (VCU) - Massey Cancer CenterRichmond23298-0070NCT06112314Map
VAVirginia Commonwealth University Massey Cancer CenterRichmond23298NCT06246916Map
VACarilion Children'sRoanoke24014NCT05675410Map
VAOncology & Hematology Associates of Southwest Virginia, Inc.Roanoke24014NCT06246916Map
VAOncology & Hematology Associates of Southwest Virginia, Inc.Roanoke24014NCT06646276Map
VAOncology and Hematology Associates of Southwest Virginia, Inc. - SalemSalem24153NCT07221149Map
VAVCU Community Memorial Health CenterSouth Hill23970NCT05677490Map
VAVCU Community Memorial Health CenterSouth Hill23970NCT05987241Map
VAVCU Health Tappahannock HospitalTappahannock22560NCT05136196Map
VAVirginia Oncology AssociatesVirginia Beach23456NCT07392892Map
VAVirginia Cancer Specialists, PCWoodbridge22191NCT07392892Map
WAProvidence Regional Cancer System-AberdeenAberdeen98520NCT04511013Map
WAProvidence Regional Cancer System-AberdeenAberdeen98520NCT05647265Map
WAProvidence Regional Cancer System-AberdeenAberdeen98520NCT05677490Map
WAPeaceHealth Saint Joseph Medical CenterBellingham98225NCT04511013Map
WAPeaceHealth Saint Joseph Medical CenterBellingham98225NCT05647265Map
WAPeaceHealth Saint Joseph Medical CenterBellingham98225NCT05677490Map
WANorthwest Medical SpecialtiesBonney Lake98391NCT02693535Map
WAProvidence Regional Cancer System-CentraliaCentralia98531NCT04511013Map
WAProvidence Regional Cancer System-CentraliaCentralia98531NCT05647265Map
WAProvidence Regional Cancer System-CentraliaCentralia98531NCT05677490Map
WASwedish Cancer Institute - EdmondsEdmonds98026NCT06646276Map
WASwedish Cancer Institute - Edmonds CampusEdmonds98026NCT06246916Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT05112601Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT04511013Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT05647265Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT05677490Map
WAProvidence Regional Cancer PartnershipEverett98201NCT04511013Map
WAProvidence Regional Cancer PartnershipEverett98201NCT05647265Map
WAProvidence Regional Cancer PartnershipEverett98201NCT05677490Map
WANorthwest Medical SpecialtiesFederal Way98003NCT02693535Map
WANorthwest Medical SpecialtiesGig Harbor98332NCT02693535Map
WASwedish Cancer Institute - Issaquah CampusIssaquah98029NCT06246916Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT05112601Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT04511013Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT05647265Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT05677490Map
WAKadlec Clinic Hematology and OncologyKennewick99336NCT03866382Map
WAKadlec Clinic Hematology and OncologyKennewick99336NCT04511013Map
WAKadlec Clinic Hematology and OncologyKennewick99336NCT05647265Map
WAKadlec Clinic Hematology and OncologyKennewick99336NCT05677490Map
WAKadlec Clinic Hematology and OncologyKennewick99336NCT06246916Map
WAProvidence Regional Cancer System-LaceyLacey98503NCT04511013Map
WAProvidence Regional Cancer System-LaceyLacey98503NCT05647265Map
WAProvidence Regional Cancer System-LaceyLacey98503NCT05677490Map
WAPeaceHealth Saint John Medical CenterLongview98632NCT04511013Map
WAPeaceHealth Saint John Medical CenterLongview98632NCT05647265Map
WAPeaceHealth Saint John Medical CenterLongview98632NCT05677490Map
WASkagit Regional Health Cancer Care CenterMount Vernon98274NCT05647265Map
WASkagit Regional Health Cancer Care CenterMount Vernon98274NCT05677490Map
WANorthwest Medical SpecialtiesOlympia98502NCT02693535Map
WAJefferson HealthcarePort Townsend98368NCT04511013Map
WANorthwest Medical SpecialtiesPuyallup98373NCT02693535Map
WAValley Medical CenterRenton98055NCT03866382Map
WAValley Medical CenterRenton98055NCT05647265Map
WAValley Medical CenterRenton98055NCT05675410Map
WAValley Medical CenterRenton98055NCT05677490Map
WAFred Hutch/University of Washington Cancer ConsortiumSeattle98109NCT05098210Map
WAFred Hutch/University of Washington Cancer ConsortiumSeattle98109NCT06745076Map
WAFred Hutchinson Cancer CenterSeattle98109NCT03686124Map
WAFred Hutchinson Cancer CenterSeattle98109NCT06581406Map
WAFred Hutchinson Cancer CenterSeattle98109NCT06697197Map
WAFred Hutchinson Cancer CenterSeattle98109NCT06743126Map
WAFred Hutchinson Cancer Center - 825 Eastlake Ave E- Site Number : 8400010Seattle98109-4405NCT05584670Map
WAFred Hutchinson Cancer Research CenterSeattle98109NCT06534983Map
WASeattle Children's HospitalSeattle98105NCT04546399Map
WASeattle Children's HospitalSeattle98105NCT05675410Map
WASeattle Children's HospitalSeattle98105NCT06064097Map
WASwedish Cancer InstituteSeattle98104NCT02693535Map
WASwedish Cancer InstituteSeattle98104NCT06246916Map
WASwedish Medical CenterSeattle98104NCT06618287Map
WASwedish Medical CenterSeattle98104NCT06646276Map
WASwedish Medical Center - Swedish Cancer Institute (SCI) - First Hill CampusSeattle98104NCT06112314Map
WASwedish Medical Center-Ballard CampusSeattle98107NCT04511013Map
WASwedish Medical Center-Ballard CampusSeattle98107NCT05647265Map
WASwedish Medical Center-Ballard CampusSeattle98107NCT05677490Map
WASwedish Medical Center-Cherry HillSeattle98122-5711NCT04511013Map
WASwedish Medical Center-Cherry HillSeattle98122-5711NCT05647265Map
WASwedish Medical Center-Cherry HillSeattle98122-5711NCT05677490Map
WASwedish Medical Center-First HillSeattle98122NCT05112601Map
WASwedish Medical Center-First HillSeattle98122NCT04511013Map
WASwedish Medical Center-First HillSeattle98122NCT05647265Map
WASwedish Medical Center-First HillSeattle98122NCT05677490Map
WASwedish Medical Center-First HillSeattle98122NCT06029270Map
WAUniversity of Washington Medical CenterSeattle98195NCT06534983Map
WAVirginia Mason Medical CenterSeattle98101NCT05327686Map
WAVirginia Mason Medical CenterSeattle98101NCT05987241Map
WAPeaceHealth United General Medical CenterSedro-Woolley98284NCT04511013Map
WAPeaceHealth United General Medical CenterSedro-Woolley98284NCT05647265Map
WAPeaceHealth United General Medical CenterSedro-Woolley98284NCT05677490Map
WAProvidence Regional Cancer System-SheltonShelton98584NCT04511013Map
WASaint Joseph Medical Center Hematology and Oncology - SilverdaleSilverdale98383NCT06632327Map
WACancer Care Northwest - Spokane SouthSpokane99202NCT05647265Map
WACancer Care Northwest - Spokane SouthSpokane99202NCT05677490Map
WACancer Care Northwest-North SpokaneSpokane99218NCT05647265Map
WACancer Care Northwest-North SpokaneSpokane99218NCT05677490Map
WACancer Care Northwest-ValleySpokane99216NCT05647265Map
WACancer Care Northwest-ValleySpokane99216NCT05677490Map
WAProvidence Sacred Heart Medical Center and Children's HospitalSpokane99204NCT04546399Map
WAProvidence Sacred Heart Medical Center and Children's HospitalSpokane99204NCT05675410Map
WAMadigan Army Medical CenterTacoma98431NCT04546399Map
WAMary Bridge Children's Hospital and Health CenterTacoma98405NCT04546399Map
WAMary Bridge Children's Hospital and Health CenterTacoma98405NCT05675410Map
WAMary Bridge Children's Hospital and Health CenterTacoma98405NCT06064097Map
WANorthwest Medical SpecialtiesTacoma98405NCT02693535Map
WANorthwest Medical SpecialtiesTacoma98405NCT06047379Map
WALegacy Cancer Institute Medical Oncology and Day TreatmentVancouver98684NCT06632327Map
WALegacy Salmon Creek HospitalVancouver98686NCT06632327Map
WAPeaceHealth Southwest Medical CenterVancouver98664NCT04511013Map
WAPeaceHealth Southwest Medical CenterVancouver98664NCT05647265Map
WAPeaceHealth Southwest Medical CenterVancouver98664NCT05677490Map
WAProvidence Saint Mary Regional Cancer CenterWalla Walla99362NCT04511013Map
WAProvidence Saint Mary Regional Cancer CenterWalla Walla99362NCT05647265Map
WAProvidence Saint Mary Regional Cancer CenterWalla Walla99362NCT05677490Map
WANorth Star Lodge Cancer Center at Yakima Valley Memorial HospitalYakima98902NCT05647265Map
WANorth Star Lodge Cancer Center at Yakima Valley Memorial HospitalYakima98902NCT05677490Map
WAProvidence Regional Cancer System-YelmYelm98597NCT04511013Map
WVWest Virginia University Charleston DivisionCharleston25304NCT04546399Map
WVWest Virginia University Charleston DivisionCharleston25304NCT05675410Map
WVWest Virginia University Charleston DivisionCharleston25304NCT05677490Map
WVWest Virginia University Charleston DivisionCharleston25304NCT05987241Map
WVEdwards Comprehensive Cancer CenterHuntington25701NCT05327686Map
WVEdwards Comprehensive Cancer CenterHuntington25701NCT05675410Map
WVWest Virginia UniversityMorgantown26506NCT06246916Map
WVWest Virginia UniversityMorgantown26506NCT06264180Map
WVWest Virginia University HealthcareMorgantown26506NCT04609046Map
WVWest Virginia University HealthcareMorgantown26506NCT04546399Map
WVWest Virginia University HealthcareMorgantown26506NCT05987241Map
WILanglade Hospital and Cancer CenterAntigo54409NCT04511013Map
WILanglade Hospital and Cancer CenterAntigo54409NCT05327686Map
WILanglade Hospital and Cancer CenterAntigo54409NCT05677490Map
WILanglade Hospital and Cancer CenterAntigo54409NCT06203600Map
WIThedaCare Regional Cancer CenterAppleton54911NCT05987241Map
WIThedaCare Regional Cancer CenterAppleton54911NCT06632327Map
WIDuluth Clinic AshlandAshland54806NCT05112601Map
WIDuluth Clinic AshlandAshland54806NCT05136196Map
WIDuluth Clinic AshlandAshland54806NCT03866382Map
WIDuluth Clinic AshlandAshland54806NCT05327686Map
WIDuluth Clinic AshlandAshland54806NCT05677490Map
WIDuluth Clinic AshlandAshland54806NCT06203600Map
WIDuluth Clinic AshlandAshland54806NCT07166406Map
WINorthwest Wisconsin Cancer CenterAshland54806NCT05112601Map
WINorthwest Wisconsin Cancer CenterAshland54806NCT05327686Map
WINorthwest Wisconsin Cancer CenterAshland54806NCT05677490Map
WINorthwest Wisconsin Cancer CenterAshland54806NCT07166406Map
WIThedaCare Cancer Care - BerlinBerlin54923NCT06632327Map
WIAurora Cancer Care - BurlingtonBurlington53105NCT02693535Map
WIAurora Cancer Care-Southern Lakes VLCCBurlington53105NCT03866382Map
WIAurora Cancer Care-Southern Lakes VLCCBurlington53105NCT05675410Map
WIAurora Cancer Care-Southern Lakes VLCCBurlington53105NCT05677490Map
WIAurora Cancer Care-Southern Lakes VLCCBurlington53105NCT06203600Map
WIMarshfield Clinic-Chippewa CenterChippewa Falls54729NCT05677490Map
WIMarshfield Clinic-Chippewa CenterChippewa Falls54729NCT06632327Map
WIAurora Saint Luke's South ShoreCudahy53110NCT05675410Map
WIAurora Saint Luke's South ShoreCudahy53110NCT05677490Map
WIAurora Saint Luke's South ShoreCudahy53110NCT05987241Map
WIAurora Saint Luke's South ShoreCudahy53110NCT06203600Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT04609046Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT05136196Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT03866382Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT04511013Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT05327686Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT05677490Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT05987241Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT06203600Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT06632327Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT07166406Map
WIMayo Clinic Health System-Eau Claire ClinicEau Claire54701NCT03866382Map
WIAurora Health Care - Germantown Health CenterGermantown53022NCT02693535Map
WIAurora Health Care Germantown Health CenterGermantown53022NCT03866382Map
WIAurora Health Care Germantown Health CenterGermantown53022NCT05675410Map
WIAurora Health Care Germantown Health CenterGermantown53022NCT05677490Map
WIAurora Health Care Germantown Health CenterGermantown53022NCT06203600Map
WIAurora Cancer Care - GraftonGrafton53024NCT02693535Map
WIAurora Cancer Care-GraftonGrafton53024NCT03866382Map
WIAurora Cancer Care-GraftonGrafton53024NCT05675410Map
WIAurora Cancer Care-GraftonGrafton53024NCT05677490Map
WIAurora Cancer Care-GraftonGrafton53024NCT05987241Map
WIAurora Cancer Care-GraftonGrafton53024NCT06203600Map
WIAurora BayCare Medical CenterGreen Bay54311NCT03866382Map
WIAurora BayCare Medical CenterGreen Bay54311NCT02693535Map
WIAurora BayCare Medical CenterGreen Bay54311NCT05675410Map
WIAurora BayCare Medical CenterGreen Bay54311NCT05677490Map
WIAurora BayCare Medical CenterGreen Bay54311NCT05987241Map
WIAurora BayCare Medical CenterGreen Bay54311NCT06203600Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT05136196Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT05327686Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT05677490Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT05987241Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT06203600Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT06632327Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT05136196Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT04546399Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT05327686Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT05675410Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT05677490Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT05987241Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT06203600Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT06632327Map
WIEssentia Health-Hayward ClinicHayward54843NCT05327686Map
WIEssentia Health-Hayward ClinicHayward54843NCT05677490Map
WIEssentia Health-Hayward ClinicHayward54843NCT07166406Map
WITamarack Health Hayward Medical CenterHayward54843NCT05677490Map
WIAurora Cancer Care - Kenosha SouthKenosha53142NCT02693535Map
WIAurora Cancer Care-Kenosha SouthKenosha53142NCT03866382Map
WIAurora Cancer Care-Kenosha SouthKenosha53142NCT05675410Map
WIAurora Cancer Care-Kenosha SouthKenosha53142NCT05677490Map
WIAurora Cancer Care-Kenosha SouthKenosha53142NCT06203600Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT04609046Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT05136196Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT04511013Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT05675410Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT05677490Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT06632327Map
WIMarshfield Medical Center - LadysmithLadysmith54848NCT05677490Map
WIMarshfield Medical Center - LadysmithLadysmith54848NCT06632327Map
WISSM Health Cancer CareMadison53717NCT04295863Map
WIUniversity of WisconsinMadison53705NCT03681561Map
WIUniversity of WisconsinMadison53705NCT05502315Map
WIUniversity of Wisconsin Carbone Cancer CenterMadison53792NCT04989946Map
WIUniversity of Wisconsin Carbone Cancer CenterMadison53792NCT04511013Map
WIUniversity of Wisconsin Carbone Cancer CenterMadison53792NCT04150640Map
WIUniversity of Wisconsin Carbone Cancer CenterMadison53792NCT06246916Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT05327686Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT05675410Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT05987241Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT06203600Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT04546399Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT05327686Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT05675410Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT05987241Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT06203600Map
WIUniversity Of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT06581406Map
WIUniversity of Wisconsin, Carbone Cancer CenterMadison53705NCT05919264Map
WIUW Carbone Cancer CenterMadison53705NCT04900818Map
WIUW Hospital and ClinicsMadison53792NCT07281924Map
WIWilliam S Middleton VA Medical CenterMadison53705NCT06203600Map
WIAurora Bay Area Medical CenterMarinette54143NCT02693535Map
WIAurora Bay Area Medical Group-MarinetteMarinette54143NCT03866382Map
WIAurora Bay Area Medical Group-MarinetteMarinette54143NCT05675410Map
WIAurora Bay Area Medical Group-MarinetteMarinette54143NCT05677490Map
WIAurora Bay Area Medical Group-MarinetteMarinette54143NCT05987241Map
WIAurora Bay Area Medical Group-MarinetteMarinette54143NCT06203600Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT04609046Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05136196Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT03866382Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT04511013Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05327686Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05675410Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05677490Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05987241Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT06203600Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT06632327Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT07166406Map
WIAspirus Medford HospitalMedford54451NCT04511013Map
WIAspirus Medford HospitalMedford54451NCT05677490Map
WIAspirus Medford HospitalMedford54451NCT06203600Map
WIFroedtert Menomonee Falls HospitalMenomonee Falls53051NCT05327686Map
WIFroedtert Menomonee Falls HospitalMenomonee Falls53051NCT06632327Map
WIAurora Cancer Care MilwaukeeMilwaukee53209NCT02693535Map
WIAurora Cancer Care-MilwaukeeMilwaukee53209NCT03866382Map
WIAurora Cancer Care-MilwaukeeMilwaukee53209NCT05675410Map
WIAurora Cancer Care-MilwaukeeMilwaukee53209NCT05677490Map
WIAurora Cancer Care-MilwaukeeMilwaukee53209NCT06203600Map
WIAurora Saint Luke's Medical CenterMilwaukee53215NCT03866382Map
WIAurora Saint Luke's Medical CenterMilwaukee53215NCT05675410Map
WIAurora Saint Luke's Medical CenterMilwaukee53215NCT05677490Map
WIAurora Saint Luke's Medical CenterMilwaukee53215NCT05987241Map
WIAurora Saint Luke's Medical CenterMilwaukee53215NCT06203600Map
WIAurora Sinai Medical CenterMilwaukee53233NCT03866382Map
WIAurora Sinai Medical CenterMilwaukee53223NCT02693535Map
WIAurora Sinai Medical CenterMilwaukee53233NCT05675410Map
WIAurora Sinai Medical CenterMilwaukee53233NCT05677490Map
WIAurora Sinai Medical CenterMilwaukee53233NCT05987241Map
WIAurora Sinai Medical CenterMilwaukee53233NCT06203600Map
WIAurora St. Luke's Medical CenterMilwaukee53215NCT02693535Map
WIAurora West Allis Medical CenterMilwaukee53227NCT02693535Map
WIChildren's Hospital of WisconsinMilwaukee53226NCT04546399Map
WIChildren's Hospital of WisconsinMilwaukee53226NCT05675410Map
WIChildren's Hospital of WisconsinMilwaukee53226NCT06064097Map
WIExelixis Clinical Site #33Milwaukee53226NCT05176483Map
WIMedical College of WisconsinMilwaukee53226NCT03259867Map
WIMedical College of WisconsinMilwaukee53226NCT05136196Map
WIMedical College of WisconsinMilwaukee53226NCT05327686Map
WIMedical College of WisconsinMilwaukee53226NCT05987241Map
WIMedical College of WisconsinMilwaukee53226NCT06632327Map
WIZablocki Veterans Administration Medical CenterMilwaukee53295NCT06632327Map
WIMarshfield Clinic-Minocqua CenterMinocqua54548NCT04511013Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT04609046Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT05136196Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT03866382Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT05327686Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT05677490Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT06203600Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT06632327Map
WIProHealth D N Greenwald CenterMukwonago53149NCT05136196Map
WIProHealth D N Greenwald CenterMukwonago53149NCT03866382Map
WIProHealth D N Greenwald CenterMukwonago53149NCT05327686Map
WIProHealth D N Greenwald CenterMukwonago53149NCT05675410Map
WIProHealth D N Greenwald CenterMukwonago53149NCT05677490Map
WIProHealth D N Greenwald CenterMukwonago53149NCT05987241Map
WIProHealth D N Greenwald CenterMukwonago53149NCT06029270Map
WIProHealth D N Greenwald CenterMukwonago53149NCT06203600Map
WIProHealth D N Greenwald CenterMukwonago53149NCT06632327Map
WIProHealth D N Greenwald CenterMukwonago53149NCT07166406Map
WIThedaCare Regional Medical Center - NeenahNeenah54956NCT06632327Map
WIMarshfield Medical Center - NeillsvilleNeillsville54456NCT05677490Map
WIMarshfield Medical Center - NeillsvilleNeillsville54456NCT06632327Map
WIThedaCare Cancer Care - New LondonNew London54961NCT06632327Map
WICancer Center of Western WisconsinNew Richmond54017NCT05136196Map
WICancer Center of Western WisconsinNew Richmond54017NCT04511013Map
WICancer Center of Western WisconsinNew Richmond54017NCT05327686Map
WICancer Center of Western WisconsinNew Richmond54017NCT05677490Map
WICancer Center of Western WisconsinNew Richmond54017NCT06632327Map
WIDrexel Town Square Health CenterOak Creek53154NCT05327686Map
WIDrexel Town Square Health CenterOak Creek53154NCT06632327Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT05136196Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT03866382Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT05327686Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT05675410Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT05677490Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT05987241Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT06029270Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT06203600Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT06632327Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT07166406Map
WISaint Vincent Hospital Cancer Center at Oconto FallsOconto Falls54154NCT05136196Map
WISaint Vincent Hospital Cancer Center at Oconto FallsOconto Falls54154NCT05677490Map
WISaint Vincent Hospital Cancer Center at Oconto FallsOconto Falls54154NCT05987241Map
WISaint Vincent Hospital Cancer Center at Oconto FallsOconto Falls54154NCT06203600Map
WISaint Vincent Hospital Cancer Center at Oconto FallsOconto Falls54154NCT06632327Map
WIThedaCare Cancer Care - OshkoshOshkosh54904NCT06632327Map
WIVince Lombardi Cancer Clinic - OshkoshOshkosh54904NCT03866382Map
WIVince Lombardi Cancer Clinic - OshkoshOshkosh54904NCT02693535Map
WIVince Lombardi Cancer Clinic - OshkoshOshkosh54904NCT05675410Map
WIVince Lombardi Cancer Clinic - OshkoshOshkosh54904NCT05677490Map
WIVince Lombardi Cancer Clinic - OshkoshOshkosh54904NCT05987241Map
WIVince Lombardi Cancer Clinic - OshkoshOshkosh54904NCT06203600Map
WIAurora Cancer Care - RacineRacine53406NCT02693535Map
WIAurora Cancer Care-RacineRacine53406NCT03866382Map
WIAurora Cancer Care-RacineRacine53406NCT05675410Map
WIAurora Cancer Care-RacineRacine53406NCT05677490Map
WIAurora Cancer Care-RacineRacine53406NCT06203600Map
WIAspirus Cancer Care - James Beck Cancer CenterRhinelander54501NCT05327686Map
WIAspirus Cancer Care - James Beck Cancer CenterRhinelander54501NCT05677490Map
WIAspirus Cancer Care - James Beck Cancer CenterRhinelander54501NCT06203600Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT03866382Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT04511013Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT05327686Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT05677490Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT06632327Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT07166406Map
WIThedaCare Cancer Care - ShawanoShawano54166NCT06632327Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT05136196Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT05327686Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT05675410Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT05677490Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT05987241Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT06203600Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT06632327Map
WISheboygan Physicians GroupSheboygan53081NCT05677490Map
WISheboygan Physicians GroupSheboygan53081NCT06203600Map
WISheboygan Physicians GroupSheboygan53081NCT06632327Map
WIVince Lombardi Cancer CenterSheboygan53081NCT02693535Map
WIVince Lombardi Cancer Clinic-SheboyganSheboygan53081NCT03866382Map
WIVince Lombardi Cancer Clinic-SheboyganSheboygan53081NCT05675410Map
WIVince Lombardi Cancer Clinic-SheboyganSheboygan53081NCT05677490Map
WIVince Lombardi Cancer Clinic-SheboyganSheboygan53081NCT05987241Map
WIVince Lombardi Cancer Clinic-SheboyganSheboygan53081NCT06203600Map
WIEssentia Health-Spooner ClinicSpooner54801NCT05327686Map
WIEssentia Health-Spooner ClinicSpooner54801NCT05677490Map
WIEssentia Health-Spooner ClinicSpooner54801NCT07166406Map
WIAscension Saint Michael's HospitalStevens Point54481NCT04511013Map
WIAspirus Cancer Care - Stevens PointStevens Point54481NCT05327686Map
WIAspirus Cancer Care - Stevens PointStevens Point54481NCT05677490Map
WIAspirus Cancer Care - Stevens PointStevens Point54481NCT06203600Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT04609046Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05136196Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT03866382Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT04511013Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05327686Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05677490Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05987241Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT06203600Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT06632327Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT07166406Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT05136196Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT05327686Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT05675410Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT05677490Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT05987241Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT06203600Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT06632327Map
WIAurora Medical Center in SummitSummit53066NCT03866382
WIAurora Medical Center in SummitSummit53066NCT02693535
WIAurora Medical Center in SummitSummit53066NCT05675410
WIAurora Medical Center in SummitSummit53066NCT05677490
WIAurora Medical Center in SummitSummit53066NCT05987241
WIAurora Medical Center in SummitSummit53066NCT06203600
WIEssentia Health Saint Mary's Hospital - SuperiorSuperior54880NCT05136196Map
WIEssentia Health Saint Mary's Hospital - SuperiorSuperior54880NCT05327686Map
WIEssentia Health Saint Mary's Hospital - SuperiorSuperior54880NCT05677490Map
WIEssentia Health Saint Mary's Hospital - SuperiorSuperior54880NCT07166406Map
WIVince Lombardi Cancer Clinic - Two RiversTwo Rivers54241NCT02693535Map
WIVince Lombardi Cancer Clinic-Two RiversTwo Rivers54241NCT03866382Map
WIVince Lombardi Cancer Clinic-Two RiversTwo Rivers54241NCT05675410Map
WIVince Lombardi Cancer Clinic-Two RiversTwo Rivers54241NCT05677490Map
WIVince Lombardi Cancer Clinic-Two RiversTwo Rivers54241NCT05987241Map
WIVince Lombardi Cancer Clinic-Two RiversTwo Rivers54241NCT06203600Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT05136196Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT03866382Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT05677490Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT05987241Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT06029270Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT06203600Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT06632327Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT05136196Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT03866382Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT05327686Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT05675410Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT05677490Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT05987241Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT06029270Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT06203600Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT06632327Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT07166406Map
WIThedaCare Cancer Care - WaupacaWaupaca54981NCT06632327Map
WIAspirus Regional Cancer CenterWausau54401NCT04511013Map
WIAspirus Regional Cancer CenterWausau54401NCT05327686Map
WIAspirus Regional Cancer CenterWausau54401NCT05677490Map
WIAspirus Regional Cancer CenterWausau54401NCT06203600Map
WIMarshfield Clinic-Wausau CenterWausau54401NCT05677490Map
WIMarshfield Clinic-Wausau CenterWausau54401NCT06632327Map
WIAurora Cancer Care - Milwaukee WestWauwatosa53226NCT02693535Map
WIAurora Cancer Care-Milwaukee WestWauwatosa53226NCT03866382Map
WIAurora Cancer Care-Milwaukee WestWauwatosa53226NCT05675410Map
WIAurora Cancer Care-Milwaukee WestWauwatosa53226NCT05677490Map
WIAurora Cancer Care-Milwaukee WestWauwatosa53226NCT05987241Map
WIAurora Cancer Care-Milwaukee WestWauwatosa53226NCT06203600Map
WIAurora West Allis Medical CenterWest Allis53227NCT03866382Map
WIAurora West Allis Medical CenterWest Allis53227NCT05675410Map
WIAurora West Allis Medical CenterWest Allis53227NCT05677490Map
WIAurora West Allis Medical CenterWest Allis53227NCT05987241Map
WIAurora West Allis Medical CenterWest Allis53227NCT06203600Map
WIFroedtert West Bend Hospital/Kraemer Cancer CenterWest Bend53095NCT05327686Map
WIFroedtert West Bend Hospital/Kraemer Cancer CenterWest Bend53095NCT06632327Map
WIMarshfield Medical Center - WestonWeston54476NCT04609046Map
WIMarshfield Medical Center - WestonWeston54476NCT05136196Map
WIMarshfield Medical Center - WestonWeston54476NCT03866382Map
WIMarshfield Medical Center - WestonWeston54476NCT04511013Map
WIMarshfield Medical Center - WestonWeston54476NCT05327686Map
WIMarshfield Medical Center - WestonWeston54476NCT05677490Map
WIMarshfield Medical Center - WestonWeston54476NCT05987241Map
WIMarshfield Medical Center - WestonWeston54476NCT06203600Map
WIMarshfield Medical Center - WestonWeston54476NCT06632327Map
WIMarshfield Medical Center - WestonWeston54476NCT07166406Map
WIAspirus Cancer Care - Wisconsin RapidsWisconsin Rapids54494NCT04511013Map
WIAspirus Cancer Care - Wisconsin RapidsWisconsin Rapids54494NCT05327686Map
WIAspirus Cancer Care - Wisconsin RapidsWisconsin Rapids54494NCT05677490Map
WIAspirus Cancer Care - Wisconsin RapidsWisconsin Rapids54494NCT06203600Map
WIMarshfield Clinic - Wisconsin Rapids CenterWisconsin Rapids54494NCT05677490Map
WIMarshfield Clinic - Wisconsin Rapids CenterWisconsin Rapids54494NCT06632327Map
WYCheyenne Regional Medical Center-WestCheyenne82001NCT04511013Map
WYMemorial Hospital of Laramie CountyCheyenne82001NCT05677490Map
WYMemorial Hospital of Laramie CountyCheyenne82001NCT06632327Map
WYBillings Clinic-CodyCody82414NCT04511013Map
WYBillings Clinic-CodyCody82414NCT05677490Map
WYBillings Clinic-CodyCody82414NCT06632327Map
WYWelch Cancer CenterSheridan82801NCT04511013Map

Nivolumab clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingenrolling by invitationcompletedterminatedwithdrawnsuspendednot yet recruitingunknownno longer availableapproved for marketingTotal
Early P17611042232
P1415411325919289325
P1/P24238111450172124289
P21221602244923851158732
P2/P36452131224
P326375410424137
P44711215
N/A12713031195170

Recruiting Nivolumab clinical trials (291)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT05732389RESET-RImmunotherapy in Patients With Early dMMR Rectal CancerP2Cancer of Rectum39Feb 2023
NCT06639607PRiME IIPEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and EpendymomaP1/P2Diffuse Midline Glioma68Jun 2026
NCT04995003CARHER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced SarcomaP1Sarcoma25Dec 2021
NCT07369791NOBLENivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.P2Advanced Biliary Tract Cancer(BTC)76May 2026
NCT06999980Neo IRENIENeo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)P2Cutaneous Melanoma494Feb 2026
NCT07195695Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsP3Non-small Cell Lung Cancer400Jan 2026
NCT06288191Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell CarcinomaP2Cutaneous Squamous Cell Carcinoma20Jun 2024
NCT07541170KRASCENDO 3A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)P3Non-small Cell Lung Cancer400Sep 2026
NCT07403877TORCH-OPTIMANeoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerP2Colorectal Cancer (MSI-H)114Feb 2026
NCT06264180VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]P3Advanced Melanoma400Jul 2024
NCT06151236Neoadjuvant Nivolumab and Relatlimab in Merkel Cell CarcinomaP2Merkel Cell Carcinoma20Mar 2024
NCT06240143MARIANEIntradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaP1/P2Melanoma96Mar 2024
NCT04248569DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaP1Fibrolamellar Hepatocellular Carcinoma (FLC)56Apr 2020
NCT07383441Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerP3Advanced Clear Cell Renal Cell Carcinoma718Jun 2026
NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)P3Von Hippel-Lindau Disease450Mar 2026
NCT07444619A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasP1Soft Tissue Sarcomas18Aug 2026
NCT07230613NEOREM-NEO-1Neo-adjuvant Immunotherapy in Patients With Localized MelanomaP2Cutaneous Melanoma, Stage III50Jan 2026
NCT07514767NOCANOEvaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell CarcinomaP2Oral Squamous Cell Carcinoma (OSCC)60May 2026
NCT06488482Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant MelanomaP3High-risk Melanoma1,792Dec 2024
NCT07510334VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaP2Advanced Clear Cell Renal Cell Carcinoma18Apr 2026
NCT06246916A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)P3Melanoma560Sep 2024
NCT07319195WINIT-BCWindow Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)Early P1Breast Cancer32Apr 2026
NCT06745076Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaP2Advanced Hodgkin Lymphoma125Mar 2025
NCT03815890BELLINIPre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IOP2Breast Cancer80Oct 2019
NCT07551583Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLP2Hodgkin Lymphoma15Oct 2026
NCT07338981The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.P3Advanced Kidney Cancer142Apr 2026
NCT07221149A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)P2/P3Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma690Mar 2026
NCT07092670MELAFERTMELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.Melanoma270Aug 2025
NCT06683755TRINITYPhase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)P1/P2Melanoma30May 2025
NCT06561386RELATIVITY1093A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%P3Non-small Cell Lung Cancer1,000Oct 2024
NCT03521830Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaP2Basal Cell Carcinoma57Nov 2018
NCT05112601Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaP2Endometrial Adenocarcinoma81Jun 2022
NCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerP2/P3Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma840May 2026
NCT07355205FLINNFirst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerP2Non-small Cell Lung Cancer Stage IV26Jun 2026
NCT03686124ACTengineACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsP1/P2Refractory Cancer375May 2019
NCT07492680A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)P2Solid Tumors260Jul 2026
NCT06364631CARE1CARE1 Pragmatic Clinical TrialP3Metastatic Kidney Cancer1,250Apr 2024
NCT06794775SWE-NEOSWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III MelanomaP3Malignant Melanoma Stage III128Jul 2025
NCT03017820A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaP1B-Cell Non-Hodgkin Lymphoma99Apr 2017
NCT03026140NICHENeoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerP2Colon Carcinoma353Mar 2017
NCT05533697Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsP1/P2Advanced Solid Tumors361Sep 2022
NCT05076760MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsP1Solid Tumor40Apr 2022
NCT07328087COLONYVAQ™-CRCCOLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal CancerEarly P1Colorectal Cancer Metastatic12Feb 2026
NCT07293351RCCA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)P1/P2Advanced Renal Cell Carcinoma (RCC)254Mar 2026
NCT07223411Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic MelanomaLocally Advanced Melanoma20Nov 2025
NCT06743126SUPRAMESUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaP3Melanoma, Cutaneous Malignant360Jan 2025
NCT06581406A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaP2/P3Metastatic Uveal Melanoma280Dec 2024
NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2P3Gastric Cancer2,130Feb 2026
NCT07246863Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCP2Metastatic Non-Squamous Non-Small Cell Lung Cancer131Oct 2025
NCT07219459GDFATHERHCC01Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureP2Unresectable or Metastatic Hepatocellular Carcinoma104Mar 2026
NCT06646276TIGOSA Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).P3Extensive-Stage Small Cell Lung Cancer530Feb 2025
NCT06871007Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell LymphomaP1/P2Primary Mediastinal (Thymic) Large B-cell Lymphoma22Sep 2024
NCT06866262Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialP1/P2Locally Advanced Clear Cell Renal Cell Carcinoma55Aug 2025
NCT06968988Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue SarcomaP1Metastatic Soft-tissue Sarcoma18Jan 2026
NCT03886311TNTTalimogene Laherparepvec, Nivolumab and Trabectedin for SarcomaP2Sarcoma200May 2019
NCT03138161SAINTSAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaP1/P2Advanced Soft Tissue Sarcoma250Apr 2017
NCT07061379PROMOTINGPatient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimenPROMs144Jul 2025
NCT06816927GIANTTrial of Glioblastoma Immunotherapy Advancement With Nivolumab and RelatlimabP2Newly Diagnosed Glioblastoma92Nov 2025
NCT03258567EBVNivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasP2Epstein-Barr Virus Infections40Apr 2018
NCT07504796ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabP4Metastatic Melanoma90Apr 2026
NCT07460765HNSCCSafety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)P1Hnscc40Apr 2026
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabP3Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v81,875May 2023
NCT07210632HGGWindow Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)Early P1Brain Cancer38Mar 2026
NCT074043325-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory TumorsP1Solid Tumor35Feb 2026
NCT06624644A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaP2/P3Melanoma (Skin Cancer)135Aug 2025
NCT02813135ESMARTEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsP1/P2Pediatric Cancer472Aug 2016
NCT06618287A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsP1/P2Lung Cancer416Feb 2025
NCT07281924Hepzato Kit and Opdualag for Metastatic Melanoma and Liver MetastasisP1/P2Metastatic Melanoma15Jun 2026
NCT07529873N'FORCEPhase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell CarcinomaP2Squamous Cell Carcinoma of Head and Neck (SCCHN)131May 2026
NCT06963905SIMONESaci Nivo Rela for TNBCP1/P2Metastatic Triple-negative Breast Cancer60Dec 2025
NCT07050043LEDANGLow Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCP3NSCLC (Non-small Cell Lung Carcinoma)123May 2025
NCT07188896RCCA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)P2Advanced Renal Cell Carcinoma (aRCC)120Apr 2026
NCT07223424PSI-ImmunePatient Preference for Subcutaneous vs. Intravenous Immune TherapyP2Renal Cell Carcinoma880Nov 2025
NCT05629546Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint InhibitorsP1Advanced Melanoma33Nov 2024
NCT06926790GALAXY 3Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)P2Lung Cancer - Non Small Cell69Feb 2025
NCT06812858PD-1 Inhibitors Maintenance for cHL Post-autoHCTP2Hodgkin Lymphoma83Jan 2024
NCT06169956NENIAn Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in GermanyResectable Non-small Cell Lung Cancer400Nov 2023
NCT05987241Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyP2/P3Muscle Invasive Bladder Urothelial Carcinoma992Feb 2024
NCT07430202FLCA DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)P1Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))27Aug 2026
NCT06365619NeoRelapseNeoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaP2Melanoma25Jun 2026
NCT07432295GIVA-2Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)P2Solid Tumor180Feb 2026
NCT0590961814Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain MetastasesP2Advanced Glioblastoma33Jul 2023
NCT07013565ACCELERATEChemoimmunotherapy for ALK+ Relapsed/Refractory ALCLP2Anaplastic Large Cell Lymphoma, ALK-Positive20Aug 2025
NCT05176483STELLAR-002Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsP1Renal Cell Carcinoma (RCC)1,314Dec 2021
NCT06889493NECSVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)P1Neuroendocrine Carcinoma36May 2025
NCT06632327Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerP3Resectable Lung Non-Small Cell Carcinoma1,100Dec 2024
NCT05802056Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal MetastasisP1Clinical Stage IV Gastric Cancer AJCC v815Nov 2023
NCT06800339NEORADJUVANTA Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung CancerP1Non-Small Cell Lung Cancer18Apr 2025
NCT06275360RIVALRepositioning Immunotherapy in VetArans With Lung CancerP2Non-Small Cell Lung Cancer25Mar 2024
NCT04665206Study to Evaluate VT3989 in Patients With Metastatic Solid TumorsP1/P2Solid Tumor, Adult434Mar 2021
NCT06712927Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesP2Melanoma60Aug 2025
NCT06319196ClearMeClear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk MelanomaP2Cutaneous Melanoma54Aug 2026
NCT07546812GS-1811Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasP2HER2-negative120May 2026
NCT07398937ECTOP-1036Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLCP2Resectable Stage II-IIIa Squamous NSCLC116Feb 2026
NCT06692491SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGSP2Rare Tumour200Jan 2025
NCT05795244NIVECStudy of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)P2Endometrial Neoplasms30Oct 2023
NCT05655312MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaP1/P2Recurrent Melanoma (Skin)300Jun 2023
NCT03685890NivoILPEvaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb PerfusionP1/P2Melanoma74Apr 2019
NCT05652673IPI-NIVOSafe Stop Ipilimumab-nivolumab (IPI-NIVO) TrialN/AMelanoma Stage IV80Feb 2023
NCT07401875SHARKA Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)P1Phase 1b35Mar 2026
NCT04562129IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsP2Melanoma Stage III29Sep 2020
NCT07174453Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care ImmunotherapiesP3Solid Tumor Malignancies192Oct 2025
NCT07563738TEADCOA 2-part Phase 1/2 Open-label Trial on ODM-212P1/P2Mesothelioma229Mar 2026
NCT06495125Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerP2Advanced Lung Adenocarcinoma50Jul 2024
NCT06519682CAYAA Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)N/AHigh Grade Glioma20Dec 2024
NCT03340129ABC-XAnti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)P2Melanoma Stage Iv218Aug 2019
NCT03899155Pan Tumor Rollover StudyP2Cancer1,500Aug 2019
NCT06463665VIRO-25Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerP2Advanced Non-squamous Non-small-cell Lung Cancer142Sep 2024
NCT06712875MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasP1/P2Low Grade Glioma27Apr 2025
NCT06794229EXPLORE-RCCNeoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable MetastasisP2Locally Advanced Renal Cell Carcinoma69Oct 2025
NCT06561087Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant LesionsP2Premalignant Lesion45Feb 2025
NCT07459543FDCA Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In IndiaP4Untreated Melanoma30Nov 2026
NCT07176975A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced CancersP1Solid Tumors46Aug 2027
NCT07532902A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerP1Diffuse Pleural Mesothelioma60Apr 2026
NCT06029270Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerP2Metastatic Nasopharyngeal Carcinoma156Jul 2024
NCT06253611BIGFirst-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric CancerP2Gastric Cancer120Apr 2024
NCT05187182CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerP1Gastric Cancer42Jun 2023
NCT07325136A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung CancerP1/P2Relapsed/Refractory Small Cell Lung Cancer240Feb 2026
NCT07187869Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept StudyP1Clear Cell Renal Cell Carcinoma16Mar 2026
NCT07501117Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaP1Uveal Melanoma15May 2026
NCT06188676Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBLP3Primary Mediastinal Lymphoma100Apr 2022
NCT03080974Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic AdenocarcinomaP2Pancreatic Adenocarcinoma10Aug 2017
NCT07572123Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaP2/P3Recurrent Classic Hodgkin Lymphoma374Dec 2026
NCT03465592HLATrial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaP1/P2Sarcoma39May 2018
NCT07166406Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialP3Advanced Hepatocellular Carcinoma226Feb 2026
NCT06983210GRAPEClinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial CarcinomaP2Urothelial Carcinoma Bladder43May 2025
NCT07221734Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] MelanomaP3Advanced (Unresectable or Metastatic) Melanoma632Dec 2025
NCT06823479MATISSE 2Towards Cure Via Only Ultra-short ICB in CSCCP2Cutaneous Squamous Cell Carcinoma (CSCC)41May 2025
NCT07233668IVE in mRCCImmediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCCN/AMetastatic Renal Cell Carcinoma ( mRCC)172Dec 2025
NCT07028125CANIQOLDigital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal CarcinomaP4Renal Cell Carcinoma (Kidney Cancer)83Oct 2025
NCT06984146Nivo40-AVD for Advanced Classic Hodgkin LymphomaP2Hodgkin Lymphoma, Adult54Apr 2025
NCT07084610Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung CancerP2Non-Small Cell Lung Cancer30Feb 2025
NCT05187429NIVO-LDLow Dose Nivolumab in Adults Living With HIV on Antiretroviral TherapyP1/P2HIV I Infection42Jan 2023
NCT06697197A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid TumorsP1/P2Advanced Solid Tumors413Feb 2025
NCT07527858GS-1811Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerP2Advanced Microsatellite Stable Colorectal Cancer170May 2026
NCT06863311EXACTTrial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCP2Advanced Renal Cell Carcinoma70Mar 2026
NCT06941857NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerP2Pancreatic Cancer20Sep 2025
NCT07209059FINISH-HLPET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaP2Hodgkin Lymphoma30Jul 2025
NCT06362369A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyP1/P2Advanced Cancer126Aug 2024
NCT06031233MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieP4Oncology776Sep 2023
NCT04989946Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate CancerP1/P2Prostate Cancer60Dec 2021
NCT02693535TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerP2Lymphoma, Non-Hodgkin4,200Mar 2016
NCT06708949RCCA Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)P2Renal Cell Carcinoma, Clear Cell15Mar 2025
NCT07226856BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaP2Metastatic Pancreatic Adenocarcinoma43Dec 2025
NCT06534190CD8 PET Imaging in Metastatic Solid TumoursP2Locally Advanced Solid Tumor30Mar 2025
NCT06295159Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaP2Melanoma Stage III90May 2024
NCT053170005-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCCP2Squamous Cell Carcinoma of Head and Neck50Mar 2023
NCT07420439Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseP2Non Small Cell Lung Cancer Metastatic108May 2026
NCT05677490mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaP3Advanced Esophageal Adenocarcinoma382Jan 2023
NCT06053658Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaP2Renal Cell Carcinoma48Jan 2024
NCT05098210Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerP1Anatomic Stage IV Breast Cancer AJCC v825Jun 2022
NCT06245356TRIFLUOX-DPSafety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerP2Metastatic Colorectal Cancer73Mar 2025
NCT07100704OrionRecurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of NivolumabP2Recurrent/ Metastatic Olfactory Neuroblastoma14Apr 2025
NCT07152678BRIGHT-ESCCBrachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell CarcinomaP2Esophageal Cancer60Sep 2025
NCT07494435Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCCP2Hepato Cellular Carcinoma (HCC)230Jun 2026
NCT07147101HCC-IM-1Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune MicroenvironmentAdvanced Hepatocellular Carcinoma (HCC)150Sep 2025
NCT06490536The Sagittarius TrialP3Colon Cancer Stage II700Oct 2024
NCT07128680EXL01Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerP1Advanced Clear Cell Renal Cell Carcinoma33Mar 2026
NCT06237920TURANDORELAStage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabP2Urologic Neoplasms90Feb 2024
NCT06204614Drug Screening Using IMD in Bladder CancerEarly P1Muscle Invasive Bladder Urothelial Carcinoma18Jun 2024
NCT05704647Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesP2Melanoma (Skin)30Feb 2023
NCT06908993COMETTepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedP3Advanced Non Small Cell Lung Cancer133Dec 2025
NCT05934331A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyP2Malignant Neoplasms of Digestive Organs276Jul 2023
NCT07482059A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular CarcinomaP1/P2Unresectable Hepatocellular Carcinoma33Feb 2026
NCT04546399B-ALLA Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)P2Down Syndrome461Dec 2020
NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsP1/P2Solid Tumor542Nov 2022
NCT05327686SAMURAITesting the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialP2Metastatic Renal Cell Carcinoma240Feb 2023
NCT03563729MEMBRAINSMelanoma Metastasized to the Brain and SteroidsP2Malignant Melanoma80Jun 2018
NCT07213557Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With ImmunotherapyP2Advanced or Metastatic Gastrooesophageal Carcinoma84Mar 2026
NCT06624475NEONNeoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaP2Basal Cell Carcinoma30Aug 2025
NCT06638931ANTARESAgnostic Therapy in Rare Solid TumorsP2Urachal Cancer28Jul 2024
NCT05845450UNICORNPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)P2Colorectal Cancer197May 2023
NCT06346197CIMECombination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasP3Gastric Cancer132Dec 2025
NCT07017816JACOBA Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.Early P1CNS Malignancies18Dec 2025
NCT06934057CABOLDCabozantinib and Nivolumab Among Older Patients With Renal Cell CarcinomaP4Kidney Cancer50May 2025
NCT07542262NIVO402025Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR CancersP2Colorectal Cancer128Jun 2025
NCT05492123Nivolumab-ipilimumab and Chemoradiation for Cervical CancerP2Uterine Cervical Neoplasms112Aug 2022
NCT07422779MAKImmunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in SloveniaN/AMetastatic Melanoma100Mar 2022
NCT07334119Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid TumorsP1HER2-Expressing Solid Tumors60Nov 2025
NCT03816345Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOP1Autoimmune Disease300Jul 2019
NCT07394062ALCG-01Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)Nonsmall Cell Lung Cancer, Stage IV400Feb 2026
NCT05428007Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaP2Melanoma105Feb 2023
NCT04380545Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar CancerP1/P2Stage III Hepatocellular Carcinoma AJCC v815Jan 2021
NCT06019130NPC-NivoNivolumab in Children and Adults With Nasopharyngeal CarcinomaP2Nasopharyngeal Carcinoma57Jan 2023
NCT06731270Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyP2Advanced Lung Non-Small Cell Carcinoma20Apr 2025
NCT05779423Cryoablation+Ipilimumab+Nivolumab in MelanomaP2Metastatic Melanoma37Sep 2023
NCT07075120Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular CancerP1Hepatocellular Carcinoma (HCC)15Apr 2026
NCT07216833Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckP1Head and Neck Cancer15Jan 2026
NCT07155317Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME TrialP2Advanced Acral Melanoma99Oct 2025
NCT06901817A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal MetastasesP2Leptomeningeal Metastasis97Mar 2025
NCT06724159SOGUG-PRINCISObservational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.Genitourinary Cancers500Dec 2024
NCT05681780Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCP1Non Small Cell Lung Cancer20Mar 2023
NCT05048212A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesP2Brain Metastases20Sep 2022
NCT05423262A Study of TRK-950 in Patients With Advanced Solid TumorsP1/P2Solid Tumor49Jul 2022
NCT04697576Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaP1Clinical Stage I Cutaneous Melanoma AJCC v836Oct 2021
NCT04900818Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsP1Solid Tumor330Jun 2021
NCT04150640Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric AdenocarcinomaP2Esophageal Adenocarcinoma52Jul 2020
NCT03803553Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerP3Metastatic Colon Cancer400Apr 2020
NCT03646617RadVaxIpilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaP2Metastatic Melanoma54Nov 2018
NCT04204837Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinP2Squamous Cell Carcinoma of the Skin61Mar 2017
NCT02925234DRUPThe Drug Rediscovery Protocol (DRUP Trial)P2Cancer1,550Aug 2016
NCT05317858LIMITLESSBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsP3Brain Tumor30Aug 2022
NCT04902443Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVP1Viral Associated Malignancies58Dec 2021
NCT06274437A Study of BND-35 in Participants With Advanced Solid TumorsP1Cancer280Jun 2024
NCT05901285Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid TumorsP1Advanced Solid Tumor48Nov 2023
NCT05039073Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsP2Recurrent Classic Hodgkin Lymphoma46May 2022
NCT03690986VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerP1Squamous Cell Carcinoma of the Head and Neck50Nov 2018
NCT03406247ADJORL1Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell CarcinomaP2Head and Neck Squamous Cell Carcinoma140Feb 2018
NCT06534983IMCODE004A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)P2Muscle-invasive Urothelial Carcinoma62Dec 2024
NCT06203600Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialP2/P3Advanced Esophageal Adenocarcinoma224Jun 2024
NCT06667154Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With ChemotherapyP2Lung Cancer, Nonsmall Cell33Oct 2023
NCT05663710Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCP1/P2Advanced Cancer100Jun 2023
NCT06112314PRISM-MEL-301IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)P3Advanced Melanoma680Jun 2024
NCT06764771A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsP1Advanced Malignant Tumors437Mar 2025
NCT04114136Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor MalignanciesP2Melanoma72Sep 2020
NCT06364917DISCERNDISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCP2Non Small Cell Lung Cancer24May 2025
NCT05310643NIPIRESCUENivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCP2Metastatic Colorectal Cancer30May 2022
NCT05112549IT-PD1Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)P1Leptomeningeal Disease46Oct 2021
NCT05498792Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in MelanomaEarly P1Locally Advanced or Metastatic Melanoma12Nov 2022
NCT04472767Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaP2Hepatocellular Carcinoma35Aug 2020
NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisP1/P2Diffuse Astrocytoma, IDH-Mutant134Nov 2023
NCT05919264FOG-001 in Locally Advanced or Metastatic Solid TumorsP1/P2Cancer595May 2023
NCT04745949PACIFICPACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyP2Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma31May 2021
NCT04741997Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in MelanomaEarly P1Melanoma Stage III50May 2021
NCT03681561Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaP1/P2Hodgkin Lymphoma54Sep 2018
NCT05361720Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyP2Advanced Clear Cell Renal Cell Carcinoma54Dec 2022
NCT05733689Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)P1Gastroesophageal Adenocarcinoma20Jun 2025
NCT06015724DARANIVOVAXAnti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung CancerP2Pancreatic Ductal Adenocarcinoma54Jan 2024
NCT04912765Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCP2Hepatocellular Carcinoma60Apr 2021
NCT04511013A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesP2Acral Lentiginous Melanoma112Jan 2021
NCT03838042INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory MalignanciesP1/P2CNS Tumor91May 2020
NCT03259867TATE-PD1Combination of TATE and PD-1 Inhibitor in Liver CancerP2Hepatocellular Carcinoma54Jul 2017
NCT05272384Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaP1Recurrent B-Cell Non-Hodgkin Lymphoma32Nov 2022
NCT06931613Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab TreatmentP2Relapsed or Refractory Hodgkin Lymphoma20Jun 2022
NCT03025256Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal DiseaseP1Acral Lentiginous Melanoma75May 2018
NCT06554613Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLCP2Non-Small Cell Lung Cancer156Jul 2024
NCT05384496Axitinib and Nivolumab for the Treatment of Mucosal MelanomaP2Mucosal Melanoma20May 2022
NCT04572451Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and MelanomaP1Melanoma50Nov 2021
NCT05715229G360-IITImmune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With ImmunotherapyP2Carcinoma, Non-Small-Cell Lung108Sep 2023
NCT05502315CANOPYStudy of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerP2Castration-resistant Prostate Cancer47Feb 2023
NCT05817903AxInAxitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC PatientsP2Metastatic Renal Cell Carcinoma118Apr 2023
NCT04609046Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaP1Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System47May 2021
NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaP1Glioblastoma (GBM)34Jun 2025
NCT05310591CAPTiRALLCombination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of PersistenceP1/P2B Acute Lymphoblastic Leukemia26Mar 2023
NCT06302426Trial of INI-4001 in Patients With Advanced Solid TumoursP1Advanced Solid Tumor50Jul 2024
NCT05597800LUNGVIRNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid SyndromeP2NSCLC Stage IV105Feb 2023
NCT05749900HERBOTFirst-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)P1/P2HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer44May 2023
NCT05263050Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsP2Metastatic Renal Cell Carcinoma111Jan 2022
NCT03866382Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsP2Bladder Adenocarcinoma314May 2019
NCT05501665Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerP1/P2Lung Non-Small Cell Carcinoma25May 2023
NCT07276373Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesP1/P2Neoplasms50Jan 2026
NCT05896839Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerP1/P2Clinical Stage III Cutaneous Melanoma AJCC v816Jul 2024
NCT05476796LOGICANOxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction CancerP2Gastric Adenocarcinoma118Jun 2023
NCT03297606CAPTURCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)P2Lymphoma, Non-Hodgkin720Mar 2018
NCT05136196BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyP2Clinical Stage III Cutaneous Melanoma AJCC v8150Dec 2022
NCT06064097NPCA Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)P2Stage II Nasopharyngeal Carcinoma AJCC v850Jun 2024
NCT06265285CCBWComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramP2Advanced Esophageal Squamous Cell Carcinoma50Apr 2024
NCT05188118Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell CarcinomaEarly P1Renal Cell Carcinoma20Feb 2023
NCT05234307PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerP1Metastatic Lung Non-Small Cell Carcinoma30Nov 2022
NCT05257590CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular CarcinomaP2Hepatocellular Carcinoma95May 2022
NCT05745233Intraperitoneal Immune Checkpoint Inhibitor for Malignant AscitesN/AMalignant Ascites30Jan 2021
NCT04477343A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaP1Pancreatic Ductal Adenocarcinoma20Nov 2020
NCT07196384GLOWOptical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CWP1Esophageal Cancer15Dec 2025
NCT05647265Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaP2Pleural Biphasic Mesothelioma26Nov 2024
NCT04159818TONIC-2Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) PatientsP2Metastatic Breast Cancer52Feb 2020
NCT06682728Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceP2Urothelial Carcinoma23Nov 2024
NCT04966663ctDNA Lung RCTUsing ctDNA to Determine Therapies for Lung CancerP2Non Small Cell Lung Cancer66Mar 2022
NCT04495296A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid TumorsP1/P2Advanced Cancer320Aug 2020
NCT06158919G/GEJ cancerA Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ CancerN/AGastric Cancer/Adenocarcinoma of Esophagogastric Junction58Nov 2023
NCT04991025Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryP2Lung Cancer60Oct 2022
NCT06399419CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerP1Advanced Clear Cell Renal Cell Carcinoma28Jun 2024
NCT04561206Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaP2Relapsed Classic Hodgkin Lymphoma31Nov 2021
NCT06532149EROSERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerNSCLC Stage IV80Aug 2024
NCT04933903LOWBrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabP2Non Small Cell Lung Cancer25Oct 2021
NCT05727410Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland CarcinomaP2High-grade Salivary Gland Carcinoma50Nov 2022
NCT03844256CRIMIA Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI StudyP1/P2Urinary Bladder Cancer50Jan 2019
NCT04866654RAFTINGRadiation Free Chemotherapy for Early Hodgkin LymphomaP2Hodgkin Lymphoma160Mar 2021
NCT06008925Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric CancerP1/P2Metastatic Gastric Cancer43Nov 2022
NCT05203913CNN-BCCisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder CancerP2Muscle-Invasive Bladder Carcinoma32May 2023
NCT05267626Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerP1/P2Advanced Solid Tumor159Apr 2022
NCT04910347Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaP2Locally Advanced Nasopharyngeal Carcinoma57Feb 2022
NCT04400539IMPALAThe IMmunotherapy Pleural 5-ALA PDTP2Mesotheliomas Pleural20May 2022
NCT04295863Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic CancersP1Metastatic Cancer264Jun 2020
NCT06163820BETTERBevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesP1/P2Melanoma Brain Metastases46May 2025
NCT05223816An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic CholangiocarcinomaP2Hepatocellular Carcinoma97Jan 2024
NCT05266612Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid TumorsP1Solid Tumor12Nov 2022
NCT04535713GALLANTGALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced SarcomaP2Sarcoma260Sep 2020
NCT03707808myDAvIpNiIntratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic NivolumabP1/P2Solid Tumor18Jan 2018
NCT06097975NEO-GLITIPNIA Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent GlioblastomaP1Recurrent Glioblastoma18Mar 2024
NCT05739045Nivolumab Combined With SOX Used in the Perioperative TreatmentP2Immune Suppression46Nov 2022
NCT04823403HIPANIVHepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaP1Hepatocellular Carcinoma27Nov 2020

Nivolumab clinical trials by indication

Melanoma (93)

NCTAcronymPhaseStatusTitle
NCT06240143MARIANEP1/P2recruitingIntradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
NCT06246916P3recruitingA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT07092670MELAFERTN/ArecruitingMELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
NCT06683755TRINITYP1/P2not yet recruitingPhase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
NCT03470922RELATIVITY-047P2/P3active not recruitingA Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT04930783P1active not recruitingNeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
NCT06365619NeoRelapseP2recruitingNeoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
NCT03999749P2active not recruitingA Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
+ 85 more, see All trials below.

Hepatocellular Carcinoma (35)

NCTAcronymPhaseStatusTitle
NCT03383458CheckMate 9DXP3active not recruitingA Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
NCT04658147HCCP1active not recruitingFeasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
NCT04472767P2recruitingCabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
NCT04912765P2recruitingNeoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
NCT03259867TATE-PD1P2recruitingCombination of TATE and PD-1 Inhibitor in Liver Cancer
NCT05257590P2recruitingCVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
NCT03695952N/Aactive not recruitingA Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
NCT04039607CheckMate 9DWP3active not recruitingA Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
+ 27 more, see All trials below.

Metastatic Melanoma (28)

NCTAcronymPhaseStatusTitle
NCT07504796P4recruitingctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NCT07281924P1/P2recruitingHepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
NCT07422779MAKN/ArecruitingImmunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
NCT05779423P2recruitingCryoablation+Ipilimumab+Nivolumab in Melanoma
NCT05034536P2active not recruitingPD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
NCT03646617RadVaxP2recruitingIpilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
NCT03122522P2active not recruitingA Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
NCT03645928P2terminatedStudy of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
+ 20 more, see All trials below.

Non-Small Cell Lung Cancer (27)

NCTAcronymPhaseStatusTitle
NCT04564157NADIM-ADJUVANTP3active not recruitingNew Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
NCT03228667P2active not recruitingQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT06800339NEORADJUVANTP1recruitingA Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
NCT06275360RIVALP2recruitingRepositioning Immunotherapy in VetArans With Lung Cancer
NCT07084610P2recruitingMetabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
NCT06946797CheckMate-1533P2active not recruitingA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT02259621NA_00092076P2active not recruitingNeoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
NCT06554613P2recruitingOlanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
+ 19 more, see All trials below.

Advanced Cancer (27)

NCTAcronymPhaseStatusTitle
NCT06362369P1/P2recruitingA Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT05663710P1/P2recruitingPhase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
NCT04495296P1/P2recruitingA Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
NCT04396821P1/P2active not recruitingA Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
NCT03459222P1/P2completedAn Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
NCT03369223P1/P2completedA Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
NCT02743494CheckMate 577P3completedAn Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
NCT03994601P1/P2completedAn Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
+ 19 more, see All trials below.

Renal Cell Carcinoma (26)

NCTAcronymPhaseStatusTitle
NCT07223424PSI-ImmuneP2recruitingPatient Preference for Subcutaneous vs. Intravenous Immune Therapy
NCT05148546NESCIOP2active not recruitingNeoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
NCT06053658P2recruitingPhase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
NCT03172754P1/P2active not recruitingStudy of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
NCT03873402P3active not recruitingA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03937219COSMIC-313P3active not recruitingStudy of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT05188118Early P1recruitingRapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
NCT05501054P1/P2active not recruitingPhase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
+ 18 more, see All trials below.

Non Small Cell Lung Cancer (25)

NCTAcronymPhaseStatusTitle
NCT03838159NADIMIIP2active not recruitingNADIM II: Neo-Adjuvant Immunotherapy
NCT05681780P1recruitingClinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
NCT05012254NIVIPI-BrainP2active not recruitingNivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
NCT06364917DISCERNP2recruitingDISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
NCT03527108P2active not recruitingNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
NCT04966663ctDNA Lung RCTP2recruitingUsing ctDNA to Determine Therapies for Lung Cancer
NCT04933903LOWP2recruitingBrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
NCT03377023P1/P2active not recruitingPhase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
+ 17 more, see All trials below.

Solid Tumor (23)

NCTAcronymPhaseStatusTitle
NCT05076760P1recruitingMEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
NCT07404332P1recruiting5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
NCT07432295GIVA-2P2recruitingGivastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
NCT05584670P1/P2recruitingA First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
NCT05423262P1/P2recruitingA Study of TRK-950 in Patients With Advanced Solid Tumors
NCT04900818P1recruitingStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT03872947P1active not recruitingA Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
NCT05266612P1recruitingPhase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
+ 15 more, see All trials below.

Cancer (23)

NCTAcronymPhaseStatusTitle
NCT03899155P2recruitingPan Tumor Rollover Study
NCT02925234DRUPP2recruitingThe Drug Rediscovery Protocol (DRUP Trial)
NCT06274437P1recruitingA Study of BND-35 in Participants With Advanced Solid Tumors
NCT05919264P1/P2recruitingFOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT04300244NIPUP2active not recruitingNivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
NCT04336241P1active not recruitingStudy of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
NCT03400332P1/P2completedA Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
NCT02966548P1completedSafety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
+ 15 more, see All trials below.

Gastric Cancer (20)

NCTAcronymPhaseStatusTitle
NCT07431281P3recruitingSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT06253611BIGP2recruitingFirst-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
NCT05187182P1recruitingCA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT06346197CIMEP3recruitingCombination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
NCT03044613P1active not recruitingNivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
NCT06256328P2active not recruitingA Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT05111626FORTITUDE-102P3active not recruitingBemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
NCT05322577FORTITUDE-103P1/P2active not recruitingA Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
+ 12 more, see All trials below.

Hodgkin Lymphoma (19)

NCTAcronymPhaseStatusTitle
NCT07551583P2not yet recruitingPhase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
NCT06812858P2recruitingPD-1 Inhibitors Maintenance for cHL Post-autoHCT
NCT07209059FINISH-HLP2recruitingPET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
NCT05723055NAHLP2active not recruitingEvaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
NCT03681561P1/P2recruitingNivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT03033914BP1/P2active not recruitingA(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
NCT03843294TAA-TP1active not recruitingTumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
NCT04938232P2active not recruitingIpilimumab With or Without Nivolumab in Relapsed/Refractory cHL
+ 11 more, see All trials below.

Non-small Cell Lung Cancer (19)

NCTAcronymPhaseStatusTitle
NCT07195695P3recruitingBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07541170KRASCENDO 3P3not yet recruitingA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT06561386RELATIVITY1093P3recruitingA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT05867121P1active not recruitingA Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
NCT04623775NSCLCP2active not recruitingA Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT05354102FIHP1unknownA First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
NCT04123379NSCLCP2completedNeoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
NCT03285321NSCLCP2completedUnresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
+ 11 more, see All trials below.

Breast Cancer (18)

NCTAcronymPhaseStatusTitle
NCT07319195WINIT-BCEarly P1recruitingWindow Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)
NCT03815890BELLINIP2recruitingPre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
NCT03546686P2active not recruitingPeri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
NCT03789110NIMBUSP2active not recruitingNIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
NCT03414684P2active not recruitingCarboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
NCT02499367TONICP2unknownNivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients
NCT04591431ROMEP2unknownThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
NCT02833233N/AcompletedA Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
+ 10 more, see All trials below.

Advanced Solid Tumors (16)

NCTAcronymPhaseStatusTitle
NCT05533697P1/P2recruitingStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT06697197P1/P2recruitingA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06544655P1active not recruitingA Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
NCT06880549P1active not recruitingA Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
NCT05888831P1/P2active not recruitingA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
NCT05407675P1/P2completedA Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
NCT05625412P1completedA Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
NCT04943900P1completedA Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
+ 8 more, see All trials below.

Colorectal Cancer (15)

NCTAcronymPhaseStatusTitle
NCT05845450UNICORNP2recruitingPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
NCT07542262NIVO402025P2enrolling by invitationLow-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers
NCT04117087P1active not recruitingPooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
NCT06410534P2withdrawnA Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
NCT03981146ANICCAP2completedA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
NCT03377361CheckMate 9N9P1/P2completedAn Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
NCT04072198NIVACORP2completedNivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
NCT04907539RNF43P2completedA Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
+ 7 more, see All trials below.

Lung Cancer (15)

NCTAcronymPhaseStatusTitle
NCT06618287P1/P2recruitingA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT05633667VELOCITY-LungP2active not recruitingStudy of Novel Treatment Combinations in Patients With Lung Cancer
NCT06572722ECTOP-1030P2withdrawnPerioperative Immunotherapy for NSCLC (ECTOP-1030)
NCT04991025P2recruitingAdding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
NCT03417037P3withdrawnAn Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT03575793P1/P2completedA Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
NCT02664181PRECISEP2completedRational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
NCT02481830CheckMate331P3completedEffectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
+ 7 more, see All trials below.

Prostate Cancer (14)

NCTAcronymPhaseStatusTitle
NCT04989946P1/P2recruitingAndrogen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
NCT03600350P2active not recruitingpTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
NCT03061539P2active not recruitingNivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
NCT03637543P2active not recruitingNivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
NCT03543189P1/P2active not recruitingCombination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
NCT03689699MAGIC-8P1/P2active not recruitingNivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
NCT04019964P2completedNivolumab in Biochemically Recurrent dMMR Prostate Cancer
NCT03338790CheckMate 9KDP2completedAn Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
+ 6 more, see All trials below.

Clear Cell Renal Cell Carcinoma (13)

NCTAcronymPhaseStatusTitle
NCT07187869P1not yet recruitingModulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
NCT03793166P3active not recruitingImmunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT04810078CheckMate-67TP3active not recruitingA Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
NCT05239533P2active not recruitingStudy of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
NCT02210117Early P1active not recruitingNivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
NCT06049576P1active not recruitingNivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
NCT04300140P1/P2terminatedSafety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT03680521P2completedNeoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
+ 5 more, see All trials below.

Head and Neck Cancer (13)

NCTAcronymPhaseStatusTitle
NCT07216833P1not yet recruitingDecitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05327270P1active not recruitingNon-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
NCT03247712P1/P2active not recruitingNeoadjuvant Immunoradiotherapy in Head & Neck Cancer
NCT02919683P2active not recruitingWindow Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
NCT03355560P2completedAdjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
NCT03700905IMSTAR-HNP3unknownStudy of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy
NCT03894891P2completedInduction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
NCT02741570CheckMate 651P3completedStudy of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
+ 5 more, see All trials below.

Metastatic Renal Cell Carcinoma (13)

NCTAcronymPhaseStatusTitle
NCT03055013P3active not recruitingNivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT05327686SAMURAIP2recruitingTesting the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05817903AxInP2recruitingAxitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
NCT05263050P2recruitingTrial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
NCT03595124P2active not recruitingA Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
NCT06284564BOOST-RCCP2active not recruitingA Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
NCT04090710CYTOSHRINKP2active not recruitingSBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
NCT03075423P2completedRandomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
+ 5 more, see All trials below.

Pancreatic Cancer (12)

NCTAcronymPhaseStatusTitle
NCT06941857P2recruitingNC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
NCT03563248P2active not recruitingLosartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
NCT05721846CheckVACP1active not recruitingNivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer
NCT04361162P2active not recruitingNivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
NCT02451982P2active not recruitingPlatform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
NCT03161379P2completedGVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
NCT05116917INFLUENCEP2terminatedImmunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
NCT03190265P2completedStudy of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
+ 4 more, see All trials below.

Glioblastoma (12)

NCTAcronymPhaseStatusTitle
NCT04323046P1active not recruitingImmunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
NCT04047706P1active not recruitingNivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT04606316P1active not recruitingSurgical Nivolumab And Ipilimumab For Recurrent GBM
NCT03743662P2active not recruitingNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
NCT03233152GlitIpNiP1/P2active not recruitingA Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.
NCT04817254ICIP2completedAssociation of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
NCT03452579P2active not recruitingNivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
NCT03493932P1completedCytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
+ 4 more, see All trials below.

Solid Tumors (10)

NCTAcronymPhaseStatusTitle
NCT07492680P2not yet recruitingA Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07176975P1not yet recruitingA Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
NCT04423029P1completedA Study of DF6002 Alone and in Combination With Nivolumab
NCT04704154P2completedA Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
NCT02426892P2completedNivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
NCT02593786CheckMate 077P1/P2completedA Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
NCT03347123ECHO-208P1/P2terminatedA Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
NCT02702492PANAMAP1terminatedPAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
+ 2 more, see All trials below.

Metastatic Colorectal Cancer (10)

NCTAcronymPhaseStatusTitle
NCT06245356TRIFLUOX-DPP2recruitingSafety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
NCT05310643NIPIRESCUEP2recruitingNivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
NCT04008030CheckMate 8HWP3active not recruitingA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT03867799P2active not recruitingiSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
NCT03547999P2terminatedA Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
NCT04166383P2terminatedVB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
NCT03832621MAYAP2completedNIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer
NCT04430985IMMUNOXP2withdrawnFOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
+ 2 more, see All trials below.

Multiple Myeloma (10)

NCTAcronymPhaseStatusTitle
NCT06523621P2active not recruitingNivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
NCT02719613P2completedContinuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT03227432P2withdrawnAn Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
NCT03292263P1/P2unknownASCT With Nivolumab in Patients With Multiple Myeloma
NCT02681302CPIT001P1/P2terminatedCheck Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence
NCT02726581CheckMate 602P3completedAn Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
NCT03782064DCP2terminatedDendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
NCT02612779P2completedA Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
+ 2 more, see All trials below.

Advanced Melanoma (10)

NCTAcronymPhaseStatusTitle
NCT06264180P3recruitingVO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT05629546P1recruitingMemory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
NCT04462406P2active not recruitingUsing Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT06112314PRISM-MEL-301P3recruitingIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT04495257RCCP1completedA Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
NCT04493203P2completedNivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
NCT07079644N/AcompletedOutcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
NCT06590480RPL-EAP-001N/Ano longer availableAn Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
+ 2 more, see All trials below.

Urothelial Carcinoma (10)

NCTAcronymPhaseStatusTitle
NCT02845323P2active not recruitingNeoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT05200988Indi-BladeP2active not recruitingCheckpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
NCT06682728P2recruitingAdjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
NCT06421311URADJN/AterminatedObservational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France
NCT03387761NABUCCOP1completedNeo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy
NCT04871594TURANDOTP1completedPre-operative Immunotherapy in Stage II-III Urothelial Cancer
NCT03511391CHEERSP2completedCHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors
NCT04200963P1completedA Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
+ 2 more, see All trials below.

Advanced Solid Tumor (10)

NCTAcronymPhaseStatusTitle
NCT05901285P1recruitingPhase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT06302426P1recruitingTrial of INI-4001 in Patients With Advanced Solid Tumours
NCT05163041P1/P2active not recruitingStudy BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
NCT04735978P1active not recruitingStudy of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
NCT05933265P1/P2active not recruitingStudy of LP-184 in Patients With Advanced Solid Tumors
NCT05267626P1/P2recruitingStudy of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT04349267P1/P2completedStudy of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
NCT04042116P1/P2suspendedA Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
+ 2 more, see All trials below.

Bladder Cancer (10)

NCTAcronymPhaseStatusTitle
NCT03171025NEXTP2active not recruitingAdjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
NCT03520491P2active not recruitingA Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
NCT06059547P2active not recruitingNeoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
NCT02553642CA209-260P2completedRelationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
NCT03558087P2completedGemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
NCT03993249MIBCP2unknownNivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy
NCT04209114P3completedA Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
NCT03980041MARIO-275P2completedStudy to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
+ 2 more, see All trials below.

Mesothelioma (9)

NCTAcronymPhaseStatusTitle
NCT07563738TEADCOP1/P2recruitingA 2-part Phase 1/2 Open-label Trial on ODM-212
NCT03907852TC-210P1/P2active not recruitingPhase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
NCT03918252P2active not recruitingNeoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
NCT04334759DREAM3RP3completedDuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
NCT04040231P1completedUsing a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
NCT02899299CheckMate743P3completedStudy of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
NCT05041062P2completedA Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
NCT03063450CONFIRMP3completedCheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
+ 1 more, see All trials below.

Head and Neck Squamous Cell Carcinoma (9)

NCTAcronymPhaseStatusTitle
NCT04848116Spark2P2active not recruitingNeoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
NCT03406247ADJORL1P2recruitingAdjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma
NCT05280457TRINITYP2active not recruitingHPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy
NCT05821751PRINCESSN/AunknownThe Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors
NCT03878979P2completedPreoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
NCT05472506P1withdrawnOral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
NCT03317327REPORTP1/P2completedREirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors
NCT03169764HNSCCP1/P2withdrawnQUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
+ 1 more, see All trials below.

Advanced Clear Cell Renal Cell Carcinoma (8)

NCTAcronymPhaseStatusTitle
NCT07383441P3recruitingAdding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
NCT07510334P2recruitingVSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT07000149eVOLVE-RCC02P3active not recruitingA Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
NCT07128680EXL01P1recruitingImmunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
NCT05361720P2recruitingGenetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
NCT05122546P1active not recruitingCBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
NCT06399419P1recruitingCBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
NCT04904302P2terminatedSitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Gastric Adenocarcinoma (8)

NCTAcronymPhaseStatusTitle
NCT06504615METAGION/Aactive not recruitingObservational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
NCT05476796LOGICANP2recruitingOxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
NCT07529613T-DXd_HER2LowP1/P2completedTrastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma
NCT05394740P1/P2completedClinical Study of Regorafenib and Nivolumab Plus Chemotherapy
NCT05001360N/AwithdrawnStudy of FMT Combined With Nivolumab in Gastric Cancer
NCT04503967OASISP2unknownEfficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
NCT02862535P1terminatedStudy to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02864381P2completedStudy to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Melanoma (Skin) (8)

NCTAcronymPhaseStatusTitle
NCT05704647P2recruitingPhase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
NCT06377111P1active not recruitingA Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
NCT03543969Early P1active not recruitingAdaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
NCT03405155P2completedNivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
NCT04901988DETECTIONP2/P3terminatedCirculating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION
NCT01176474P1completedVaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
NCT03949153CRIRINP1/P2completedCryotherapy With in Situ Immunotherapy in Melanoma Metastasis
NCT02652455Early P1completedCombining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Carcinoma, Non-Small-Cell Lung (8)

NCTAcronymPhaseStatusTitle
NCT04025879P3active not recruitingA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT05715229G360-IITP2recruitingImmune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
NCT03083691BIOLUMAP2completedBIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
NCT03669523DENIVOSP2completedDenosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)
NCT03262779P2completedIpilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
NCT02954991P2terminatedPhase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
NCT03663166NSCLCP1/P2terminatedRadiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
NCT04023617P2unknownA Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC

Squamous Cell Carcinoma of the Head and Neck (8)

NCTAcronymPhaseStatusTitle
NCT03690986P1recruitingVX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
NCT03341936P2active not recruitingNeodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
NCT04326257P2completedPersonalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
NCT04659369P1terminatedStudy of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
NCT05068609VOLUME-PRON/AcompletedA Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
NCT02105636P3completedTrial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
NCT03349710P3completedNivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
NCT02124850P1terminatedA Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Esophageal Cancer (7)

NCTAcronymPhaseStatusTitle
NCT03544736INECP1/P2active not recruitingSafety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)
NCT07152678BRIGHT-ESCCP2recruitingBrachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma
NCT07196384GLOWP1not yet recruitingOptical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW
NCT05491616SANO-3P2active not recruitingNivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
NCT06499298N/AcompletedRetrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
NCT03416244RAMONAP2completedA Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
NCT02569242P3completedStudy of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Non-small Cell Lung Cancer (NSCLC) (7)

NCTAcronymPhaseStatusTitle
NCT06487156FINNN/Aactive not recruitingA Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07215962N/Aactive not recruitingLong-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
NCT07141563N/AcompletedA Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
NCT06735781N/AcompletedClinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France
NCT03735628P1completedAn Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
NCT05468294NivokinP1/P2unknownF16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer
NCT02840994P1completedA Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8 (7)

NCTAcronymPhaseStatusTitle
NCT04940299P2active not recruitingTocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
NCT05896839P1/P2recruitingImmunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT05136196P2recruitingBiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT02224781P3active not recruitingDabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT03816332P1active not recruitingTacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
NCT04967196P1terminatedIpilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
NCT03033576P2completedTesting Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Malignant Melanoma (7)

NCTAcronymPhaseStatusTitle
NCT03563729MEMBRAINSP2recruitingMelanoma Metastasized to the Brain and Steroids
NCT05089370DEC-CP1/P2active not recruitingOral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
NCT04223648MEDI4736Early P1withdrawnProgrammed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
NCT04382664P2completedUV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
NCT02523313P2completedImmunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
NCT02935790P1completedSelective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
NCT02186249CheckMate218N/Ano longer availableExpanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

Acute Myeloid Leukemia (7)

NCTAcronymPhaseStatusTitle
NCT02275533P2active not recruitingTesting Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
NCT04913922AARONP2unknownRelatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML
NCT03092674P2/P3completedAzacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT04277442P1completedTesting Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
NCT03417154P2completedNivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
NCT03358719P1completedDEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT03381118P2terminatedHaploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients

Small Cell Lung Cancer (7)

NCTAcronymPhaseStatusTitle
NCT03670056P2active not recruitingIpilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
NCT03043599P1/P2completedIpilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
NCT02247349P1/P2completedBMS-986012 in Relapsed/Refractory SCLC
NCT03958045P2completedCombination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
NCT03406715SCLCP2terminatedCombination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
NCT03325816P1/P2completedNivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
NCT03026166P1/P2terminatedA Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Advanced Renal Cell Carcinoma (6)

NCTAcronymPhaseStatusTitle
NCT06863311EXACTP2recruitingTrial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT05928806ARCITECTP2suspendedAdvanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
NCT02231749P3completedNivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT03117309P2completedStudy of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
NCT03829111CBM588P1completedCBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
NCT04203901P2terminatedDendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Colorectal Cancer Metastatic (6)

NCTAcronymPhaseStatusTitle
NCT07328087COLONYVAQ™-CRCEarly P1recruitingCOLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer
NCT04730544NIPISAFEP2active not recruitingTwo Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.
NCT03388190METIMMOXP2completedMETIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
NCT04721301P1completedIpilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
NCT03647839MODULATEP2completedModulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
NCT03982121ISILIP1withdrawnStudy of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy

Neoplasms (6)

NCTAcronymPhaseStatusTitle
NCT02817633AMBERP1active not recruitingA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT07276373P1/P2recruitingTwo Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
NCT05964101GALAXY-1P2unknownNivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
NCT05898828RP1/P2withdrawnPhase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
NCT04350463P2completedA Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
NCT03792724INTRUSTP1/P2unknownPhase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors

Ovarian Cancer (6)

NCTAcronymPhaseStatusTitle
NCT04024878P1active not recruitingNeoVax With Nivolumab in Patients With Ovarian Cancer
NCT03355976P2active not recruitingBrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
NCT05601752SURPASS-3P2active not recruitingADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
NCT05715216OMP-313M32P2active not recruitingEON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
NCT02737787P1completedA Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
NCT03959761ICONICP1/P2completedTolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma

Carcinoma, Hepatocellular (6)

NCTAcronymPhaseStatusTitle
NCT05337137RELATIVITY-106P1/P2completedA Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
NCT03418922P1completedA Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
NCT04310709RENOBATEP2completedCombination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma
NCT03572582IMMUTACEP2completedTransarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
NCT02859324HCCP1/P2completedA Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
NCT03939975P2completedAnti-PD-1therapy Combined With Thermal Ablation for Advanced HCC

Sarcoma (6)

NCTAcronymPhaseStatusTitle
NCT04995003CARP1recruitingHER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
NCT03886311TNTP2recruitingTalimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
NCT03465592HLAP1/P2recruitingTrial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
NCT03463408Early P1active not recruitingImmunotherapy + Radiation in Resectable Soft Tissue Sarcoma
NCT04535713GALLANTP2recruitingGALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
NCT04741438RAR-ImmuneP3unknownEfficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Metastatic Cancer (6)

NCTAcronymPhaseStatusTitle
NCT03693014P2active not recruitingA Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
NCT04295863P1recruitingComparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
NCT05043714NEBULAP1completedStudy of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
NCT04208958ConsortiumIOP1/P2completedStudy of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
NCT03453892ST-ICIN/AcompletedInvestigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition
NCT03758781P1completedIRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Uveal Melanoma (5)

NCTAcronymPhaseStatusTitle
NCT07501117P1not yet recruitingNeoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
NCT04463368SCANDIUM IIP1completedIsolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
NCT02913417P1/P2unknownYttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
NCT03922880P1completedStudy of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
NCT02626962GEM1402P2completedTrial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma

Cutaneous Melanoma (5)

NCTAcronymPhaseStatusTitle
NCT06999980Neo IRENIEP2recruitingNeo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
NCT06319196ClearMeP2recruitingClear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
NCT03929029P1active not recruitingNeoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
NCT02519322P2completedNeoadjuvant and Adjuvant Checkpoint Blockade
NCT03633110P1/P2completedSafety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Melanoma Stage III (5)

NCTAcronymPhaseStatusTitle
NCT04562129P2recruitingIL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT06295159P2recruitingNeoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
NCT04741997Early P1recruitingAdjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
NCT04013854P2active not recruitingAdjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
NCT04007588BMS-986205P2withdrawnA Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Squamous Cell Carcinoma of Head and Neck (5)

NCTAcronymPhaseStatusTitle
NCT05317000P2recruiting5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
NCT03576417NIVOPOSTOPP3active not recruitingA Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
NCT05743270P2withdrawnStudy of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
NCT05027204SCCHNP1/P2unknownA Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)
NCT05802290NIVACTORP3completedNIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN

NSCLC (5)

NCTAcronymPhaseStatusTitle
NCT05684276DUMASP2active not recruitingDUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
NCT05180799P1/P2active not recruitingA Phase 1/2 Study of BA3071 in Patients With Solid Tumors
NCT06094296NSCLCP2terminatedA Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT05583188VIGORP4terminatedNeoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
NCT05061017PG545P2completedPixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

Colorectal Adenocarcinoma (5)

NCTAcronymPhaseStatusTitle
NCT05504252METIMMOX-2P2active not recruitingMETIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
NCT04963283MSSP2active not recruitingStudy of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
NCT04457284P2active not recruitingTemozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
NCT03576963P1/P2withdrawnGuadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
NCT03800602P2completedNivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

Lymphoma, Non-Hodgkin (5)

NCTAcronymPhaseStatusTitle
NCT02693535TAPURP2recruitingTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT03297606CAPTURP2recruitingCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
NCT05255601RELATIVITY-069P1/P2completedA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
NCT03366272NIVEAUP2/P3completedNivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
NCT03310619PLATFORMP1/P2completedA Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Solid Tumor, Adult (5)

NCTAcronymPhaseStatusTitle
NCT04665206P1/P2recruitingStudy to Evaluate VT3989 in Patients With Metastatic Solid Tumors
NCT04165330P1/P2active not recruitingEvaluation of AL3818 in Combination With Nivolumab in Solid Tumors
NCT04143711P1/P2completedStudy of DF1001 in Patients With Advanced Solid Tumors
NCT04761198P1/P2completedA Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
NCT03728179RACINP1completedRACIN in Patients With Advanced TIL-negative Solid Tumors

Advanced Malignant Solid Neoplasm (5)

NCTAcronymPhaseStatusTitle
NCT04317105P1/P2active not recruitingTesting the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
NCT04021043BMS-986156P1/P2completedBMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
NCT02419495KPT-330P1terminatedPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
NCT02408861P1terminatedNivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT03326258P1/P2withdrawnGlembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Carcinoma, Renal Cell (5)

NCTAcronymPhaseStatusTitle
NCT03138512CheckMate 914P3completedA Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
NCT03012581AcSéP2completedSecured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
NCT02917772TITAN-RCCP2completedTailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
NCT03136627P1/P2completedPhase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
NCT02962804RCCP2withdrawnCombination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

Various Advanced Cancer (5)

NCTAcronymPhaseStatusTitle
NCT02632409CheckMate 274P3active not recruitingAn Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
NCT03143153CheckMate 648P3completedA Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
NCT02488759CheckMate358P1/P2completedAn Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
NCT03130959CheckMate 908P2completedA Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies
NCT02387996P2completedA Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Recurrent Classic Hodgkin Lymphoma (4)

NCTAcronymPhaseStatusTitle
NCT07572123P2/P3not yet recruitingEvaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT05039073P2recruitingBrentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
NCT05162976P1active not recruitingCC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
NCT01896999P1/P2active not recruitingBrentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Non Small Cell Lung Cancer Metastatic (4)

NCTAcronymPhaseStatusTitle
NCT07420439P2not yet recruitingTreatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT03168464P1/P2terminatedRadiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
NCT03304093CHIVA2P2completedImmunotherapy by Nivolumab for HIV+ Patients
NCT03353675NSCLCP2completedA Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Hepatocellular Carcinoma (HCC) (4)

NCTAcronymPhaseStatusTitle
NCT07075120P1recruitingIpilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
NCT03510871HCCP2completedNivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
NCT07053202N/AcompletedTACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
NCT03071094HCCP1/P2terminatedA Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT07166406P3recruitingTesting Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT04611165NextrahP2completedConcurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC
NCT03841201P2completedImmunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
NCT03059147P1terminatedPhase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Metastatic Pancreatic Adenocarcinoma (4)

NCTAcronymPhaseStatusTitle
NCT07226856P2recruitingBMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
NCT04787991REVOLUTIONP1completedExploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
NCT04050085SD-101P1completedSD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
NCT03214250P1/P2completedSafety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Malignant Melanoma Stage III (4)

NCTAcronymPhaseStatusTitle
NCT06794775SWE-NEOP3recruitingSWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
NCT04949113NADINAP3active not recruitingNeoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
NCT02977052OpACIN-neoP2unknownOptimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab
NCT04133948DONIMIP1/P2completedMulticenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Metastatic Uveal Melanoma (4)

NCTAcronymPhaseStatusTitle
NCT06581406P2/P3recruitingA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT05987332P2/P3active not recruitingIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT04552223P2completedNivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
NCT01585194P2completedNivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Recurrent Glioblastoma (4)

NCTAcronymPhaseStatusTitle
NCT04003649P1active not recruitingIL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
NCT06097975NEO-GLITIPNIP1recruitingA Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma
NCT02017717CheckMate 143P3completedA Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
NCT03430791P2terminatedTrial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

Merkel Cell Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT06151236P2recruitingNeoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
NCT03071406P2active not recruitingRandomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
NCT02196961ADMEC-OP2completedAdjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation
NCT03798639P1completedNivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

Muscle-Invasive Bladder Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT04506554P2active not recruitingA Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
NCT05203913CNN-BCP2recruitingCisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
NCT04876313NURE-ComboP2unknownAn Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
NCT04610671P1completedStudy of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Nasopharyngeal Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT06019130NPC-NivoP2recruitingNivolumab in Children and Adults With Nasopharyngeal Carcinoma
NCT03097939P2unknownPhase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
NCT03267498NPCP2completedNivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
NCT03390738P2withdrawnNivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Esophageal Squamous Cell Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT04229459P2active not recruitingTrial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
NCT05213312P2/P3unknownStudy of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
NCT03987815P2unknownNeoadjuvant Nivolumab for Operable Esophageal Carcinoma
NCT04936399EAMSN/AcompletedA Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Epithelial Ovarian Cancer (4)

NCTAcronymPhaseStatusTitle
NCT03522246ATHENAP3active not recruitingA Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT04620954ORION-02P1/P2unknownClinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
NCT03824704ARIESP2terminatedA Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
NCT03100006ORION-01P1/P2terminatedPhase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Head and Neck Squamous Cell Carcinoma (HNSCC) (4)

NCTAcronymPhaseStatusTitle
NCT04080804P2active not recruitingStudy of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
NCT04603248N/AcompletedA Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
NCT02764593P1completedSafety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
NCT02684253SBRTP2completedScreening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Malignant Pleural Mesothelioma (4)

NCTAcronymPhaseStatusTitle
NCT04162015P1active not recruitingA Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
NCT04013334P2unknownMTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
NCT03048474INITIATEP2completedIpilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
NCT02497508NivoMesP2completedNivolumab in Patients With Recurrent Malignant Mesothelioma

Biliary Tract Cancer (4)

NCTAcronymPhaseStatusTitle
NCT03785873P1/P2completedPhase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
NCT03639935P2completedRucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
NCT02829918P2completedStudy of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
NCT04057365BTCP2terminatedStudy of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

Lymphoma (4)

NCTAcronymPhaseStatusTitle
NCT03502733P1active not recruitingTesting the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
NCT03229278P1completedTrigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
NCT02038946FLP2completedStudy of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
NCT02857426CheckMate 647P2completedA Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Recurrent Non-Small Cell Lung Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT03048500P2unknownNivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT02823990P2completedTG4010 and Nivolumab in Patients With Lung Cancer
NCT03023904P2withdrawnNivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
NCT03121417P2withdrawnNivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer

High Grade Glioma (3)

NCTAcronymPhaseStatusTitle
NCT06519682CAYAN/ArecruitingA Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
NCT04267146NIVOGLIOP1/P2completedNivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma
NCT03925246REVOLUMABP2completedEfficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas

NSCLC Stage IV (3)

NCTAcronymPhaseStatusTitle
NCT05597800LUNGVIRP2not yet recruitingNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome
NCT06532149EROSN/ArecruitingERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
NCT04507906P1/P2completedNivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

Metastatic Nasopharyngeal Carcinoma (3)

NCTAcronymPhaseStatusTitle
NCT06029270P2recruitingTesting the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
NCT05904080P2suspendedTesting Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
NCT04458909P3terminatedTesting the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Pancreatic Ductal Adenocarcinoma (3)

NCTAcronymPhaseStatusTitle
NCT06015724DARANIVOVAXP2recruitingAnti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
NCT04477343P1recruitingA Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT03496662PDACP1/P2completedBMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Brain Metastases (3)

NCTAcronymPhaseStatusTitle
NCT05048212P2recruitingA Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
NCT03458455TREATMENTN/AunknownImproved Therapy Response Assessment in Metastatic Brain Tumors
NCT02460068NIBIT-M2P3unknownA Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis

Classical Hodgkin Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT05352828ACTIONP1active not recruitingAutologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
NCT02940301P2active not recruitingIbrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT03004833NIVAHLP2completedNivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Metastatic Colon Adenocarcinoma (3)

NCTAcronymPhaseStatusTitle
NCT05308446P2active not recruitingTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
NCT04599140P1/P2active not recruitingSX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
NCT04044430P1terminatedEncorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

Locally Advanced Bladder Urothelial Carcinoma (3)

NCTAcronymPhaseStatusTitle
NCT04637594IMAGINEP3active not recruitingTrying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04953104P2active not recruitingARID1A and/or KDM6A Mutation and CXCL13 Expression
NCT04848519P2active not recruitingImmune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Advanced Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT02465060P2active not recruitingTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT06400264P2withdrawnTesting Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
NCT04439214P2completedTesting Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Osteosarcoma (3)

NCTAcronymPhaseStatusTitle
NCT04803877SARC038P2active not recruitingSARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
NCT03628209P1active not recruitingNivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
NCT05302921P2completedNeoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Metastatic Malignant Solid Neoplasm (3)

NCTAcronymPhaseStatusTitle
NCT04840589P1suspendedTesting the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
NCT04957615P2active not recruitingNivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
NCT03525925P1completedIbrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

HNSCC (3)

NCTAcronymPhaseStatusTitle
NCT03917537N/AunknownWGA in Platinum-refractory HNSCC Underwent Nivolumab
NCT04272333Early P1terminatedIntratumoral Microdosing of Motolimod in HNSCC
NCT03652142N/AunknownPredictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma

Acral Lentiginous Melanoma (3)

NCTAcronymPhaseStatusTitle
NCT04511013P2recruitingA Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT03025256P1recruitingIntravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
NCT02978443P2terminatedA Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Metastatic Breast Cancer (3)

NCTAcronymPhaseStatusTitle
NCT04159818TONIC-2P2recruitingImmune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
NCT03807765P1completedStereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
NCT04061863KORNELIAP1/P2unknownNivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer

Urinary Bladder Neoplasms (3)

NCTAcronymPhaseStatusTitle
NCT03661320P3active not recruitingA Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
NCT04149574CheckMate 7G8P3terminatedA Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
NCT03519256CheckMate 9UTP2terminatedA Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Pancreatic Adenocarcinoma (3)

NCTAcronymPhaseStatusTitle
NCT03080974P2recruitingImmunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT03816358P1active not recruitingTesting the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
NCT03404960ParpvaxP1/P2completedNiraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

Non-Small Cell Lung Cancer (NSCLC) (3)

NCTAcronymPhaseStatusTitle
NCT03767348IGNYTEP2active not recruitingStudy of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT04026412CheckMate73LP3completedA Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
NCT03444766P4completedStudy of Nivolumab for Advanced Cancers in India

Soft Tissue Sarcoma (3)

NCTAcronymPhaseStatusTitle
NCT03277924ImmunoSarcP1/P2completedTrial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
NCT04118166P2completedIpilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
NCT02982486P2unknownA Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Melanoma Stage Iv (3)

NCTAcronymPhaseStatusTitle
NCT03340129ABC-XP2recruitingAnti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
NCT03991130P2terminatedHigh Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
NCT03161756CHARLIP1/P2unknownEvaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

Urinary Bladder Cancer (3)

NCTAcronymPhaseStatusTitle
NCT03844256CRIMIP1/P2recruitingA Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
NCT03529890RACE ITP2unknownRadio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder
NCT02897765NEO-PV-01P1completedA Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Recurrent Hodgkin Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT01703949P2active not recruitingBrentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
NCT03016871P2active not recruitingNivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
NCT03739619P1/P2completedGemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Neoplasms by Site (3)

NCTAcronymPhaseStatusTitle
NCT01968109P1/P2completedAn Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
NCT03656718P1/P2completedA Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
NCT01629758P1completedSafety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

Advanced Malignancies (3)

NCTAcronymPhaseStatusTitle
NCT03126110P1/P2completedPhase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
NCT03158272P1completedA Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
NCT03241173P1/P2completedA Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Hodgkin Disease (3)

NCTAcronymPhaseStatusTitle
NCT02927769CheckMate 744P2completedA Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
NCT01716806HLP2completedA Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
NCT02181738CheckMate 205P2completedStudy of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Metastatic Malignant Neoplasm in the Brain (3)

NCTAcronymPhaseStatusTitle
NCT02696993P1/P2active not recruitingNivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
NCT02910700P2active not recruitingNivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
NCT02716948P1completedSRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

Leukemia (3)

NCTAcronymPhaseStatusTitle
NCT02530463P2active not recruitingNivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
NCT02464657MDSP1/P2completedStudy of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
NCT02599649MDSP2terminatedLirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Soft Tissue Sarcomas (2)

NCTAcronymPhaseStatusTitle
NCT07444619P1not yet recruitingA Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
NCT03149120P2withdrawnStudy of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Advanced Renal Cell Carcinoma (aRCC) (2)

NCTAcronymPhaseStatusTitle
NCT07188896RCCP2recruitingA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
NCT06345183N/AcompletedReal-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Brain Cancer (2)

NCTAcronymPhaseStatusTitle
NCT07210632HGGEarly P1recruitingWindow Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
NCT02617589CheckMate 498P3completedAn Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Advanced Non-squamous Non-small-cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06463665VIRO-25P2recruitingEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
NCT07485166N/Aactive not recruitingEmulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases

Colorectal Cancer (MSI-H) (2)

NCTAcronymPhaseStatusTitle
NCT07403877TORCH-OPTIMAP2not yet recruitingNeoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
NCT07523763NIVO1002024P2active not recruitingNeoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer

Cutaneous Melanoma, Stage III (2)

NCTAcronymPhaseStatusTitle
NCT07230613NEOREM-NEO-1P2recruitingNeo-adjuvant Immunotherapy in Patients With Localized Melanoma
NCT03719131P2active not recruitingRituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Metastatic Soft-tissue Sarcoma (2)

NCTAcronymPhaseStatusTitle
NCT06968988P1recruitingZanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
NCT04551430P2active not recruitingCabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Advanced Non Small Cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06908993COMETP3recruitingTepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
NCT03351361eNERGYP3completedNivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients

Clinical Stage IV Cutaneous Melanoma AJCC v8 (2)

NCTAcronymPhaseStatusTitle
NCT05717140P1withdrawnAerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
NCT05341349P1terminatedStereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Metastatic Non-Squamous Non-Small Cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT07246863P2recruitingTrial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
NCT03906071SAPPHIREP3completedPhase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Basal Cell Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT03521830P2recruitingNivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
NCT06624475NEONP2recruitingNeoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

Non Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT06767956P1/P2withdrawnGolcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
NCT03620578HO152P2active not recruitingDA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL

Gastroesophageal Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT05733689P1recruitingResponse Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
NCT04021108P2active not recruitingPhase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Neuroendocrine Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT06889493NECP1recruitingSVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
NCT03591731NIPINECP2completedNivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Kidney Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06934057CABOLDP4recruitingCabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
NCT04322955Cyto-KIKP2active not recruitingCYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

Leptomeningeal Metastasis (2)

NCTAcronymPhaseStatusTitle
NCT06901817P2recruitingA Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
NCT05598853IT-IOP1active not recruitingIntrathecal Double Checkpoint Inhibition

Advanced Esophageal Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT05677490P3recruitingmFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT06203600P2/P3recruitingAdding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Cutaneous Squamous Cell Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT06288191P2recruitingNeoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
NCT04620200MATISSEP2completedNeo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery

Recurrent Transformed Chronic Lymphocytic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT06247540P2withdrawnVenetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT05672173P2active not recruitingLisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Muscle Invasive Bladder Urothelial Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT05987241P2/P3recruitingTesting the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT06204614Early P1enrolling by invitationDrug Screening Using IMD in Bladder Cancer

Lung Cancer, Nonsmall Cell (2)

NCTAcronymPhaseStatusTitle
NCT06667154P2recruitingEfficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
NCT06003075P2terminatedInduction Chemo-Nivo in Unresectable Stage III NSCLC

Endometrial Neoplasms (2)

NCTAcronymPhaseStatusTitle
NCT05795244NIVECP2recruitingStudy of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
NCT04570839P1/P2completedCOM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Upper Gastrointestinal Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06361563N/AcompletedReal-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada
NCT06361576N/AcompletedReal-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

Oncology (2)

NCTAcronymPhaseStatusTitle
NCT06031233MINUTEP4recruitingEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT04299880P1completedRollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Esophageal Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT04150640P2recruitingOxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
NCT05480384P2active not recruitingAdjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Lung Non-Small Cell Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT05501665P1/P2recruitingSplit Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
NCT05022394P1/P2withdrawnSapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

Castration-resistant Prostate Cancer (2)

NCTAcronymPhaseStatusTitle
NCT05502315CANOPYP2recruitingStudy of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT03554317COMBAT-CRPCP2completedCOMbination of Bipolar Androgen Therapy and Nivolumab

Cancer of Rectum (2)

NCTAcronymPhaseStatusTitle
NCT05732389RESET-RP2recruitingImmunotherapy in Patients With Early dMMR Rectal Cancer
NCT02948348P1/P2unknownStudy to Nivolumab Following Preoperative Chemoradiotherapy

Metastatic Gastric Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06008925P1/P2recruitingClinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
NCT05859477NIVOFGFR2P2unknownNivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer

Lung Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT04929041P2/P3suspendedTesting the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
NCT03391869P3active not recruitingNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Chronic Hepatitis B (2)

NCTAcronymPhaseStatusTitle
NCT05343481P2completedEfficacy of VTP-300 in Chronic Hepatitis B Infection
NCT04891770SLGNP2completedStudy to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Urothelial Cancer (2)

NCTAcronymPhaseStatusTitle
NCT03036098CheckMate901P3active not recruitingStudy of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT05219435VEXILLUMP2completedStudy of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Non-Small Cell Lung Cancer Metastatic (2)

NCTAcronymPhaseStatusTitle
NCT03469960DICIPLEP3completedDouble Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
NCT05265650NoeliaP1/P2unknownStudy of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

Endometrial Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT05112601P2recruitingTesting Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT04106414P2active not recruitingStudy of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Mucosal Melanoma (2)

NCTAcronymPhaseStatusTitle
NCT05384496P2recruitingAxitinib and Nivolumab for the Treatment of Mucosal Melanoma
NCT03241186P2active not recruitingIpilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

Advanced Pancreatic Cancer (2)

NCTAcronymPhaseStatusTitle
NCT05162118P1/P2unknownClinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
NCT03336216P2completedA Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Prostatic Neoplasms, Castration-Resistant (2)

NCTAcronymPhaseStatusTitle
NCT04717154INSPIREP2completedIpilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer
NCT05169684P2terminatedA Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Mesothelioma, Malignant (2)

NCTAcronymPhaseStatusTitle
NCT05136677CheckMate 6DWP2completedA Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
NCT03502746P2terminatedPhase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Stage IV Pancreatic Cancer (2)

NCTAcronymPhaseStatusTitle
NCT05088889P1unknownMaintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
NCT04377048P2unknownNivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

Renal Cancer Metastatic (2)

NCTAcronymPhaseStatusTitle
NCT05215470CLARAP2active not recruitingCLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
NCT03469713NIVESP2completedNivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma

Pancreatic Cancer Stage IV (2)

NCTAcronymPhaseStatusTitle
NCT03697564P2completedNivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
NCT04953962P2completedStudy of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

Renal Cell Carcinoma (RCC) (2)

NCTAcronymPhaseStatusTitle
NCT05176483STELLAR-002P1recruitingStudy of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
NCT03311334P1/P2terminatedA Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Metastatic Non Small Cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04884282COMBI-TEDP2active not recruitingEfficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
NCT05236608ADIVO LungP1/P2unknownA Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC

Unresectable Melanoma (2)

NCTAcronymPhaseStatusTitle
NCT04688658P1/P2terminatedDuvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
NCT01927419CheckMate 069P2completedStudy of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

Adult Solid Tumor (2)

NCTAcronymPhaseStatusTitle
NCT04892043P1terminatedStudy of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
NCT04084951P1completedStudy of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Unresectable or Metastatic Melanoma (2)

NCTAcronymPhaseStatusTitle
NCT04674683P3active not recruitingStudy Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT01844505P3completedPhase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Advanced Biliary Tract Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04969887MOST-CIRCUITP2active not recruitingCombination Immunotherapy in Rare Cancers Under InvesTigation
NCT04172402P2completedNGS as the First-line Treatment in Advanced Biliary Tract Cancer

Metastatic Ovarian Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04611126P1/P2terminatedT-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
NCT03287674P1/P2completedTIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Locally Advanced Esophageal Squamous Cell Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT03914443P1completedA Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
NCT05130684Neo-NTP-CRTP2unknownNeo-NTP-CRT for Locally Advanced ESCC

Stage III Hepatocellular Carcinoma AJCC v8 (2)

NCTAcronymPhaseStatusTitle
NCT04380545P1/P2recruitingNivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
NCT03439891P2completedSorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

Small-cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04610658P1terminatedImmune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
NCT04173325P1terminatedFeasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Triple Negative Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04331067P1/P2active not recruitingNeoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
NCT03487666OXELP2completedOXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

Anal Basaloid Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT03233711P3active not recruitingNivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT04444921EA2176P3active not recruitingEA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

Leiomyosarcoma (2)

NCTAcronymPhaseStatusTitle
NCT04420975P1active not recruitingNivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
NCT04624178P2active not recruitingA Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Metastatic Castration-resistant Prostate Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04109729Rad2NivoP1active not recruitingStudy of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
NCT03835533PORTERP1completedPlatform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Advanced Non-small Cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04263051Optim-UCPVaxP2completedEvaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer
NCT02639234P2withdrawnVigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer

Gliosarcoma (2)

NCTAcronymPhaseStatusTitle
NCT04396860P2/P3completedTesting the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
NCT02311920P1completedIpilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT04310007P2active not recruitingTesting the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
NCT03468985P2completedNivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage II (2)

NCTAcronymPhaseStatusTitle
NCT04699721P2active not recruitingClinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC
NCT03383302STILEP1/P2completedSBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects

Metastatic Pancreatic Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04212026IREP2terminatedIrreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.
NCT02866383CheckPACP2completedImmune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients

Rectal Cancer (2)

NCTAcronymPhaseStatusTitle
NCT03921684P2active not recruitingTrial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
NCT04124601CHINORECP2completedNeoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer

Lung Squamous Cell Carcinoma Stage IV (2)

NCTAcronymPhaseStatusTitle
NCT04306042N/AunknownA Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
NCT02831933ENSIGNP2terminatedTrial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

Myelodysplastic Syndromes (2)

NCTAcronymPhaseStatusTitle
NCT04044209P2withdrawnA Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
NCT03259516P1/P2terminatedNivolumab With Chemotherapy in Refractory MDS

Neuroblastoma (2)

NCTAcronymPhaseStatusTitle
NCT02914405MiniVanP1active not recruitingPhase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
NCT04239040P1terminatedGVAX Plus Checkpoint Blockade in Neuroblastoma

Chronic Lymphocytic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT03884998P1active not recruitingCopanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
NCT03892044P1completedDuvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Liver Cancer (2)

NCTAcronymPhaseStatusTitle
NCT03143270Early P1active not recruitingA Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
NCT04707547RFAP4completedImmune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy

Neuroendocrine Tumors (2)

NCTAcronymPhaseStatusTitle
NCT03980925GEPP2completedPlatinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
NCT03420521P2terminatedNivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Metastatic Hepatocellular Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT03893695HCCP1/P2completedCombination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
NCT03695250P1/P2terminatedBMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Peripheral T Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03927105BMS-986227P2completedNivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
NCT03586999P1/P2completedNivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Chordoma (2)

NCTAcronymPhaseStatusTitle
NCT02989636P1active not recruitingNivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
NCT03623854P2completedNivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Small Cell Lung Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT03850067P1completedA Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
NCT03662074P2terminatedSubsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

Aggressive Non-Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03749018P2active not recruitingNivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT03704714P1/P2suspendedNivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Colorectal Neoplasms Malignant (2)

NCTAcronymPhaseStatusTitle
NCT03507699P1completedCombined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
NCT03993626CAROSELLP1/P2unknownA Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer

Ann Arbor Stage I Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03233347P2active not recruitingDoxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
NCT03712202P2active not recruitingBrentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Cervical Cancer (2)

NCTAcronymPhaseStatusTitle
NCT03298893NiCOLP1/P2completedNivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)
NCT03527264P2terminatedBrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

Recurrent Plasma Cell Myeloma (2)

NCTAcronymPhaseStatusTitle
NCT03605719P1completedDexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
NCT03333746P2terminatedLenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Diffuse Large B Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03311958Early P1completedMolecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
NCT03259529BeGeRNP1/P2completedSafety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

Glioblastoma Multiforme (2)

NCTAcronymPhaseStatusTitle
NCT04195139NUTMEGP2active not recruitingNivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
NCT02550249Neo-nivoP2completedNeoadjuvant Nivolumab in Glioblastoma

Hematologic Malignancies (2)

NCTAcronymPhaseStatusTitle
NCT02663518TTI-621P1terminatedA Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
NCT02985554P1terminatedPhase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies

Squamous Non-Small Cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT02924233P1/P2withdrawnSym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
NCT02475382CheckMate 169N/Ano longer availableExpanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

Advanced Solid Tumors Cancer (2)

NCTAcronymPhaseStatusTitle
NCT02099058PKP1active not recruitingA Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
NCT02955251P1completedA Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

Malignant Glioma (2)

NCTAcronymPhaseStatusTitle
NCT02829931P1completedHypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
NCT02529072AVERTP1completedNivolumab With DC Vaccines for Recurrent Brain Tumors

Pediatric Cancer (2)

NCTAcronymPhaseStatusTitle
NCT02813135ESMARTP1/P2recruitingEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
NCT03126643N/Aapproved for marketingExpanded Access to Nivolumab (Opdivo)

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 (2)

NCTAcronymPhaseStatusTitle
NCT02595944ANVILP3active not recruitingNivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02194738N/Aactive not recruitingGenetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Malignant Solid Tumor (2)

NCTAcronymPhaseStatusTitle
NCT02754141P1/P2completedAn Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
NCT02518958PRIMETIMEP1completedA Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

Recurrent Squamous Cell Lung Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT02785952P3active not recruitingLung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02154490N/AcompletedLung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT01642004NSCLCP3completedStudy of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
NCT01721759BMS-936558P2completedStudy of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

Untreated Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT07459543FDCP4not yet recruitingA Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) (1)

NCTAcronymPhaseStatusTitle
NCT07430202FLCP1not yet recruitingA DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Hepato Cellular Carcinoma (HCC) (1)

NCTAcronymPhaseStatusTitle
NCT07494435P2not yet recruitingPhase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

Advanced Biliary Tract Cancer(BTC) (1)

NCTAcronymPhaseStatusTitle
NCT07369791NOBLEP2not yet recruitingNivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.

Squamous Cell Carcinoma of Head and Neck (SCCHN) (1)

NCTAcronymPhaseStatusTitle
NCT07529873N'FORCEP2not yet recruitingPhase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma

Oral Squamous Cell Carcinoma (OSCC) (1)

NCTAcronymPhaseStatusTitle
NCT07514767NOCANOP2not yet recruitingEvaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma

Diffuse Midline Glioma (1)

NCTAcronymPhaseStatusTitle
NCT06639607PRiME IIP1/P2recruitingPEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

Advanced Microsatellite Stable Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT07527858GS-1811P2recruitingStudy of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Advanced Kidney Cancer (1)

NCTAcronymPhaseStatusTitle
NCT07338981P3not yet recruitingThe Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

HER2-negative (1)

NCTAcronymPhaseStatusTitle
NCT07546812GS-1811P2recruitingStudy of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Hnscc (1)

NCTAcronymPhaseStatusTitle
NCT07460765HNSCCP1not yet recruitingSafety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT07392892P2/P3recruitingSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Diffuse Pleural Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT07532902P1recruitingA Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Non-small Cell Lung Cancer Stage IV (1)

NCTAcronymPhaseStatusTitle
NCT07355205FLINNP2not yet recruitingFirst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Advanced Renal Cell Carcinoma (RCC) (1)

NCTAcronymPhaseStatusTitle
NCT07293351RCCP1/P2recruitingA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Phase 1b (1)

NCTAcronymPhaseStatusTitle
NCT07401875SHARKP1recruitingA Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

Von Hippel-Lindau Disease (1)

NCTAcronymPhaseStatusTitle
NCT07405164P3recruitingExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Unresectable or Metastatic Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT07219459GDFATHERHCC01P2recruitingVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Advanced or Metastatic Gastrooesophageal Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT07213557P2recruitingSimvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT07221149P2/P3recruitingA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Nonsmall Cell Lung Cancer, Stage IV (1)

NCTAcronymPhaseStatusTitle
NCT07394062ALCG-01N/ArecruitingReal-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

Unresectable Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT07482059P1/P2recruitingA Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma

Resectable Stage II-IIIa Squamous NSCLC (1)

NCTAcronymPhaseStatusTitle
NCT07398937ECTOP-1036P2recruitingComparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC

Relapsed/Refractory Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT07325136P1/P2recruitingA Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

Advanced (Unresectable or Metastatic) Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT07221734P3recruitingStudy to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

Metastatic Triple-negative Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06963905SIMONEP1/P2recruitingSaci Nivo Rela for TNBC

CNS Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT07017816JACOBEarly P1recruitingA Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

Metastatic Renal Cell Carcinoma ( mRCC) (1)

NCTAcronymPhaseStatusTitle
NCT07233668IVE in mRCCN/Anot yet recruitingImmediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC

Newly Diagnosed Glioblastoma (1)

NCTAcronymPhaseStatusTitle
NCT06816927GIANTP2recruitingTrial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

HER2-Expressing Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT07334119P1recruitingSafety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Locally Advanced Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT07223411N/ArecruitingOpdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

Locally Advanced Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06794229EXPLORE-RCCP2recruitingNeoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

Advanced Acral Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT07155317P2recruitingTime-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Solid Tumor Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT07174453P3recruitingTrial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Renal Cell Carcinoma (Kidney Cancer) (1)

NCTAcronymPhaseStatusTitle
NCT07028125CANIQOLP4recruitingDigital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Advanced Hepatocellular Carcinoma (HCC) (1)

NCTAcronymPhaseStatusTitle
NCT07147101HCC-IM-1N/ArecruitingDifferent First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Microsatellite-stable Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT07011550P2suspendedPhase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Locally Advanced Clear Cell Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06866262P1/P2recruitingInulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Anaplastic Large Cell Lymphoma, ALK-Positive (1)

NCTAcronymPhaseStatusTitle
NCT07013565ACCELERATEP2recruitingChemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Melanoma (Skin Cancer) (1)

NCTAcronymPhaseStatusTitle
NCT06624644P2/P3recruitingA Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Recurrent High-grade Glioma (1)

NCTAcronymPhaseStatusTitle
NCT07031765Peds CHAMP1ONP1active not recruitingPeds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

PROMs (1)

NCTAcronymPhaseStatusTitle
NCT07061379PROMOTINGN/ArecruitingPatient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen

Glioblastoma (GBM) (1)

NCTAcronymPhaseStatusTitle
NCT06896110P1enrolling by invitationIntrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

Melanoma Brain Metastases (1)

NCTAcronymPhaseStatusTitle
NCT06163820BETTERP1/P2recruitingBevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

NSCLC (Non-small Cell Lung Carcinoma) (1)

NCTAcronymPhaseStatusTitle
NCT07050043LEDANGP3recruitingLow Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

Cutaneous Squamous Cell Carcinoma (CSCC) (1)

NCTAcronymPhaseStatusTitle
NCT06823479MATISSE 2P2recruitingTowards Cure Via Only Ultra-short ICB in CSCC

Urothelial Carcinoma Bladder (1)

NCTAcronymPhaseStatusTitle
NCT06983210GRAPEP2recruitingClinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma

Recurrent/ Metastatic Olfactory Neuroblastoma (1)

NCTAcronymPhaseStatusTitle
NCT07100704OrionP2recruitingRecurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab

Hodgkin Lymphoma, Adult (1)

NCTAcronymPhaseStatusTitle
NCT06984146P2recruitingNivo40-AVD for Advanced Classic Hodgkin Lymphoma

Advanced Lung Non-Small Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06731270P2recruitingDiclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Low Grade Glioma (1)

NCTAcronymPhaseStatusTitle
NCT06712875P1/P2recruitingMAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Advanced Malignant Tumors (1)

NCTAcronymPhaseStatusTitle
NCT06764771P1recruitingA Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Renal Cell Carcinoma, Clear Cell (1)

NCTAcronymPhaseStatusTitle
NCT06708949RCCP2recruitingA Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Locally Advanced Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT06534190P2recruitingCD8 PET Imaging in Metastatic Solid Tumours

Advanced Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06745076P2recruitingPersonalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

Premalignant Lesion (1)

NCTAcronymPhaseStatusTitle
NCT06561087P2recruitingPhase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

Extensive-Stage Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06646276TIGOSP3recruitingA Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Lung Cancer - Non Small Cell (1)

NCTAcronymPhaseStatusTitle
NCT06926790GALAXY 3P2recruitingNeoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)

Melanoma, Cutaneous Malignant (1)

NCTAcronymPhaseStatusTitle
NCT06743126SUPRAMEP3recruitingSUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Rare Tumour (1)

NCTAcronymPhaseStatusTitle
NCT06692491SPRINGP2not yet recruitingStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

High-risk Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT06488482P3recruitingAssessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

Genitourinary Cancers (1)

NCTAcronymPhaseStatusTitle
NCT06724159SOGUG-PRINCISN/ArecruitingObservational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

Resectable Lung Non-Small Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06632327P3recruitingComparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

LOCALLY ADVANCED CERVICAL CANCERS (1)

NCTAcronymPhaseStatusTitle
NCT06715241COLIBRI-2P2active not recruitingA MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

Muscle-invasive Urothelial Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06534983IMCODE004P2recruitingA Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

Diffuse Hemispheric Glioma, H3 G34-Mutant (1)

NCTAcronymPhaseStatusTitle
NCT05457959P1withdrawnPeptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Pleural Biphasic Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT05647265P2recruitingTesting the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Progressive Glioblastoma (1)

NCTAcronymPhaseStatusTitle
NCT06325683P2suspendedAnti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Metastatic Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT07024862N/Aactive not recruitingLong-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Colon Cancer Stage II (1)

NCTAcronymPhaseStatusTitle
NCT06490536P3recruitingThe Sagittarius Trial

Primary Mediastinal (Thymic) Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06871007P1/P2enrolling by invitationNivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma

Advanced Lung Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06495125P2recruitingDefactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Urachal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06638931ANTARESP2recruitingAgnostic Therapy in Rare Solid Tumors

Recurrent Ependymoma (1)

NCTAcronymPhaseStatusTitle
NCT06466798P1withdrawnFourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Cancer of Gastrointestinal Tract (1)

NCTAcronymPhaseStatusTitle
NCT05153304P1/P2withdrawnPersonalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

Stage II Nasopharyngeal Carcinoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT06064097NPCP2recruitingA Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Oropharyngeal Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06771674N/AcompletedReal-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Recurrent Squamous Cell Carcinoma of the Head and Neck (1)

NCTAcronymPhaseStatusTitle
NCT06357858P1withdrawnASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Adenocarcinoma of the Esophagogastric Junction (1)

NCTAcronymPhaseStatusTitle
NCT06681298P2active not recruitingA Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab

Advanced Esophageal Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06265285CCBWP2recruitingComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Metastatic Kidney Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06364631CARE1P3recruitingCARE1 Pragmatic Clinical Trial

ICB-refractory Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT06250335ICBP2active not recruitingImpact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

Urologic Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT06237920TURANDORELAP2recruitingStage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT06191796XL092P1terminatedStudy of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Resectable Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06169956NENIN/ArecruitingAn Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

Clinical Stage IV Gastric Cancer AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT05802056P1recruitingAldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction (1)

NCTAcronymPhaseStatusTitle
NCT06158919G/GEJ cancerN/ArecruitingA Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

Unresectable Pleural Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT06097728eVOLVE-MesoP3active not recruitingMEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases (1)

NCTAcronymPhaseStatusTitle
NCT05504642CERAD-IMMUNEP2withdrawnChemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients

Diffuse Astrocytoma, IDH-Mutant (1)

NCTAcronymPhaseStatusTitle
NCT06047379P1/P2recruitingSafety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Locally Advanced Extraskeletal Myxoid Chondrosarcoma (1)

NCTAcronymPhaseStatusTitle
NCT05836571P2active not recruitingTesting Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

IDH1-mutant Cholangiocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05921760P1/P2terminatedIvosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

Follicular Lymphoma Stage II (1)

NCTAcronymPhaseStatusTitle
NCT05788081TOP-FLORP2active not recruitingTreatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Stage II Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT05418972Neo ReNi IIP2active not recruitingA Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma

Atypical Teratoid Rhabdoid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT05407441P1/P2active not recruitingTazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Malignant Neoplasms of Digestive Organs (1)

NCTAcronymPhaseStatusTitle
NCT05934331P2recruitingA LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Advanced Glioblastoma (1)

NCTAcronymPhaseStatusTitle
NCT0590961814P2recruitingCrizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

Acute Anterior ST Segment Elevation Myocardial Infarction (1)

NCTAcronymPhaseStatusTitle
NCT05887830P1/P2unknownEffect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial

Metastatic Prostate Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05445609CMP-001P2suspendedVidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Recurrent Melanoma (Skin) (1)

NCTAcronymPhaseStatusTitle
NCT05655312P1/P2recruitingMC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Refractory Tumor (1)

NCTAcronymPhaseStatusTitle
NCT05767684P1unknownNeoantigen Derived DCs as Cancer Treatment

HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05749900HERBOTP1/P2recruitingFirst-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT05675410P3recruitingA Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Resectable Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05472623Neo-KanP2withdrawnNeoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

B Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT05310591CAPTiRALLP1/P2recruitingCombination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

Safety Issues (1)

NCTAcronymPhaseStatusTitle
NCT05772624P2unknownLowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

Melanoma Stage IV (1)

NCTAcronymPhaseStatusTitle
NCT05652673IPI-NIVON/ArecruitingSafe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05500092P2active not recruitingAn Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

HIV I Infection (1)

NCTAcronymPhaseStatusTitle
NCT05187429NIVO-LDP1/P2recruitingLow Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy

BCLC Stage B Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05199285P2terminatedA Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Non-Clear Cell Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05678673STELLAR-304P3active not recruitingStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Gastroenteropancreatic Neuroendocrine Tumor (1)

NCTAcronymPhaseStatusTitle
NCT05262556P1active not recruitingNP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Locally Advanced or Metastatic Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT05498792Early P1recruitingStudy of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Advanced Upper Gastrointestinal Tract Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05568095STAR-221P3active not recruitingA Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Metastatic Lung Non-Small Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05234307P1recruitingPBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

High-grade Salivary Gland Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05727410P2recruitingNeoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

Immune Suppression (1)

NCTAcronymPhaseStatusTitle
NCT05739045P2recruitingNivolumab Combined With SOX Used in the Perioperative Treatment

Recurrent B-Cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05272384P1recruitingTesting the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Colorectal Cancer Liver Metastases (1)

NCTAcronymPhaseStatusTitle
NCT05588297P2unknownPreoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

Carcinomas (1)

NCTAcronymPhaseStatusTitle
NCT05347212P2active not recruitingPhase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

Pancreas Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05435053CHECKPOINTP2terminatedIrreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer

Uterine Cervical Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT05492123P2recruitingNivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Chronic Hepatitis B Infection (1)

NCTAcronymPhaseStatusTitle
NCT04638439P1101P1completedThe Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

Brain Tumor (1)

NCTAcronymPhaseStatusTitle
NCT05317858LIMITLESSP3recruitingBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Anal Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT05111574P2active not recruitingUsing Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Melanoma, Ocular (1)

NCTAcronymPhaseStatusTitle
NCT05169957HAMMER IP1completedHepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

AIDS-Related Anal Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04929028P2active not recruitingTherapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

PD-1 Antibody (1)

NCTAcronymPhaseStatusTitle
NCT05461235P2unknownAnti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Hematopoietic and Lymphoid Cell Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT04781855P1withdrawnIpilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Refractory Central Nervous System Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04845139N/AunknownA Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma

Primary Myelofibrosis (1)

NCTAcronymPhaseStatusTitle
NCT05393674P2completedFedratinib in Combination With Nivolumab

Anatomic Stage IV Breast Cancer AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT05098210P1recruitingPersonalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Refractory Cutaneous Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT05200143P2terminatedStudy of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Relapsed or Refractory Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06931613P2enrolling by invitationAutologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

B Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05385263P2unknownAddition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Mesotheliomas Pleural (1)

NCTAcronymPhaseStatusTitle
NCT04400539IMPALAP2recruitingThe IMmunotherapy Pleural 5-ALA PDT

Prostatic Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT05150236ANZUP2001P2unknownEVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

Colorectal Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT05328908RELATIVITY-123P3terminatedA Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

Resectable Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04965714P2withdrawnNivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

Primary Mediastinal Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06188676P3recruitingMulticenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Lung Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT05144529TOP2101P2terminatedA Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

Locally Advanced Rectal Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04751370P2active not recruitingTesting Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Locally Advanced Nasopharyngeal Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04910347P2recruitingConsolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Viral Associated Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT04902443P1recruitingPomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Advanced Differentiated Thyroid Gland Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04514484P1active not recruitingTesting the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Relapsed Classic Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04561206P2recruitingBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT04652960P1active not recruitingDuvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Clinical Stage I Cutaneous Melanoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT04697576P1recruitingIntralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Leptomeningeal Disease (1)

NCTAcronymPhaseStatusTitle
NCT05112549IT-PD1P1recruitingIntrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

Primary Mediastinal Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04759586P3active not recruitingNivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Metastatic Head-and-neck Squamous-cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04831320P2active not recruitingNab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Solid Tumour (1)

NCTAcronymPhaseStatusTitle
NCT04891718Early P1withdrawnCIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

Metastatic Uveal Melanoma in the Liver (1)

NCTAcronymPhaseStatusTitle
NCT04935229PERIOP1terminatedIntrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Advanced or Metastatic Solid Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT04887870P2/P3completedStudy of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Advanced or Metastatic Esophageal Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04785820RO7121661P2completedA Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Nerve Sheath Tumors (1)

NCTAcronymPhaseStatusTitle
NCT04465643P1completedNeoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Metastatic Prostate Neuroendocrine Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04709276CHAMPP2active not recruitingA Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Ependymoma (1)

NCTAcronymPhaseStatusTitle
NCT04730349PIVOT IO 020P1/P2terminatedA Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Gastro-Oesophageal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04879368INTEGRATEIIbP3completedRegoNivo vs Standard of Care Chemotherapy in AGOC

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System (1)

NCTAcronymPhaseStatusTitle
NCT04609046P1recruitingTesting the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04745949PACIFICP2recruitingPACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Metastatic Urothelial Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04863885P1/P2active not recruitingCombination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Carcinoma, Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04151563CheckMate 79XP1/P2withdrawnA Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Advanced Bladder Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04902040P1/P2terminatedPlinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Non Small Cell Lung Cancer Stage III (1)

NCTAcronymPhaseStatusTitle
NCT04577638AIRINGP2completedAccelerated Radio-Immunotherapy for Lung Cancer

Advanced Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04785287BMS986218P1/P2terminatedAnti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Rectal Cancer Stage II (1)

NCTAcronymPhaseStatusTitle
NCT04503694REGINAP2active not recruitingNeoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

Extensive-stage Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04702880P2completedA Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Advance Solid Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT04850755P1completedA Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Effect of Drug (1)

NCTAcronymPhaseStatusTitle
NCT05482451Early P1active not recruitingNivolumab and All-trans Retinoic Acid for Pancreatic Cancer

Carcinosarcoma of Ovary (1)

NCTAcronymPhaseStatusTitle
NCT04149275P2withdrawnCabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

Metastatic Colorectal Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04729322P2active not recruitingFecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Metastatic Hormone Refractory Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04477512P1completedCabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Esophagogastric Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04757363P2active not recruitingA Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Constitutional Mismatch Repair Deficiency Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT04500548P1withdrawnTesting the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC) (1)

NCTAcronymPhaseStatusTitle
NCT04594811P1terminatedNT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

Malignant Ascites (1)

NCTAcronymPhaseStatusTitle
NCT05745233N/Aenrolling by invitationIntraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

Upper Urinary Tract Urothelial Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05160285P2unknownNeoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma

Astrocytoma, IDH-Mutant, Grade 4 (1)

NCTAcronymPhaseStatusTitle
NCT04145115P2active not recruitingA Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Hepatitis B (1)

NCTAcronymPhaseStatusTitle
NCT04778904VTP-300P1/P2completedFirst-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV

Down Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT04546399B-ALLP2recruitingA Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Kidney Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT04513522CheckMate 7C9P4completedA Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India

Clinical Stage III Cutaneous Melanoma AJCC V8 (1)

NCTAcronymPhaseStatusTitle
NCT04375527P2terminatedBinimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Papillary Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04413123P2active not recruitingCabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Brain Metastases, Adult (1)

NCTAcronymPhaseStatusTitle
NCT04434560P2terminatedNeoadjuvant Immunotherapy in Brain Metastases

Skin Angiosarcoma (1)

NCTAcronymPhaseStatusTitle
NCT04339738P2active not recruitingTesting the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

Metastatic Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04315155BENEFITP1withdrawnEvaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation

BRAF NP_004324.2:p.V600M (1)

NCTAcronymPhaseStatusTitle
NCT04061980P2active not recruitingEncorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Metastatic Microsatellite Stable Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04575922P2unknownNivolumab+Ipilimumab+RT in MSS mCRC

Cancer, Hepatocellular (1)

NCTAcronymPhaseStatusTitle
NCT04340193CheckMate 74WP3completedA Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

Malignant Rhabdoid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04416568P2active not recruitingStudy of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Advanced Malignant Skin Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT04387084P1active not recruitingShort-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Clear-Cell Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04518046P1completedStudy of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Renal Cell Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT04749602P2completedIntrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.

Metastatic Large Cell Neuroendocrine Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04079712P2active not recruitingTesting the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Adrenocortical Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04187404SpencerP1/P2terminatedA Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

B Cell Lymphomas (1)

NCTAcronymPhaseStatusTitle
NCT03920631MicroBLITZP1withdrawnMicrotransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

Cervix Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04256213COLIBRIN/AcompletedCOL Immunotherapy Before Radiochimio + Ipilimumab

Malignant Melanoma Stage II (1)

NCTAcronymPhaseStatusTitle
NCT04309409NivoMelaP3active not recruitingAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03575234P1withdrawnNivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Neuroendocrine Tumours (NET) (1)

NCTAcronymPhaseStatusTitle
NCT04525638P2unknownA Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04311710CheckMate 76UP1terminatedA Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

Obesity, COVID-19 Infection (1)

NCTAcronymPhaseStatusTitle
NCT04413838NIVISCOP2unknownEfficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection

Indolent Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04431635P1terminatedDose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Recurrent Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT04205409P2completedNivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Metastatic or Unresectable Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT04187833P2completedNivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04282109NIVOTAXP2completedStudy to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04247165LAPTOPP1/P2completedNivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.

Advanced Colon Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04362839P1completedRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

CNS Tumor (1)

NCTAcronymPhaseStatusTitle
NCT03838042P1/P2recruitingINFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

Primary Central Nervous System Lymphoma (PCNSL) (1)

NCTAcronymPhaseStatusTitle
NCT04401774P2completedNivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Progress Free Survival (PFS) and Overall Survival (OS) (1)

NCTAcronymPhaseStatusTitle
NCT04393220P2completedCombination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma

Hormone Sensitive Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04126070P2active not recruitingNivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Fibrolamellar Hepatocellular Carcinoma (FLC) (1)

NCTAcronymPhaseStatusTitle
NCT04248569P1recruitingDNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Metastatic Colon Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03803553P3recruitingIdentification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

COVID19- Infection With SARS-CoV-2 Virus (1)

NCTAcronymPhaseStatusTitle
NCT04343144CORIMUNO-NIVOP2unknownTrial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.

COVID-19 (1)

NCTAcronymPhaseStatusTitle
NCT04356508COVID-19P2unknownCOVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1

Leukemia, Myeloid, Acute (1)

NCTAcronymPhaseStatusTitle
NCT04361058P1withdrawnNivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCTAcronymPhaseStatusTitle
NCT03878524SMMARTP1terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Brain and Nervous System (1)

NCTAcronymPhaseStatusTitle
NCT04022980P1completedNivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

SCCHN (1)

NCTAcronymPhaseStatusTitle
NCT04107103NivoPlusP2completedNivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma

NSCLC Stage II (1)

NCTAcronymPhaseStatusTitle
NCT04205552NEOpredictP2completedNeoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

Soft Tissue Sarcoma Adult (1)

NCTAcronymPhaseStatusTitle
NCT04095208CONGRATSP2completedCombination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

HER2-positive Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT04278144P1/P2terminatedA First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Relapsed Multiple Myeloma (1)

NCTAcronymPhaseStatusTitle
NCT04119336P2terminatedNivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Non-small Cell Lung Cancer Stage I (1)

NCTAcronymPhaseStatusTitle
NCT04271384P2completedStereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

Differentiated Thyroid Gland Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03914300P2active not recruitingTesting the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

BCC - Basal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04570683Early P1unknownLaser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas

Esophagus Cancer, Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03995017RiMEP1/P2unknownRucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

Lung Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT05081674BLISSP2completedBrazilian Lung Immunotherapy Study

Carcinoid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04197310P2completedCabozantinib and Nivolumab for Carcinoid Tumors

Recurrent Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03484819P2completedCopanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (1)

NCTAcronymPhaseStatusTitle
NCT03767582P1/P2completedTrial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

NK/T Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04230330P1withdrawnNivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Cancer of Unknown Primary Site (1)

NCTAcronymPhaseStatusTitle
NCT04131621CheCUPP2unknownNivolumab/Ipilimumab in Second Line CUP-syndrome

Uveal Melanoma, Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT04283890CHOPINP1/P2active not recruitingPHP and Immunotherapy in Metastasized UM

Giant Cell Glioblastoma (1)

NCTAcronymPhaseStatusTitle
NCT03014804P2withdrawnAutologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

AML, Childhood (1)

NCTAcronymPhaseStatusTitle
NCT03825367P1/P2unknownNivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Stage III Non-small-cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04085250P2unknownStudy of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Prostate Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT05655715CheckPROP2completedCheckpoint Inhibitors and SBRT for MCRPC

Recurrent/Metastatic Carcinosarcoma (1)

NCTAcronymPhaseStatusTitle
NCT05224999P2unknownNivolumab for Recurrent/Metastatic Carcinosarcoma

Castration Levels of Testosterone (1)

NCTAcronymPhaseStatusTitle
NCT04159896P2terminatedESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Advanced Solid Tumor Historically Known for High EphA2 Expression (1)

NCTAcronymPhaseStatusTitle
NCT04180371P1/P2active not recruitingStudy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Localized Oesogastric Adenocarcimona (1)

NCTAcronymPhaseStatusTitle
NCT04006262NEONIPIGAP2active not recruitingPre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Melanoma With Brain Metastasis (1)

NCTAcronymPhaseStatusTitle
NCT03903640P2terminatedOptune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Aml (1)

NCTAcronymPhaseStatusTitle
NCT04128020P1withdrawnAzacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Basaloid Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03952585P2/P3active not recruitingDe-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

ALK Gene Rearrangement (1)

NCTAcronymPhaseStatusTitle
NCT04013542P1active not recruitingIpilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

Advanced Cutaneous Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03834233CA209-9JCP2unknownNivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Oropharynx Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03829722P2completedRadiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

Solid Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT04078295E7389-LFP1/P2active not recruitingA Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Relapsed Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04134325Early P1active not recruitingStudy of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Ann Arbor Stage III Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03907488P3active not recruitingImmunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Human Papilloma Virus (1)

NCTAcronymPhaseStatusTitle
NCT03944915DEPENDP2completedDe-Escalation Therapy for Human Papillomavirus Negative Disease

Endometrial Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04044859SURPASSP1active not recruitingADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03811015P3active not recruitingTesting Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Advanced NSCLC (1)

NCTAcronymPhaseStatusTitle
NCT04043195NSCLCP1/P2active not recruitingNivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

Pituitary (1)

NCTAcronymPhaseStatusTitle
NCT04042753P2completedNivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Basal Cell Nevus Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT03767439P2withdrawnNivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03799445P2terminatedIpilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Oropharynx Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03838263IMMUNEBOOSTP2completedFeasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

Borderline Resectable Pancreatic Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03970252Early P1completedNivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Gastric and Esophagogastric Junction Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03443856VESTIGEP2active not recruitingPostoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

Autoimmune Disease (1)

NCTAcronymPhaseStatusTitle
NCT03816345P1recruitingTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Recurrent Head and Neck Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03727061P1terminatedPorfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer

Anatomic Stage 0 Breast Cancer AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT04185311P1terminatedIpilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Carcinoma, Squamous Cell (1)

NCTAcronymPhaseStatusTitle
NCT03906526P1terminatedA Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Anaplastic Thyroid Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05696548NAVIGATIONP2active not recruitingNivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Autoimmune Diseases (1)

NCTAcronymPhaseStatusTitle
NCT03656627P1terminatedNivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck (1)

NCTAcronymPhaseStatusTitle
NCT04050761ProNiHNN/AcompletedA Study of Nivolumab in Patients With Head and Neck Cancer.

Grade 2 Meningioma (1)

NCTAcronymPhaseStatusTitle
NCT03604978P1/P2active not recruitingNivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

BRAF NP_004324.2:p.V600E (1)

NCTAcronymPhaseStatusTitle
NCT04017650P1/P2active not recruitingEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Resectable Biliary Tract Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03768531P2withdrawnSafety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

DDR Gene Mutation (1)

NCTAcronymPhaseStatusTitle
NCT04761744P2unknownA Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

Refractory Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03686124ACTengineP1/P2recruitingACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Bladder Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03866382P2recruitingTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Squamous Cell Carcinoma of the Oral Cavity (1)

NCTAcronymPhaseStatusTitle
NCT03721757NICOP2completedCA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer

Clinical Stage II Esophageal Adenocarcinoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03604991P2/P3suspendedNivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Advanced Colorectal Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04771715PD-1N/AunknownRegorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Urinary Bladder Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT03785925PIVOT-10P2completedA Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

Renal Cell Carcinoma, Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT03562507ERICAP2terminatedMulti-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Oral Cavity Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03843515NeoNivoP1unknownNeoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction

Lip (1)

NCTAcronymPhaseStatusTitle
NCT03854032P2active not recruitingNivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Breast Neoplasm Female (1)

NCTAcronymPhaseStatusTitle
NCT03650894HERP2active not recruitingNivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Glioma (1)

NCTAcronymPhaseStatusTitle
NCT03718767P2active not recruitingNivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

Advanced Solid Cancers (1)

NCTAcronymPhaseStatusTitle
NCT03956680P1completedAn Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Childhood Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT03585465Metro-PD1P1/P2terminatedNivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors

Acute Myeloid Leukemia and Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT02846376CPIT-002P1terminatedSingle Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

Gastroesophageal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03610711REACTIONP1/P2active not recruitingREACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

Malignant Pleural Effusion (1)

NCTAcronymPhaseStatusTitle
NCT03597009P1/P2terminatedA Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

Recurrent Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03655002IRX-2P1active not recruitingIRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

Central Nervous System B-Cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03770416P2completedNivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

Mucinous Adenocarcinoma of the Colon (1)

NCTAcronymPhaseStatusTitle
NCT03693846P2terminatedNivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

Microsatellite Stable (MSS) Colorectal Adenocarcinomas (1)

NCTAcronymPhaseStatusTitle
NCT03642067MSSP2completedStudy of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Metastatic Hormone-sensitive Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03879122P2/P3unknownA Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Pleural Mesothelioma Malignant (1)

NCTAcronymPhaseStatusTitle
NCT04177953P2completedNivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Bronchial Dysplasia (1)

NCTAcronymPhaseStatusTitle
NCT03347838P2active not recruitingNivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

Recurrent Nervous System Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03798314P1completedNivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT03711058MSSP1/P2completedStudy of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Inoperable œsophageal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03437200CRUCIALP2terminatedCombination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer

Radiotherapy (1)

NCTAcronymPhaseStatusTitle
NCT03589339P1active not recruitingNBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Cervix Uteri--Diseases (1)

NCTAcronymPhaseStatusTitle
NCT03808168P2withdrawnNivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia

Metastatic Malignant Neoplasm in the Bone (1)

NCTAcronymPhaseStatusTitle
NCT03749460P1/P2completedNivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Clinical Stage 0 Gastric Cancer AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03776487P2active not recruitingNivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03703050NIVO-ALCLP2active not recruitingNivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

Bladder Cancer TNM Staging Primary Tumor (T) T2 (1)

NCTAcronymPhaseStatusTitle
NCT03518320P1terminatedSafety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

Locally Advanced Gastric Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06235164N/AunknownThe Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

Grade I Neuroendocrine Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03728361P2active not recruitingNivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

ALK-Positive Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03038672P2active not recruitingNivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Metastatic Castration Resistant Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03570619IMPACTP2completedImmunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03769155P1active not recruitingVX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Intermediate Risk Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03815942ADVANCEP1/P2terminatedVAccination in Early and ADvanced Prostate caNCEr

Leukoplakia, Oral (1)

NCTAcronymPhaseStatusTitle
NCT03692325P2completedSafety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia

Locally Advanced Unresectable Pancreatic Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04098432CA209-9KHP1/P2completedSTR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy (1)

NCTAcronymPhaseStatusTitle
NCT03607890LP2active not recruitingStudy of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Carcinoma, Squamous Cell of Head and Neck (1)

NCTAcronymPhaseStatusTitle
NCT03715946P2completedAdjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Adenocarcinoma of the Stomach (1)

NCTAcronymPhaseStatusTitle
NCT03647969P2completedModified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Recurrent Squamous Cell Carcinoma of the Head or Neck (1)

NCTAcronymPhaseStatusTitle
NCT03652233P1withdrawnAfatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) (1)

NCTAcronymPhaseStatusTitle
NCT03684811P1/P2completedA Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Pan Tumor (1)

NCTAcronymPhaseStatusTitle
NCT03668119CheckMate 848P2completedA Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Unresectable Stage III Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT03235245EBINP2active not recruitingImmunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Advanced Metastatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03651271P2completedNivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Follicular Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03121677P1terminatedPersonalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

Allogeneic Hematopoietic Stem Cell Transplantation Recipient (1)

NCTAcronymPhaseStatusTitle
NCT03600155P1completedNivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Lymphoma, B-Cell (1)

NCTAcronymPhaseStatusTitle
NCT03569696NivoMP2unknownImproving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy

Colon Adenoma (1)

NCTAcronymPhaseStatusTitle
NCT03631641P2terminatedNivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy

Germ Cell Tumors (1)

NCTAcronymPhaseStatusTitle
NCT03726281P2withdrawnNivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors

High-Risk Resectable NSCLC (1)

NCTAcronymPhaseStatusTitle
NCT03732664P1completedICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Recurrent Adult Brain Tumor (1)

NCTAcronymPhaseStatusTitle
NCT03890952P2completedTranslational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

Solid Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03721679P1/P2terminatedPoly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Malignant Peritoneal Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT03508570P1completedNivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Metastatic Hormone-Sensitive Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03532217P1completedNeoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Acute Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT03588936P1terminatedNivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Melanoma Stage Iii (1)

NCTAcronymPhaseStatusTitle
NCT03620019P2completedDenosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Squamous Cell Carcinoma, Head And Neck (1)

NCTAcronymPhaseStatusTitle
NCT03575598SNOWEarly P1completedSitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study

Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03635892P2active not recruitingA Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Toxicity, Drug (1)

NCTAcronymPhaseStatusTitle
NCT03638375ACTMEP1/P2unknownTIL and Anti-PD1 in Metastatic Melanoma

Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (1)

NCTAcronymPhaseStatusTitle
NCT03620123OPTIMP2completedA Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

Thymic Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03583086P1/P2completedPhase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Pharmacokinetics of Zolbetuximab (1)

NCTAcronymPhaseStatusTitle
NCT03505320ILUSTROP2active not recruitingA Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

Recurrent Head and Neck Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03521570P2completedIntensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

Melanoma Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT03514901P2unknownTo Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Recurrent Central Nervous System Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03558750P1terminatedRituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

Gliomas (1)

NCTAcronymPhaseStatusTitle
NCT03557359P2completedNivolumab for Recurrent or Progressive IDH Mutant Gliomas

Colon Cancer Stage II/III (1)

NCTAcronymPhaseStatusTitle
NCT04123925NICOLEP2completedPreoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study

Recurrent or Metastatic Nasopharyngeal Carcinom (1)

NCTAcronymPhaseStatusTitle
NCT06440187HN17-11P2completedNivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11

Metastatic Adult Soft Tissue Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03590210NiTraSarcP2completedCombined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas

Adenocarcinoma of the Lung (1)

NCTAcronymPhaseStatusTitle
NCT04046614NintNivoP1/P2completedFeasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology

Extensive Stage Lung Small Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03382561P2completedCisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

Locally Advanced Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03299946HCCP1completedFeasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Relapsed Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03305445P1completedNivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Metastatic Urothelial Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03451331P2completedGemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Kaposi Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03316274Early P1completedIntra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

Metastatic Malignant Neoplasm in the Liver (1)

NCTAcronymPhaseStatusTitle
NCT03472586P2completedIpilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Bone Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03449108TNBCP2active not recruitingLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Epstein-Barr Virus Infections (1)

NCTAcronymPhaseStatusTitle
NCT03258567EBVP2recruitingNivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 (1)

NCTAcronymPhaseStatusTitle
NCT03421652P2completedNivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

Advanced Endometrial Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03367741P2active not recruitingCabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Thymoma Type B3 (1)

NCTAcronymPhaseStatusTitle
NCT03134118NIVOTHYMP2active not recruitingNivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

Classic Kaposi Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03219671CKSP2unknownNivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

Breast Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03432741P1terminatedDirect Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Colon Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03442569P2completedPhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Newly Diagnosed High Grade Glioma (1)

NCTAcronymPhaseStatusTitle
NCT03425292P1completedA Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Glioma, Malignant (1)

NCTAcronymPhaseStatusTitle
NCT03576612GMCIP1completedGMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

Myeloma (1)

NCTAcronymPhaseStatusTitle
NCT03184194P2completedNivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

Leptomeningeal Carcinomatosis (1)

NCTAcronymPhaseStatusTitle
NCT02939300P2completedIpilimumab and Nivolumab in Leptomeningeal Metastases

Breast Cancer Female (1)

NCTAcronymPhaseStatusTitle
NCT03342417P2terminatedCombination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

MGMT-unmethylated Glioblastoma (GBM) (1)

NCTAcronymPhaseStatusTitle
NCT03367715P2completedNivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

Metastatic Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT03388632P1completedRecombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Muscle Invasive Bladder Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03294304MIBCP2completedBLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Non Small Cell Lung Cancer Stage IIIB (1)

NCTAcronymPhaseStatusTitle
NCT03302247P2terminatedDepletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

Advanced and Metastatic Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT03406871REGONIVOP1completedRegorafenib and Nivolumab Simultaneous Combination Therapy

Adenocarcinoma of Lung (1)

NCTAcronymPhaseStatusTitle
NCT03371381P1/P2terminatedAn Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

Genitourinary Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03333616P2active not recruitingNivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Non-Squamous Non-Small Cell Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03366766P2terminatedNivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Squamous Cell Carcinoma of the Oropharynx (1)

NCTAcronymPhaseStatusTitle
NCT03370276P1/P2completedCetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Colon Carcinoma Metastatic in the Liver (1)

NCTAcronymPhaseStatusTitle
NCT03373188P1completedVX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Kidney Medullary Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03274258P2terminatedPhase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Metastatic Cancer Colorectal (1)

NCTAcronymPhaseStatusTitle
NCT03350126NIPICOLP2active not recruitingiRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03342911P2completedNivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Metastatic Cholangiocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03250273P2completedA Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Cervical Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03220009P2withdrawnNivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic (1)

NCTAcronymPhaseStatusTitle
NCT03283046P1withdrawnStudy of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Renal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03203473P2active not recruitingStudy of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

Recurrent B Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02879695P1active not recruitingBlinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

MSS (1)

NCTAcronymPhaseStatusTitle
NCT03271047MSSP2completedStudy of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Dedifferentiated Liposarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03307616P2active not recruitingNivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

Thyroid Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03246958P2completedNivolumab Plus Ipilimumab in Thyroid Cancer

Anaplastic Large Cell Lymphoma, ALK-Negative (1)

NCTAcronymPhaseStatusTitle
NCT02978625P2active not recruitingTalimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Squamous Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03542461EDENP3unknownEarly Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)

HER2/Neu Negative (1)

NCTAcronymPhaseStatusTitle
NCT02892734P2terminatedIpilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Squamous-Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03823625SQUINTP2unknownAn Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)

SARCOMA (1)

NCTAcronymPhaseStatusTitle
NCT03282344P2active not recruitingA Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Biliary Tract Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT03101566P2completedStudy of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer

Stage IV Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03223155COSINRP1active not recruitingConcurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer

Ewing Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03190174P1/P2completedNivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Gastrointestinal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02923934P2completedA Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 (1)

NCTAcronymPhaseStatusTitle
NCT02819804P1terminatedNivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

METASTATIC NON-SMALL CELL LUNG CANCER (1)

NCTAcronymPhaseStatusTitle
NCT03224871Early P1completedUCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.

Lip, Oral Cavity and Pharynx (1)

NCTAcronymPhaseStatusTitle
NCT03238365Early P1completedWindow of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

High Grade Serous Ovarian (1)

NCTAcronymPhaseStatusTitle
NCT03245892P1completedA Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Uterine Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03241745P2completedA Study of Nivolumab in Selected Uterine Cancer Patients

Recurrent/Metastatic Gastric Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05535569EBVP1/P2completedPhase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer

Medulloblastoma (1)

NCTAcronymPhaseStatusTitle
NCT03173950P2completedImmune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Recurrent and/or Metastatic Platinum-refractory SCCHN (1)

NCTAcronymPhaseStatusTitle
NCT03226756TopNIVOP2completedNivolumab in Recurrent and/or Metastatic SCCHN

Transitional Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03219775TITAN-TCCP2unknownTailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

EGFR Gene Mutation (1)

NCTAcronymPhaseStatusTitle
NCT02947386P1completedNimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

HPV-Related Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03107182OPTIMA-IIP2completedChemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

Lung Atypical Carcinoid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT03110978P2active not recruitingStereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

Hodgkin's Disease (1)

NCTAcronymPhaseStatusTitle
NCT03138499CheckMate 812P3terminatedA Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Hematopoietic/Lymphoid Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03121534P2terminatedIbrutinib, Nivolumab and Blinatumomab in Richter Transformation

Stage I Lung Non-Small Cell Cancer AJCC v7 (1)

NCTAcronymPhaseStatusTitle
NCT03158129P2completedNivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

ALK Gene Translocation (1)

NCTAcronymPhaseStatusTitle
NCT02846792P1/P2terminatedNivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Metastatic Kidney Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03050060P2terminatedImage Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

Malignant Melanoma Stage IV (1)

NCTAcronymPhaseStatusTitle
NCT03166397P2unknownAdoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Clear-Cell Metastatic Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02978404P2completedCombining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

Clear Cell Metastatic Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02960906BIONIKKP2completedA BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

Oral Cavity SCC (1)

NCTAcronymPhaseStatusTitle
NCT03021993P2completedTrial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03343652NB001P1/P2completedA Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Salivary Gland Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03172624P2completedStudy of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Advanced Solid Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT03061188P1completedPhase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Major Salivary Gland Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03146650P2unknownNivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Blastic Plasmacytoid Dendritic Cell Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT03075553P2terminatedNivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Refractory or Recurrent Hypermutated Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT02992964P1/P2terminatedPilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Larynx (1)

NCTAcronymPhaseStatusTitle
NCT03162731Early P1completedNivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

Microsatellite Stable Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03104439P2active not recruitingNivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Haematological Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT03146468NIVALLOP2unknownNivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation

Locally Advanced Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03119428P1terminatedA Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced Soft Tissue Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03138161SAINTP1/P2recruitingSAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Peritoneal Carcinomatosis (1)

NCTAcronymPhaseStatusTitle
NCT03172416PIPACP1unknownPressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis

B-Cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03017820P1recruitingA Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Classic Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03057795P2active not recruitingNivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Colon Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03026140NICHEP2recruitingNeoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Salivary Gland Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03132038NISCAHNP2completedNivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck

Non-Small-Cell Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02864251CheckMate722P3completedA Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

EGFR Activating Mutation (1)

NCTAcronymPhaseStatusTitle
NCT02949843P2terminatedTargeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Squamous Cell Carcinoma of the Skin (1)

NCTAcronymPhaseStatusTitle
NCT04204837P2recruitingNivolumab for Treatment of Squamous Cell Carcinoma of the Skin

Kidney Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT03065179RADVAXP2completedSBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients

Immunotherapy (1)

NCTAcronymPhaseStatusTitle
NCT03003637IMCISIONP1/P2completedImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma

Acute Adult T-Cell Leukemia/Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02631746P2completedNivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Grade 3a Follicular Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03015896P1/P2active not recruitingNivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Carcinoma,Non-Small-Cell Lung (1)

NCTAcronymPhaseStatusTitle
NCT03044626FORCEP2completedFostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC

Cancer Treated With Immune-checkpoint Inhibitors (1)

NCTAcronymPhaseStatusTitle
NCT03963518SURROGATE-ICIN/AcompletedImmune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

Acinar Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02834013P2active not recruitingNivolumab and Ipilimumab in Treating Patients With Rare Tumors

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (1)

NCTAcronymPhaseStatusTitle
NCT03041181P2terminatedSingle Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Adult Solid Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT02775292NYMP1completedGene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

Solid Tumors Induced by Prior Radiation Exposure (1)

NCTAcronymPhaseStatusTitle
NCT02864316P2terminatedPhase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure

Non-Small-Cell Lung Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT02967133P2terminatedA Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Lung Cancer, Nonsmall Cell, Stage I (1)

NCTAcronymPhaseStatusTitle
NCT02950038NSCLCP2withdrawnStudy of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Advanced Head and Neck Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02955290P1/P2active not recruitingCIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

HepatoCellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03033446P2completedStudy of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

Gastrointestinal Stromal Tumor (1)

NCTAcronymPhaseStatusTitle
NCT02880020P2completedNivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery

Severe Sepsis (1)

NCTAcronymPhaseStatusTitle
NCT02960854P1completedA Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

Stage III/IV Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02857569NIVIPITP1/P2completedA Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma

Colorectal Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT02991196P1terminatedAntibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

Broad Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT02913313P1/P2completedA Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Antibodies, Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT02901145P1/P2unknownNivolumab in Relapsed Pediatric Solid Tumors

Advanced Gastric Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02935634FRACTION-GCP2completedA Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Stage III Skin Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02437279OpACINP1unknownStudy to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

Diffuse Intrinsic Pontine Glioma (1)

NCTAcronymPhaseStatusTitle
NCT02960230P1/P2completedH3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

Metastatic Renal Cell Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02899078P1/P2completedIbrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

Peritoneal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02873962P2active not recruitingA Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Smoldering Multiple Myeloma (1)

NCTAcronymPhaseStatusTitle
NCT02903381P2completedA Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Refractory Metastatic Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02860546P2completedA Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Non-small Cell Lung Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT02812667NSCLCP1completedNivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Triple-Negative Breast Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT02834247P1terminatedA Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Clear Cell Renal Cell Carcinoma (ccRCC) (1)

NCTAcronymPhaseStatusTitle
NCT02771626NSCLCP1/P2terminatedStudy CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Stage IIIA Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02837029P1completedNivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer

Metastatic Clear Cell Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02781506P2terminatedNivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma

Ann Arbor Stage IB Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02758717P2active not recruitingNivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Brain Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT02667587CheckMate548P3completedAn Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Solid Tumors and Hematologic Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT02712905P1/P2terminatedAn Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Untreated Metastatic Pancreatic Ductal Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02754726P2completedCombination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Stage IIIC Skin Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02941744ipnivP1/P2completedA Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases

Meningiomas (1)

NCTAcronymPhaseStatusTitle
NCT02648997P2active not recruitingAn Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Metastatic Carcinoma in the Adrenal Cortex (1)

NCTAcronymPhaseStatusTitle
NCT02720484P2terminatedNivolumab in Treating Patients With Metastatic Adrenocortical Cancer

NonHodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02973113PREVALEP1completedNivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

Non-Small-Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02659059CheckMate 568P2completedNivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Anatomic Stage III Breast Cancer AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT02453620P1active not recruitingEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Non-Hodgkin's Disease (1)

NCTAcronymPhaseStatusTitle
NCT02581631CheckMate 436P1/P2completedAn Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Squamous Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02852083ModuLungP2unknownA Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC

Advanced Solid Tumors (Part A/B/C/D) (1)

NCTAcronymPhaseStatusTitle
NCT02637531P1unknownA Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Limited Stage Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02046733STIMULIP2completedSmall Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

Encephalitis (1)

NCTAcronymPhaseStatusTitle
NCT02856451N/AcompletedRisk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

Non-small Cell Lung Cancer Stage III (1)

NCTAcronymPhaseStatusTitle
NCT02434081NICOLASP2completedNIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

Stage III Cutaneous Melanoma AJCC v7 (1)

NCTAcronymPhaseStatusTitle
NCT02339571P2/P3active not recruitingA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Malignant Tumors (1)

NCTAcronymPhaseStatusTitle
NCT02534506P1completedStudy of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT02532231P2completedNivolumab in AML in Remission at High Risk for Relapse

Human Papillomavirus-Related Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02379520HESTIAP1completedHPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

Locally Advanced Bone Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT02500797P2completedNivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Recurrent Fallopian Tube Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02498600P2completedNivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Bladder Small Cell Neuroendocrine Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02496208P1active not recruitingCabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Nasopharyngeal Nonkeratinizing Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02339558P2completedNivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

Triple-Negative Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02393794TNBCP1/P2active not recruitingCisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Loss of Chromosome 17p (1)

NCTAcronymPhaseStatusTitle
NCT02420912P2completedNivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

Advanced Tumors (1)

NCTAcronymPhaseStatusTitle
NCT02419417BETP1/P2completedStudy of BMS-986158 in Subjects With Select Advanced Cancers

ALK-positive NSCLC (1)

NCTAcronymPhaseStatusTitle
NCT02393625P1active not recruitingStudy of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Metastatic Leiomyosarcoma (1)

NCTAcronymPhaseStatusTitle
NCT02428192P2completedNivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

Cervical Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02257528P2active not recruitingNivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Hepatomegaly (1)

NCTAcronymPhaseStatusTitle
NCT02421354P2terminatedNivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

Anal Canal Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02314169P2active not recruitingNivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Acute Bilineal Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02397720P2completedNivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Hematologic Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT02329847P1/P2completedA Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

Squamous Cell Carcinoma of the Head and Neck (SCCHN) (1)

NCTAcronymPhaseStatusTitle
NCT02335918P1/P2completedA Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Advanced Stage Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02350764P2completedEvaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02213289PANGEA-IMBBPP2completedPANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Breast Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT02309177P1completedSafety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Previously Treated Metastatic Adenocarcinoma of the Pancreas (1)

NCTAcronymPhaseStatusTitle
NCT02243371P2completedGVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

B-cell Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT02327078ECHO-204P1/P2completedA Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

ccRCC (1)

NCTAcronymPhaseStatusTitle
NCT02293980MK-3795-001P1active not recruitingA Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Stage III (Unresectable) or Stage IV Advanced Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02142218Checkmate 168N/Ano longer availableExpanded Access Program With Nivolumab to Treat Melanoma

Stage IV Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02054520P2terminatedImmunotherapy Study for Patients With Stage IV Melanoma

Select Advanced Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT02118337AMP-514P1/P2completedA Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Non Small Cell Lung Cancer (NSCLC) (1)

NCTAcronymPhaseStatusTitle
NCT02066636CheckMate153P3completedA Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen

Stage IV or Recurrent Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02041533P3completedAn Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Microsatellite Unstable Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02060188CheckMate142P2completedA Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Lymphoma. Non-Hodgkin (1)

NCTAcronymPhaseStatusTitle
NCT02038933DLBCLP2completedStudy of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Chronic Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02011945P1completedA Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

Advanced or Metastatic Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT01928394P1/P2completedA Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

BRAF V600E Mutation Present (1)

NCTAcronymPhaseStatusTitle
NCT01940809P1terminatedIpilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Allogeneic Hematopoietic Stem Cell Transplant Recipient (1)

NCTAcronymPhaseStatusTitle
NCT01822509P1completedIpilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Advanced or Metastatic Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT01783938P2completedStudy of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Non-Squamous Cell Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01673867CheckMate057P3completedStudy of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01668784BMS-936558P3completedStudy of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

CANCER,NOS (1)

NCTAcronymPhaseStatusTitle
NCT01714739P1/P2completedA Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01592370P1/P2completedAn Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Other (1)

NCTAcronymPhaseStatusTitle
NCT05170685N/Ano longer availableExpanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab

Nivolumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
FDCNCT07459543P4not yet recruitingUntreated Melanoma30
CANIQOLNCT07028125P4recruitingRenal Cell Carcinoma (Kidney Cancer)83
MINUTENCT06031233P4recruitingOncology776
CABOLDNCT06934057P4recruitingKidney Cancer50
NIVOPTIMIZENCT06116461P4unknownMelanoma34
VIGORNCT05583188P4terminatedNSCLC5PMID 24384493
CheckMate 7C9NCT04513522P4completedKidney Neoplasms101
CHECKMATE 920NCT02982954P4completedRenal Cell Carcinoma211PMID 35210307
CheckMate 374NCT02596035P4completedRenal Cell Carcinoma197
RFANCT04707547P4completedLiver Cancer5PMID 18202772
PAIRNCT02626065P4completedMetastatic Melanoma32PMID 38939518
KRASCENDO 3NCT07541170P3not yet recruitingNon-small Cell Lung Cancer400
RELATIVITY1093NCT06561386P3recruitingNon-small Cell Lung Cancer1,000
eVOLVE-RCC02NCT07000149P3active not recruitingAdvanced Clear Cell Renal Cell Carcinoma1,116
CARE1NCT06364631P3recruitingMetastatic Kidney Cancer1,250
SWE-NEONCT06794775P3recruitingMalignant Melanoma Stage III128
SUPRAMENCT06743126P3recruitingMelanoma, Cutaneous Malignant360
TIGOSNCT06646276P3recruitingExtensive-Stage Small Cell Lung Cancer530
NADIM-ADJUVANTNCT04564157P3active not recruitingNon-Small Cell Lung Cancer210
CheckMate 9DXNCT03383458P3active not recruitingHepatocellular Carcinoma545
LEDANGNCT07050043P3recruitingNSCLC (Non-small Cell Lung Carcinoma)123
ATHENANCT03522246P3active not recruitingEpithelial Ovarian Cancer1,097PMID 35658487
IMAGINENCT04637594P3active not recruitingLocally Advanced Bladder Urothelial Carcinoma3
NADINANCT04949113P3active not recruitingMalignant Melanoma Stage III423PMID 37104746
eVOLVE-MesoNCT06097728P3active not recruitingUnresectable Pleural Mesothelioma861
COMETNCT06908993P3recruitingAdvanced Non Small Cell Lung Cancer133
STELLAR-304NCT05678673P3active not recruitingNon-Clear Cell Renal Cell Carcinoma317PMID 40008409
CIMENCT06346197P3recruitingGastric Cancer132
NivoMelaNCT04309409P3active not recruitingMalignant Melanoma Stage II374
LIMITLESSNCT05317858P3recruitingBrain Tumor30
RELATIVITY-127NCT05625399P3active not recruitingMelanoma579
PRISM-MEL-301NCT06112314P3recruitingAdvanced Melanoma680
NIVOPOSTOPNCT03576417P3active not recruitingSquamous Cell Carcinoma of Head and Neck680PMID 41448222
CheckMate76KNCT04099251P3active not recruitingMelanoma790PMID 40139004
CheckMate 274NCT02632409P3active not recruitingVarious Advanced Cancer709PMID 35288066
CheckMate-67TNCT04810078P3active not recruitingClear Cell Renal Cell Carcinoma681
EA2176NCT04444921P3active not recruitingAnal Basaloid Carcinoma205
COSMIC-313NCT03937219P3active not recruitingRenal Cell Carcinoma855PMID 34550754
FORTITUDE-102NCT05111626P3active not recruitingGastric Cancer515PMID 38308771
ANVILNCT02595944P3active not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7903PMID 41911908
CheckMate 9DWNCT04039607P3active not recruitingHepatocellular Carcinoma732PMID 40349714
STAR-221NCT05568095P3active not recruitingAdvanced Upper Gastrointestinal Tract Adenocarcinoma1,040
CheckMate 8HWNCT04008030P3active not recruitingMetastatic Colorectal Cancer839PMID 39602630
CheckMate901NCT03036098P3active not recruitingUrothelial Cancer1,314PMID 37870949
CheckMate 9ERNCT03141177P3active not recruitingRenal Cell Carcinoma701PMID 41617395
DICIPLENCT03469960P3completedNon-Small Cell Lung Cancer Metastatic265
SAPPHIRENCT03906071P3completedMetastatic Non-Squamous Non-Small Cell Lung Cancer577
RAR-ImmuneNCT04741438P3unknownSarcoma96
RELATIVITY-123NCT05328908P3terminatedColorectal Neoplasms770
DREAM3RNCT04334759P3completedMesothelioma214PMID 33358660
INTEGRATEIIbNCT04879368P3completedGastro-Oesophageal Cancer462PMID 36814222
RELATIVITY-098NCT05002569P3terminatedMelanoma1,093PMID 41109920
CheckMate 648NCT03143153P3completedVarious Advanced Cancer970PMID 37139963
CheckMate 816NCT02998528P3completedNon Small Cell Lung Cancer505PMID 40454642
CheckMate73LNCT04026412P3completedNon-Small Cell Lung Cancer (NSCLC)925PMID 34489161
CheckMate 577NCT02743494P3completedAdvanced Cancer794PMID 33789008
CheckMate 227NCT02477826P3completedNon-Small Cell Lung Cancer2,747PMID 31195357
CheckMate 9LANCT03215706P3completedNon-Small Cell Lung Cancer719PMID 39270380
CheckMate 238NCT02388906P3completedMelanoma906PMID 39378385
CheckMate 7DXNCT04100018P3completedProstate Cancer1,030PMID 41449150
CheckMate 143NCT02017717P3completedRecurrent Glioblastoma529PMID 30522968
CheckMate649NCT02872116P3completedGastric Cancer2,031PMID 37713657
IMSTAR-HNNCT03700905P3unknownHead and Neck Cancer276PMID 27247226
CheckMate548NCT02667587P3completedBrain Neoplasms716PMID 35511454
CheckMate-6GENCT05297565P3completedMelanoma14
CheckMate 914NCT03138512P3completedCarcinoma, Renal Cell1,641PMID 36774933
CheckMate 7FLNCT04109066P3completedBreast Cancer521PMID 38913933
CheckMate 74WNCT04340193P3completedCancer, Hepatocellular26
CheckMate 078NCT02613507P3completedNon-Small Cell Lung Cancer504PMID 30659987
CheckMate 7G8NCT04149574P3terminatedUrinary Bladder Neoplasms13
CheckMate743NCT02899299P3completedMesothelioma605PMID 33206991
CONFIRMNCT03063450P3completedMesothelioma332PMID 29669604
EDENNCT03542461P3unknownSquamous Non-small Cell Lung Cancer125PMID 39700681
TKINCT03729245P3terminatedRenal Cell Carcinoma623PMID 38838287
CheckMate722NCT02864251P3completedNon-Small-Cell Lung Carcinoma367PMID 38252907
PIVOT-12NCT04410445P3terminatedMelanoma765PMID 35073733
CheckMate 651NCT02741570P3completedHead and Neck Cancer947PMID 33684371
CheckMate331NCT02481830P3completedLung Cancer569
eNERGYNCT03351361P3completedAdvanced Non Small Cell Lung Cancer217PMID 39486424
CheckMate 602NCT02726581P3completedMultiple Myeloma170
CheckMate 498NCT02617589P3completedBrain Cancer560PMID 35419607
CheckMate 384NCT02713867P3completedLung Cancer363
CheckMate057NCT01673867P3completedNon-Squamous Cell Non-small Cell Lung Cancer582PMID 29408986
CheckMate 451NCT02538666P3completedLung Cancer907PMID 33683919
CheckMate153NCT02066636P3completedNon Small Cell Lung Cancer (NSCLC)1,428PMID 31121324
NSCLCNCT01642004P3completedSquamous Cell Non-small Cell Lung Cancer272PMID 29023213
BMS-936558NCT01668784P3completedAdvanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma821PMID 31272883
CheckMate870NCT03195491P3completedLung Cancer400
CheckMate 066NCT01721772P3completedMelanoma418PMID 32997575
CheckMate 812NCT03138499P3terminatedHodgkin's Disease23
CheckMate 915NCT03068455P3completedMelanoma1,844PMID 35512259
NIVACTORNCT05802290P3completedSquamous Cell Carcinoma of Head and Neck124
CheckMate 401NCT02599402P3completedMelanoma533PMID 37307514
NIBIT-M2NCT02460068P3unknownBrain Metastases168PMID 25538176
CheckMate 955NCT03048136P3withdrawnNon-Small Cell Lung Cancer0
RESET-RNCT05732389P2recruitingCancer of Rectum39
NOBLENCT07369791P2not yet recruitingAdvanced Biliary Tract Cancer(BTC)76
Neo IRENIENCT06999980P2recruitingCutaneous Melanoma494
Neo ReNi IINCT05418972P2active not recruitingStage II Melanoma20
TORCH-OPTIMANCT07403877P2not yet recruitingColorectal Cancer (MSI-H)114
NEOREM-NEO-1NCT07230613P2recruitingCutaneous Melanoma, Stage III50
NOCANONCT07514767P2not yet recruitingOral Squamous Cell Carcinoma (OSCC)60
BELLININCT03815890P2recruitingBreast Cancer80PMID 39284953
REGINANCT04503694P2active not recruitingRectal Cancer Stage II72
FLINNNCT07355205P2not yet recruitingNon-small Cell Lung Cancer Stage IV26
NICHENCT03026140P2recruitingColon Carcinoma353PMID 34606846
GDFATHERHCC01NCT07219459P2recruitingUnresectable or Metastatic Hepatocellular Carcinoma104
TNTNCT03886311P2recruitingSarcoma200
GIANTNCT06816927P2recruitingNewly Diagnosed Glioblastoma92PMID 40016450
EBVNCT03258567P2recruitingEpstein-Barr Virus Infections40
N'FORCENCT07529873P2not yet recruitingSquamous Cell Carcinoma of Head and Neck (SCCHN)131
COLIBRI-2NCT06715241P2active not recruitingLOCALLY ADVANCED CERVICAL CANCERS77
RCCNCT07188896P2recruitingAdvanced Renal Cell Carcinoma (aRCC)120
PSI-ImmuneNCT07223424P2recruitingRenal Cell Carcinoma880
Spark2NCT04848116P2active not recruitingHead and Neck Squamous Cell Carcinoma24
GALAXY 3NCT06926790P2recruitingLung Cancer - Non Small Cell69
NeoRelapseNCT06365619P2recruitingMelanoma25
GIVA-2NCT07432295P2recruitingSolid Tumor180
14NCT05909618P2recruitingAdvanced Glioblastoma33
ACCELERATENCT07013565P2recruitingAnaplastic Large Cell Lymphoma, ALK-Positive20
RIVALNCT06275360P2recruitingNon-Small Cell Lung Cancer25
ClearMeNCT06319196P2recruitingCutaneous Melanoma54
GS-1811NCT07546812P2recruitingHER2-negative120
ECTOP-1036NCT07398937P2recruitingResectable Stage II-IIIa Squamous NSCLC116
SPRINGNCT06692491P2not yet recruitingRare Tumour200
NIVECNCT05795244P2recruitingEndometrial Neoplasms30PMID 39530558
VELOCITY-LungNCT05633667P2active not recruitingLung Cancer192
ECTOP-1030NCT06572722P2withdrawnLung Cancer0
ABC-XNCT03340129P2recruitingMelanoma Stage Iv218PMID 33450821
VIRO-25NCT06463665P2recruitingAdvanced Non-squamous Non-small-cell Lung Cancer142
EXPLORE-RCCNCT06794229P2recruitingLocally Advanced Renal Cell Carcinoma69
BIGNCT06253611P2recruitingGastric Cancer120
NESCIONCT05148546P2active not recruitingRenal Cell Carcinoma69
GRAPENCT06983210P2recruitingUrothelial Carcinoma Bladder43PMID 38849479
MATISSE 2NCT06823479P2recruitingCutaneous Squamous Cell Carcinoma (CSCC)41
ICBNCT06250335P2active not recruitingICB-refractory Melanoma4
GS-1811NCT07527858P2recruitingAdvanced Microsatellite Stable Colorectal Cancer170
EXACTNCT06863311P2recruitingAdvanced Renal Cell Carcinoma70
FINISH-HLNCT07209059P2recruitingHodgkin Lymphoma30
IGNYTENCT03767348P2active not recruitingNon-Small Cell Lung Cancer (NSCLC)340PMID 40627813
TAPURNCT02693535P2recruitingLymphoma, Non-Hodgkin4,200PMID 36753688
ABCNCT02374242P2active not recruitingMelanoma76PMID 37132182
RCCNCT06708949P2recruitingRenal Cell Carcinoma, Clear Cell15
NAHLNCT05723055P2active not recruitingHodgkin Lymphoma9
NADIMIINCT03838159P2active not recruitingNon Small Cell Lung Cancer90PMID 41805895
CheckMate-1533NCT06946797P2active not recruitingNon-Small Cell Lung Cancer76
TRIFLUOX-DPNCT06245356P2recruitingMetastatic Colorectal Cancer73
OrionNCT07100704P2recruitingRecurrent/ Metastatic Olfactory Neuroblastoma14
BRIGHT-ESCCNCT07152678P2recruitingEsophageal Cancer60
COMBI-TEDNCT04884282P2active not recruitingMetastatic Non Small Cell Lung Cancer105PMID 36946237
CHAMPNCT04709276P2active not recruitingMetastatic Prostate Neuroendocrine Carcinoma41
TURANDORELANCT06237920P2recruitingUrologic Neoplasms90
B-ALLNCT04546399P2recruitingDown Syndrome461
CMP-001NCT05445609P2suspendedMetastatic Prostate Adenocarcinoma10
SAMURAINCT05327686P2recruitingMetastatic Renal Cell Carcinoma240
MEMBRAINSNCT03563729P2recruitingMalignant Melanoma80
DUMASNCT05684276P2active not recruitingNSCLC22
NEONNCT06624475P2recruitingBasal Cell Carcinoma30
ANTARESNCT06638931P2recruitingUrachal Cancer28PMID 32101663
UNICORNNCT05845450P2recruitingColorectal Cancer197
NIPISAFENCT04730544P2active not recruitingColorectal Cancer Metastatic96
NIVO402025NCT07542262P2enrolling by invitationColorectal Cancer128
METIMMOX-2NCT05504252P2active not recruitingColorectal Adenocarcinoma80PMID 20421432
Cyto-KIKNCT04322955P2active not recruitingKidney Cancer38
NPC-NivoNCT06019130P2recruitingNasopharyngeal Carcinoma57
RadVaxNCT03646617P2recruitingMetastatic Melanoma54
NIVOTHYMNCT03134118P2active not recruitingThymoma Type B355PMID 34393061
DRUPNCT02925234P2recruitingCancer1,550PMID 37424386
NIVIPI-BrainNCT05012254P2active not recruitingNon Small Cell Lung Cancer71
ADJORL1NCT03406247P2recruitingHead and Neck Squamous Cell Carcinoma140
IMCODE004NCT06534983P2recruitingMuscle-invasive Urothelial Carcinoma62
ARCITECTNCT05928806P2suspendedAdvanced Renal Cell Carcinoma120
NEXTNCT03171025P2active not recruitingBladder Cancer200PMID 40102029
NA_00092076NCT02259621P2active not recruitingNon-Small Cell Lung Cancer39PMID 31754049
CheckMate 7UANCT04495010P2withdrawnMelanoma0
DISCERNNCT06364917P2recruitingNon Small Cell Lung Cancer24
NIPIRESCUENCT05310643P2recruitingMetastatic Colorectal Cancer30
Indi-BladeNCT05200988P2active not recruitingUrothelial Carcinoma50PMID 37711193
PACIFICNCT04745949P2recruitingAnn Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma31
DARANIVOVAXNCT06015724P2recruitingPancreatic Ductal Adenocarcinoma54
TATE-PD1NCT03259867P2recruitingHepatocellular Carcinoma54PMID 35504436
TOP-FLORNCT05788081P2active not recruitingFollicular Lymphoma Stage II40
ILUSTRONCT03505320P2active not recruitingPharmacokinetics of Zolbetuximab143PMID 40341124
NIVO-ALCLNCT03703050P2active not recruitingRelapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma45
TNBCNCT03449108P2active not recruitingBone Sarcoma30
G360-IITNCT05715229P2recruitingCarcinoma, Non-Small-Cell Lung108PMID 32816849
CANOPYNCT05502315P2recruitingCastration-resistant Prostate Cancer47
AxInNCT05817903P2recruitingMetastatic Renal Cell Carcinoma118
NIVO1002024NCT07523763P2active not recruitingColorectal Cancer (MSI-H)30
LUNGVIRNCT05597800P2not yet recruitingNSCLC Stage IV105
NIPUNCT04300244P2active not recruitingCancer118PMID 39133306
MOST-CIRCUITNCT04969887P2active not recruitingAdvanced Biliary Tract Cancer240PMID 40608313
NIMBUSNCT03789110P2active not recruitingBreast Cancer30PMID 40360544
MSSNCT04963283P2active not recruitingColorectal Adenocarcinoma48
LOGICANNCT05476796P2recruitingGastric Adenocarcinoma118PMID 38762353
TRINITYNCT05280457P2active not recruitingHead and Neck Squamous Cell Carcinoma21
EBINNCT03235245P2active not recruitingUnresectable Stage III Melanoma271PMID 40449497
CAPTURNCT03297606P2recruitingLymphoma, Non-Hodgkin720
NPCNCT06064097P2recruitingStage II Nasopharyngeal Carcinoma AJCC v850
CCBWNCT06265285P2recruitingAdvanced Esophageal Squamous Cell Carcinoma50
NAVIGATIONNCT05696548P2active not recruitingAnaplastic Thyroid Cancer51
HERNCT03650894P2active not recruitingBreast Neoplasm Female30
TONIC-2NCT04159818P2recruitingMetastatic Breast Cancer52
ctDNA Lung RCTNCT04966663P2recruitingNon Small Cell Lung Cancer66
CLARANCT05215470P2active not recruitingRenal Cancer Metastatic100
SANO-3NCT05491616P2active not recruitingEsophageal Cancer77
LNCT03607890P2active not recruitingRefractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy38
HO152NCT03620578P2active not recruitingNon Hodgkin Lymphoma97
BOOST-RCCNCT06284564P2active not recruitingMetastatic Renal Cell Carcinoma10
LOWNCT04933903P2recruitingNon Small Cell Lung Cancer25
SURPASS-3NCT05601752P2active not recruitingOvarian Cancer66
CERAD-IMMUNENCT05504642P2withdrawnCervical Cancer ≥ FIGO IIB and or Lymph Node Metastases0
CYTOSHRINKNCT04090710P2active not recruitingMetastatic Renal Cell Carcinoma66
RAFTINGNCT04866654P2recruitingHodgkin Lymphoma160PMID 40135712
SARC038NCT04803877P2active not recruitingOsteosarcoma48
VESTIGENCT03443856P2active not recruitingGastric and Esophagogastric Junction Adenocarcinoma197PMID 32083013
IVNCT05496192P2withdrawnMelanoma0
CNN-BCNCT05203913P2recruitingMuscle-Invasive Bladder Carcinoma32
GALAXY-1NCT05964101P2unknownNeoplasms25
IMPALANCT04400539P2recruitingMesotheliomas Pleural20
AARONNCT04913922P2unknownAcute Myeloid Leukemia30
CONGRATSNCT04095208P2completedSoft Tissue Sarcoma Adult68
ICINCT04817254P2completedGlioblastoma47
ANIMATENCT03337919P2unknownHodgkin Lymphoma78
NSCLCNCT04623775P2active not recruitingNon-small Cell Lung Cancer468
OMP-313M32NCT05715216P2active not recruitingOvarian Cancer20
PORTSIDENCT05926960P2terminatedMelanoma38
GALLANTNCT04535713P2recruitingSarcoma260PMID 27234989
NUTMEGNCT04195139P2active not recruitingGlioblastoma Multiforme103PMID 39777725
NIPICOLNCT03350126P2active not recruitingMetastatic Cancer Colorectal57PMID 37269904
INSPIRENCT04717154P2completedProstatic Neoplasms, Castration-Resistant69
NEOpredictNCT04205552P2completedNSCLC Stage II90PMID 38689060
CheckMate 6DWNCT05136677P2completedMesothelioma, Malignant102
NEONIPIGANCT04006262P2active not recruitingLocalized Oesogastric Adenocarcimona32PMID 35969830
Neo-KanNCT05472623P2withdrawnResectable Non-Small Cell Lung Cancer0
TONICNCT02499367P2unknownBreast Cancer84PMID 41406937
NSCLCNCT04123379P2completedNon-small Cell Lung Cancer48
VEXILLUMNCT05219435P2completedUrothelial Cancer25
NURE-ComboNCT04876313P2unknownMuscle-Invasive Bladder Carcinoma29PMID 39241203
ROMENCT04591431P2unknownBreast Cancer400PMID 41963505
OpACIN-neoNCT02977052P2unknownMalignant Melanoma Stage III186PMID 36989829
IMAGINENCT04062656P2unknownGastric Cancer21
REFINENCT04913025P2unknownRenal Cell Carcinoma160PMID 36519749
PICASSONCT04988841P2completedMelanoma70
NIBIT-ML1NCT04250246P2unknownMelanoma184PMID 24384533
NICONCT03721757P2completedSquamous Cell Carcinoma of the Oral Cavity21
ATLASNCT04966676P2terminatedNon Small Cell Lung Cancer5
RO7121661NCT04785820P2completedAdvanced or Metastatic Esophageal Squamous Cell Carcinoma190
CheckMate 9KDNCT03338790P2completedProstate Cancer292PMID 35977756
MATISSENCT04620200P2completedCutaneous Squamous Cell Carcinoma50PMID 41062829
CheckMate 650NCT02985957P2completedProstate Cancer351PMID 32916128
ANZUP2001NCT05150236P2unknownProstatic Neoplasms93
NIPINECNCT03591731P2completedNeuroendocrine Carcinoma185PMID 41774886
NIVOFGFR2NCT05859477P2unknownMetastatic Gastric Cancer23
Optim-UCPVaxNCT04263051P2completedAdvanced Non-small Cell Lung Cancer60PMID 23264913
ANICCANCT03981146P2completedColorectal Cancer35PMID 41407398
IMMUNEBOOSTNCT03838263P2completedOropharynx Cancer62PMID 41570275
NPCNCT03267498P2completedNasopharyngeal Carcinoma40
NIVACORNCT04072198P2completedColorectal Cancer73PMID 32867715
CheckMate142NCT02060188P2completedMicrosatellite Unstable Colorectal Cancer385PMID 28734759
TOP2101NCT05144529P2terminatedLung Cancer Metastatic19
MSSNCT03642067P2completedMicrosatellite Stable (MSS) Colorectal Adenocarcinomas59
OPTIMA-IINCT03107182P2completedHPV-Related Squamous Cell Carcinoma72PMID 38842838
ADMEC-ONCT02196961P2completedMerkel Cell Carcinoma180PMID 37451295
CheckPRONCT05655715P2completedProstate Cancer Metastatic90PMID 36717150
CMP-001NCT04401995P2completedMelanoma9
NSCLCNCT06094296P2terminatedNSCLC1
SLGNNCT04891770P2completedChronic Hepatitis B103
HCCNCT03510871P2completedHepatocellular Carcinoma (HCC)43PMID 40972843
SECOMBITNCT02631447P2completedMetastatic Melanoma251PMID 39315864
CheckMate 744NCT02927769P2completedHodgkin Disease72PMID 36564047
PRECISENCT02664181P2completedLung Cancer13
OXELNCT03487666P2completedTriple Negative Breast Cancer45PMID 40274284
BreastImmune03NCT03818685P2unknownBreast Cancer95PMID 41314029
CA209-260NCT02553642P2completedBladder Cancer81PMID 29489427
RNF43NCT04907539P2completedColorectal Cancer25
IMPACTNCT03570619P2completedMetastatic Castration Resistant Prostate Cancer56
NIVOTAXNCT04282109P2completedRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma141
PG545NCT05061017P2completedNSCLC13PMID 36634920
METIMMOXNCT03388190P2completedColorectal Cancer Metastatic80PMID 38664577
CHINORECNCT04124601P2completedRectal Cancer80PMID 40844778
CheckMate 9TNNCT03770299P2withdrawnNon-Small Cell Lung Cancer0
Neo-NTP-CRTNCT05130684P2unknownLocally Advanced Esophageal Squamous Cell Carcinoma43PMID 41862680
NSCLCNCT03285321P2completedNon-small Cell Lung Cancer105
CHEERSNCT03511391P2completedUrothelial Carcinoma99PMID 37410476
GEJNCT03662659P2completedGastric Cancer274PMID 38723227
MIBCNCT03993249P2unknownBladder Cancer78
NextrahNCT04611165P2completedAdvanced Hepatocellular Carcinoma50PMID 38463541
BIOLUMANCT03083691P2completedCarcinoma, Non-Small-Cell Lung90
AG-120NCT04056910P2completedAdvanced Solid Tumor15PMID 41138165
AcSéNCT03012581P2completedCarcinoma, Renal Cell269
DEPENDNCT03944915P2completedHuman Papilloma Virus35PMID 40048190
INFLUENCENCT05116917P2terminatedPancreatic Cancer19
DENIVOSNCT03669523P2completedCarcinoma, Non-Small-Cell Lung82
NivoMNCT03569696P2unknownLymphoma, B-Cell50
HLNCT01716806P2completedHodgkin Disease131PMID 24359243
RACE ITNCT03529890P2unknownUrinary Bladder Cancer33PMID 31900121
CHECKPOINTNCT05435053P2terminatedPancreas Cancer9
NIVOLEPNCT03630640P2completedHepatocellular Carcinoma43PMID 28453431
CheckMate 848NCT03668119P2completedPan Tumor212PMID 39107131
BLISSNCT05081674P2completedLung Neoplasm154
IRENCT04212026P2terminatedMetastatic Pancreatic Cancer8
BMS-986227NCT03927105P2completedPeripheral T Cell Lymphoma4
TOP1705NCT03573947P2completedNon-small Cell Lung Cancer46
IBCNCT03742986P2completedBreast Cancer8
GEPNCT03980925P2completedNeuroendocrine Tumors37
TKINCT05039736P2withdrawnHepatocellular Carcinoma0
NivoPlusNCT04107103P2completedSCCHN6PMID 19934295
CheckMate 592NCT03001882P2completedNon-Small Cell Lung Cancer230
AIRINGNCT04577638P2completedNon Small Cell Lung Cancer Stage III8
NA_00084192NCT01928576P2completedNon-Small Cell Lung Cancer143
TITAN-TCCNCT03219775P2unknownTransitional Cell Carcinoma169PMID 38722641
COMBAT-CRPCNCT03554317P2completedCastration-resistant Prostate Cancer45PMID 38167882
Nivo-DHAPNCT04091490P2completedHodgkin Lymphoma40PMID 12377653
CheCUPNCT04131621P2unknownCancer of Unknown Primary Site194PMID 37875494
UNISoNNCT03177239P2unknownRenal Cell Carcinoma85
CheckMate 205NCT02181738P2completedHodgkin Disease294PMID 27451390
CA209-9JCNCT03834233P2unknownAdvanced Cutaneous Squamous Cell Carcinoma24PMID 36274573
RENOBATENCT04310709P2completedCarcinoma, Hepatocellular42PMID 38374347
CheckPACNCT02866383P2completedMetastatic Pancreatic Cancer160PMID 37744345
MARIO-275NCT03980041P2completedBladder Cancer49
TITAN-RCCNCT02917772P2completedCarcinoma, Renal Cell200PMID 37844597
ERICANCT03562507P2terminatedRenal Cell Carcinoma, Metastatic8
CRUCIALNCT03437200P2terminatedInoperable œsophageal Cancer8
BTCNCT04057365P2terminatedBiliary Tract Cancer15
CKSNCT03219671P2unknownClassic Kaposi Sarcoma20
CheckMate 9UTNCT03519256P2terminatedUrinary Bladder Neoplasms142
LNCT03606174P2terminatedUrothelial Carcinoma260
NIVAHLNCT03004833P2completedClassical Hodgkin Lymphoma110PMID 41926569
PIVOT-10NCT03785925P2completedUrinary Bladder Neoplasm192
OPTIMNCT03620123P2completedRecurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck54
TopNIVONCT03226756P2completedRecurrent and/or Metastatic Platinum-refractory SCCHN351
SCLCNCT03406715P2terminatedSmall Cell Lung Cancer14
ICONNCT03409198P2completedBreast Cancer82PMID 38242720
FRACTION-GCNCT02935634P2completedAdvanced Gastric Cancer190
ILLUMINATE-206NCT03865082P2active not recruitingSolid Tumor30
CheckMate 714NCT02823574P2completedHead and Neck Cancer425PMID 37022706
CheckMate 907NCT03090737P2completedNon-Small Cell Lung Cancer129
CheckMate 568NCT02659059P2completedNon-Small-Cell Lung Cancer324PMID 30785829
INTEGANCT03409848P2completedGastric Cancer97PMID 32487035
ImmunoProstNCT03040791P2unknownProstate Cancer38
NIVALLONCT03146468P2unknownHaematological Malignancy14
CHIVA2NCT03304093P2completedNon Small Cell Lung Cancer Metastatic30
NiTraSarcNCT03590210P2completedMetastatic Adult Soft Tissue Sarcoma92
NIMBLeNCT03461952P2terminatedAdvanced Solid Tumors4
STIMULINCT02046733P2completedLimited Stage Small Cell Lung Cancer222PMID 22858559
CheckMate 908NCT03130959P2completedVarious Advanced Cancer166PMID 36808285
IMMUTACENCT03572582P2completedCarcinoma, Hepatocellular49
TRIPPLE-RNCT04258150P2terminatedPancreatic Cancer26PMID 36592507
FRACTION-RCCNCT02996110P2completedAdvanced Cancer182PMID 36328377
RAMONANCT03416244P2completedEsophageal Cancer66PMID 30871493
NISCAHNNCT03132038P2completedSalivary Gland Carcinoma98PMID 39886516
STARVE-PCNCT02601014P2completedProstate Cancer32PMID 33636027
MAYANCT03832621P2completedMetastatic Colorectal Cancer135PMID 35258987
NIVISCONCT04413838P2unknownObesity, COVID-19 Infection120
IMMUNOXNCT04430985P2withdrawnMetastatic Colorectal Cancer0
COVID-19NCT04356508P2unknownCOVID-1915
Checkmate 171NCT02409368P2completedNon-Small Cell Lung Cancer812PMID 32028209
REVOLUMABNCT03925246P2completedHigh Grade Glioma43PMID 38537315
CC-122NCT03834623P2completedMelanoma23
OASISNCT04503967P2unknownGastric Adenocarcinoma48PMID 39406730
NIRVANANCT02799901P2completedMelanoma72PMID 34088741
CheckMate 7A8NCT04075604P2completedBreast Cancer23
GEM1402NCT02626962P2completedUveal Melanoma52PMID 33417511
NIVESNCT03469713P2completedRenal Cancer Metastatic69PMID 32203306
MIBCNCT03294304P2completedMuscle Invasive Bladder Cancer43
NIVORENNCT03013335P2completedMetastatic Renal Cell Carcinoma730PMID 35977881
CheckMate 627NCT02832167P2completedCancer239
CONTESSA TRIONCT03952325P2terminatedBreast Cancer294
HN17-11NCT06440187P2completedRecurrent or Metastatic Nasopharyngeal Carcinom38
BMS-936558NCT01721759P2completedSquamous Cell Non-small Cell Lung Cancer117PMID 25704439
MDX-1106NCT01354431P2completedRenal Cell Carcinoma168PMID 25452452
MODULATENCT03647839P2completedColorectal Cancer Metastatic90
SQUINTNCT03823625P2unknownSquamous-Cell Lung Cancer112PMID 39836372
CheckMate 069NCT01927419P2completedUnresectable Melanoma142PMID 25891304
MSSNCT03271047P2completedMSS75PMID 38600471
NSCLCNCT03353675P2completedNon Small Cell Lung Cancer Metastatic44
BIONIKKNCT02960906P2completedClear Cell Metastatic Renal Cell Carcinoma200PMID 35390339
DCNCT03782064P2terminatedMultiple Myeloma5
NIVOSWITCHNCT02959554P2terminatedMetastatic Renal Cell Carcinoma49PMID 33058158
SBRTNCT02684253P2completedHead and Neck Squamous Cell Carcinoma (HNSCC)65PMID 32822275
FORCENCT03044626P2completedCarcinoma,Non-Small-Cell Lung101PMID 31703637
FLNCT02038946P2completedLymphoma116PMID 32870269
CheckMate 647NCT02857426P2completedLymphoma66
RADVAXNCT03065179P2completedKidney Cancer Metastatic29
ENSIGNNCT02831933P2terminatedLung Squamous Cell Carcinoma Stage IV11
NASIR-HCCNCT03380130P2completedHepatocellular Carcinoma41PMID 31848672
DLBCLNCT02038933P2completedLymphoma. Non-Hodgkin121PMID 30620669
CORIMUNO-NIVONCT04343144P2unknownCOVID19- Infection With SARS-CoV-2 Virus92
CheckMate204NCT02320058P2completedMelanoma119PMID 33880555
ARIESNCT03824704P2terminatedEpithelial Ovarian Cancer1
PANGEA-IMBBPNCT02213289P2completedAdenocarcinoma80
ModuLungNCT02852083P2unknownSquamous Cell Lung Cancer86
SBRTNCT03599362P2terminatedPancreatic Cancer7
GIADANCT04659551P2completedBreast Cancer43PMID 34667023
NICOLASNCT02434081P2completedNon-small Cell Lung Cancer Stage III94PMID 28551359
Cypress 2NCT03382912P2terminatedNon Small Cell Lung Cancer52PMID 33166722
FRACTION-LungNCT02750514P2terminatedAdvanced Cancer295
RISE-MNCT03634800P2terminatedMultiple Myeloma6
INITIATENCT03048474P2completedMalignant Pleural Mesothelioma36PMID 33166791
BMS-986205NCT04007588P2withdrawnMelanoma Stage III0
NLG2107NCT03301636P2terminatedMelanoma21
NICOLENCT04123925P2completedColon Cancer Stage II/III22
MAPS2NCT02716272P2completedMesothelioma125PMID 30660609
MDSNCT02599649P2terminatedLeukemia10PMID 30001986
BMS-936558NCT02156804P2completedMelanoma1,009PMID 31581055
ADAPTeRNCT02446860P2terminatedRenal Cell Carcinoma15PMID 34715028
CA209-322NCT02621515P2terminatedMelanoma7
NivoMesNCT02497508P2completedMalignant Pleural Mesothelioma33
Neo-nivoNCT02550249P2completedGlioblastoma Multiforme29
NSCLCNCT02950038P2withdrawnLung Cancer, Nonsmall Cell, Stage I0
RCCNCT02962804P2withdrawnCarcinoma, Renal Cell0

Terminated and withdrawn Nivolumab trials (315)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

All Nivolumab trials (1624)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT05732389RESET-RImmunotherapy in Patients With Early dMMR Rectal CancerP2recruiting39Odense University HospitalFeb 2023
NCT06639607PRiME IIPEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and EpendymomaP1/P2recruiting68Washington University School of MedicineJun 2026
NCT04995003CARHER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced SarcomaP1recruiting25Baylor College of MedicineDec 2021
NCT07369791NOBLENivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.P2not yet recruiting76National Health Research Institutes, TaiwanMay 2026
NCT03544736INECSafety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)P1/P2active not recruiting30Oslo University HospitalApr 2018
NCT06999980Neo IRENIENeo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)P2recruiting494Melanoma Institute AustraliaFeb 2026
NCT05352828ACTIONAutologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline TherapyP1active not recruiting15Tessa TherapeuticsJul 2022
NCT04134325Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaEarly P1active not recruiting10UNC Lineberger Comprehensive Cancer CenterSep 2019
NCT04044859SURPASSADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)P1active not recruiting120USWM CT, LLCAug 2019
NCT07195695Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsP3recruiting400Boehringer IngelheimJan 2026
NCT06288191Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell CarcinomaP2recruiting20Melanoma Institute AustraliaJun 2024
NCT05418972Neo ReNi IIA Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous MelanomaP2active not recruiting20Melanoma Institute AustraliaAug 2023
NCT07541170KRASCENDO 3A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)P3not yet recruiting400Hoffmann-La RocheSep 2026
NCT07403877TORCH-OPTIMANeoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerP2not yet recruiting114Fudan UniversityFeb 2026
NCT06264180VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]P3recruiting400Replimune, Inc.Jul 2024
NCT06151236Neoadjuvant Nivolumab and Relatlimab in Merkel Cell CarcinomaP2recruiting20Melanoma Institute AustraliaMar 2024
NCT06240143MARIANEIntradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaP1/P2recruiting96The Netherlands Cancer InstituteMar 2024
NCT04248569DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaP1recruiting56Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsApr 2020
NCT07383441Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerP3recruiting718SWOG Cancer Research NetworkJun 2026
NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)P3recruiting450Merck Sharp & Dohme LLCMar 2026
NCT07444619A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasP1not yet recruiting18M.D. Anderson Cancer CenterAug 2026
NCT07230613NEOREM-NEO-1Neo-adjuvant Immunotherapy in Patients With Localized MelanomaP2recruiting50UNICANCERJan 2026
NCT07514767NOCANOEvaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell CarcinomaP2not yet recruiting60Prof. Lars Olaf CardellMay 2026
NCT06488482Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant MelanomaP3recruiting1,792Uppsala UniversityDec 2024
NCT07510334VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaP2recruiting18Mayo ClinicApr 2026
NCT06246916A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)P3recruiting560Regeneron PharmaceuticalsSep 2024
NCT02339571A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaP2/P3active not recruiting600National Cancer Institute (NCI)Nov 2015
NCT07319195WINIT-BCWindow Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)Early P1recruiting32Jennifer ZhangApr 2026
NCT06745076Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaP2recruiting125University of WashingtonMar 2025
NCT03815890BELLINIPre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IOP2recruiting80The Netherlands Cancer InstituteOct 2019
NCT07551583Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLP2not yet recruiting15M.D. Anderson Cancer CenterOct 2026
NCT07338981The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.P3not yet recruiting142Guliz OzgunApr 2026
NCT07031765Peds CHAMP1ONPeds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade GliomaP1active not recruiting12University of FloridaJul 2025
NCT04503694REGINANeoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal CancerP2active not recruiting72Jules Bordet InstituteMar 2021
NCT03769155VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaP1active not recruiting41Emory UniversityDec 2018
NCT07221149A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)P2/P3recruiting690Bristol-Myers SquibbMar 2026
NCT07092670MELAFERTMELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.recruiting270Intergruppo Melanoma ItalianoAug 2025
NCT06683755TRINITYPhase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)P1/P2not yet recruiting30M.D. Anderson Cancer CenterMay 2025
NCT06561386RELATIVITY1093A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%P3recruiting1,000Bristol-Myers SquibbOct 2024
NCT03521830Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaP2recruiting57Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNov 2018
NCT05112601Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaP2recruiting81National Cancer Institute (NCI)Jun 2022
NCT07000149eVOLVE-RCC02A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCP3active not recruiting1,116AstraZenecaJul 2025
NCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerP2/P3recruiting840PfizerMay 2026
NCT07355205FLINNFirst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerP2not yet recruiting26Washington University School of MedicineJun 2026
NCT03686124ACTengineACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsP1/P2recruiting375Immatics US, Inc.May 2019
NCT07492680A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)P2not yet recruiting260Bristol-Myers SquibbJul 2026
NCT06364631CARE1CARE1 Pragmatic Clinical TrialP3recruiting1,250Gustave Roussy, Cancer Campus, Grand ParisApr 2024
NCT06794775SWE-NEOSWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III MelanomaP3recruiting128Hildur HelgadottirJul 2025
NCT03017820A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaP1recruiting99Mayo ClinicApr 2017
NCT03026140NICHENeoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerP2recruiting353The Netherlands Cancer InstituteMar 2017
NCT05533697Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsP1/P2recruiting361ModernaTX, Inc.Sep 2022
NCT05076760MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsP1recruiting40Memgen, Inc.Apr 2022
NCT06247540Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaP2withdrawn0Northwestern UniversityMar 2024
NCT07328087COLONYVAQ™-CRCCOLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal CancerEarly P1recruiting12Biogenea Pharmaceuticals Ltd.Feb 2026
NCT07293351RCCA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)P1/P2recruiting254Bristol-Myers SquibbMar 2026
NCT07223411Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanomarecruiting20John KirkwoodNov 2025
NCT06743126SUPRAMESUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaP3recruiting360Immatics US, Inc.Jan 2025
NCT06581406A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaP2/P3recruiting280Replimune, Inc.Dec 2024
NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2P3recruiting2,130AstraZenecaFeb 2026
NCT07246863Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCP2recruiting131CatalYm GmbHOct 2025
NCT07219459GDFATHERHCC01Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureP2recruiting104CatalYm GmbHMar 2026
NCT04929028Therapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerP2active not recruiting40National Cancer Institute (NCI)Aug 2022
NCT06646276TIGOSA Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).P3recruiting530Bristol-Myers SquibbFeb 2025
NCT06871007Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell LymphomaP1/P2enrolling by invitation22St. Petersburg State Pavlov Medical UniversitySep 2024
NCT06866262Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialP1/P2recruiting55University of Michigan Rogel Cancer CenterAug 2025
NCT06968988Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue SarcomaP1recruiting18Washington University School of MedicineJan 2026
NCT03886311TNTTalimogene Laherparepvec, Nivolumab and Trabectedin for SarcomaP2recruiting200Sarcoma Oncology Research Center, LLCMay 2019
NCT03138161SAINTSAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaP1/P2recruiting250Sarcoma Oncology Research Center, LLCApr 2017
NCT07061379PROMOTINGPatient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimenrecruiting144IRCCS San RaffaeleJul 2025
NCT03055013Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyP3active not recruiting819National Cancer Institute (NCI)Apr 2017
NCT06816927GIANTTrial of Glioblastoma Immunotherapy Advancement With Nivolumab and RelatlimabP2recruiting92Duke UniversityNov 2025
NCT03258567EBVNivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasP2recruiting40National Cancer Institute (NCI)Apr 2018
NCT07504796ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabP4recruiting90NYU Langone HealthApr 2026
NCT07460765HNSCCSafety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)P1not yet recruiting40Vanderbilt-Ingram Cancer CenterApr 2026
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabP3recruiting1,875National Cancer Institute (NCI)May 2023
NCT04564157NADIM-ADJUVANTNew Adjuvant Trial of Chemotherapy vs Chemo-immunotherapyP3active not recruiting210Fundación GECPJan 2021
NCT07210632HGGWindow Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)Early P1recruiting38Eben RosenthalMar 2026
NCT074043325-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory TumorsP1recruiting35Mohammed MilhemFeb 2026
NCT06624644A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaP2/P3recruiting135Linnaeus Therapeutics, Inc.Aug 2025
NCT02813135ESMARTEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsP1/P2recruiting472Gustave Roussy, Cancer Campus, Grand ParisAug 2016
NCT03383458CheckMate 9DXA Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationP3active not recruiting545Bristol-Myers SquibbApr 2018
NCT06618287A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsP1/P2recruiting416Bristol-Myers SquibbFeb 2025
NCT07281924Hepzato Kit and Opdualag for Metastatic Melanoma and Liver MetastasisP1/P2recruiting15University of Wisconsin, MadisonJun 2026
NCT07529873N'FORCEPhase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell CarcinomaP2not yet recruiting131Groupe Oncologie Radiotherapie Tete et CouMay 2026
NCT06963905SIMONESaci Nivo Rela for TNBCP1/P2recruiting60Yale UniversityDec 2025
NCT07050043LEDANGLow Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCP3recruiting123Dr Arvindran A/L AlagaMay 2025
NCT06715241COLIBRI-2A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERSP2active not recruiting77ARCAGY/ GINECO GROUPDec 2024
NCT03228667QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsP2active not recruiting40ImmunityBio, Inc.Dec 2018
NCT03522246ATHENAA Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyP3active not recruiting1,097pharmaand GmbHMay 2018
NCT03470922RELATIVITY-047A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaP2/P3active not recruiting714Bristol-Myers SquibbApr 2018
NCT04929041Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeP2/P3suspended427National Cancer Institute (NCI)Oct 2022
NCT05457959Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutantP1withdrawn0Jonsson Comprehensive Cancer CenterDec 2024
NCT07188896RCCA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)P2recruiting120Brian RiniApr 2026
NCT07223424PSI-ImmunePatient Preference for Subcutaneous vs. Intravenous Immune TherapyP2recruiting880Diwakar DavarNov 2025
NCT05629546Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint InhibitorsP1recruiting33Washington University School of MedicineNov 2024
NCT04848116Spark2Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck CaP2active not recruiting24Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsApr 2021
NCT06926790GALAXY 3Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)P2recruiting69The First Affiliated Hospital of Guangzhou Medical UniversityFeb 2025
NCT06487156FINNA Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Canceractive not recruiting404Bristol-Myers SquibbOct 2023
NCT06812858PD-1 Inhibitors Maintenance for cHL Post-autoHCTP2recruiting83St. Petersburg State Pavlov Medical UniversityJan 2024
NCT06169956NENIAn Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germanyrecruiting400Bristol-Myers SquibbNov 2023
NCT04637594IMAGINETrying to Find the Correct Length of Treatment With Immune Checkpoint TherapyP3active not recruiting3Alliance for Clinical Trials in OncologyMay 2022
NCT04930783NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaP1active not recruiting10Dana-Farber Cancer InstituteJan 2022
NCT04462406Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop TrialP2active not recruiting150ECOG-ACRIN Cancer Research GroupFeb 2021
NCT05987241Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyP2/P3recruiting992National Cancer Institute (NCI)Feb 2024
NCT07430202FLCA DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)P1not yet recruiting27Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAug 2026
NCT06365619NeoRelapseNeoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaP2recruiting25University of UtahJun 2026
NCT07432295GIVA-2Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)P2recruiting180I-Mab Biopharma US LimitedFeb 2026
NCT0590961814Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain MetastasesP2recruiting33Sheba Medical CenterJul 2023
NCT07011550Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal CancerP2suspended7M.D. Anderson Cancer CenterAug 2025
NCT07013565ACCELERATEChemoimmunotherapy for ALK+ Relapsed/Refractory ALCLP2recruiting20New York Medical CollegeAug 2025
NCT05176483STELLAR-002Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsP1recruiting1,314ExelixisDec 2021
NCT01703949Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaP2active not recruiting28University of WashingtonMar 2013
NCT06889493NECSVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)P1recruiting36Peter Hosein, MDMay 2025
NCT04658147HCCFeasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)P1active not recruiting31Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMay 2021
NCT05500092An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung CancerP2active not recruiting17Montefiore Medical CenterJan 2023
NCT06632327Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerP3recruiting1,100Alliance for Clinical Trials in OncologyDec 2024
NCT05802056Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal MetastasisP1recruiting15Mayo ClinicNov 2023
NCT03999749A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaP2active not recruiting71NYU Langone HealthJun 2019
NCT06800339NEORADJUVANTA Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung CancerP1recruiting18University of Maryland, BaltimoreApr 2025
NCT06275360RIVALRepositioning Immunotherapy in VetArans With Lung CancerP2recruiting25VA Office of Research and DevelopmentMar 2024
NCT04665206Study to Evaluate VT3989 in Patients With Metastatic Solid TumorsP1/P2recruiting434Vivace Therapeutics, IncMar 2021
NCT06712927Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesP2recruiting60Stanford UniversityAug 2025
NCT06319196ClearMeClear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk MelanomaP2recruiting54University Health Network, TorontoAug 2026
NCT07546812GS-1811Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasP2recruiting120Gilead SciencesMay 2026
NCT07398937ECTOP-1036Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLCP2recruiting116Fudan UniversityFeb 2026
NCT06692491SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGSP2not yet recruiting200Peking University Shenzhen HospitalJan 2025
NCT05795244NIVECStudy of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)P2recruiting30Yonsei UniversityOct 2023
NCT05655312MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaP1/P2recruiting300Perspective TherapeuticsJun 2023
NCT04283890CHOPINPHP and Immunotherapy in Metastasized UMP1/P2active not recruiting83Leiden University Medical CenterDec 2019
NCT03685890NivoILPEvaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb PerfusionP1/P2recruiting74Vastra Gotaland RegionApr 2019
NCT05652673IPI-NIVOSafe Stop Ipilimumab-nivolumab (IPI-NIVO) TrialN/Arecruiting80Erasmus Medical CenterFeb 2023
NCT07401875SHARKA Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)P1recruiting35M.D. Anderson Cancer CenterMar 2026
NCT04562129IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsP2recruiting29H. Lee Moffitt Cancer Center and Research InstituteSep 2020
NCT03921684Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer PatientsP2active not recruiting29Baruch BrennerApr 2019
NCT07174453Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care ImmunotherapiesP3recruiting192University of Kansas Medical CenterOct 2025
NCT07563738TEADCOA 2-part Phase 1/2 Open-label Trial on ODM-212P1/P2recruiting229Orion Corporation, Orion PharmaMar 2026
NCT05633667VELOCITY-LungStudy of Novel Treatment Combinations in Patients With Lung CancerP2active not recruiting192Gilead SciencesMar 2023
NCT06495125Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerP2recruiting50Emory UniversityJul 2024
NCT06572722ECTOP-1030Perioperative Immunotherapy for NSCLC (ECTOP-1030)P2withdrawn0Fudan UniversitySep 2024
NCT06519682CAYAA Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)N/Arecruiting20Daniel MorgensternDec 2024
NCT03340129ABC-XAnti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)P2recruiting218Melanoma Institute AustraliaAug 2019
NCT03899155Pan Tumor Rollover StudyP2recruiting1,500Bristol-Myers SquibbAug 2019
NCT06463665VIRO-25Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerP2recruiting142Genelux CorporationSep 2024
NCT06712875MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasP1/P2recruiting27Ann & Robert H Lurie Children's Hospital of ChicagoApr 2025
NCT06794229EXPLORE-RCCNeoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable MetastasisP2recruiting69Qian QinOct 2025
NCT06561087Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant LesionsP2recruiting45M.D. Anderson Cancer CenterFeb 2025
NCT07459543FDCA Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In IndiaP4not yet recruiting30Bristol-Myers SquibbNov 2026
NCT07176975A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced CancersP1not yet recruiting46Boehringer IngelheimAug 2027
NCT06681298A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With TrastuzumabP2active not recruiting36xiaohua liMay 2024
NCT07532902A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerP1recruiting60Memorial Sloan Kettering Cancer CenterApr 2026
NCT06029270Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerP2recruiting156National Cancer Institute (NCI)Jul 2024
NCT06253611BIGFirst-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric CancerP2recruiting120GERCOR - Multidisciplinary Oncology Cooperative GroupApr 2024
NCT05187182CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerP1recruiting42Washington University School of MedicineJun 2023
NCT05148546NESCIONeoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell CancerP2active not recruiting69The Netherlands Cancer InstituteApr 2022
NCT04024878NeoVax With Nivolumab in Patients With Ovarian CancerP1active not recruiting22Dana-Farber Cancer InstituteNov 2020
NCT07325136A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung CancerP1/P2recruiting240Bristol-Myers SquibbFeb 2026
NCT07187869Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept StudyP1not yet recruiting16M.D. Anderson Cancer CenterMar 2026
NCT07501117Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaP1not yet recruiting15Inge Marie SvaneMay 2026
NCT06188676Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBLP3recruiting100National Research Center for Hematology, RussiaApr 2022
NCT03080974Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic AdenocarcinomaP2recruiting10University of LouisvilleAug 2017
NCT07572123Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaP2/P3not yet recruiting374National Cancer Institute (NCI)Dec 2026
NCT03465592HLATrial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaP1/P2recruiting39Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMay 2018
NCT07166406Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialP3recruiting226NRG OncologyFeb 2026
NCT06983210GRAPEClinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial CarcinomaP2recruiting43Nagoya UniversityMay 2025
NCT07221734Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] MelanomaP3recruiting632mAbxience Research S.L.Dec 2025
NCT06823479MATISSE 2Towards Cure Via Only Ultra-short ICB in CSCCP2recruiting41The Netherlands Cancer InstituteMay 2025
NCT07233668IVE in mRCCImmediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCCN/Anot yet recruiting172Seoul National University HospitalDec 2025
NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsP1/P2active not recruiting49Susan Chi, MDAug 2023
NCT04551430Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaP2active not recruiting105Washington University School of MedicineJan 2021
NCT07028125CANIQOLDigital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal CarcinomaP4recruiting83Centre Francois BaclesseOct 2025
NCT06984146Nivo40-AVD for Advanced Classic Hodgkin LymphomaP2recruiting54National Medical Research Radiological Centre of the Ministry of Health of RussiaApr 2025
NCT07084610Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung CancerP2recruiting30Hospital das Clínicas de Ribeirão PretoFeb 2025
NCT05187429NIVO-LDLow Dose Nivolumab in Adults Living With HIV on Antiretroviral TherapyP1/P2recruiting42University of MelbourneJan 2023
NCT06250335ICBImpact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma PatientsP2active not recruiting4M.D. Anderson Cancer CenterMar 2024
NCT06697197A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid TumorsP1/P2recruiting413Bristol-Myers SquibbFeb 2025
NCT07527858GS-1811Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerP2recruiting170Gilead SciencesMay 2026
NCT06863311EXACTTrial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCP2recruiting70Karie RuncieMar 2026
NCT06941857NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerP2recruiting20Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSep 2025
NCT07209059FINISH-HLPET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaP2recruiting30National Research Center for Hematology, RussiaJul 2025
NCT06523621Nivolumab in Multiple Myeloma Patients After Idecabtagene VicleucelP2active not recruiting1Wake Forest University Health SciencesFeb 2025
NCT06362369A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyP1/P2recruiting1267 Hills Pharma, LLCAug 2024
NCT06031233MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieP4recruiting776IsalaSep 2023
NCT04989946Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate CancerP1/P2recruiting60University of Wisconsin, MadisonDec 2021
NCT03767348IGNYTEStudy of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)P2active not recruiting340Replimune, Inc.Sep 2017
NCT02693535TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerP2recruiting4,200American Society of Clinical OncologyMar 2016
NCT02374242ABCAnti-PD 1 Brain Collaboration for Patients With Melanoma Brain MetastasesP2active not recruiting76Melanoma Institute AustraliaNov 2014
NCT04061980Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid CancerP2active not recruiting24Providence Health & ServicesOct 2020
NCT04949113NADINANeoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III MelanomaP3active not recruiting423The Netherlands Cancer InstituteJul 2021
NCT06708949RCCA Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)P2recruiting15M.D. Anderson Cancer CenterMar 2025
NCT07226856BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaP2recruiting43Mayo ClinicDec 2025
NCT06534190CD8 PET Imaging in Metastatic Solid TumoursP2recruiting30University Medical Center GroningenMar 2025
NCT06295159Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaP2recruiting90H. Lee Moffitt Cancer Center and Research InstituteMay 2024
NCT05723055NAHLEvaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin LymphomaP2active not recruiting9University of UtahMay 2023
NCT053170005-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCCP2recruiting50Barbara BurtnessMar 2023
NCT04506554A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder CancerP2active not recruiting81Fox Chase Cancer CenterDec 2020
NCT03838159NADIMIINADIM II: Neo-Adjuvant ImmunotherapyP2active not recruiting90Fundación GECPMay 2019
NCT06097728eVOLVE-MesoMEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaP3active not recruiting861AstraZenecaNov 2023
NCT07420439Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseP2not yet recruiting108Intergroupe Francophone de Cancerologie ThoraciqueMay 2026
NCT05677490mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaP3recruiting382Alliance for Clinical Trials in OncologyJan 2023
NCT03907852TC-210Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerP1/P2active not recruiting57TCR2 TherapeuticsApr 2019
NCT06053658Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaP2recruiting48M.D. Anderson Cancer CenterJan 2024
NCT05098210Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerP1recruiting25Fred Hutchinson Cancer CenterJun 2022
NCT06946797CheckMate-1533A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)P2active not recruiting76Bristol-Myers SquibbSep 2025
NCT06245356TRIFLUOX-DPSafety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerP2recruiting73UNICANCERMar 2025
NCT07100704OrionRecurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of NivolumabP2recruiting14National Cancer Center Hospital EastApr 2025
NCT07152678BRIGHT-ESCCBrachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell CarcinomaP2recruiting60National Taiwan University HospitalSep 2025
NCT04884282COMBI-TEDEfficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)P2active not recruiting105Fondazione Ricerca TraslazionaleOct 2021
NCT03929029Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaP1active not recruiting11Dana-Farber Cancer InstituteNov 2020
NCT07494435Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCCP2not yet recruiting230Zhejiang Haichang Biotech Co., Ltd.Jun 2026
NCT07147101HCC-IM-1Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironmentrecruiting150Fudan UniversitySep 2025
NCT06490536The Sagittarius TrialP3recruiting700IFOM ETS - The AIRC Institute of Molecular OncologyOct 2024
NCT04840589Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsP1suspended66National Cancer Institute (NCI)Feb 2022
NCT06504615METAGIOObservational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in Franceactive not recruiting208Bristol-Myers SquibbDec 2024
NCT04709276CHAMPA Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerP2active not recruiting41Andrew J. Armstrong, MDJun 2021
NCT07128680EXL01Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerP1recruiting33City of Hope Medical CenterMar 2026
NCT06237920TURANDORELAStage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabP2recruiting90The Netherlands Cancer InstituteFeb 2024
NCT06204614Drug Screening Using IMD in Bladder CancerEarly P1enrolling by invitation18Brigham and Women's HospitalJun 2024
NCT05704647Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesP2recruiting30M.D. Anderson Cancer CenterFeb 2023
NCT06908993COMETTepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedP3recruiting133Intergroupe Francophone de Cancerologie ThoraciqueDec 2025
NCT06325683Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaP2suspended184National Cancer Institute (NCI)Nov 2024
NCT05934331A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyP2recruiting276LaNova Medicines Zhejiang Co., Ltd.Jul 2023
NCT07482059A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular CarcinomaP1/P2recruiting33West China HospitalFeb 2026
NCT05678673STELLAR-304Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaP3active not recruiting317ExelixisJan 2023
NCT04546399B-ALLA Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)P2recruiting461National Cancer Institute (NCI)Dec 2020
NCT04323046Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young AdultsP1active not recruiting9Sabine Mueller, MD, PhDOct 2020
NCT03546686Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerP2active not recruiting51University of Texas Southwestern Medical CenterNov 2019
NCT03918252Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural MesotheliomaP2active not recruiting30Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOct 2019
NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsP1/P2recruiting542SanofiNov 2022
NCT05445609CMP-001Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerP2suspended10Emory UniversityJun 2023
NCT05904080Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal CancerP2suspended50National Cancer Institute (NCI)Feb 2024
NCT05327686SAMURAITesting the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialP2recruiting240NRG OncologyFeb 2023
NCT03563729MEMBRAINSMelanoma Metastasized to the Brain and SteroidsP2recruiting80Inge Marie SvaneJun 2018
NCT05684276DUMASDUMAS: Neo-Adjuvant Immunotherapy for Pancoast TumorsP2active not recruiting22Fundación GECPMay 2023
NCT07213557Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With ImmunotherapyP2recruiting84National Cancer Institute, NaplesMar 2026
NCT06624475NEONNeoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaP2recruiting30University of California, San DiegoAug 2025
NCT06638931ANTARESAgnostic Therapy in Rare Solid TumorsP2recruiting28Instituto do Cancer do Estado de São PauloJul 2024
NCT05845450UNICORNPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)P2recruiting197Gruppo Oncologico del Nord-OvestMay 2023
NCT06346197CIMECombination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasP3recruiting132Centre Leon BerardDec 2025
NCT07017816JACOBA Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.Early P1recruiting18Children's National Research InstituteDec 2025
NCT06767956Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell TherapyP1/P2withdrawn0University of PittsburghJun 2025
NCT06934057CABOLDCabozantinib and Nivolumab Among Older Patients With Renal Cell CarcinomaP4recruiting50Gustave Roussy, Cancer Campus, Grand ParisMay 2025
NCT04730544NIPISAFETwo Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.P2active not recruiting96GERCOR - Multidisciplinary Oncology Cooperative GroupMay 2021
NCT07542262NIVO402025Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR CancersP2enrolling by invitation128Blokhin's Russian Cancer Research CenterJun 2025
NCT05492123Nivolumab-ipilimumab and Chemoradiation for Cervical CancerP2recruiting112Hospital Israelita Albert EinsteinAug 2022
NCT07422779MAKImmunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in SloveniaN/Arecruiting100Institute of Oncology LjubljanaMar 2022
NCT04165330Evaluation of AL3818 in Combination With Nivolumab in Solid TumorsP1/P2active not recruiting56Sarcoma Oncology Research Center, LLCOct 2019
NCT07334119Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid TumorsP1recruiting60Myeloid TherapeuticsNov 2025
NCT03816345Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOP1recruiting300National Cancer Institute (NCI)Jul 2019
NCT05504252METIMMOX-2METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by OxaliplatinP2active not recruiting80University Hospital, AkershusOct 2022
NCT07394062ALCG-01Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)recruiting400Gazi UniversityFeb 2026
NCT05428007Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaP2recruiting105NYU Langone HealthFeb 2023
NCT04322955Cyto-KIKCYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase InhibitionP2active not recruiting38Mark SteinJun 2020
NCT04380545Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar CancerP1/P2recruiting15M.D. Anderson Cancer CenterJan 2021
NCT04420975Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaP1active not recruiting14Jonsson Comprehensive Cancer CenterOct 2020
NCT04309409NivoMelaAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk MelanomaP3active not recruiting374University Hospital, EssenJul 2020
NCT06054555A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic MelanomaP3active not recruiting633AmgenNov 2023
NCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyP3active not recruiting1,175National Cancer Institute (NCI)Jun 2019
NCT05987332IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaP2/P3active not recruiting420IDEAYA BiosciencesOct 2023
NCT06019130NPC-NivoNivolumab in Children and Adults With Nasopharyngeal CarcinomaP2recruiting57German Society for Pediatric Oncology and Hematology GPOH gGmbHJan 2023
NCT06731270Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyP2recruiting20Emory UniversityApr 2025
NCT05779423Cryoablation+Ipilimumab+Nivolumab in MelanomaP2recruiting37Massachusetts General HospitalSep 2023
NCT07075120Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular CancerP1recruiting15University of HawaiiApr 2026
NCT07216833Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckP1not yet recruiting15Kyunghee Burkitt, DO, PhDJan 2026
NCT07155317Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME TrialP2recruiting99Emory UniversityOct 2025
NCT06901817A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal MetastasesP2recruiting97Shanghai Cancer Hospital, ChinaMar 2025
NCT06724159SOGUG-PRINCISObservational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.recruiting500Spanish Oncology Genito-Urinary GroupDec 2024
NCT05681780Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCP1recruiting20H. Lee Moffitt Cancer Center and Research InstituteMar 2023
NCT05048212A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesP2recruiting20M.D. Anderson Cancer CenterSep 2022
NCT05423262A Study of TRK-950 in Patients With Advanced Solid TumorsP1/P2recruiting49Toray Industries, IncJul 2022
NCT05034536PD-1 Antibody Therapy + Infliximab for Metastatic MelanomaP2active not recruiting36Massachusetts General HospitalFeb 2022
NCT04697576Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaP1recruiting36Carlo ContrerasOct 2021
NCT04940299Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaP2active not recruiting35M.D. Anderson Cancer CenterSep 2021
NCT04900818Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsP1recruiting330I-Mab Biopharma US LimitedJun 2021
NCT04729322Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-respondersP2active not recruiting15M.D. Anderson Cancer CenterFeb 2021
NCT04150640Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric AdenocarcinomaP2recruiting52University of Wisconsin, MadisonJul 2020
NCT04699721Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLCP2active not recruiting60Xiangya Hospital of Central South UniversityJul 2020
NCT03803553Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerP3recruiting400Massachusetts General HospitalApr 2020
NCT04013542Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung CancerP1active not recruiting21M.D. Anderson Cancer CenterSep 2019
NCT03610711REACTIONREACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric CancerP1/P2active not recruiting21Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2019
NCT03646617RadVaxIpilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaP2recruiting54Abramson Cancer Center at Penn MedicineNov 2018
NCT03600350pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate CancerP2active not recruiting19University of Wisconsin, MadisonSep 2018
NCT03233711Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal CancerP3active not recruiting344National Cancer Institute (NCI)Jul 2018
NCT03134118NIVOTHYMNivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)P2active not recruiting55European Organisation for Research and Treatment of Cancer - EORTCApr 2018
NCT03223155COSINRConcurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung CancerP1active not recruiting78University of ChicagoSep 2017
NCT02845323Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the BladderP2active not recruiting15Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMay 2017
NCT04204837Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinP2recruiting61Salzburger LandesklinikenMar 2017
NCT02696993Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung CancerP1/P2active not recruiting80M.D. Anderson Cancer CenterDec 2016
NCT02925234DRUPThe Drug Rediscovery Protocol (DRUP Trial)P2recruiting1,550The Netherlands Cancer InstituteAug 2016
NCT04017650Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerP1/P2active not recruiting38M.D. Anderson Cancer CenterJun 2019
NCT03661320A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerP3active not recruiting855Bristol-Myers SquibbNov 2018
NCT05012254NIVIPI-BrainNivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesP2active not recruiting71Fundación GECPNov 2021
NCT02955290CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck CancerP1/P2active not recruiting51Roswell Park Cancer InstituteDec 2016
NCT02910700Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaP2active not recruiting52M.D. Anderson Cancer CenterDec 2016
NCT05317858LIMITLESSBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsP3recruiting30InSightecAug 2022
NCT04902443Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVP1recruiting58National Cancer Institute (NCI)Dec 2021
NCT06274437A Study of BND-35 in Participants With Advanced Solid TumorsP1recruiting280Biond BiologicsJun 2024
NCT05901285Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid TumorsP1recruiting48Vaxiion TherapeuticsNov 2023
NCT05039073Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsP2recruiting46Emory UniversityMay 2022
NCT03690986VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerP1recruiting50Emory UniversityNov 2018
NCT03406247ADJORL1Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell CarcinomaP2recruiting140Gustave Roussy, Cancer Campus, Grand ParisFeb 2018
NCT05625399RELATIVITY-127A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaP3active not recruiting579Bristol-Myers SquibbMar 2023
NCT06534983IMCODE004A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)P2recruiting62Hoffmann-La RocheDec 2024
NCT05928806ARCITECTAdvanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialP2suspended120Michael B. Atkins, MDSep 2023
NCT06203600Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialP2/P3recruiting224National Cancer Institute (NCI)Jun 2024
NCT06667154Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With ChemotherapyP2recruiting33Aline Fusco Fares, MDOct 2023
NCT04863885Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsP1/P2active not recruiting46H. Lee Moffitt Cancer Center and Research InstituteApr 2021
NCT03307616Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryP2active not recruiting32M.D. Anderson Cancer CenterOct 2017
NCT03171025NEXTAdjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder CancerP2active not recruiting200University of UtahJul 2017
NCT02259621NA_00092076Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLCP2active not recruiting39Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSep 2014
NCT05663710Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCP1/P2recruiting100M.D. Anderson Cancer CenterJun 2023
NCT04495010CheckMate 7UANeoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsP2withdrawn0Bristol-Myers SquibbMar 2021
NCT06112314PRISM-MEL-301IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)P3recruiting680Immunocore LtdJun 2024
NCT06764771A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsP1recruiting437Bristol-Myers SquibbMar 2025
NCT06544655A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid TumorsP1active not recruiting213Bristol-Myers SquibbOct 2024
NCT04114136Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor MalignanciesP2recruiting72Dan ZandbergSep 2020
NCT06364917DISCERNDISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCP2recruiting24University of Alabama at BirminghamMay 2025
NCT05310643NIPIRESCUENivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCP2recruiting30GERCOR - Multidisciplinary Oncology Cooperative GroupMay 2022
NCT05112549IT-PD1Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)P1recruiting46University Hospital TuebingenOct 2021
NCT03576417NIVOPOSTOPA Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and NeckP3active not recruiting680Groupe Oncologie Radiotherapie Tete et CouOct 2018
NCT02530463Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeP2active not recruiting99M.D. Anderson Cancer CenterSep 2015
NCT05200988Indi-BladeCheckpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UCP2active not recruiting50The Netherlands Cancer InstituteMar 2022
NCT05498792Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in MelanomaEarly P1recruiting12Fox Chase Cancer CenterNov 2022
NCT04472767Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaP2recruiting35University of California, IrvineAug 2020
NCT02978625Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersP2active not recruiting68National Cancer Institute (NCI)Sep 2017
NCT06377111A Study to Test the Benefit of Vitamin B5 in Patients With MelanomaP1active not recruiting12University Health Network, TorontoJun 2024
NCT06101134A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsP2active not recruiting100Bristol-Myers SquibbNov 2023
NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisP1/P2recruiting134Neonc Technologies, Inc.Nov 2023
NCT05919264FOG-001 in Locally Advanced or Metastatic Solid TumorsP1/P2recruiting595Parabilis Medicines, Inc.May 2023
NCT03044613Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal CancerP1active not recruiting32Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJul 2017
NCT03589339NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyP1active not recruiting145NanobiotixJan 2019
NCT04387084Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyP1active not recruiting10University of Southern CaliforniaAug 2020
NCT06880549A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsP1active not recruiting42ModernaTX, Inc.Mar 2025
NCT04745949PACIFICPACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyP2recruiting31M.D. Anderson Cancer CenterMay 2021
NCT06256328A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)P2active not recruiting226Ono Pharmaceutical Co., Ltd.Jan 2024
NCT04741997Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in MelanomaEarly P1recruiting50H. Lee Moffitt Cancer Center and Research InstituteMay 2021
NCT04180371Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionP1/P2active not recruiting288BicycleTx LimitedNov 2019
NCT03681561Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaP1/P2recruiting54Veronika BachanovaSep 2018
NCT04025879A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerP3active not recruiting461Bristol-Myers SquibbNov 2019
NCT05347212Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaP2active not recruiting30M.D. Anderson Cancer CenterSep 2022
NCT06466798Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS MalignanciesP1withdrawn0Jeffrey TreiberJul 2024
NCT05361720Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyP2recruiting54Vanderbilt-Ingram Cancer CenterDec 2022
NCT05733689Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)P1recruiting20University of California, IrvineJun 2025
NCT05153304Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract CancersP1/P2withdrawn0University of California, San DiegoJun 2024
NCT06015724DARANIVOVAXAnti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung CancerP2recruiting54Georgetown UniversityJan 2024
NCT04835805A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.P1active not recruiting65Genentech, Inc.May 2021
NCT04912765Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCP2recruiting60National Cancer Centre, SingaporeApr 2021
NCT04511013A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesP2recruiting112SWOG Cancer Research NetworkJan 2021
NCT03838042INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory MalignanciesP1/P2recruiting91University Hospital HeidelbergMay 2020
NCT03061539Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic SignatureP2active not recruiting380University College, LondonFeb 2018
NCT03259867TATE-PD1Combination of TATE and PD-1 Inhibitor in Liver CancerP2recruiting54Teclison Ltd.Jul 2017
NCT04099251CheckMate76KEffectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaP3active not recruiting790Bristol-Myers SquibbOct 2019
NCT05272384Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaP1recruiting32National Cancer Institute (NCI)Nov 2022
NCT05912244A Study of IO102/IO103, Nivolumab, and Relatlimab in People With MelanomaP2active not recruiting43Memorial Sloan Kettering Cancer CenterJun 2023
NCT05788081TOP-FLORTreatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.P2active not recruiting40Olivia Newton-John Cancer Research InstituteAug 2023
NCT05308446Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationP2active not recruiting86National Cancer Institute (NCI)Jul 2022
NCT06931613Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab TreatmentP2enrolling by invitation20St. Petersburg State Pavlov Medical UniversityJun 2022
NCT04117087Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerP1active not recruiting27Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMay 2020
NCT04047706Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaP1active not recruiting18Northwestern UniversityAug 2019
NCT03025256Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal DiseaseP1recruiting75M.D. Anderson Cancer CenterMay 2018
NCT02834013Nivolumab and Ipilimumab in Treating Patients With Rare TumorsP2active not recruiting798National Cancer Institute (NCI)Jan 2017
NCT06554613Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLCP2recruiting156Second Affiliated Hospital of Nanchang UniversityJul 2024
NCT05384496Axitinib and Nivolumab for the Treatment of Mucosal MelanomaP2recruiting20Memorial Sloan Kettering Cancer CenterMay 2022
NCT04572451Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and MelanomaP1recruiting50Yana NajjarNov 2021
NCT04957615Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 ExpressionP2active not recruiting16M.D. Anderson Cancer CenterSep 2021
NCT03505320ILUSTROA Study of Zolbetuximab (IMAB362) in Adults With Gastric CancerP2active not recruiting143Astellas Pharma Global Development, Inc.Jun 2018
NCT02632409CheckMate 274An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerP3active not recruiting709Bristol-Myers SquibbMar 2016
NCT04464759LIMITA Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced MelanomaP1/P2active not recruiting41Ravi Amaravadi, MDOct 2020
NCT04810078CheckMate-67TA Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadP3active not recruiting681Bristol-Myers SquibbMay 2021
NCT04317105Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENP1/P2active not recruiting54National Cancer Institute (NCI)Jul 2020
NCT03527108Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLCP2active not recruiting36Fox Chase Cancer CenterOct 2020
NCT03703050NIVO-ALCLNivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)P2active not recruiting45Gustave Roussy, Cancer Campus, Grand ParisJan 2019
NCT03563248Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic CancerP2active not recruiting168Massachusetts General HospitalAug 2018
NCT03449108TNBCLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasP2active not recruiting30M.D. Anderson Cancer CenterApr 2018
NCT03104439Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic CancerP2active not recruiting84Massachusetts General HospitalMay 2017
NCT03143270A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver CancerEarly P1active not recruiting20Memorial Sloan Kettering Cancer CenterApr 2017
NCT03122522A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyP2active not recruiting70Memorial Sloan Kettering Cancer CenterApr 2017
NCT05715229G360-IITImmune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With ImmunotherapyP2recruiting108Hackensack Meridian HealthSep 2023
NCT05162976CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or RelapsedP1active not recruiting33City of Hope Medical CenterJan 2022
NCT05502315CANOPYStudy of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerP2recruiting47Rana McKay, MDFeb 2023
NCT02393625Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerP1active not recruiting57Novartis PharmaceuticalsMay 2015
NCT03172754Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell CarcinomaP1/P2active not recruiting98Fox Chase Cancer CenterJun 2017
NCT04229459Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.P2active not recruiting12Baruch BrennerFeb 2020
NCT05817903AxInAxitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC PatientsP2recruiting118Consorzio OncotechApr 2023
NCT04609046Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaP1recruiting47National Cancer Institute (NCI)May 2021
NCT02785952Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersP3active not recruiting275SWOG Cancer Research NetworkDec 2015
NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaP1enrolling by invitation34Andrew P. GrovesJun 2025
NCT07523763NIVO1002024Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal CancerP2active not recruiting30Blokhin's Russian Cancer Research CenterMar 2024
NCT05310591CAPTiRALLCombination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of PersistenceP1/P2recruiting26Assistance Publique - Hôpitaux de ParisMar 2023
NCT05239533Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerP2active not recruiting9Memorial Sloan Kettering Cancer CenterFeb 2022
NCT04444921EA2176EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer PatientsP3active not recruiting205National Cancer Institute (NCI)Nov 2020
NCT04078295E7389-LFA Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorP1/P2active not recruiting125Eisai Co., Ltd.Sep 2019
NCT03391869Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung CancerP3active not recruiting339M.D. Anderson Cancer CenterDec 2017
NCT06302426Trial of INI-4001 in Patients With Advanced Solid TumoursP1recruiting50Inimmune CorporationJul 2024
NCT05597800LUNGVIRNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid SyndromeP2not yet recruiting105Universita di VeronaFeb 2023
NCT02257528Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical CancerP2active not recruiting26National Cancer Institute (NCI)May 2015
NCT03907488Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaP3active not recruiting994National Cancer Institute (NCI)Aug 2019
NCT02314169Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerP2active not recruiting143National Cancer Institute (NCI)May 2015
NCT03604978Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaP1/P2active not recruiting38National Cancer Institute (NCI)Jun 2019
NCT04300244NIPUNivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant MesotheliomaP2active not recruiting118Åslaug HellandMay 2020
NCT07485166Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databasesactive not recruiting810Brigham and Women's HospitalMar 2026
NCT05289193CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaP2active not recruiting28Memorial Sloan Kettering Cancer CenterMar 2022
NCT03873402A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerP3active not recruiting437Bristol-Myers SquibbJun 2019
NCT03655002IRX-2IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerP1active not recruiting8City of Hope Medical CenterFeb 2019
NCT04969887MOST-CIRCUITCombination Immunotherapy in Rare Cancers Under InvesTigationP2active not recruiting240Olivia Newton-John Cancer Research InstituteAug 2021
NCT02817633AMBERA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)P1active not recruiting463Tesaro, Inc.Jul 2016
NCT05749900HERBOTFirst-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)P1/P2recruiting44Yonsei UniversityMay 2023
NCT05263050Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsP2recruiting111Fox Chase Cancer CenterJan 2022
NCT04757363A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric CancerP2active not recruiting39Memorial Sloan Kettering Cancer CenterFeb 2021
NCT03866382Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsP2recruiting314National Cancer Institute (NCI)May 2019
NCT03789110NIMBUSNIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerP2active not recruiting30Dana-Farber Cancer InstituteMar 2019
NCT03057795Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin LymphomaP2active not recruiting62City of Hope Medical CenterApr 2017
NCT04963283MSSStudy of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerP2active not recruiting48University of Colorado, DenverJun 2021
NCT04514484Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVP1active not recruiting8National Cancer Institute (NCI)Nov 2021
NCT05327270Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant LesionsP1active not recruiting18M.D. Anderson Cancer CenterSep 2022
NCT05501665Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerP1/P2recruiting25Vanderbilt-Ingram Cancer CenterMay 2023
NCT07276373Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesP1/P2recruiting50Corcept TherapeuticsJan 2026
NCT05896839Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerP1/P2recruiting16National Cancer Institute (NCI)Jul 2024
NCT05476796LOGICANOxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction CancerP2recruiting118UNICANCERJun 2023
NCT05280457TRINITYHPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination TherapyP2active not recruiting21Yonsei UniversityApr 2022
NCT04831320Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 InhibitorP2active not recruiting46Washington University School of MedicineSep 2021
NCT03816358Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerP1active not recruiting74National Cancer Institute (NCI)Dec 2019
NCT03937219COSMIC-313Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaP3active not recruiting855ExelixisJun 2019
NCT03235245EBINImmunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and BinimetinibP2active not recruiting271European Organisation for Research and Treatment of Cancer - EORTCOct 2018
NCT03520491A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for ChemotherapyP2active not recruiting52Memorial Sloan Kettering Cancer CenterApr 2018
NCT03297606CAPTURCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)P2recruiting720Canadian Cancer Trials GroupMar 2018
NCT03033914BA(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)P1/P2active not recruiting82Memorial Sloan Kettering Cancer CenterJan 2017
NCT02873962A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibP2active not recruiting72Dana-Farber Cancer InstituteNov 2016
NCT05111626FORTITUDE-102Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.P3active not recruiting515AmgenMar 2022
NCT04339738Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue SarcomaP2active not recruiting90National Cancer Institute (NCI)Nov 2020
NCT05122546CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerP1active not recruiting31City of Hope Medical CenterNov 2021
NCT05136196BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyP2recruiting150National Cancer Institute (NCI)Dec 2022
NCT03811015Testing Immunotherapy Versus Observation in Patients With HPV Throat CancerP3active not recruiting636National Cancer Institute (NCI)Aug 2019
NCT06064097NPCA Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)P2recruiting50National Cancer Institute (NCI)Jun 2024
NCT06265285CCBWComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramP2recruiting50Mayo ClinicApr 2024
NCT05721846CheckVACNivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic CancerP1active not recruiting20Inna Chen, MDMay 2023
NCT05188118Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell CarcinomaEarly P1recruiting20Icahn School of Medicine at Mount SinaiFeb 2023
NCT05234307PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerP1recruiting30Dwight OwenNov 2022
NCT05257590CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular CarcinomaP2recruiting95TaiRx, Inc.May 2022
NCT04751370Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal CancerP2active not recruiting31National Cancer Institute (NCI)Feb 2022
NCT05163041Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 ExpressionP1/P2active not recruiting200BicycleTx LimitedNov 2021
NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaP3active not recruiting244National Cancer Institute (NCI)Oct 2021
NCT04953104ARID1A and/or KDM6A Mutation and CXCL13 ExpressionP2active not recruiting6M.D. Anderson Cancer CenterSep 2021
NCT04674683Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced MelanomaP3active not recruiting450HUYABIO International, LLC.Aug 2021
NCT04606316Surgical Nivolumab And Ipilimumab For Recurrent GBMP1active not recruiting63Patrick Wen, MDFeb 2021
NCT05745233Intraperitoneal Immune Checkpoint Inhibitor for Malignant AscitesN/Aenrolling by invitation30China Medical University HospitalJan 2021
NCT04145115A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenP2active not recruiting37National Cancer Institute (NCI)Dec 2020
NCT04477343A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaP1recruiting20University of RochesterNov 2020
NCT04109729Rad2NivoStudy of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate CancerP1active not recruiting39University of UtahSep 2020
NCT04310007Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerP2active not recruiting117National Cancer Institute (NCI)Jul 2020
NCT04091750Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaP2active not recruiting14Georgetown UniversityMar 2020
NCT04043195NSCLCNivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLCP1/P2active not recruiting30Hatim HusainAug 2019
NCT05696548NAVIGATIONNivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)P2active not recruiting51National Cancer Center Hospital EastJul 2019
NCT03604991Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgeryP2/P3suspended278National Cancer Institute (NCI)May 2019
NCT03650894HERNivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsP2active not recruiting30Providence Health & ServicesApr 2019
NCT03347838Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former SmokersP2active not recruiting19University of Colorado, DenverJan 2019
NCT03749018Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's LymphomaP2active not recruiting30David Bond, MDJan 2019
NCT03637543Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate CancerP2active not recruiting29Beth Israel Deaconess Medical CenterOct 2018
NCT03543189Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation TherapyP1/P2active not recruiting44H. Lee Moffitt Cancer Center and Research InstituteOct 2018
NCT03543969Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant MelanomaEarly P1active not recruiting14H. Lee Moffitt Cancer Center and Research InstituteJun 2018
NCT03247712Neoadjuvant Immunoradiotherapy in Head & Neck CancerP1/P2active not recruiting22Providence Health & ServicesJan 2018
NCT03333616Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsP2active not recruiting100Dana-Farber Cancer InstituteDec 2017
NCT03015896Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaP1/P2active not recruiting36David Bond, MDFeb 2017
NCT02919683Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityP2active not recruiting30Dana-Farber Cancer InstituteNov 2016
NCT02595944ANVILNivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)P3active not recruiting903National Cancer Institute (NCI)Jul 2016
NCT02465060Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)P2active not recruiting6,452National Cancer Institute (NCI)Aug 2015
NCT02210117Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by SurgeryEarly P1active not recruiting104M.D. Anderson Cancer CenterNov 2014
NCT01896999Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaP1/P2active not recruiting146National Cancer Institute (NCI)Mar 2014
NCT07196384GLOWOptical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CWP1not yet recruiting15University Medical Center GroningenDec 2025
NCT03776487Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric CancerP2active not recruiting32M.D. Anderson Cancer CenterJan 2019
NCT04413123Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCP2active not recruiting60Bradley A. McGregor, MDNov 2020
NCT02224781Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaP3active not recruiting267National Cancer Institute (NCI)Sep 2015
NCT03914300Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerP2active not recruiting11National Cancer Institute (NCI)Feb 2020
NCT05647265Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaP2recruiting26Alliance for Clinical Trials in OncologyNov 2024
NCT04159818TONIC-2Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) PatientsP2recruiting52The Netherlands Cancer InstituteFeb 2020
NCT03952585De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal CancerP2/P3active not recruiting384National Cancer Institute (NCI)Oct 2019
NCT04848519Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaP2active not recruiting6Emory UniversityMay 2021
NCT04652960Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeP1active not recruiting38National Cancer Institute (NCI)Oct 2021
NCT06682728Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceP2recruiting23University of California, IrvineNov 2024
NCT04966663ctDNA Lung RCTUsing ctDNA to Determine Therapies for Lung CancerP2recruiting66University Health Network, TorontoMar 2022
NCT04495296A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid TumorsP1/P2recruiting320Suzhou Transcenta Therapeutics Co., Ltd.Aug 2020
NCT05215470CLARACLARA: Somatic and Germline Mechanisms That Impact Renal Cancer ImmunotherapyP2active not recruiting100Hospital das Clínicas de Ribeirão PretoJan 2022
NCT04735978Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursP1active not recruiting123Replimune, Inc.Dec 2020
NCT04396821A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid TumorsP1/P2active not recruiting150Suzhou Transcenta Therapeutics Co., Ltd.May 2020
NCT04162015A Study of Nivolumab and Chemotherapy Followed by Surgery for MesotheliomaP1active not recruiting22Memorial Sloan Kettering Cancer CenterNov 2019
NCT03718767Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator PhenotypeP2active not recruiting62National Cancer Institute (NCI)Mar 2019
NCT03743662Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated GlioblastomaP2active not recruiting39Memorial Sloan Kettering Cancer CenterNov 2018
NCT02989636Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic ChordomaP1active not recruiting21Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2017
NCT02293980MK-3795-001A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)P1active not recruiting110Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Nov 2014
NCT06158919G/GEJ cancerA Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ CancerN/Arecruiting58Fudan UniversityNov 2023
NCT03233152GlitIpNiA Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.P1/P2active not recruiting110Universitair Ziekenhuis BrusselNov 2016
NCT04624178A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaP2active not recruiting20Memorial Sloan Kettering Cancer CenterNov 2020
NCT03595124A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)P2active not recruiting15National Cancer Institute (NCI)Jan 2019
NCT03884998Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaP1active not recruiting27City of Hope Medical CenterFeb 2019
NCT05501054Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.P1/P2active not recruiting50M.D. Anderson Cancer CenterFeb 2023
NCT04991025Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryP2recruiting60Memorial Sloan Kettering Cancer CenterOct 2022
NCT05491616SANO-3Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 StudyP2active not recruiting77Erasmus Medical CenterSep 2022
NCT05089370DEC-COral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal MelanomaP1/P2active not recruiting8University of Colorado, DenverJun 2022
NCT04361162Nivolumab + Ipilimumab + Radiation in MSS Pancreatic CancerP2active not recruiting30Massachusetts General HospitalMay 2020
NCT04336241Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsP1active not recruiting36Replimune, Inc.Oct 2019
NCT03728361Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerP2active not recruiting55Dwight OwenDec 2018
NCT03607890LStudy of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorP2active not recruiting38Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNov 2018
NCT03693014A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsP2active not recruiting69Memorial Sloan Kettering Cancer CenterOct 2018
NCT03620578HO152DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLP2active not recruiting97Stichting Hemato-Oncologie voor Volwassenen NederlandAug 2018
NCT03038672Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasP2active not recruiting54National Cancer Institute (NCI)Dec 2018
NCT06399419CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerP1recruiting28Osel, Inc.Jun 2024
NCT04080804Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck CancerP2active not recruiting80Dan ZandbergDec 2019
NCT06059547Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder CancerP2active not recruiting31CatalYm GmbHSep 2023
NCT02275533Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN TrialP2active not recruiting82National Cancer Institute (NCI)Jul 2015
NCT04561206Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaP2recruiting31City of Hope Medical CenterNov 2021
NCT06284564BOOST-RCCA Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)P2active not recruiting10M.D. Anderson Cancer CenterAug 2024
NCT06532149EROSERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancerrecruiting80Fondazione Policlinico Universitario Agostino Gemelli IRCCSAug 2024
NCT05888831A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsP1/P2active not recruiting100Bristol-Myers SquibbJun 2023
NCT04933903LOWBrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabP2recruiting25Brown UniversityOct 2021
NCT04106414Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to TreatmentP2active not recruiting24Memorial Sloan Kettering Cancer CenterSep 2019
NCT02914405MiniVanPhase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory NeuroblastomaP1active not recruiting44University Hospital Southampton NHS Foundation TrustMay 2018
NCT03355976BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasP2active not recruiting46Brown UniversityApr 2018
NCT03282344A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced SarcomaP2active not recruiting88Memorial Sloan Kettering Cancer CenterSep 2017
NCT02451982Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the PancreasP2active not recruiting76Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2016
NCT02496208Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsP1active not recruiting152National Cancer Institute (NCI)Jul 2015
NCT02194738Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)N/Aactive not recruiting8,300National Cancer Institute (NCI)Sep 2014
NCT04003649IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMP1active not recruiting20City of Hope Medical CenterDec 2019
NCT03816332Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersP1active not recruiting12National Cancer Institute (NCI)Nov 2019
NCT03071406Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell CarcinomaP2active not recruiting50H. Lee Moffitt Cancer Center and Research InstituteMar 2017
NCT02453620Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerP1active not recruiting57National Cancer Institute (NCI)Feb 2016
NCT05672173Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's TransformationP2active not recruiting9City of Hope Medical CenterJun 2023
NCT05111574Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryP2active not recruiting101National Cancer Institute (NCI)Aug 2022
NCT05727410Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland CarcinomaP2recruiting50Myung-Ju AhnNov 2022
NCT04013854Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabP2active not recruiting67Abramson Cancer Center at Penn MedicineJan 2020
NCT03843294TAA-TTumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for LymphomaP1active not recruiting18Catherine BollardJun 2019
NCT03635892A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell CarcinomaP2active not recruiting60Memorial Sloan Kettering Cancer CenterAug 2018
NCT03377023Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerP1/P2active not recruiting66H. Lee Moffitt Cancer Center and Research InstituteFeb 2018
NCT02099058PKA Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsP1active not recruiting237AbbVieJan 2014
NCT04015778A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in ChinaP2active not recruiting316Guangdong Association of Clinical TrialsAug 2019
NCT04079712Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsP2active not recruiting17National Cancer Institute (NCI)Aug 2020
NCT02940301Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaP2active not recruiting18Ohio State University Comprehensive Cancer CenterDec 2016
NCT05601752SURPASS-3ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)P2active not recruiting66USWM CT, LLCJun 2023
NCT05322577FORTITUDE-103A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.P1/P2active not recruiting72AmgenMay 2022
NCT04938232Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLP2active not recruiting13Dana-Farber Cancer InstituteJun 2021
NCT03463408Immunotherapy + Radiation in Resectable Soft Tissue SarcomaEarly P1active not recruiting14University of RochesterJul 2018
NCT05504642CERAD-IMMUNEChemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer PatientsP2withdrawn0Universitätsklinikum KölnNov 2023
NCT04457284Temozolomide, Cisplatin, and Nivolumab in People With Colorectal CancerP2active not recruiting18Memorial Sloan Kettering Cancer CenterNov 2020
NCT04599140SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 TrialP1/P2active not recruiting51M.D. Anderson Cancer CenterOct 2020
NCT04090710CYTOSHRINKSBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney CancerP2active not recruiting66Ontario Clinical Oncology Group (OCOG)Jan 2020
NCT03844256CRIMIA Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI StudyP1/P2recruiting50Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Jan 2019
NCT02393794TNBCCisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)P1/P2active not recruiting51Priyanka SharmaJul 2015
NCT03695952A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitorsactive not recruiting100Asan Medical CenterJul 2018
NCT03414684Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast CancerP2active not recruiting78Dana-Farber Cancer InstituteJan 2018
NCT05933265Study of LP-184 in Patients With Advanced Solid TumorsP1/P2active not recruiting64Lantern Pharma Inc.Jun 2023
NCT03367741Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerP2active not recruiting82National Cancer Institute (NCI)Apr 2018
NCT02879695Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaP1active not recruiting28National Cancer Institute (NCI)Oct 2017
NCT04331067Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast CancerP1/P2active not recruiting15Washington University School of MedicineNov 2020
NCT04039607CheckMate 9DWA Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaP3active not recruiting732Bristol-Myers SquibbSep 2019
NCT03233347Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin LymphomaP2active not recruiting82Academic and Community Cancer Research UnitedOct 2017
NCT03341936Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNP2active not recruiting29Dana-Farber Cancer InstituteMar 2018
NCT04866654RAFTINGRadiation Free Chemotherapy for Early Hodgkin LymphomaP2recruiting160Medical University of GdanskMar 2021
NCT03502733Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaP1active not recruiting64National Cancer Institute (NCI)Aug 2018
NCT05867121A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010P1active not recruiting102Genentech, Inc.Oct 2023
NCT05262556NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasP1active not recruiting15Amr Mohamed MDDec 2022
NCT05568095STAR-221A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyP3active not recruiting1,040Arcus Biosciences, Inc.Nov 2022
NCT06008925Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric CancerP1/P2recruiting43CNBG-Virogin Biotech (Shanghai) Ltd.Nov 2022
NCT05180799A Phase 1/2 Study of BA3071 in Patients With Solid TumorsP1/P2active not recruiting320BioAtla, Inc.Aug 2022
NCT04803877SARC038SARC038: Phase 2 Study of Regorafenib and Nivolumab in OsteosarcomaP2active not recruiting48Sarcoma Alliance for Research through CollaborationJun 2021
NCT04416568Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersP2active not recruiting45Dana-Farber Cancer InstituteAug 2020
NCT04126070Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed TumorsP2active not recruiting47Xiao X. Wei, MDMay 2020
NCT04021108Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)P2active not recruiting80Weill Medical College of Cornell UniversityJul 2019
NCT03443856VESTIGEPostoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for RecurrenceP2active not recruiting197European Organisation for Research and Treatment of Cancer - EORTCJul 2019
NCT03719131Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab TherapyP2active not recruiting15Emory UniversityJun 2019
NCT04268888TACE-3Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCCP2/P3suspended522The Clatterbridge Cancer Centre NHS Foundation TrustMay 2019
NCT03872947A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsP1active not recruiting138Toray Industries, IncApr 2019
NCT03110978Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerP2active not recruiting140M.D. Anderson Cancer CenterJun 2017
NCT03016871Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HLP2active not recruiting78City of Hope Medical CenterApr 2017
NCT02656706Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV MelanomaP2active not recruiting22Brown UniversityJul 2016
NCT03203473Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)P2active not recruiting85Toni Choueiri, MDOct 2017
NCT05496192IVA Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerP2withdrawn0Bristol-Myers SquibbMay 2023
NCT06049576Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell CarcinomaP1active not recruiting31City of Hope Medical CenterOct 2023
NCT05203913CNN-BCCisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder CancerP2recruiting32Fondazione Policlinico Universitario Agostino Gemelli IRCCSMay 2023
NCT05267626Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerP1/P2recruiting159Aulos Bioscience, Inc.Apr 2022
NCT04008030CheckMate 8HWA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)P3active not recruiting839Bristol-Myers SquibbAug 2019
NCT05743270Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHNP2withdrawn0Replimune, Inc.Jan 2024
NCT04042753Nivolumab and Ipilimumab in People With Aggressive Pituitary TumorsP2completed10Memorial Sloan Kettering Cancer CenterJul 2019
NCT03166397Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma PatientsP2unknown30Sheba Medical CenterJun 2017
NCT02648997An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent MeningiomaP2active not recruiting40Dana-Farber Cancer InstituteMar 2016
NCT05964101GALAXY-1Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell CarcinomaP2unknown25The First Affiliated Hospital of Guangzhou Medical UniversityOct 2023
NCT05480384Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal JunctionP2active not recruiting1Brown UniversityJul 2023
NCT04910347Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaP2recruiting57Yonsei UniversityFeb 2022
NCT05836571Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaP2active not recruiting66National Cancer Institute LAOOct 2023
NCT03036098CheckMate901Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerP3active not recruiting1,314Bristol-Myers SquibbMar 2017
NCT04151563CheckMate 79XA Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyP1/P2withdrawn0Bristol-Myers SquibbApr 2021
NCT04400539IMPALAThe IMmunotherapy Pleural 5-ALA PDTP2recruiting20University Hospital, LilleMay 2022
NCT03628209Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable OsteosarcomaP1active not recruiting21H. Lee Moffitt Cancer Center and Research InstituteOct 2019
NCT03355560Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive TherapyP2completed39Trisha Wise-DraperDec 2017
NCT03799445Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaP2terminated37M.D. Anderson Cancer CenterJul 2019
NCT04295863Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic CancersP1recruiting264University of ChicagoJun 2020
NCT04638439P1101The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D InfectionP1completed20PharmaEssentiaAug 2022
NCT04913922AARONRelatlimab With Nivolumab and 5-Azacytidine for the Treatment of AMLP2unknown30Ludwig-Maximilians - University of MunichMay 2021
NCT05767684Neoantigen Derived DCs as Cancer TreatmentP1unknown12National Health Research Institutes, TaiwanJun 2023
NCT04095208CONGRATSCombination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II StudyP2completed68Institut BergoniéFeb 2020
NCT04817254ICIAssociation of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaP2completed47National Cancer Institute (NCI)Dec 2021
NCT04603248A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaN/Acompleted50Yonsei UniversityDec 2020
NCT04904302Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerP2terminated15M.D. Anderson Cancer CenterMay 2022
NCT04495257RCCA Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)P1completed26Yale UniversitySep 2020
NCT07215962Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%active not recruiting300Bristol-Myers SquibbNov 2024
NCT06357858ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and NeckP1withdrawn0Case Comprehensive Cancer CenterJun 2024
NCT06354387Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1P1completed5China Medical University HospitalFeb 2022
NCT03337919ANIMATEANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin LymphomaP2unknown78University College, LondonDec 2018
NCT04623775NSCLCA Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)P2active not recruiting468Bristol-Myers SquibbFeb 2021
NCT04785287BMS986218Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid MalignanciesP1/P2terminated13M.D. Anderson Cancer CenterMar 2021
NCT02719613Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabP2completed67Bristol-Myers SquibbJul 2016
NCT03645928Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsP2terminated225Iovance Biotherapeutics, Inc.May 2019
NCT05715216OMP-313M32EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian CancerP2active not recruiting20M.D. Anderson Cancer CenterMar 2023
NCT05926960PORTSIDEA Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaP2terminated38PfizerJun 2023
NCT03575234Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal CancerP1withdrawn0Emory UniversityJul 2020
NCT03689699MAGIC-8Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)P1/P2active not recruiting59Mark SteinOct 2018
NCT02379520HESTIAHPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIAP1completed32Baylor College of MedicineSep 2015
NCT06163820BETTERBevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesP1/P2recruiting46Melanoma and Skin Cancer Trials LimitedMay 2025
NCT05717140Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the LungP1withdrawn0Mayo ClinicOct 2025
NCT04401774Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line ChemotherapyP2completed14Memorial Sloan Kettering Cancer CenterMay 2020
NCT07526961Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Polandcompleted240Bristol-Myers SquibbDec 2025
NCT04987203Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaP3completed343AVEO Pharmaceuticals, Inc.Sep 2021
NCT03141177CheckMate 9ERA Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaP3active not recruiting701Bristol-Myers SquibbJul 2017
NCT05393674Fedratinib in Combination With NivolumabP2completed30Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestJun 2022
NCT05343481Efficacy of VTP-300 in Chronic Hepatitis B InfectionP2completed121Barinthus BiotherapeuticsSep 2022
NCT04205409Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesP2completed20University of WashingtonJun 2020
NCT04552223Nivolumab Plus Relatlimab in Patients With Metastatic Uveal MelanomaP2completed27Jose Lutzky, MDNov 2020
NCT05223816An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic CholangiocarcinomaP2recruiting97Virogin Biotech Canada LtdJan 2024
NCT07529613T-DXd_HER2LowTrastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction AdenocarcinomaP1/P2completed30National Cancer Center Hospital EastDec 2023
NCT05887830Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical TrialP1/P2unknown96Second Affiliated Hospital, School of Medicine, Zhejiang UniversityJun 2023
NCT05598853IT-IOIntrathecal Double Checkpoint InhibitionP1active not recruiting26University of ZurichNov 2022
NCT05266612Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid TumorsP1recruiting12Virogin Biotech Canada LtdNov 2022
NCT04535713GALLANTGALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced SarcomaP2recruiting260Sarcoma Oncology Research Center, LLCSep 2020
NCT04074967Study of ARRY-614 Plus Either Nivolumab or Nivolumab+IpilimumabP1/P2active not recruiting70Dan ZandbergJun 2020
NCT03854032Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and NeckP2active not recruiting45Thomas Jefferson UniversityApr 2019
NCT03670056Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based ChemotherapyP2active not recruiting25Yale UniversityDec 2018
NCT04195139NUTMEGNivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBMP2active not recruiting103University of SydneyFeb 2018
NCT03350126NIPICOLiRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and IpilimumabP2active not recruiting57GERCOR - Multidisciplinary Oncology Cooperative GroupDec 2017
NCT06235164The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancerunknown585Fujian Medical UniversityJan 2019
NCT03585465Metro-PD1Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid TumorsP1/P2terminated63Centre Oscar LambretMar 2019
NCT03707808myDAvIpNiIntratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic NivolumabP1/P2recruiting18Universitair Ziekenhuis BrusselJan 2018
NCT04396860Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaP2/P3completed159National Cancer Institute (NCI)Sep 2020
NCT05162118Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic CancerP1/P2unknown51Zhejiang UniversityMar 2022
NCT04022980Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS LymphomaP1completed14Wake Forest University Health SciencesMar 2020
NCT04717154INSPIREIpilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate CancerP2completed69Radboud University Medical CenterJan 2021
NCT03405155Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by SurgeryP2completed26Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityJan 2018
NCT04362839Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerP1completed39City of Hope Medical CenterMay 2020
NCT03958383IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaP1/P2terminated8University of Wisconsin, MadisonJan 2020
NCT04143711Study of DF1001 in Patients With Advanced Solid TumorsP1/P2completed270Dragonfly TherapeuticsNov 2019
NCT03400332A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersP1/P2completed281Bristol-Myers SquibbFeb 2018
NCT03245892A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian CancerP1completed27Memorial Sloan Kettering Cancer CenterAug 2017
NCT05255601RELATIVITY-069A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaP1/P2completed5Bristol-Myers SquibbSep 2022
NCT05821751PRINCESSThe Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint InhibitorsN/Aunknown40Fondazione del Piemonte per l'OncologiaDec 2021
NCT06097975NEO-GLITIPNIA Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent GlioblastomaP1recruiting18Universitair Ziekenhuis BrusselMar 2024
NCT05461235Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive CarcinomaP2unknown1China Medical University, ChinaJul 2022
NCT05178043GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular CarcinomaP2unknown5Suzhou Kintor Pharmaceutical Inc,Aug 2021
NCT05354102FIHA First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128P1unknown11Biomica Ltd.May 2022
NCT03638375ACTMETIL and Anti-PD1 in Metastatic MelanomaP1/P2unknown34Leiden UniversityJul 2018
NCT04702880A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerP2completed135Bristol-Myers SquibbMar 2021
NCT04205552NEOpredictNeoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer PatientsP2completed90University Hospital, EssenMar 2020
NCT04423029A Study of DF6002 Alone and in Combination With NivolumabP1completed170Dragonfly TherapeuticsJul 2020
NCT03274258Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary CarcinomaP2terminated10M.D. Anderson Cancer CenterDec 2017
NCT04567615A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase InhibitorsP2completed266Bristol-Myers SquibbFeb 2021
NCT07141563A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLCcompleted70Bristol-Myers SquibbMay 2025
NCT05337137RELATIVITY-106A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerP1/P2completed83Bristol-Myers SquibbMay 2022
NCT05136677CheckMate 6DWA Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsP2completed102Bristol-Myers SquibbJan 2022
NCT07091695Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumabcompleted100Bristol-Myers SquibbMay 2025
NCT05907122A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaP3completed256AmgenJul 2023
NCT05588297Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver MetastasesP2unknown12Shanghai Changzheng HospitalOct 2022
NCT04006262NEONIPIGAPre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.P2active not recruiting32GERCOR - Multidisciplinary Oncology Cooperative GroupOct 2019
NCT02812667NSCLCNivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)P1completed18Lyudmila Bazhenova, M.D.Aug 2016
NCT03469960DICIPLEDouble Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancErP3completed265Intergroupe Francophone de Cancerologie ThoraciqueMay 2018
NCT03520686Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerP3terminated102ImmunityBio, Inc.May 2018
NCT04315155BENEFITEvaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof MutationP1withdrawn0University of UtahOct 2020
NCT03906071SAPPHIREPhase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerP3completed577Mirati Therapeutics Inc.Jul 2019
NCT03647163Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsP1/P2active not recruiting33Vyriad, Inc.Apr 2019
NCT04887870Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyP2/P3completed52Mirati Therapeutics Inc.Jun 2021
NCT02758717Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin LymphomaP2active not recruiting46Academic and Community Cancer Research UnitedMay 2016
NCT04477512Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)P1completed18Washington University School of MedicineFeb 2021
NCT06410534A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal CancerP2withdrawn0National Cancer Institute (NCI)Sep 2025
NCT05199285A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabP2terminated15Academic and Community Cancer Research UnitedJan 2023
NCT05472623Neo-KanNeoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without NivolumabP2withdrawn0Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2023
NCT04741438RAR-ImmuneEfficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare SubtypeP3unknown96Centre Leon BerardMar 2021
NCT02499367TONICNivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) PatientsP2unknown84The Netherlands Cancer InstituteAug 2015
NCT05394740Clinical Study of Regorafenib and Nivolumab Plus ChemotherapyP1/P2completed30National Cancer Center Hospital EastJun 2022
NCT04123379NSCLCNeoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)P2completed48Icahn School of Medicine at Mount SinaiMar 2020
NCT03417037An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerP3withdrawn0Bristol-Myers SquibbMay 2018
NCT03146650Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland CancerP2unknown25Northwestern UniversityMay 2017
NCT04787991REVOLUTIONExploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaP1completed45Cancer Insight, LLCAug 2021
NCT04465643Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorP1completed13Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJun 2021
NCT06452329A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancercompleted260Bristol-Myers SquibbFeb 2024
NCT02498600Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerP2completed100National Cancer Institute (NCI)Aug 2015
NCT05407675A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsP1/P2completed68Bristol-Myers SquibbAug 2022
NCT05328908RELATIVITY-123A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal CancerP3terminated770Bristol-Myers SquibbApr 2022
NCT05219435VEXILLUMStudy of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial CancerP2completed25Spanish Oncology Genito-Urinary GroupJul 2022
NCT04107168Microbiome Immunotherapy Toxicity and Response Evaluationunknown1,800CCTU- Cancer ThemeJul 2020
NCT04019964Nivolumab in Biochemically Recurrent dMMR Prostate CancerP2completed8Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJan 2020
NCT07024862Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapyactive not recruiting100Bristol-Myers SquibbOct 2024
NCT04876313NURE-ComboAn Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)P2unknown29IRCCS San RaffaeleJan 2022
NCT04334759DREAM3RDuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaP3completed214PrECOG, LLC.Feb 2021
NCT04591431ROMEThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyP2unknown400Fondazione per la Medicina PersonalizzataOct 2020
NCT03711058MSSStudy of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal CancerP1/P2completed48Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJan 2019
NCT03452579Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBMP2active not recruiting90David PeereboomMay 2018
NCT02977052OpACIN-neoOptimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabP2unknown186The Netherlands Cancer InstituteNov 2016
NCT02437279OpACINStudy to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma PatientsP1unknown20The Netherlands Cancer InstituteNov 2016
NCT03383302STILESBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung EffectsP1/P2completed29Royal Marsden NHS Foundation TrustFeb 2018
NCT03173950Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS CancersP2completed133National Cancer Institute (NCI)Jul 2017
NCT03704714Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaP1/P2suspended30Northwestern UniversityNov 2018
NCT04062656IMAGINEPerioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEGP2unknown21University Hospital, EssenSep 2019
NCT04526730Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma PatientsP2completed17H. Lee Moffitt Cancer Center and Research InstituteDec 2020
NCT06191796XL092Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)P1terminated25ExelixisJan 2024
NCT05625412A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid TumorsP1completed70Bristol-Myers SquibbDec 2022
NCT03388632Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory CancersP1completed31National Cancer Institute (NCI)Feb 2018
NCT04913025REFINEREduced Frequency ImmuNE Checkpoint Inhibition in CancersP2unknown160University College, LondonMay 2022
NCT04879368INTEGRATEIIbRegoNivo vs Standard of Care Chemotherapy in AGOCP3completed462Australasian Gastro-Intestinal Trials GroupMay 2021
NCT03739619Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaP1/P2completed3Emory UniversityNov 2018
NCT03297593Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaP2completed74Swiss Cancer InstituteDec 2017
NCT04988841PICASSOAssessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOmaP2completed70Assistance Publique - Hôpitaux de ParisJan 2022
NCT06499298Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancercompleted64Bristol-Myers SquibbDec 2024
NCT04021043BMS-986156BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver CancersP1/P2completed51M.D. Anderson Cancer CenterAug 2019
NCT04493203Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced MelanomaP2completed31Yana NajjarDec 2020
NCT06421311URADJObservational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in Franceterminated176Bristol-Myers SquibbJul 2024
NCT05002569RELATIVITY-098A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaP3terminated1,093Bristol-Myers SquibbOct 2021
NCT07079644Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Databasecompleted678Bristol-Myers SquibbNov 2024
NCT04250246NIBIT-ML1A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1P2unknown184Italian Network for Tumor Biotherapy FoundationMar 2020
NCT03914443A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal CarcinomaP1completed37National Cancer Center, JapanMay 2019
NCT03313544Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1P4unknown50Assistance Publique Hopitaux De MarseilleApr 2018
NCT02231749Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)P3completed1,096Bristol-Myers SquibbOct 2014
NCT03807765Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain MetastasesP1completed14H. Lee Moffitt Cancer Center and Research InstituteJan 2019
NCT04850755A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid MalignanciesP1completed11National University Hospital, SingaporeMar 2021
NCT04925284JEWEL-101Study of XB002 in Subjects With Solid Tumors (JEWEL-101)P1completed269ExelixisJun 2021
NCT05660993Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin LymphomaP2unknown50National Research Center for Hematology, RussiaAug 2019
NCT06771674Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinomacompleted662Hookipa Biotech GmbHJun 2024
NCT05482451Nivolumab and All-trans Retinoic Acid for Pancreatic CancerEarly P1active not recruiting10China Medical University HospitalMar 2021
NCT04223648MEDI4736Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaEarly P1withdrawn0Yale UniversityAug 2020
NCT04943900A Study of BMS-986416 With and Without Nivolumab in Select Solid TumorsP1completed67Bristol-Myers SquibbAug 2021
NCT04902040Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesP1/P2terminated19M.D. Anderson Cancer CenterApr 2021
NCT03721757NICOCA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity CancerP2completed21The Clatterbridge Cancer Centre NHS Foundation TrustMay 2019
NCT04781855Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationP1withdrawn0M.D. Anderson Cancer CenterJul 2022
NCT04966676ATLASStudy of Nivolumab-Ipilimumab and cfDNA in Lung CancerP2terminated5University Health Network, TorontoJan 2022
NCT03459222An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadP1/P2completed229Bristol-Myers SquibbMay 2018
NCT04278144A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsP1/P2terminated175Bolt Biotherapeutics, Inc.Feb 2020
NCT03557359Nivolumab for Recurrent or Progressive IDH Mutant GliomasP2completed35Fabio Iwamoto, MDJun 2018
NCT03770416Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaP2completed18M.D. Anderson Cancer CenterFeb 2019
NCT01968109An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsP1/P2completed1,482Bristol-Myers SquibbNov 2013
NCT04688658Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable MelanomaP1/P2terminated13John KirkwoodOct 2021
NCT03767582Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.P1/P2completed22Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDec 2019
NCT06116461NIVOPTIMIZENivolumab Dose Optimization in Patients With a Complete, Partial or Stable ResponseP4unknown34Erasmus Medical CenterJan 2022
NCT04085250Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation TherapyP2unknown264Sun Yat-sen UniversityNov 2019
NCT04050462Nivolumab Combined With BMS-986253 in HCC PatientsP2terminated13NYU Langone HealthSep 2019
NCT03382561Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerP2completed160National Cancer Institute (NCI)May 2018
NCT04785820RO7121661A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusP2completed190Hoffmann-La RocheJun 2021
NCT04177953Nivolumab With Chemotherapy in Pleural Mesothelioma After SurgeryP2completed92Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestFeb 2019
NCT03117309Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell CarcinomaP2completed164Michael B. Atkins, MDApr 2017
NCT03366272NIVEAUNivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma PatientsP2/P3completed348Universität des SaarlandesDec 2017
NCT03143153CheckMate 648A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinP3completed970Bristol-Myers SquibbJun 2017
NCT03338790CheckMate 9KDAn Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerP2completed292Bristol-Myers SquibbDec 2017
NCT04620200MATISSENeo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to SurgeryP2completed50The Netherlands Cancer InstituteAug 2020
NCT03387761NABUCCONeo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapyP1completed54The Netherlands Cancer InstituteJan 2018
NCT02985957CheckMate 650A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)P2completed351Bristol-Myers SquibbMar 2017
NCT03991130High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell CarcinomaP2terminated6Gregory DanielsMay 2019
NCT05739045Nivolumab Combined With SOX Used in the Perioperative TreatmentP2recruiting46Xiangdong ChengNov 2022
NCT05150236ANZUP2001EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCP2unknown93Australian and New Zealand Urogenital and Prostate Cancer Trials GroupApr 2022
NCT03995017RiMERucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal AdenocarcinomaP1/P2unknown34University of Kansas Medical CenterJan 2020
NCT04172402NGS as the First-line Treatment in Advanced Biliary Tract CancerP2completed48National Health Research Institutes, TaiwanDec 2019
NCT03879122A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate CancerP2/P3unknown135Spanish Oncology Genito-Urinary GroupFeb 2019
NCT03227432An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaP2withdrawn0Dana-Farber Cancer InstituteDec 2018
NCT03472586Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the LiverP2completed14Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityMay 2018
NCT03172416PIPACPressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal CarcinomatosisP1unknown21National University Hospital, SingaporeApr 2017
NCT03097939Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal CarcinomaP2unknown113National Cancer Centre, SingaporeMar 2017
NCT03458455TREATMENTImproved Therapy Response Assessment in Metastatic Brain Tumorsunknown200Oslo University HospitalMar 2013
NCT04871594TURANDOTPre-operative Immunotherapy in Stage II-III Urothelial CancerP1completed15The Netherlands Cancer InstituteAug 2021
NCT05160285Neoadjuvant Nivolumab for Upper Tract Urothelial CarcinomaP2unknown29YULISUDec 2020
NCT03292263ASCT With Nivolumab in Patients With Multiple MyelomaP1/P2unknown30St. Petersburg State Pavlov Medical UniversityApr 2017
NCT03712202Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaP2active not recruiting155City of Hope Medical CenterNov 2018
NCT03172624Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland CancerP2completed64Memorial Sloan Kettering Cancer CenterMay 2017
NCT03591731NIPINECNivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)P2completed185Intergroupe Francophone de Cancerologie ThoraciqueJan 2019
NCT02998528CheckMate 816A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)P3completed505Bristol-Myers SquibbMar 2017
NCT04247165LAPTOPNivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.P1/P2completed55Herlev HospitalJun 2020
NCT03600155Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeP1completed29M.D. Anderson Cancer CenterOct 2018
NCT03442569PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRCP2completed56UNC Lineberger Comprehensive Cancer CenterMar 2018
NCT05859477NIVOFGFR2Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric CancerP2unknown23Kidney Cancer Research BureauJun 2022
NCT04823403HIPANIVHepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaP1recruiting27Gustave Roussy, Cancer Campus, Grand ParisNov 2020
NCT04263051Optim-UCPVaxEvaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung CancerP2completed60Centre Hospitalier Universitaire de BesanconSep 2020
NCT04133948DONIMIMulticenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaP1/P2completed44The Netherlands Cancer InstituteJan 2020
NCT04026412CheckMate73LA Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryP3completed925Bristol-Myers SquibbOct 2019
NCT03981146ANICCAA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal CancerP2completed35University of BirminghamAug 2019
NCT04267146NIVOGLIONivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade GliomaP1/P2completed41Gustave Roussy, Cancer Campus, Grand ParisJul 2019
NCT04375527Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaP2terminated3Jonsson Comprehensive Cancer CenterDec 2020
NCT05921760Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant CholangiocarcinomaP1/P2terminated7Servier Bio-Innovation LLCOct 2023
NCT03838263IMMUNEBOOSTFeasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx CancerP2completed62UNICANCERJul 2019
NCT01928394A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsP1/P2completed1,163Bristol-Myers SquibbOct 2013
NCT03785873Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract CancerP1/P2completed34University of Michigan Rogel Cancer CenterMay 2019
NCT04040231Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in MesotheliomaP1completed10Memorial Sloan Kettering Cancer CenterJul 2019
NCT03158129Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung CancerP2completed101M.D. Anderson Cancer CenterJun 2017
NCT01658878CheckMate040An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerP1/P2completed657Bristol-Myers SquibbOct 2012
NCT03508570Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisP1completed26M.D. Anderson Cancer CenterSep 2018
NCT03369223A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsP1/P2completed356Bristol-Myers SquibbDec 2017
NCT02743494CheckMate 577An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction CancerP3completed794Bristol-Myers SquibbJul 2016
NCT03377361CheckMate 9N9An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadP1/P2completed325Bristol-Myers SquibbJan 2018
NCT06034860Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesP1terminated15Molecular Templates, Inc.Nov 2023
NCT05385263Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at LymphodepletionP2unknown20Tel-Aviv Sourasky Medical CenterMay 2022
NCT03267498NPCNivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)P2completed40Sue YomFeb 2018
NCT04072198NIVACORNivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm PatientsP2completed73Gruppo Oncologico Italiano di Ricerca ClinicaSep 2019
NCT02477826CheckMate 227An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)P3completed2,747Bristol-Myers SquibbAug 2015
NCT03727061Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck CancerP1terminated5Roswell Park Cancer InstituteJul 2019
NCT02060188CheckMate142A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadP2completed385Bristol-Myers SquibbMar 2014
NCT03215706CheckMate 9LAA Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLCP3completed719Bristol-Myers SquibbAug 2017
NCT02388906CheckMate 238Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaP3completed906Bristol-Myers SquibbMar 2015
NCT03404960ParpvaxNiraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based ChemotherapyP1/P2completed104University of PennsylvaniaJan 2018
NCT04581382Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of MelanomaEarly P1completed18Mayo ClinicDec 2020
NCT05043714NEBULAStudy of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial TumoursP1completed30Akamis BioDec 2021
NCT04187404SpencerA Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/ParagangliomaP1/P2terminated70EnteromeJul 2020
NCT06735781Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in Francecompleted101Bristol-Myers SquibbSep 2024
NCT04981899NICE-40A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin LymphomaP1/P2unknown30St. Petersburg State Pavlov Medical UniversityMar 2021
NCT04125719PPD1PVSRIPO in Combination With Nivolumab in MelanomaP1withdrawn0Darell BignerJun 2020
NCT04731467A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid TumorsP1/P2completed79Famewave Ltd.Mar 2021
NCT04525638A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine TumoursP2unknown30Fundación de investigación HMJun 2020
NCT03704077An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaP2withdrawn0Bristol-Myers SquibbOct 2019
NCT03867799iSCORE: Immunotherapy Sequencing in COlon and REctal CancerP2active not recruiting25Royal Marsden NHS Foundation TrustMar 2019
NCT05144529TOP2101A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLCP2terminated19Eziafa Oduah, MD, PhD, MPHMar 2022
NCT06590480RPL-EAP-001An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanomano longer available0Replimune, Inc.
NCT03642067MSSStudy of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerP2completed59Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsFeb 2019
NCT02419495KPT-330Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesP1terminated221M.D. Anderson Cancer CenterJun 2015
NCT05543629A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerP1/P2terminated36Bristol-Myers SquibbOct 2022
NCT03656718A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)P1/P2completed139Bristol-Myers SquibbOct 2018
NCT03107182OPTIMA-IIChemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck CancerP2completed72University of ChicagoJun 2017
NCT03994601An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid CancersP1/P2completed219Bristol-Myers SquibbSep 2019
NCT02408861Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryP1terminated79National Cancer Institute (NCI)Oct 2015
NCT02196961ADMEC-OAdjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs ObservationP2completed180Prof. Dr. med. Dirk SchadendorfJun 2014
NCT05655715CheckPROCheckpoint Inhibitors and SBRT for MCRPCP2completed90Herlev and Gentofte HospitalNov 2019
NCT03692325Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous LeukoplakiaP2completed33Dana-Farber Cancer InstituteDec 2018
NCT03446040An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have SpreadP1/P2terminated92Bristol-Myers SquibbMar 2018
NCT03646123Clinical Trial of Brentuximab Vedotin in Classical Hodgkin LymphomaP2terminated255Seagen Inc.Jan 2019
NCT04349267Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsP1/P2completed44Bristol-Myers SquibbJul 2020
NCT05704933Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain MetastasesEarly P1completed1H. Lee Moffitt Cancer Center and Research InstituteJun 2023
NCT05298592A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced TumorsP1completed77Bristol-Myers SquibbMar 2022
NCT04401995CMP-001Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. NivolumabP2completed9Diwakar DavarSep 2020
NCT03484819Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell LymphomaP2completed12National Cancer Institute (NCI)Dec 2019
NCT04326257Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyP2completed20Dan ZandbergMay 2020
NCT06094296NSCLCA Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)P2terminated1Bristol-Myers SquibbNov 2023
NCT04256213COLIBRICOL Immunotherapy Before Radiochimio + IpilimumabN/Acompleted40ARCAGY/ GINECO GROUPJul 2020
NCT05898828RPhase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerP1/P2withdrawn0National Cancer Institute (NCI)Aug 2024
NCT03890952Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent GlioblastomaP2completed40Ulrik LassenOct 2018
NCT05220722Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsP1/P2terminated23TriSalus Life Sciences, Inc.Mar 2022
NCT04463368SCANDIUM IIIsolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesP1completed18Vastra Gotaland RegionMar 2021
NCT04610671Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBCP1completed21H. Lee Moffitt Cancer Center and Research InstituteOct 2020
NCT03496662PDACBMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)P1/P2completed40Washington University School of MedicineAug 2018
NCT05200143Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaP2terminated4Providence Health & ServicesJun 2022
NCT04695977CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaP2/P3terminated20Regeneron PharmaceuticalsFeb 2021
NCT04891770SLGNStudy to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)P2completed103Gilead SciencesAug 2021
NCT03647969Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerP2completed262Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNov 2018
NCT05169957HAMMER IHepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)P1completed2University of Michigan Rogel Cancer CenterAug 2022
NCT04935229PERIOIntrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal MelanomaP1terminated67TriSalus Life Sciences, Inc.Aug 2021
NCT03850067A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung CancerP1completed90CelgeneMar 2019
NCT05375084SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS MutationP1terminated21Navire Pharma Inc., a BridgeBio companyOct 2022
NCT04170556GOINGRegorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)P1/P2completed69Fundacion Clinic per a la Recerca BiomédicaMar 2020
NCT02966548Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsP1completed35Bristol-Myers SquibbJan 2017
NCT01592370An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaP1/P2completed320Bristol-Myers SquibbAug 2012
NCT04050761ProNiHNA Study of Nivolumab in Patients With Head and Neck Cancer.completed502Bristol-Myers SquibbJun 2019
NCT06003075Induction Chemo-Nivo in Unresectable Stage III NSCLCP2terminated1Ralph G ZinnerDec 2023
NCT03743766Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic SettingP2completed42John KirkwoodMar 2019
NCT05088889Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic CancerP1unknown10Sheba Medical CenterJan 2022
NCT03575793A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerP1/P2completed39Salma SabbourSep 2018
NCT05265650NoeliaStudy of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLCP1/P2unknown30Clinica Universidad de Navarra, Universidad de NavarraJun 2022
NCT04575922Nivolumab+Ipilimumab+RT in MSS mCRCP2unknown32Massachusetts General HospitalOct 2020
NCT03277924ImmunoSarcTrial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasP1/P2completed197Grupo Espanol de Investigacion en SarcomasMay 2017
NCT03092674Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeP2/P3completed76National Cancer Institute (NCI)Feb 2018
NCT04100018CheckMate 7DXA Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerP3completed1,030Bristol-Myers SquibbFeb 2020
NCT02017717CheckMate 143A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsP3completed529Bristol-Myers SquibbFeb 2014
NCT03829722Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck CancerP2completed26University of Michigan Rogel Cancer CenterSep 2019
NCT02833233A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast CancerN/Acompleted5Memorial Sloan Kettering Cancer CenterJun 2016
NCT03475134TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)P1completed18Centre Hospitalier Universitaire VaudoisFeb 2018
NCT02872116CheckMate649Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerP3completed2,031Bristol-Myers SquibbOct 2016
NCT05772624Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's LymphomaP2unknown16Hospital Universitario Dr. Jose E. GonzalezFeb 2023
NCT05341349Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain MetastasesP1terminated1Emory UniversityOct 2022
NCT04782791Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric CancerP2unknown30Chinese PLA General HospitalMay 2022
NCT05236608ADIVO LungA Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLCP1/P2unknown53National University Hospital, SingaporeNov 2021
NCT04146324An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australiacompleted150Bristol-Myers SquibbDec 2019
NCT03510871HCCNivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)P2completed43National Health Research Institutes, TaiwanFeb 2019
NCT03700905IMSTAR-HNStudy of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant TherapyP3unknown276Universitätsklinikum Hamburg-EppendorfAug 2018
NCT02631447SECOMBITSequential Combo Immuno and Target Therapy (SECOMBIT) StudyP2completed251Fondazione Melanoma OnlusNov 2016
NCT05116202A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)P1/P2completed110Hoffmann-La RocheFeb 2022
NCT02927769CheckMate 744A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line TreatmentP2completed72Bristol-Myers SquibbMar 2017
NCT03970252Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic CancerEarly P1completed28Jonsson Comprehensive Cancer CenterJul 2019
NCT04305249ERASERSafety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological MalignanciesP1terminated36Antengene Therapeutics LimitedAug 2020
NCT02664181PRECISERational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE TrialP2completed13Case Comprehensive Cancer CenterJun 2017
NCT04570839COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.P1/P2completed48Compugen LtdAug 2020
NCT03502330APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaP1completed42Yale UniversityJun 2018
NCT01585194Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaP2completed67M.D. Anderson Cancer CenterNov 2012
NCT02681302CPIT001Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceP1/P2terminated46Hackensack Meridian HealthJun 2016
NCT03487666OXELOXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual DiseaseP2completed45Georgetown UniversityMay 2018
NCT03818685BreastImmune03Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual DiseaseP2unknown95Centre Leon BerardJul 2019
NCT03639935Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyP2completed32University of Michigan Rogel Cancer CenterMar 2019
NCT02553642CA209-260Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)P2completed81Memorial Sloan Kettering Cancer CenterSep 2015
NCT03583086Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsP1/P2completed88Vanderbilt-Ingram Cancer CenterJul 2018
NCT03956680An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid CancersP1completed54Bristol-Myers SquibbMar 2019
NCT01844505Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)P3completed945Bristol-Myers SquibbJun 2013
NCT04967196Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic MelanomaP1terminated6Mayo ClinicSep 2021
NCT05581719A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor MalignancyP1/P2terminated14Enlivex Therapeutics RDO Ltd.Nov 2022
NCT04382664UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of MelanomaP2completed156Ultimovacs ASAMay 2020
NCT02667587CheckMate548An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)P3completed716Bristol-Myers SquibbMay 2016
NCT06345183Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patientscompleted327Bristol-Myers SquibbFeb 2024
NCT03110107First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid TumorsP1/P2terminated376Bristol-Myers SquibbMay 2017
NCT04907539RNF43A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)P2completed25Redx Pharma LtdNov 2021
NCT03241745A Study of Nivolumab in Selected Uterine Cancer PatientsP2completed35Memorial Sloan Kettering Cancer CenterAug 2017
NCT07436390MAKIFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic MelanomaN/Acompleted132Institute of Oncology LjubljanaMar 2024
NCT03715946Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx CancerP2completed40Robert L. Ferris, MD, PhDNov 2018
NCT03825367Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AMLP1/P2unknown13Therapeutic Advances in Childhood Leukemia ConsortiumNov 2019
NCT04704154A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid TumorsP2completed175BayerFeb 2021
NCT03570619IMPACTImmunotherapy in Patients With Metastatic Cancers and CDK12 MutationsP2completed56University of Michigan Rogel Cancer CenterDec 2018
NCT02754726Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaP2completed35HonorHealth Research InstituteApr 2016
NCT04282109NIVOTAXStudy to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)P2completed141Grupo Español de Tratamiento de Tumores de Cabeza y CuelloJun 2020
NCT03033576Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaP2completed94National Cancer Institute (NCI)Oct 2017
NCT03635983A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaP3completed783Bristol-Myers SquibbSep 2018
NCT05583188VIGORNeoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLCP4terminated5Galvanize Therapeutics, Inc.Feb 2023
NCT05061017PG545Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)P2completed13Diwakar DavarDec 2021
NCT03388190METIMMOXMETIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatinP2completed80University Hospital, AkershusMay 2018
NCT04124601CHINORECNeoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal CancerP2completed80Johannes Laengle, MD, PhDJun 2020
NCT03770299CheckMate 9TNAn Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseP2withdrawn0Bristol-Myers SquibbJan 2021
NCT03547999A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRCP2terminated17Patrick BolandJun 2018
NCT05302921Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid TumorsP2completed5Children's National Research InstituteFeb 2022
NCT03558087Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder SparingP2completed76Matthew GalskyJul 2018
NCT04611126T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerP1/P2terminated6Inge Marie SvaneApr 2021
NCT05213312Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCCP2/P3unknown90Shanghai Zhongshan HospitalJun 2022
NCT05130684Neo-NTP-CRTNeo-NTP-CRT for Locally Advanced ESCCP2unknown43National Taiwan University HospitalFeb 2021
NCT03784040da VINciNivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.P1unknown40National University Hospital, SingaporeFeb 2019
NCT04239040GVAX Plus Checkpoint Blockade in NeuroblastomaP1terminated19Dana-Farber Cancer InstituteJan 2020
NCT03161379GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic CancerP2completed31Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsFeb 2018
NCT03552380Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaP2terminated12Roberto PiliJul 2018
NCT03892044Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaP1completed7David Bond, MDNov 2019
NCT05297565CheckMate-6GEA Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionP3completed14Bristol-Myers SquibbAug 2022
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaP3completed743Bristol-Myers SquibbDec 2015
NCT03285321NSCLCUnresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)P2completed105Greg Durm, MDSep 2017
NCT04698187CMP-001 in Combination With Nivolumab in Subjects With Advanced MelanomaP2terminated44Regeneron PharmaceuticalsMar 2021
NCT03138512CheckMate 914A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyP3completed1,641Bristol-Myers SquibbJul 2017
NCT04429321Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected PrimaryP1terminated1Abramson Cancer Center at Penn MedicineAug 2020
NCT04197310Cabozantinib and Nivolumab for Carcinoid TumorsP2completed19Dana-Farber Cancer InstituteDec 2019
NCT04042116A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorP1/P2suspended227Clovis Oncology, Inc.Jul 2019
NCT03374839Nivo-TILCombined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma PatientsP1/P2unknown11Nantes University HospitalFeb 2018
NCT03667716COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.P1completed121Compugen LtdSep 2018
NCT03311958Molecular Monitoring With Circulating Tumor DNA and Nivolumab MaintenanceEarly P1completed15Fox Chase Cancer CenterMay 2018
NCT06361563Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canadacompleted250Bristol-Myers SquibbSep 2023
NCT06361576Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canadacompleted700Bristol-Myers SquibbSep 2023
NCT03184194Nivolumab Combined With Daratumumab With or Without Low-dose CyclophosphamideP2completed62Amsterdam UMC, location VUmcFeb 2018
NCT02913313A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsP1/P2completed101Bristol-Myers SquibbNov 2016
NCT05834348DELINORA Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.completed5,279PfizerJun 2023
NCT03511391CHEERSCHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid TumorsP2completed99University Hospital, GhentMar 2018
NCT02635061Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung CancerP1terminated17CelgeneAug 2016
NCT05498480RELATIVITY-111Study of Relatlimab in Combination With Nivolumab in Chinese ParticipantsP1completed6Bristol-Myers SquibbJul 2022
NCT04540705PIVOT IO 011A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has SpreadP1completed30Bristol-Myers SquibbSep 2020
NCT03712943MMRRegorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal CancerP1completed52H. Lee Moffitt Cancer Center and Research InstituteOct 2018
NCT03662659GEJAn Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) CancersP2completed274Bristol-Myers SquibbOct 2018
NCT03195478A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid TumorsP1/P2completed37Bristol-Myers SquibbAug 2017
NCT04513522CheckMate 7C9A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaP4completed101Bristol-Myers SquibbDec 2020
NCT05027204SCCHNA Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)P1/P2unknown94CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Mar 2022
NCT07053202TACE With Immune Agents for Angiogenesis in Hepatocellular CarcinomaN/Acompleted140The First Hospital of Hebei Medical UniversityOct 2021
NCT05224999Nivolumab for Recurrent/Metastatic CarcinosarcomaP2unknown28Yonsei UniversityNov 2019
NCT03993249MIBCNivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing CystectomyP2unknown78Hellenic GenitoUrinary Cancer GroupMay 2019
NCT03618641CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node DiseaseP2completed34Diwakar DavarAug 2018
NCT03161756CHARLIEvaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic MelanomaP1/P2unknown72Melanoma and Skin Cancer Trials LimitedDec 2017
NCT02978404Combining Radiosurgery and Nivolumab in the Treatment of Brain MetastasesP2completed26Centre hospitalier de l'Université de Montréal (CHUM)Jun 2017
NCT02960230H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other GliomasP1/P2completed50Sabine Mueller, MD, PhDNov 2016
NCT04060407CINDICD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)P1/P2withdrawn0Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Jun 2021
NCT04109066CheckMate 7FLStudy of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerP3completed521Bristol-Myers SquibbNov 2019
NCT03370276Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaP1/P2completed95H. Lee Moffitt Cancer Center and Research InstituteDec 2017
NCT02846376CPIT-002Single Agent and Combined Inhibition After Allogeneic Stem Cell TransplantP1terminated8Hackensack Meridian HealthMar 2019
NCT04263090Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line TreatmentP1/P2completed25Icahn School of Medicine at Mount SinaiJun 2020
NCT04350463A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced CancersP2completed92CelgeneJul 2020
NCT04611165NextrahConcurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCCP2completed50National Cancer Center, KoreaNov 2019
NCT03829111CBM588CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney CancerP1completed30City of Hope Medical CenterMay 2019
NCT04340193CheckMate 74WA Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver CancerP3completed26Bristol-Myers SquibbSep 2020
NCT02923934A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare CancersP2completed120Olivia Newton-John Cancer Research InstituteAug 2017
NCT05169684A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate CancerP2terminated10Bristol-Myers SquibbFeb 2022
NCT03682276PRIME-HCCSafety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular CarcinomaP1/P2unknown32Imperial College LondonMar 2019
NCT02933255PROSTVAC in Combination With Nivolumab in Men With Prostate CancerP1/P2completed24National Cancer Institute (NCI)Apr 2017
NCT05001360Study of FMT Combined With Nivolumab in Gastric CancerN/Awithdrawn0Fujian Cancer HospitalOct 2021
NCT03439891Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver CancerP2completed16Robin Kate KelleyApr 2018
NCT02613507CheckMate 078Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung CancerP3completed504Bristol-Myers SquibbDec 2015
NCT03075423Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCCP2completed316Goethe UniversityNov 2017
NCT02992964Pilot Study of Nivolumab in Pediatric Patients With Hypermutant CancersP1/P2terminated11The Hospital for Sick ChildrenMay 2017
NCT03083691BIOLUMABIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung CancerP2completed90Lung Cancer Group CologneApr 2017
NCT03043599Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerP1/P2completed21H. Lee Moffitt Cancer Center and Research InstituteFeb 2017
NCT04271384Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung CancerP2completed25Hospital Israelita Albert EinsteinFeb 2020
NCT04431635Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaP1terminated6University of Michigan Rogel Cancer CenterJun 2020
NCT04056910AG-120Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant TumorsP2completed15Jason J. Luke, MDSep 2021
NCT03012581AcSéSecured Access to Nivolumab for Adult Patients With Selected Rare Cancer TypesP2completed269UNICANCERJun 2017
NCT06163170A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanomacompleted100Bristol-Myers SquibbAug 2023
NCT03502746Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated MesotheliomaP2terminated34Arkadiusz Z. Dudek, MDJun 2018
NCT03980314A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete ResectionP1completed261Bristol-Myers SquibbJun 2019
NCT03749460Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersP1/P2completed20University of WashingtonJan 2019
NCT04892043Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsP1terminated5SQZ BiotechnologiesAug 2021
NCT03944915DEPENDDe-Escalation Therapy for Human Papillomavirus Negative DiseaseP2completed35University of ChicagoAug 2019
NCT04149574CheckMate 7G8A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)P3terminated13Bristol-Myers SquibbJan 2020
NCT04761198A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsP1/P2completed76Mereo BioPharmaMar 2021
NCT03728179RACINRACIN in Patients With Advanced TIL-negative Solid TumorsP1completed40Centre Hospitalier Universitaire VaudoisJan 2019
NCT03425292A Longitudinal Assessment of Tumor Evolution in Patients With Brain CancerP1completed49Saint John's Cancer InstituteMar 2018
NCT03126331Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and NivolumabP2completed26Case Comprehensive Cancer CenterAug 2017
NCT05116917INFLUENCEImmunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.P2terminated19Herlev HospitalNov 2021
NCT03812562Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical ResectionEarly P1terminated2Northwestern UniversityFeb 2019
NCT03669523DENIVOSDenosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)P2completed82Centre Hospitalier Annecy GenevoisNov 2018
NCT03081689Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer PatientsP2completed46Spanish Lung Cancer GroupApr 2017
NCT03878979Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHNP2completed26Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJul 2019
NCT04659369Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCCP1terminated21Taizhou Mabtech Pharmaceutical Co.,LtdSep 2020
NCT04187833Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness GenesP2completed8Case Comprehensive Cancer CenterJun 2020
NCT02397720Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaP2completed150M.D. Anderson Cancer CenterApr 2015
NCT04044209A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDSP2withdrawn0Yale UniversityFeb 2020
NCT03569696NivoMImproving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance TherapyP2unknown50Meirav Kedmi MDOct 2018
NCT03241186Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal MelanomaP2active not recruiting36Robert R. McWilliams, MDSep 2017
NCT02718066Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung CancerP1/P2completed96HUYABIO International, LLC.Aug 2016
NCT03447470Study to Evaluate the Safety and Tolerability of RXC004 in Advanced MalignanciesP1completed46Redx Pharma LtdMar 2019
NCT04203901Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell CarcinomaP2terminated16CoImmuneJul 2020
NCT03623854Nivolumab and Relatlimab in Treating Participants With Advanced ChordomaP2completed10Jonsson Comprehensive Cancer CenterApr 2019
NCT04270864PRIMOIntratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced CancersP1terminated25Gustave Roussy, Cancer Campus, Grand ParisApr 2020
NCT02350764Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCsP2completed29Memorial Sloan Kettering Cancer CenterJan 2015
NCT04046614NintNivoFeasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma HistologyP1/P2completed56AIO-Studien-gGmbHMay 2018
NCT03523572Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerP1completed86Daiichi SankyoAug 2018
NCT01716806HLA Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)P2completed131Seagen Inc.Oct 2012
NCT03521570Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell CancerP2completed62Emory UniversityJun 2018
NCT03529890RACE ITRadio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the BladderP2unknown33Technical University of MunichFeb 2019
NCT05435053CHECKPOINTIrreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic CancerP2terminated9Ismail GögenurSep 2022
NCT03190265Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic CancerP2completed61Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDec 2017
NCT03630640NIVOLEPNeoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by ElectroporationP2completed43Assistance Publique - Hôpitaux de ParisOct 2018
NCT04458909Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal CancerP3terminated15National Cancer Institute (NCI)Dec 2020
NCT03620019Denosumab + PD-1 in Subjects With Stage III/ IV MelanomaP2completed25UNC Lineberger Comprehensive Cancer CenterSep 2018
NCT04300140Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell CarcinomaP1/P2terminated72Aravive, Inc.Feb 2021
NCT05395052FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsP1terminated5Fate TherapeuticsMay 2022
NCT03293784TICIMELTNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanomaP1completed33Institut Claudius RegaudOct 2017
NCT02532231Nivolumab in AML in Remission at High Risk for RelapseP2completed15M.D. Anderson Cancer CenterOct 2015
NCT03121677Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular LymphomaP1terminated4Washington University School of MedicineOct 2018
NCT03668119CheckMate 848A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)P2completed212Bristol-Myers SquibbOct 2018
NCT05175235Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA MeasurementsP1/P2unknown10National University Hospital, SingaporeAug 2021
NCT04233840P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular CarcinomaP1/P2unknown72National Taiwan University HospitalFeb 2019
NCT05081674BLISSBrazilian Lung Immunotherapy StudyP2completed154Hospital Israelita Albert EinsteinJan 2020
NCT03451331Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial CancerP2completed49Matthew GalskyMay 2018
NCT02009449IVYA Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsP1completed353Eli Lilly and CompanyNov 2013
NCT04200963A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial CarcinomaP1completed78Ikena OncologyDec 2019
NCT03697564Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic CancerP2completed2Hitendra PatelOct 2019
NCT04212026IREIrreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.P2terminated8University Hospital, Basel, SwitzerlandJun 2020
NCT03927105BMS-986227Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell LymphomaP2completed4University of Michigan Rogel Cancer CenterApr 2019
NCT04021420SONIMEL01Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With MelanomaP1/P2unknown21Assistance Publique - Hôpitaux de ParisOct 2019
NCT04518046Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesP1completed22Mirati Therapeutics Inc.Aug 2020
NCT03651271Nivolumab With or Without Ipilimumab in Advanced Metastatic CancerP2completed100Parker Institute for Cancer ImmunotherapyOct 2018
NCT03528408Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular MelanomaP2unknown52Suthee RapisuwonJul 2018
NCT03576612GMCIGMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade GliomasP1completed41Candel Therapeutics, Inc.Feb 2018
NCT02913417Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesP1/P2unknown26David Minor, MDOct 2016
NCT03493932Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeP1completed21National Institute of Neurological Disorders and Stroke (NINDS)Sep 2018
NCT03573947TOP1705Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLCP2completed46Jeffrey ClarkeOct 2018
NCT03184870A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsP1/P2completed332Bristol-Myers SquibbAug 2017
NCT03742986IBCTrial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)P2completed8NYU Langone HealthMay 2019
NCT03980925GEPPlatinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.P2completed37Grupo Espanol de Tumores NeuroendocrinosOct 2019
NCT03215810TILNivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerP1completed20H. Lee Moffitt Cancer Center and Research InstituteOct 2017
NCT04209114A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerP3completed114Bristol-Myers SquibbFeb 2020
NCT04612530IREPANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic CancerP1unknown18Amsterdam UMC, location VUmcSep 2020
NCT03336216A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerP2completed205Bristol-Myers SquibbDec 2017
NCT04899921Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsP2terminated1Dana-Farber Cancer InstituteJun 2021
NCT04594811NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal AdenocarcinomaP1terminated10NeoImmuneTechJan 2021
NCT02829918Study of Nivolumab in Patients With Advanced Refractory Biliary Tract CancersP2completed54H. Lee Moffitt Cancer Center and Research InstituteOct 2016
NCT03680521Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaP2completed25Mirati Therapeutics Inc.Oct 2018
NCT04185311Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedP1terminated6Jonsson Comprehensive Cancer CenterJul 2019
NCT03920631MicroBLITZMicrotransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell LymphomasP1withdrawn0Ahmed Galal, MDJul 2020
NCT05039736TKIA Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line TherapyP2withdrawn0M.D. Anderson Cancer CenterFeb 2023
NCT03841201Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular CarcinomaP2completed50Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestJun 2019
NCT05472506Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck CancerP1withdrawn0Ikena OncologyMar 2023
NCT03514901To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.P2unknown120Intergruppo Melanoma ItalianoJun 2018
NCT04107103NivoPlusNivolumab Plus Pemetrexed for Head and Neck Squamous Cell CarcinomaP2completed6AHS Cancer Control AlbertaMar 2020
NCT02899299CheckMate743Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsP3completed605Bristol-Myers SquibbNov 2016
NCT03033446Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular CarcinomaP2completed40National Cancer Centre, SingaporeDec 2016
NCT03001882CheckMate 592An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)P2completed230Bristol-Myers SquibbMar 2017
NCT04322643Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaP2terminated4Case Comprehensive Cancer CenterMar 2020
NCT04577638AIRINGAccelerated Radio-Immunotherapy for Lung CancerP2completed8Center Eugene MarquisMar 2021
NCT04953962Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic CancerP2completed36CanBas Co. Ltd.Dec 2021
NCT05041062A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaP2completed2University of ChicagoDec 2021
NCT02737787A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian CancerP1completed11Memorial Sloan Kettering Cancer CenterApr 2016
NCT03436862Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression RiskP2completed37SCRI Development Innovations, LLCMay 2018
NCT01928576NA_00084192Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.P2completed143Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNov 2013
NCT02500797Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by SurgeryP2completed164National Cancer Institute (NCI)Aug 2015
NCT03006705Study of Adjuvant ONO-4538 With Resected Gastric CancerP3completed800Ono Pharmaceutical Co., Ltd.Jan 2017
NCT02304458Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasP1/P2completed140National Cancer Institute (NCI)Mar 2015
NCT03565445A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid TumorsP1completed190Astellas Pharma Global Development, Inc.Jul 2018
NCT04610658Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCP1terminated9H. Lee Moffitt Cancer Center and Research InstituteNov 2020
NCT03732664ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerP1completed27Second Affiliated Hospital, School of Medicine, Zhejiang UniversityOct 2018
NCT03421652Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for ChemoP2completed20Barbara Ann Karmanos Cancer InstituteApr 2018
NCT04721301Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE TrialP1completed50University Hospital HeidelbergJan 2017
NCT03953235A Study of a Personalized Cancer Vaccine Targeting Shared NeoantigensP1/P2completed39Gritstone bio, Inc.Jul 2019
NCT04749602Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.P2completed26Kidney Cancer Research BureauAug 2020
NCT04112498A Phase 1, Bioavailability Study of Relatlimab in Combination With NivolumabP1completed24Bristol-Myers SquibbOct 2019
NCT04778904VTP-300First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBVP1/P2completed55Barinthus BiotherapeuticsDec 2020
NCT02523469ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung CancerP1/P2completed67Medical University of South CarolinaJan 2016
NCT04208958ConsortiumIOStudy of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic CancerP1/P2completed56Vedanta Biosciences, Inc.Jan 2020
NCT03219775TITAN-TCCTailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell CarcinomaP2unknown169AIO-Studien-gGmbHJul 2017
NCT03310619PLATFORMA Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesP1/P2completed62CelgeneDec 2017
NCT04965714Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver CancerP2withdrawn0M.D. Anderson Cancer CenterApr 2022
NCT04084951Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsP1completed30SQZ BiotechnologiesJan 2020
NCT03366766Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung CancerP2terminated14Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityDec 2017
NCT03063450CONFIRMCheckpOiNt Blockade For Inhibition of Relapsed MesotheliomaP3completed332University of SouthamptonMar 2017
NCT03768531Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract CancerP2withdrawn0Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJun 2019
NCT03542461EDENEarly Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)P3unknown125Gruppo Oncologico Italiano di Ricerca ClinicaSep 2017
NCT04901988DETECTIONCirculating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTIONP2/P3terminated8The Christie NHS Foundation TrustNov 2021
NCT03576963Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal CancerP1/P2withdrawn0University of Southern CaliforniaJan 2020
NCT03792724INTRUSTPhase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid TumorsP1/P2unknown32Clinica Universidad de Navarra, Universidad de NavarraJan 2019
NCT02519322Neoadjuvant and Adjuvant Checkpoint BlockadeP2completed53M.D. Anderson Cancer CenterFeb 2016
NCT03922880Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal MelanomaP1completed9Memorial Sloan Kettering Cancer CenterApr 2019
NCT04311710CheckMate 76UA Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesP1terminated21Bristol-Myers SquibbJun 2020
NCT06400264Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)P2withdrawn0National Cancer Institute (NCI)Feb 2022
NCT03554317COMBAT-CRPCCOMbination of Bipolar Androgen Therapy and NivolumabP2completed45Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSep 2018
NCT01176474Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaP1completed73H. Lee Moffitt Cancer Center and Research InstituteAug 2010
NCT04319224JTX-2011Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid TumorsP1/P2terminated4Jounce Therapeutics, Inc.Mar 2020
NCT04013334MTG201 Plus Nivolumab in Patients With Relapsed Pleural MesotheliomaP2unknown12Momotaro-Gene Inc.Aug 2019
NCT04166383VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)P2terminated14National Cancer Institute (NCI)Aug 2020
NCT05471674Neoadjuvant Anti-PD1 in HCCP2completed20Dr Tan-to CHEUNGJul 2020
NCT04377048Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerP2unknown38National Taiwan University HospitalJul 2020
NCT04306042A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapyunknown1,000Guangdong Association of Clinical TrialsMar 2020
NCT04091490Nivo-DHAPCombination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)P2completed40State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaFeb 2020
NCT04131621CheCUPNivolumab/Ipilimumab in Second Line CUP-syndromeP2unknown194University Hospital HeidelbergDec 2019
NCT04061863KORNELIANivolumab and Eribulin in HER2 Negative Metastatic Breast CancerP1/P2unknown90Seoul National University HospitalAug 2019
NCT03785210Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersP2terminated22National Cancer Institute (NCI)Jun 2019
NCT03126461SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma PatientsP2withdrawn0University of Texas Southwestern Medical CenterMar 2018
NCT03047928Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic MelanomaP1/P2completed48Inge Marie SvaneFeb 2018
NCT03177239UNISoNPhase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)P2unknown85Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOct 2017
NCT02637531A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549P1unknown219Infinity Pharmaceuticals, Inc.Dec 2015
NCT04801966TAILORSafety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyN/Aterminated3Peter MacCallum Cancer Centre, AustraliaSep 2021
NCT03453892ST-ICIInvestigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibitioncompleted150University of Erlangen-Nürnberg Medical SchoolApr 2017
NCT03414983CheckMate 9X8An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has SpreadP2/P3completed196Bristol-Myers SquibbFeb 2018
NCT03418922A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaP1completed30Eisai Co., Ltd.Jan 2018
NCT05005273A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerP2completed1Bristol-Myers SquibbOct 2022
NCT02181738CheckMate 205Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)P2completed294Bristol-Myers SquibbAug 2014
NCT04887194PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesP1completed40Mirati Therapeutics Inc.Apr 2021
NCT02311920Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaP1completed32National Cancer Institute (NCI)Apr 2015
NCT02247349BMS-986012 in Relapsed/Refractory SCLCP1/P2completed106Bristol-Myers SquibbNov 2014
NCT03468985Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerP2completed3National Cancer Institute (NCI)May 2018
NCT03894891Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal CancerP2completed6Dana-Farber Cancer InstituteJun 2019
NCT03850691Radiation and Combination Immunotherapy for MelanomaP2completed4Masonic Cancer Center, University of MinnesotaMay 2019
NCT03798639Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell CancerP1completed7Claire VerschraegenJan 2019
NCT03014804Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaP2withdrawn0Jonsson Comprehensive Cancer CenterDec 2019
NCT03834233CA209-9JCNivolumab in Patients With Advanced Cutaneous Squamous Cell CarcinomaP2unknown24Instituto do Cancer do Estado de São PauloSep 2019
NCT04845139A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System LymphomaN/Aunknown1Second Affiliated Hospital, School of Medicine, Zhejiang UniversityJul 2022
NCT04310709RENOBATECombination of Regorafenib and Nivolumab in Unresectable Hepatocellular CarcinomaP2completed42Asan Medical CenterJun 2020
NCT03652233Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckP1withdrawn0Vanderbilt-Ingram Cancer CenterNov 2018
NCT02866383CheckPACImmune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer PatientsP2completed160Herlev HospitalNov 2016
NCT03311334A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsP1/P2terminated47Sumitomo Pharma America, Inc.Dec 2017
NCT03317327REPORTREirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck TumorsP1/P2completed20Oslo University HospitalSep 2017
NCT02663518TTI-621A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsP1terminated249PfizerJan 2016
NCT02829931Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade GliomasP1completed33H. Lee Moffitt Cancer Center and Research InstituteAug 2016
NCT03162731Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck CancerEarly P1completed24Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityMay 2017
NCT03980041MARIO-275Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)P2completed49Infinity Pharmaceuticals, Inc.Sep 2019
NCT03958045Combination Rucaparib With Nivolumab in Small Cell Lung CarcinomaP2completed33Zhonglin HaoSep 2019
NCT03841110FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsP1completed37Fate TherapeuticsFeb 2019
NCT03639714A Study of a Personalized Neoantigen Cancer VaccineP1/P2completed29Gritstone bio, Inc.Feb 2019
NCT02439450HS-110A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung CancerP1/P2completed121Heat BiologicsApr 2015
NCT02917772TITAN-RCCTailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell CarcinomaP2completed200AIO-Studien-gGmbHOct 2016
NCT03229278Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaP1completed14Rutgers, The State University of New JerseyOct 2017
NCT02488759CheckMate358An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated TumorsP1/P2completed578Bristol-Myers SquibbOct 2015
NCT03729245TKIA Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)P3terminated623Nektar TherapeuticsDec 2018
NCT03562507ERICAMulti-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell CarcinomaP2terminated8University of Michigan Rogel Cancer CenterApr 2019
NCT02864251CheckMate722A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyP3completed367Bristol-Myers SquibbMar 2017
NCT03735628An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid TumorsP1completed16BayerOct 2018
NCT03605719Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple MyelomaP1completed23Emory UniversityOct 2018
NCT03437200CRUCIALCombination of Chemoradiation With Immunotherapy in Inoperable œsophageal CancerP2terminated8European Organisation for Research and Treatment of Cancer - EORTCJan 2019
NCT03532451PrE0807Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerP1completed43PrECOG, LLC.Mar 2019
NCT03959761ICONICTolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian CarcinomaP1/P2completed22Hospices Civils de LyonOct 2019
NCT03835533PORTERPlatform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsP1completed43Parker Institute for Cancer ImmunotherapyJun 2019
NCT03432741Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerP1terminated17Mayo ClinicMar 2018
NCT04044651Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus InfectionP2/P3withdrawn0Shi MingOct 2019
NCT04098432CA209-9KHSTR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic AdenocarcinomaP1/P2completed15University Hospital Hradec KraloveDec 2018
NCT03893695HCCCombination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)P1/P2completed20Suzhou Kintor Pharmaceutical Inc,May 2019
NCT04057365BTCStudy of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)P2terminated15Massachusetts General HospitalOct 2019
NCT04410445PIVOT-12Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for RecurrenceP3terminated765Nektar TherapeuticsJul 2020
NCT02741570CheckMate 651Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckP3completed947Bristol-Myers SquibbOct 2016
NCT04655157QUAD01Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaP1/P2terminated2Jason J. Luke, MDMay 2021
NCT03586999Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell LymphomasP1/P2completed18University of Colorado, DenverNov 2018
NCT03222076Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver CancerP2completed30M.D. Anderson Cancer CenterSep 2017
NCT03238365Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and NeckEarly P1completed50Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityAug 2017
NCT02947386Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung CancerP1completed7Roswell Park Cancer InstituteJun 2017
NCT03829436TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersP1completed38Tempest TherapeuticsMar 2019
NCT04277442Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaP1completed1National Cancer Institute (NCI)Mar 2020
NCT03015740Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney CancerP1/P2completed42M.D. Anderson Cancer CenterApr 2017
NCT03219671CKSNivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)P2unknown20Alona ZerApr 2018
NCT03843515NeoNivoNeoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response PredictionP1unknown17Amsterdam UMC, location VUmcApr 2019
NCT02948348Study to Nivolumab Following Preoperative ChemoradiotherapyP1/P2unknown90Takayuki YoshinoOct 2016
NCT02481830CheckMate331Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerP3completed569Bristol-Myers SquibbSep 2015
NCT03519256CheckMate 9UTA Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderP2terminated142Bristol-Myers SquibbAug 2018
NCT03606174LA Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaP2terminated260Mirati Therapeutics Inc.Sep 2018
NCT03004833NIVAHLNivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaP2completed110University of CologneFeb 2017
NCT04132817A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadP1completed12Bristol-Myers SquibbSep 2020
NCT03970382A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid TumorsP1suspended21PACT Pharma, Inc.Jul 2019
NCT02880020Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by SurgeryP2completed36Jonsson Comprehensive Cancer CenterDec 2016
NCT02978443A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabP2terminated14Georgetown UniversityJul 2017
NCT04620954ORION-02Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginP1/P2unknown31National Cancer Centre, SingaporeOct 2020
NCT04044430Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal CancerP1terminated2University of California, San FranciscoAug 2020
NCT03987815Neoadjuvant Nivolumab for Operable Esophageal CarcinomaP2unknown20Samsung Medical CenterAug 2019
NCT04017897The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic MelanomaP2unknown52Yonsei UniversityJul 2019
NCT03525925Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid TumorsP1completed16Ohio State University Comprehensive Cancer CenterJul 2018
NCT03351361eNERGYNivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC PatientsP3completed217Rennes University HospitalFeb 2018
NCT05468294NivokinF16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung CancerP1/P2unknown3Philogen S.p.A.Mar 2017
NCT03532217Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerP1completed19Washington University School of MedicineSep 2018
NCT03785925PIVOT-10A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial CancerP2completed192Nektar TherapeuticsApr 2019
NCT03149120Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue SarcomasP2withdrawn0NYU Langone HealthAug 2017
NCT04730349PIVOT IO 020A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerP1/P2terminated15Bristol-Myers SquibbJun 2021
NCT04500548Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyP1withdrawn0National Cancer Institute (NCI)May 2021
NCT03620123OPTIMA Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and NeckP2completed54AIO-Studien-gGmbHJul 2018
NCT03684811A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 MutationP1/P2completed93Forma Therapeutics, Inc.Nov 2018
NCT04891718CIVO Intratumoural Microdosing of Anti-Cancer Therapies in AustraliaEarly P1withdrawn0Presage BiosciencesSep 2021
NCT03808480Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%P2unknown22National Cancer Center, KoreaJan 2019
NCT03226756TopNIVONivolumab in Recurrent and/or Metastatic SCCHNP2completed351UNICANCERJul 2017
NCT02041533An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)P3completed541Bristol-Myers SquibbMar 2014
NCT04173325Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung CancerP1terminated10Augusta UniversityJan 2020
NCT03507699Combined Immunotherapy and Radiosurgery for Metastatic Colorectal CancerP1completed19Sheba Medical CenterDec 2018
NCT02857569NIVIPITA Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic MelanomaP1/P2completed90Gustave Roussy, Cancer Campus, Grand ParisDec 2016
NCT03406715SCLCCombination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)P2terminated14H. Lee Moffitt Cancer Center and Research InstituteMar 2018
NCT04050085SD-101SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic CancerP1completed6University of California, DavisAug 2019
NCT02869789An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced CancersP4completed1,041Bristol-Myers SquibbOct 2016
NCT03409198ICONPhase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast CancerP2completed82Oslo University HospitalJan 2018
NCT02935634FRACTION-GCA Study to Test Combination Treatments in Participants With Advanced Gastric CancerP2completed190Bristol-Myers SquibbNov 2016
NCT03435640REVEALREVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesP1/P2terminated64Nektar TherapeuticsMar 2018
NCT02970981Study of Combination of Ipilimumab and Nivolumab in Patients With MelanomaP2completed18NYU Langone HealthNov 2016
NCT03865082ILLUMINATE-206Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)P2active not recruiting30Idera Pharmaceuticals, Inc.Oct 2019
NCT03781960Abemaciclib and Nivolumab for Subjects With Hepatocellular CarcinomaP2terminated7Abramson Cancer Center at Penn MedicineJul 2019
NCT02983045PIVOT-02A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsP1/P2completed557Nektar TherapeuticsDec 2016
NCT04118166Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaP2completed30Kristen GanjooOct 2019
NCT02823574CheckMate 714Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckP2completed425Bristol-Myers SquibbNov 2016
NCT03495713Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERSP2terminated7Abramson Cancer Center at Penn MedicineNov 2018
NCT03519308A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic CancerEarly P1terminated3Abramson Cancer Center at Penn MedicineJul 2020
NCT02154490Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancercompleted1,864SWOG Cancer Research NetworkJul 2014
NCT02712905An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesP1/P2terminated116Incyte CorporationMay 2016
NCT03431948C4-MOSARTStereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for CancerP1completed60University of ChicagoMar 2018
NCT04122625SMARTPLUS-106Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143P1/P2completed46Debiopharm International SAApr 2019
NCT04507906Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLCP1/P2completed21Shanghai Chest HospitalNov 2020
NCT03917537WGA in Platinum-refractory HNSCC Underwent Nivolumabunknown80Chang Gung Memorial HospitalApr 2018
NCT04119336Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaP2terminated2Andrew Yee, MDFeb 2020
NCT04126733Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)P2completed70BayerOct 2019
NCT04272333Intratumoral Microdosing of Motolimod in HNSCCEarly P1terminated1Presage BiosciencesOct 2021
NCT03949153CRIRINCryotherapy With in Situ Immunotherapy in Melanoma MetastasisP1/P2completed19University Hospital, Strasbourg, FranceAug 2019
NCT03367715Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated GlioblastomaP2completed10NYU Langone HealthFeb 2018
NCT03396211A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic CancerP1completed30Elevar TherapeuticsDec 2017
NCT03090737CheckMate 907Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung CancerP2completed129Bristol-Myers SquibbJun 2017
NCT03168464Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)P1/P2terminated15Weill Medical College of Cornell UniversityOct 2017
NCT02726581CheckMate 602An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaP3completed170Bristol-Myers SquibbAug 2016
NCT03298893NiCOLNivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)P1/P2completed21Institut CurieNov 2017
NCT02659059CheckMate 568Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung CancerP2completed324Bristol-Myers SquibbFeb 2016
NCT03409848INTEGAIpilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric AdenocarcinomaP2completed97AIO-Studien-gGmbHMar 2018
NCT03817125MCGRAWMelanoma Checkpoint and Gut Microbiome Alteration With Microbiome InterventionP1completed14Parker Institute for Cancer ImmunotherapyJan 2019
NCT02617589CheckMate 498An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)P3completed560Bristol-Myers SquibbMar 2016
NCT01940809Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryP1terminated15National Cancer Institute (NCI)Aug 2013
NCT04159896ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerP2terminated10Barbara Ann Karmanos Cancer InstituteNov 2019
NCT03040791ImmunoProstNivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)P2unknown38Hospital Moinhos de VentoJun 2018
NCT03146468NIVALLONivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell TransplantationP2unknown14Melbourne HealthMay 2017
NCT03633110Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted VaccineP1/P2completed24Genocea Biosciences, Inc.Aug 2018
NCT03214250Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaP1/P2completed129Parker Institute for Cancer ImmunotherapyJul 2017
NCT02764593Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck CancerP1completed40RTOG Foundation, Inc.Jun 2016
NCT03304093CHIVA2Immunotherapy by Nivolumab for HIV+ PatientsP2completed30Intergroupe Francophone de Cancerologie ThoraciqueOct 2017
NCT03444753An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be RemovedP1terminated82Bristol-Myers SquibbApr 2018
NCT02420912Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationP2completed37M.D. Anderson Cancer CenterJun 2015
NCT03590210NiTraSarcCombined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue SarcomasP2completed92University Medicine GreifswaldJun 2018
NCT03121534Ibrutinib, Nivolumab and Blinatumomab in Richter TransformationP2terminated9M.D. Anderson Cancer CenterJun 2017
NCT03461952NIMBLeNivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)P2terminated4Canadian Cancer Trials GroupMar 2019
NCT02329847A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic MalignanciesP1/P2completed144Janssen Research & Development, LLCMar 2015
NCT02581631CheckMate 436An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin LymphomasP1/P2completed145Bristol-Myers SquibbFeb 2016
NCT03662074Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung CancerP2terminated14Wake Forest University Health SciencesNov 2018
NCT02046733STIMULISmall Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited DiseaseP2completed222ETOP IBCSG Partners FoundationDec 2015
NCT04955262NKTR-214A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and NivolumabP1withdrawn0Nektar TherapeuticsAug 2019
NCT05714371Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanomacompleted618Novartis PharmaceuticalsOct 2021
NCT03417154Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDSP2completed12Masonic Cancer Center, University of MinnesotaAug 2018
NCT03906526A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck CancerP1terminated15CelgeneJul 2019
NCT02713867CheckMate 384A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 WeeksP3completed363Bristol-Myers SquibbMay 2016
NCT03130959CheckMate 908A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) MalignanciesP2completed166Bristol-Myers SquibbJun 2017
NCT03262779Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.P2completed20Yale UniversityJul 2017
NCT04211896Anlotinib Combined With Nivolumab for Non-Small Cell Lung CancerP2unknown70The First Affiliated Hospital with Nanjing Medical UniversityJan 2020
NCT03927248PAC-1 for Treatment of Refractory, Metastatic Kidney CancerP1/P2withdrawn0HealthPartners InstituteSep 2020
NCT04134182Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.P2unknown8Kidney Cancer Research BureauOct 2019
NCT04761744A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid CancersP2unknown48Korean Cancer Study GroupJun 2019
NCT03169777CRCQUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCP1/P2withdrawn0ImmunityBio, Inc.Aug 2018
NCT03169738NSCLCQUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsP1/P2withdrawn0ImmunityBio, Inc.Feb 2018
NCT03167177QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyP1/P2withdrawn0ImmunityBio, Inc.Dec 2017
NCT03169764HNSCCQUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyP1/P2withdrawn0ImmunityBio, Inc.Dec 2017
NCT05170685Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimabno longer available0Bristol-Myers Squibb
NCT04758949FL-101 in Surgically Resectable Non-Small Cell Lung CancerP2withdrawn0Flame BiosciencesAug 2021
NCT03251924A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsP1/P2terminated80Bristol-Myers SquibbSep 2017
NCT01673867CheckMate057Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLCP3completed582Bristol-Myers SquibbNov 2012
NCT03655613APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCCP1/P2terminated20Apollomics (Australia) Pty. Ltd.Sep 2018
NCT03572582IMMUTACETransarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular CarcinomaP2completed49AIO-Studien-gGmbHJun 2018
NCT04936399EAMSA Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdomcompleted87Bristol-Myers SquibbJun 2020
NCT05611229Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burdencompleted1,975Novartis PharmaceuticalsJun 2020
NCT03711188A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced MelanomaP2completed16Immodulon Therapeutics LtdOct 2018
NCT03190174Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersP1/P2completed34Sarcoma Oncology Research Center, LLCAug 2017
NCT04570683Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell CarcinomasEarly P1unknown30Bispebjerg HospitalJan 2020
NCT04069936Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLCP2terminated19WindMIL TherapeuticsOct 2019
NCT02426892Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid TumorsP2completed33M.D. Anderson Cancer CenterDec 2015
NCT03425331Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCP2terminated5Dana-Farber Cancer InstituteApr 2018
NCT03420521Nivolumab With Ipilimumab in Subjects With Neuroendocrine TumorsP2terminated9Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2018
NCT04258150TRIPPLE-RIpilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic CancerP2terminated26Herlev HospitalApr 2020
NCT02996110FRACTION-RCCA Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaP2completed182Bristol-Myers SquibbFeb 2017
NCT05535569EBVPhase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric CancerP1/P2completed50Yonsei UniversityJul 2017
NCT03416244RAMONAA Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell CancerP2completed66AIO-Studien-gGmbHFeb 2018
NCT04088500A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaP2terminated5Bristol-Myers SquibbSep 2020
NCT03021993Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity CancerP2completed17Medical University of South CarolinaMay 2017
NCT02387996A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder CancerP2completed270Bristol-Myers SquibbMar 2015
NCT02538666CheckMate 451An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyP3completed907Bristol-Myers SquibbOct 2015
NCT03126110Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesP1/P2completed145Incyte Biosciences International SàrlApr 2017
NCT02954991Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerP2terminated161Mirati Therapeutics Inc.Nov 2016
NCT03903640Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain MetastasisP2terminated2Washington University School of MedicineOct 2019
NCT03373188VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerP1completed10Emory UniversityDec 2017
NCT02658890An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadP1/P2completed627Bristol-Myers SquibbApr 2016
NCT03663166NSCLCRadiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)P1/P2terminated19H. Lee Moffitt Cancer Center and Research InstituteNov 2018
NCT02572167A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin LymphomaP1/P2completed93Seagen Inc.Oct 2015
NCT03132038NISCAHNNivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and NeckP2completed98UNICANCERMar 2017
NCT05068609VOLUME-PROA Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)completed509Bristol-Myers SquibbAug 2020
NCT02754141An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With NivolumabP1/P2completed235Bristol-Myers SquibbJun 2016
NCT02636036SPICEPhase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial TumorsP1completed51Akamis BioJan 2016
NCT02982954CHECKMATE 920A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell CancerP4completed211Bristol-Myers SquibbJan 2017
NCT02601014STARVE-PCBiomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7P2completed32Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2016
NCT02066636CheckMate153A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy RegimenP3completed1,428Bristol-Myers SquibbApr 2014
NCT03299946HCCFeasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)P1completed15Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMay 2018
NCT03832621MAYANIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerP2completed135Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoMar 2019
NCT03048500Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryP2unknown17Northwestern UniversityJul 2017
NCT02593786CheckMate 077A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid TumorsP1/P2completed58Bristol-Myers SquibbJan 2016
NCT02903381A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaP2completed8Dana-Farber Cancer InstituteOct 2016
NCT04413838NIVISCOEfficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) InfectionP2unknown120Hospices Civils de LyonJun 2020
NCT03798314Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell LymphomaP1completed3Mayo ClinicJan 2019
NCT02105636Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)P3completed361Bristol-Myers SquibbMay 2014
NCT04430985IMMUNOXFOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal CancerP2withdrawn0Dorte NielsenSep 2020
NCT03800602Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal CancerP2completed29Emory UniversityJan 2019
NCT04393220Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular CarcinomaP2completed60Fuda Cancer Hospital, GuangzhouMay 2020
NCT04356508COVID-19COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1P2unknown15Dr Gerry Gin Wai KwokApr 2020
NCT02716948SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or SpineP1completed17Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJun 2016
NCT02409368Checkmate 171An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCP2completed812Bristol-Myers SquibbApr 2015
NCT03335540ADVISEAn Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentP1completed20Bristol-Myers SquibbMay 2018
NCT03358719DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaP1completed8Roswell Park Cancer InstituteMar 2018
NCT03925246REVOLUMABEfficacy of Nivolumab for Recurrent IDH Mutated High-Grade GliomasP2completed43Assistance Publique - Hôpitaux de ParisJul 2019
NCT01642004NSCLCStudy of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)P3completed272Bristol-Myers SquibbOct 2012
NCT03580408Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin LymphomaP2completed64The Lymphoma Academic Research OrganisationAug 2018
NCT03758781IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid TumorsP1completed12H. Lee Moffitt Cancer Center and Research InstituteFeb 2019
NCT03834623CC-122Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaP2completed23H. Lee Moffitt Cancer Center and Research InstituteMay 2019
NCT04503967OASISEfficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal CancerP2unknown48Shanghai Zhongshan HospitalAug 2020
NCT03246958Nivolumab Plus Ipilimumab in Thyroid CancerP2completed53Dana-Farber Cancer InstituteOct 2017
NCT02799901NIRVANANivolumab Plus Radiotherapy in Advanced MelanomaP2completed72Centre Hospitalier Universitaire de NiceMar 2017
NCT04075604CheckMate 7A8A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerP2completed23Bristol-Myers SquibbOct 2019
NCT01454102BMS-936558Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)P1completed472Bristol-Myers SquibbDec 2011
NCT02939300Ipilimumab and Nivolumab in Leptomeningeal MetastasesP2completed18Massachusetts General HospitalFeb 2018
NCT02626962GEM1402Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaP2completed52Grupo Español Multidisciplinar de MelanomaApr 2016
NCT01668784BMS-936558Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)P3completed821Bristol-Myers SquibbOct 2012
NCT03469713NIVESNivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell CarcinomaP2completed69Gruppo Oncologico Italiano di Ricerca ClinicaJul 2017
NCT03294304MIBCBLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing CystectomyP2completed43Masonic Cancer Center, University of MinnesotaJan 2018
NCT03220009Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaP2withdrawn0National Cancer Institute (NCI)Nov 2017
NCT03636477A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102P1completed21Alaunos TherapeuticsJun 2018
NCT03316274Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi SarcomaEarly P1completed12University of California, San FranciscoMay 2018
NCT03371992NO3DEXPLPilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLCEarly P1unknown25Nilogen OncosystemsMar 2018
NCT03013335NIVORENNivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic RegimenP2completed730UNICANCERJan 2016
NCT02523313Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NEDP2completed167Prof. Dr. med. Dirk SchadendorfSep 2015
NCT02832167CheckMate 627An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have SpreadP2completed239Bristol-Myers SquibbFeb 2016
NCT03952325CONTESSA TRIOTesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBCP2terminated294Odonate Therapeutics, Inc.Jul 2019
NCT03136627Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCP1/P2completed28AVEO Pharmaceuticals, Inc.Mar 2017
NCT04434560Neoadjuvant Immunotherapy in Brain MetastasesP2terminated1Sarah Sammons, MDNov 2020
NCT01822509Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantP1completed71National Cancer Institute (NCI)May 2013
NCT03195491CheckMate870A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in AsiaP3completed400Bristol-Myers SquibbDec 2017
NCT03101566Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract CancerP2completed75University of Michigan Rogel Cancer CenterSep 2017
NCT01472081RCCNivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)P1completed194Bristol-Myers SquibbFeb 2012
NCT04299880Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored ProtocolsP1completed7Sumitomo Pharma America, Inc.Feb 2020
NCT04023617A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLCP2unknown72Peking University Cancer Hospital & InstituteJul 2019
NCT02714218A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic MelanomaP3completed387Bristol-Myers SquibbApr 2016
NCT02781506Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell CarcinomaP2terminated7University of Texas Southwestern Medical CenterJun 2016
NCT02596035CheckMate 374An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell CarcinomaP4completed197Bristol-Myers SquibbJan 2016
NCT01721772CheckMate 066Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic MelanomaP3completed418Bristol-Myers SquibbJan 2013
NCT03646461Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCP2terminated5University of California, San DiegoOct 2018
NCT06440187HN17-11Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11P2completed38Seoul National University HospitalJun 2018
NCT01721759BMS-936558Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic RegimensP2completed117Bristol-Myers SquibbNov 2012
NCT04361058Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant CyclophosphamideP1withdrawn0SCRI Development Innovations, LLCApr 2020
NCT01354431MDX-1106BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)P2completed168Bristol-Myers SquibbMay 2011
NCT03647839MODULATEModulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal CancerP2completed90Australasian Gastro-Intestinal Trials GroupSep 2018
NCT03305445Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCLP1completed6Icahn School of Medicine at Mount SinaiMay 2018
NCT04771715PD-1Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancerunknown100Peking Union Medical College HospitalMay 2019
NCT03879811Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal CancerP2withdrawn0Memorial Sloan Kettering Cancer CenterMar 2019
NCT03307603Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal CancerP1/P2withdrawn0Case Comprehensive Cancer CenterDec 2018
NCT03656627Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune DiseaseP1terminated7Alliance Foundation Trials, LLC.Jun 2019
NCT02419417BETStudy of BMS-986158 in Subjects With Select Advanced CancersP1/P2completed83Bristol-Myers SquibbJun 2015
NCT03695250BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver CancerP1/P2terminated8Edward KimOct 2018
NCT03693846Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal TumorsP2terminated11Abramson Cancer Center at Penn MedicineFeb 2019
NCT03425461Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaP1terminated6Jonsson Comprehensive Cancer CenterJun 2018
NCT04149275Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaP2withdrawn0University of Alabama at BirminghamFeb 2021
NCT03823625SQUINTAn Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)P2unknown112Fondazione Ricerca TraslazionaleSep 2017
NCT01927419CheckMate 069Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaP2completed142Bristol-Myers SquibbAug 2013
NCT03271047MSSStudy of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS MutationP2completed75PfizerOct 2017
NCT02823990TG4010 and Nivolumab in Patients With Lung CancerP2completed13Megan Daly, MDDec 2016
NCT02899078Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney CancerP1/P2completed31University of California, DavisNov 2016
NCT03138499CheckMate 812A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,P3terminated23Bristol-Myers SquibbJun 2017
NCT05022394Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyP1/P2withdrawn0M.D. Anderson Cancer CenterFeb 2021
NCT03353675NSCLCA Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)P2completed44TransgeneJan 2018
NCT02960906BIONIKKA BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerP2completed200Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieMay 2017
NCT03003637IMCISIONImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck CarcinomaP1/P2completed33The Netherlands Cancer InstituteFeb 2017
NCT02323126Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung CancerP2terminated64Novartis PharmaceuticalsFeb 2015
NCT03071094HCCA Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)P1/P2terminated14TransgeneJul 2017
NCT03068455CheckMate 915An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaP3completed1,844Bristol-Myers SquibbApr 2017
NCT03782064DCDendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple MyelomaP2terminated5Beth Israel Deaconess Medical CenterFeb 2019
NCT03453164CIRCUITCheckpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)P1/P2completed41Fukushima Medical UniversityMar 2018
NCT02959554NIVOSWITCHStudy in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease ControlP2terminated49AIO-Studien-gGmbHDec 2016
NCT03347123ECHO-208A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)P1/P2terminated11Incyte CorporationMar 2018
NCT02467361A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced CancersP1completed104Sumitomo Pharma America, Inc.Aug 2015
NCT02428192Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine LeiomyosarcomaP2completed20National Cancer Institute (NCI)May 2015
NCT03430791Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent GlioblastomaP2terminated5Baptist Health South FloridaDec 2018
NCT04042506SBRT as a Vaccination for Metastatic MelanomaP2withdrawn0Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNov 2019
NCT03721679Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1P1/P2terminated7Oncovir, Inc.Sep 2018
NCT02702492PANAMAPAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)P1terminated60Karyopharm Therapeutics IncJun 2016
NCT03631641Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial ColectomyP2terminated3John HaysOct 2018
NCT02684253SBRTScreening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)P2completed65Memorial Sloan Kettering Cancer CenterFeb 2016
NCT02949843Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic MutationsP2terminated19Wake Forest University Health SciencesMar 2017
NCT02054520Immunotherapy Study for Patients With Stage IV MelanomaP2terminated47NewLink Genetics CorporationJun 2014
NCT03728465Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of MelanomaP2terminated6University Hospital TuebingenApr 2018
NCT02983006Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV MelanomaP1completed12NYU Langone HealthOct 2016
NCT03422094Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaP1terminated3Washington University School of MedicineOct 2018
NCT02982486A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial CarcinomaP2unknown60Assaf-Harofeh Medical CenterDec 2017
NCT03044626FORCEFostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLCP2completed101AIO-Studien-gGmbHFeb 2017
NCT03963518SURROGATE-ICIImmune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)completed631Institut BergoniéJan 2017
NCT02856451Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumabcompleted486Bristol-Myers SquibbDec 2015
NCT03661632An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid TumorsP1completed27Bristol-Myers SquibbSep 2018
NCT02038946FLStudy of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)P2completed116Bristol-Myers SquibbMar 2014
NCT03792750A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid TumorsP1/P2completed12Bristol-Myers SquibbDec 2018
NCT03406871REGONIVORegorafenib and Nivolumab Simultaneous Combination TherapyP1completed50Kohei ShitaraJan 2018
NCT03878524SMMARTSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialP1terminated2OHSU Knight Cancer InstituteApr 2020
NCT03526185A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous LymphocytesEarly P1terminated6Yale UniversityFeb 2018
NCT02857426CheckMate 647A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)P2completed66Bristol-Myers SquibbOct 2016
NCT03250273A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic AdenocarcinomaP2completed44Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNov 2017
NCT03065179RADVAXSBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer PatientsP2completed29University of Texas Southwestern Medical CenterMar 2017
NCT03123783CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabP1/P2completed140Apexigen America, Inc.Jul 2017
NCT03527264BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical CancerP2terminated4Brown UniversityNov 2018
NCT02831933ENSIGNTrial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal MelanomaP2terminated11Eric Bernicker, MDFeb 2017
NCT03380130NASIR-HCCA Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCCP2completed41Clinica Universidad de Navarra, Universidad de NavarraSep 2017
NCT02737475An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have SpreadP1/P2completed166Bristol-Myers SquibbJun 2016
NCT02837029Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver CancerP1completed27Northwestern UniversityJul 2016
NCT03283046Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaP1withdrawn0M.D. Anderson Cancer CenterOct 2017
NCT03354962BOOSTER MELANOMAInduction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)P1/P2terminated6Institut Claudius RegaudOct 2018
NCT02569242Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal CancerP3completed419Ono Pharmaceutical Co., Ltd.Dec 2015
NCT03115801A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary CancersP2terminated6Weill Medical College of Cornell UniversityNov 2016
NCT02038933DLBCLStudy of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)P2completed121Bristol-Myers SquibbMar 2014
NCT03342911Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by SurgeryP2completed34Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNov 2017
NCT03572478Rucaparib and Nivolumab in Patients With Prostate or Endometrial CancerP1/P2terminated12University of ChicagoAug 2018
NCT04343144CORIMUNO-NIVOTrial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.P2unknown92Assistance Publique - Hôpitaux de ParisApr 2020
NCT04128020Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk MyelodysplasiaP1withdrawn0Sherif FaragOct 2019
NCT03259425Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a MelanomaP2terminated7University of UtahJan 2018
NCT02320058CheckMate204An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfP2completed119Bristol-Myers SquibbMar 2015
NCT02652455Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic MelanomaEarly P1completed11H. Lee Moffitt Cancer Center and Research InstituteMar 2016
NCT03824704ARIESA Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)P2terminated1pharmaand GmbHAug 2019
NCT03655444Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based ChemotherapyP1/P2terminated6Washington University School of MedicineMay 2019
NCT02213289PANGEA-IMBBPPANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond ProgressionP2completed80University of ChicagoJan 2015
NCT01783938Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)P2completed138Bristol-Myers SquibbApr 2013
NCT03597282NEO-PV-01A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaP1terminated22BioNTech US Inc.Oct 2018
NCT03325816Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung CancerP1/P2completed9Georgetown UniversityNov 2017
NCT03203876A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsP1completed10Bristol-Myers SquibbJul 2017
NCT03061188Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & LymphomaP1completed15Northwestern UniversityMay 2017
NCT02595918Nivolumab in Treating Patients With High-Risk Kidney Cancer Before SurgeryP1terminated19National Cancer Institute (NCI)May 2016
NCT02466568Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the LungP1/P2withdrawn0H. Lee Moffitt Cancer Center and Research InstituteJul 2018
NCT02852083ModuLungA Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLCP2unknown86University Hospital RegensburgJan 2016
NCT03023904Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation LoadsP2withdrawn0Vanderbilt-Ingram Cancer CenterDec 2017
NCT02659540Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV MelanomaP1completed20Ludwig Institute for Cancer ResearchOct 2016
NCT04707547RFAImmune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) TherapyP4completed5Taipei Medical University WanFang HospitalOct 2019
NCT03588936Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic TransplantP1terminated2Medical College of WisconsinSep 2018
NCT02628574Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or NivolumabP1completed109Leap Therapeutics, Inc.Jan 2016
NCT03050060Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerP2terminated21University of WashingtonJun 2017
NCT02973113PREVALENivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)P1completed8Baylor College of MedicineFeb 2016
NCT02423343LY2157299A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular CarcinomaP1/P2completed41Eli Lilly and CompanyJan 2015
NCT03098550A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have SpreadP1/P2completed105Bristol-Myers SquibbJun 2017
NCT03329846An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced MelanomaP3completed20Bristol-Myers SquibbNov 2017
NCT03296137Adoptive Cell Therapy Across Cancer DiagnosesP1/P2completed25Inge Marie SvaneOct 2017
NCT02904226ICONICJTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsP1/P2completed242Jounce Therapeutics, Inc.Aug 2016
NCT03059147Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular CarcinomaP1terminated7SignalRX Pharmaceuticals, Inc.Mar 2017
NCT03815942ADVANCEVAccination in Early and ADvanced Prostate caNCErP1/P2terminated23University of OxfordDec 2018
NCT02989714Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell CancerP1/P2completed13University of Michigan Rogel Cancer CenterMar 2017
NCT02985554Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic MalignanciesP1terminated3University of ChicagoMar 2017
NCT03707457Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of GlioblastomaP1terminated3Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2019
NCT02327078ECHO-204A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)P1/P2completed307Incyte CorporationNov 2014
NCT03599362SBRTStudy of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic CancerP2terminated7NYU Langone HealthJul 2018
NCT03993626CAROSELLA Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal CancerP1/P2unknown55Celleron Therapeutics Ltd.May 2018
NCT04230330Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell LymphomaP1withdrawn0National Cancer Centre, SingaporeDec 2019
NCT02612779A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.P2completed74Bristol-Myers SquibbFeb 2016
NCT02575222Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell CarcinomaP1completed17Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsFeb 2016
NCT03808168Nivolumab Based Immunotherapy for Treatment of High Grade Cervical DysplasiaP2withdrawn0University of Texas Southwestern Medical CenterJan 2019
NCT03287674TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian CancerP1/P2completed7Inge Marie SvaneOct 2017
NCT02897765NEO-PV-01A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerP1completed34BioNTech US Inc.Oct 2016
NCT03724968Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II ExpressionP2terminated2Elizabeth DavisJan 2019
NCT03511222X-82Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid TumorsP1terminated16Washington University School of MedicineSep 2018
NCT04659551GIADANeoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsP2completed43Istituto Oncologico Veneto IRCCSOct 2017
NCT04439214Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)P2completed47National Cancer Institute (NCI)May 2016
NCT03758729Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.P2withdrawn0Samsung Medical CenterMay 2020
NCT02464657MDSStudy of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)P1/P2completed44M.D. Anderson Cancer CenterJul 2015
NCT02341625A Study of BMS-986148 in Patients With Select Advanced Solid TumorsP1/P2terminated126Bristol-Myers SquibbJun 2015
NCT03652142Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinomaunknown50Attikon HospitalMay 2018
NCT02771626NSCLCStudy CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)P1/P2terminated118Calithera Biosciences, IncAug 2016
NCT03100006ORION-01Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginP1/P2terminated13National Cancer Centre, SingaporeFeb 2017
NCT02574078CheckMate370A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)P1/P2completed341Bristol-Myers SquibbNov 2015
NCT02848443Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal CancerP1completed78Institut de Recherches Internationales ServierMay 2016
NCT02901145Nivolumab in Relapsed Pediatric Solid TumorsP1/P2unknown30Hadassah Medical OrganizationNov 2016
NCT02946671Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer PatientsP1completed16Osaka UniversityMar 2016
NCT02434081NICOLASNIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung CarcinomaP2completed94ETOP IBCSG Partners FoundationNov 2015
NCT03343652NB001A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's LymphomaP1/P2completed30St. Petersburg State Pavlov Medical UniversityMay 2017
NCT02859324HCCA Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)P1/P2completed21CelgeneSep 2016
NCT05802290NIVACTORNIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHNP3completed124Gruppo Oncologico del Nord-OvestNov 2017
NCT02118337AMP-514A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced MalignanciesP1/P2completed97MedImmune LLCMay 2014
NCT03382912Cypress 2Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung CancerP2terminated52Eli Lilly and CompanyMar 2018
NCT03767439Nivolumab With Vismodegib in Patients With Basal Cell Nevus SyndromeP2withdrawn0Columbia UniversityJul 2019
NCT03575598SNOWSitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity StudyEarly P1completed10University Health Network, TorontoAug 2018
NCT03982121ISILIStudy of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and ChemotherapyP1withdrawn0Gustave Roussy, Cancer Campus, Grand ParisJun 2019
NCT03597009A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural EffusionP1/P2terminated1UNC Lineberger Comprehensive Cancer CenterMar 2019
NCT02599402CheckMate 401Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced MelanomaP3completed533Bristol-Myers SquibbDec 2015
NCT02840994A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung CancerP1completed24Bavarian NordicDec 2016
NCT02460068NIBIT-M2A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain MetastasisP3unknown168Italian Network for Tumor Biotherapy FoundationDec 2012
NCT02750514FRACTION-LungAn Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerP2terminated295Bristol-Myers SquibbMay 2016
NCT03259529BeGeRNSafety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCLP1/P2completed30St. Petersburg State Pavlov Medical UniversityMar 2017
NCT03634800RISE-MRadiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)P2terminated6Weill Medical College of Cornell UniversityOct 2018
NCT03565406A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaP1terminated11NYU Langone HealthApr 2018
NCT03224871UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.Early P1completed3University of California, DavisAug 2017
NCT03539198Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancerterminated19Mayo ClinicJul 2018
NCT03048474INITIATEIpilimumab and Nivolumab in the Treatment of Malignant Pleural MesotheliomaP2completed36The Netherlands Cancer InstituteSep 2016
NCT02529072AVERTNivolumab With DC Vaccines for Recurrent Brain TumorsP1completed6Gary Archer Ph.D.Jan 2016
NCT03343665Nivo40Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins LymphomaP1/P2completed30St. Petersburg State Pavlov Medical UniversityAug 2017
NCT04007588BMS-986205A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaP2withdrawn0Dana-Farber Cancer InstituteSep 2019
NCT03745807An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid TumorsP1completed3Bristol-Myers SquibbApr 2019
NCT02598960An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.P1/P2completed295Bristol-Myers SquibbOct 2015
NCT01714739A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid TumorsP1/P2completed337Bristol-Myers SquibbOct 2012
NCT03518320Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerP1terminated13Taris Biomedical LLCJan 2019
NCT03363776An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial CancersP1/P2terminated10Bristol-Myers SquibbDec 2017
NCT03091491Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung CancerP2terminated31National Cancer Centre, SingaporeApr 2017
NCT02526017FPA008-003Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced CancersP1completed313Five Prime Therapeutics, Inc.Sep 2015
NCT03301636NLG2107A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic MelanomaP2terminated21NewLink Genetics CorporationDec 2017
NCT02955251A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid TumorsP1completed61AbbVieNov 2016
NCT02905266A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With MelanomaP3completed106Bristol-Myers SquibbOct 2016
NCT02862535Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction AdenocarcinomaP1terminated36Gilead SciencesSep 2016
NCT03158272A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has SpreadP1completed19Bristol-Myers SquibbMay 2017
NCT03349710Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck CancerP3completed74Bristol-Myers SquibbDec 2017
NCT02944396NSCLCStudy of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)P1completed25AbbVieDec 2016
NCT03048136CheckMate 955A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung CancerP3withdrawn0Bristol-Myers SquibbMar 2018
NCT03241173A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesP1/P2completed52Incyte Biosciences International SàrlOct 2017
NCT04123925NICOLEPreoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity StudyP2completed22National Cancer Institute, NaplesJun 2018
NCT02999295A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ CancerP1/P2completed46National Cancer Center, JapanJan 2017
NCT03316586A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast CancerP2completed18Dana-Farber Cancer InstituteNov 2017
NCT02864381Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction AdenocarcinomaP2completed144Gilead SciencesSep 2016
NCT03256136Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLCP2completed9Massachusetts General HospitalNov 2017
NCT03939975Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCCP2completed50Sun Yat-sen UniversityJun 2019
NCT02631746Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaP2completed3National Cancer Institute (NCI)Feb 2017
NCT03444766Study of Nivolumab for Advanced Cancers in IndiaP4completed100Bristol-Myers SquibbMar 2018
NCT03302247Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 TherapyP2terminated3Fox Chase Cancer CenterJan 2018
NCT03026166A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerP1/P2terminated42AbbVieMar 2017
NCT02073123Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic MelanomaP1/P2completed131NewLink Genetics CorporationJul 2014
NCT03509584Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer PatientsP1terminated6Assistance Publique Hopitaux De MarseilleJun 2018
NCT03382886NUANCENivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular CarcinomaP1terminated1University of UtahApr 2018
NCT03726281Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell TumorsP2withdrawn0Hospital Beatriz ÂngeloOct 2018
NCT03390738Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous ChemotherapyP2withdrawn0The University of Hong KongJun 2018
NCT02716272MAPS2Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) PatientsP2completed125Intergroupe Francophone de Cancerologie ThoraciqueMar 2016
NCT02614456Combination of Interferon-gamma and Nivolumab for Advanced Solid TumorsP1completed26Fox Chase Cancer CenterDec 2015
NCT02483247A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced CancerP1completed165Sumitomo Pharma America, Inc.Sep 2015
NCT03342417Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer PatientsP2terminated5ExcellaBio LLCFeb 2018
NCT03075553Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaP2terminated12Mayo ClinicMay 2017
NCT02253992An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's LymphomaP1/P2terminated232Bristol-Myers SquibbSep 2014
NCT03041181Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 InhibitorP2terminated3Nasser Hanna, M.D.Jan 2017
NCT03119428A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid TumorsP1terminated33OncoMed Pharmaceuticals, Inc.May 2017
NCT03558750Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaP1terminated6Vanderbilt-Ingram Cancer CenterJun 2018
NCT02775292NYMGene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1P1completed1Jonsson Comprehensive Cancer CenterJan 2017
NCT03203304SBRTStereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver CancerP1terminated14University of ChicagoAug 2017
NCT03121417Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung CancerP2withdrawn0Emory UniversityJul 2017
NCT02731729Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor TherapyP2completed20Parker Institute for Cancer ImmunotherapyJun 2016
NCT02892734Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast CancerP2terminated3Northwestern UniversitySep 2017
NCT02941744ipnivA Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma MacrometastasesP1/P2completed56Universitair Ziekenhuis BrusselMar 2016
NCT02599649MDSLirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)P2terminated10M.D. Anderson Cancer CenterMar 2016
NCT02768558Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLCP3terminated20RTOG Foundation, Inc.Oct 2016
NCT02156804BMS-936558A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)P2completed1,009Bristol-Myers SquibbOct 2014
NCT02011945A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid LeukemiaP1completed35Bristol-Myers SquibbFeb 2014
NCT03259516Nivolumab With Chemotherapy in Refractory MDSP1/P2terminated2St. Petersburg State Pavlov Medical UniversityMay 2017
NCT02476123KW-0761Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid TumorsP1completed118Kyowa Kirin Co., Ltd.Jun 2015
NCT02335918A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid TumorsP1/P2completed175Celldex TherapeuticsJan 2015
NCT03192943A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced TumorsP1completed11Bristol-Myers SquibbJun 2017
NCT02834247A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsP1terminated41Calithera Biosciences, IncAug 2016
NCT03333746Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple MyelomaP2terminated1Yvonne EfeberaMar 2018
NCT02720484Nivolumab in Treating Patients With Metastatic Adrenocortical CancerP2terminated10Northwestern UniversityMar 2016
NCT01621490PD-1PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaP1completed170Bristol-Myers SquibbSep 2012
NCT02705105Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid TumorsP1/P2completed114Kyowa Kirin, Inc.Feb 2016
NCT03371381An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the LungP1/P2terminated12Janssen Research & Development, LLCJan 2018
NCT02302339A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaP2terminated132Celldex TherapeuticsNov 2014
NCT03381118Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML PatientsP2terminated16St. Petersburg State Pavlov Medical UniversityJun 2017
NCT02864316Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation ExposureP2terminated6Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDec 2016
NCT03132493NIVEXNivolumab in the Real World: Analysis of the Expanded Use in Spanish Patientcompleted676Spanish Lung Cancer GroupJun 2017
NCT02309177Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast CancerP1completed114CelgeneJan 2015
NCT02446860ADAPTeRA Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)P2terminated15Royal Marsden NHS Foundation TrustApr 2015
NCT02819804Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaP1terminated1Northwestern UniversityAug 2017
NCT03351231An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced CancerP1/P2terminated7Bristol-Myers SquibbNov 2017
NCT02846792Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung CancerP1/P2terminated5University of WashingtonJun 2017
NCT02923531Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaP1/P2terminated9X4 PharmaceuticalsDec 2016
NCT02259231RTA 408 Capsules in Patients With Melanoma - REVEALP1/P2completed41BiogenOct 2014
NCT02142218Checkmate 168Expanded Access Program With Nivolumab to Treat Melanomano longer available0Bristol-Myers SquibbJun 2014
NCT02621515CA209-322Nivo/Ipi Combination Therapy in Symptomatic Brain MetastasesP2terminated7University Medical Center GroningenAug 2016
NCT03348904Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung CancerP3terminated2Incyte CorporationDec 2017
NCT03106610Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG ImmunotherapyP1terminated1M.D. Anderson Cancer CenterJul 2017
NCT02723006Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaP1terminated22Millennium Pharmaceuticals, Inc.Jun 2016
NCT03326258Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryP1/P2withdrawn0National Cancer Institute (NCI)Apr 2018
NCT03342352Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)P3withdrawn0Incyte CorporationDec 2017
NCT03386838An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and NeckP3withdrawn0Bristol-Myers SquibbMar 2018
NCT02421354Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera MyelofibrosisP2terminated8M.D. Anderson Cancer CenterMay 2015
NCT03149159Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabP2withdrawn0Medical University of South CarolinaApr 2018
NCT02469701Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic DiseaseP2terminated10howard safranFeb 2016
NCT01998126Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerP1completed14University of UtahDec 2013
NCT03023527Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple MyelomaP1terminated6PETHEMA FoundationJan 2017
NCT02967133A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung CancerP2terminated7Alliance Foundation Trials, LLC.Dec 2016
NCT02828124A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver CancerP1/P2terminated25Bristol-Myers SquibbAug 2016
NCT02960854A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.P1completed38Bristol-Myers SquibbDec 2016
NCT02626065PAIRImmune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal AntibodiesP4completed32Hospices Civils de LyonApr 2015
NCT02423954NivoPlusStudy of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)P1/P2terminated33Western Regional Medical CenterApr 2015
NCT03165409Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spreadcompleted1,828Bristol-Myers SquibbFeb 2017
NCT02991196Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal CancerP1terminated4Daiichi SankyoDec 2016
NCT02860546A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRCP2completed18Taiho Oncology, Inc.Aug 2016
NCT02497508NivoMesNivolumab in Patients With Recurrent Malignant MesotheliomaP2completed33The Netherlands Cancer InstituteJul 2015
NCT02243371GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without NivolumabP2completed93Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJan 2015
NCT03126643Expanded Access to Nivolumab (Opdivo)approved for marketing0Bristol-Myers Squibb
NCT02935790Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and NivolumabP1completed1CelgeneSep 2016
NCT02639234Vigil™ + Nivolumab in Advanced Non-Small Cell Lung CancerP2withdrawn0Gradalis, Inc.Mar 2016
NCT02550249Neo-nivoNeoadjuvant Nivolumab in GlioblastomaP2completed29Clinica Universidad de Navarra, Universidad de NavarraJun 2015
NCT02924233Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung CancerP1/P2withdrawn0Symphogen A/SNov 2016
NCT02648633Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent GlioblastomaP1terminated4University of VirginiaMay 2016
NCT02736123Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab AloneP1/P2withdrawn0University of PittsburghOct 2016
NCT02472977CXCessoR4Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid TumorsP1/P2terminated61Bristol-Myers SquibbJul 2015
NCT02950038NSCLCStudy of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)P2withdrawn0M.D. Anderson Cancer CenterDec 2016
NCT02534506Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant TumorsP1completed18Bristol-Myers SquibbNov 2015
NCT02962804RCCCombination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)P2withdrawn0University of Kansas Medical Center
NCT02124850A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus NivolumabP1terminated18CelgeneOct 2014
NCT02518958PRIMETIMEA Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and NivolumabP1completed12EpicentRx, Inc.Jul 2015
NCT02400385A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced MelanomaP2withdrawn0California Pacific Medical Center Research InstituteOct 2014
NCT02357732Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or TrametinibP1withdrawn0University of PittsburghAug 2015
NCT02339558Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal CancerP2completed45National Cancer Institute (NCI)Jul 2015
NCT02475382CheckMate 169Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimenno longer available0Bristol-Myers Squibb
NCT01629758Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid TumorsP1completed33Bristol-Myers SquibbJun 2012
NCT02186249CheckMate218Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanomano longer available0Bristol-Myers Squibb

Nivolumab clinical trials: frequently asked questions

How many Nivolumab clinical trials are there?
1624 Nivolumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 266 are actively recruiting participants. 596 are marked completed.
Are Nivolumab clinical trials recruiting in 2026?
Yes — 266 Nivolumab trials are actively recruiting in 2026, with 4858 U.S. sites across 51 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Nivolumab being studied for?
Nivolumab is being studied for Melanoma, Metastatic Melanoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Non Small Cell Lung Cancer and 2364 more. The trials are grouped by indication on this page.
What phase is Nivolumab in?
Nivolumab clinical trials span 15 Phase 4, 137 Phase 3, 732 Phase 2, 325 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Nivolumab clinical trials?
The lead sponsor across the most Nivolumab trials is Bristol-Myers Squibb, with 541 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Nivolumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: